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ABSTRACT 
Enterovirus A71 (EV-A71) is the main causative agent of hand, foot and mouth disease 
(HFMD). Recent EV-A71 outbreaks in Asia-Pacific were not limited to mild HFMD, 
but were associated with neurological complications including aseptic meningitis, 
brainstem encephalitis and deaths. The absence of licensed therapeutics for clinical use 
has intensified research into anti-EV-A71 development. Since virus-host receptor 
interaction is the first essential event during virus infection, inhibitors that block this 
event could act as potential therapeutics. EV-A71 VP1 capsid protein is involved in 
viral-host receptor interactions and carries multiple receptor binding sites. Screening of 
95 overlapping peptides covering the entire EV-A71 VP1 capsid protein was 
hypothesized to identify potential viral attachment inhibitors, as well as unknown 
receptors. Out of 95 overlapping peptides, a peptide designated as SP40 peptide 
significantly inhibited EV-A71-induced cytopathic effect, plaque formation, RNA 
synthesis and viral protein synthesis. Mechanism of action analysis revealed that SP40 
peptide is not virucidal, but blocked EV-A71 attachment to the cell surface. Alanine 
scanning analysis showed that positively charged amino acids were critical for the 
antiviral activities. Sequence analysis revealed that SP40 peptide carried a heparan 
sulfate-specific binding domain (-RRKV-), which led to the hypothesis that EV-A71 
could use cell surface heparan sulfate as an attachment receptor. Highly sulfated heparin, 
dextran sulfate and suramin significantly inhibited EV-A71 infections in a dose-
dependent manner. Interference with heparan sulfate biosynthesis either by sodium 
chlorate treatment or through transient knockdown of N-deacetylase/N-sulfotransferase-
1 and exostosin-1 expression reduced EV-A71 infection. Enzymatic removal of cell 
surface heparan sulfate by heparinase I/II/III inhibited EV-A71 infection. Biochemistry 
analysis revealed that EV-A71 interacts with heparan sulfate through electrostatic 
interactions. These findings support the hypothesis and confirmed that EV-A71 uses 
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cell surface heparan sulfate as an attachment receptor. Other than the attachment 
inhibitor, this study also tested DNA-like antisense-mediated morpholino oligomers as 
anti-EV-A71 agents. Two octaguanidinium-conjugated morpholino oligomers (vivo-
MOs) targeting EV-A71 internal ribosome entry site (IRES) significantly inhibited EV-
A71 infections at multiple time points, in a dose-dependent manner. EV-A71 resistance 
to vivo-MO-1 arose after 8 blind passages in the presence of increased concentrations of 
vivo-MO-1, but not vivo-MO-2. A single nucleotide mutation at the extreme 3’ end (T 
to C substitution at position 533) was sufficient to confer vivo-MO-1 resistance. In 
mismatch tolerance analysis, results demonstrated that the positions and the number of 
mismatches affect vivo-MO-1 efficacy. A single mismatch at the center of the targeted 
region was more tolerable compared to a mismatch at the end of the targeted region. In 
conclusion, this study has identified an antiviral peptide that potentially blocks viral 
attachment to heparan sulfate, and led to the discovery of a novel EV-A71 attachment 
receptor. This study also identified two antisense-mediated vivo-MOs targeted sites for 
antiviral intervention. This study suggests that blocking of viral attachment and viral 
RNA translation are good strategies for antiviral intervention.  
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ABSTRAK 
Enterovirus A71 (EV-A71) adalah agen utama penyebab penyakit kaki, tangan dan 
mulut (HFMD). Tanda-tanda klinikal HFMD adalah demam, ruam di tapak tangan dan 
kaki dan juga ulser di dalam mulut. Walau bagaimanapun, wabak EV-A71 di Asia 
Pasifik tidak terhad kepada HFMD yang ringan, tetapi dihubungkait dengan komplikasi 
neurologi seperti meningitis aseptik, ensefalitis, paralisis dan kematian. Pilihan rawatan 
untuk jangkitan EV-A71 adalah terhad kepada melegakan gejala jangkitan dan tiada 
agen antivirus yang berkesan untuk penggunaan klinikal. Oleh itu, pembangunan agen 
antivirus yang berkesan terhadap jangkitan EV-A71 adalah amat diperlukan dengan 
segera. Protein kapsid EV-A71 VP1 merupakan tapak pengikatan reseptor. Pemeriksaan 
95 peptida bertindih meliputi seluruh EV-A71 VP1 protein kapsid dapat mengenalpasti 
inhibitor reseptor penyikat yang berpotensi serta mengenalpasti reseptor yang tidak 
diketahui. Daripada 95 peptida bertindih, peptida bernama SP40, didapati menghalang 
EV-A71 jangkitan dalam bentuk kesan sitopati (CPE), pembentukan plak, sintesis RNA 
dan sintesis protein di dalam kultur tisu. Analisis mekanisme tindakan membuktikan 
bahawa SP40 tidak menyahaktif virus, tetapi menyekat pengikatan  reseptor EV-A71. 
Imbasan alanine mendedahkan bahawa asid amino yang bercas positif adalah penting 
untuk aktiviti-aktiviti antiviral. Analisis urutan peptida mendedahkan bahawa SP40 
mempunyai domain pengikatan heparan sulfat (-RRKV-) yang spesifik. Ini telah 
menuju hipotesis penyelidikan bahawa EV-A71 menggunakan heparan sulfat sebagai 
tapak pengikatan reseptor. Heparin, dextran sulfat dan suramin didapati menghalang 
jangkitan EV-A71 dengan ketara. Dengan menggunakan varian heparin yang 
kekurangan kumpulan O-sulfat atau kedua-dua kumpulan O-sulfat and N-sulfat serta 
natrium klorat, kajian ini telah mengenalpastikan bahawa kumpulan sulfat dalam 
heparin adalah kritikal untuk kesan antivirus. Penyingkiran sel permukaan heparan 
sulfat dengan enzim heparinase atau halangan biosistensis heparan sulfat dengan siRNA 
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telah mengurangkan jangkitan EV-A71 dengan ketara. Analisis biokimia mendedahkan 
bahawa EV-A71berinteraksi dengan heparan sulfat melalui interaksi elektrostatik. 
Selain daripada inhibitor adhesi, kajian ini telah mengenal pasti dua perantara-antierti 
morpholino oligonukleotida berkonjugasi dengan octaguanidinium dendrimer (vivo-MO) 
yang menyasarkan tapak kemasukan internal ribosom (IRES) mempunyai aktiviti 
antivirus yang berkesan terhadap jangkitan EV-A71. Penyelidikan masa rawatan telah 
mengenalpastikan bahawa vivo-MO mengekalkan aktiviti-aktiviti antivirus apabila 
rawatan diberikan 4 jam sebelum atau 6 jam selepas jangkitan EV-A71. EV-A71 yang 
mempunyai rintangan terhadap vivo-MO-1 didapati mempunyai mutasi daripada T 
kepada C, dalam kedudukan 533 selepas lapan kali sub-kultur. Dengan menggunakan 
mutasi berarahan-tapak spesifik untuk analisi toleransi sepadan, kajian ini telah 
mengenalpastikan bahawa kedudukan mutasi dan juga bilangan mutasi adalah penting 
untuk aktiviti-aktiviti antivirus oleh vivo-MO. Mutasi di tengah-tengah rantau yang 
disasarkan adalah lebih ditoleransi berbanding dengan mutasi di hujung rantau yang 
disasarkan. Dalam kajian ini, saya telah mengenalpasti peptida antivirus yang 
berpotensi menyekat EV-A71 adhesi kepada heparan sulfat dan telah membawa kepada 
penemuan peranan heparan sulfat sebagai reseptor adhesi untuk EV-A71. Kajian ini 
juga mengenalpasti dua perantara-antierti vivo-MO tapak sasaran untuk pembangunan 
antivirus yang berkesan.  
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CHAPTER 1 
INTRODUCTION 
Human enterovirus A71 (EV-A71) is the main causative agent of hand, foot and mouth 
disease (HFMD). EV-A71 was first described in 1969 during an outbreak of HFMD 
with central nervous system complications in California, USA. Since then, the virus has 
been subsequently associated with many other outbreaks including Bulgaria (Chumakov 
et al., 1979), Hungary (Nagy et al., 1982; Kapusinszky et al., 2010), Japan (Hagiwara et 
al., 1978), Singapore (Chan et al., 2003), Taiwan (Chen et al., 2007), Malaysia 
(AbuBakar et al., 2000), China (Tan et al., 2011) and Vietnam (Thoa Le et al., 2013). 
The clinical symptoms of HFMD are mild febrile illness, rashes on palms and feet, and 
oral ulcers (Ooi et al., 2010). Unlike other enteroviruses that cause HFMD, EV-A71 is 
associated with neurological complications such as aseptic meningitis, brainstem 
encephalitis and poliomyelitis-like acute flaccid paralysis with deaths among infants 
and children aged below 6 years old (Ooi et al., 2010). Considering the impact of 
fatality and long-term neurological sequelae in severely infected children, EV-A71 
should be regarded as the most feared neurotropic enterovirus after the eradication of 
poliovirus (PV) (Chang et al., 2007). To date, no effective antiviral agent is available 
for treatment of EV-A71 infection. Therefore, there is an urgent need to develop 
effective antiviral agents against EV-A71 infection.  
Virus-host receptor interaction is the first essential event during virus infection. Viruses 
fail to enter cells to initiate infection when susceptible receptors are not available. 
Therefore, receptor availability is one the factors that determine virus tissue tropism and 
virulence. Receptor antagonists are often used as antiviral intervention. To date, five 
EV-A71 receptors have been identified, which are scavenger receptor class B2 
(SCARB2) (Yamayoshi et al., 2009), P-selectin glycoprotein ligand-1 (PSGL-1) 
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(Nishimura et al., 2009), sialylated glycan (Yang et al., 2009), annexin II (Yang et al., 
2011) and vimentin (Du et al., 2014). Antibodies targeting SCARB2 and PSGL-1 
significantly inhibited EV-A71 infection, but were insufficient to completely abrogate it 
(Yamayoshi et al., 2009; Nishimura et al., 2009). Thus, there are likely to be multiple 
receptors involved during EV-A71 infection. 
Peptides that can block viral attachment or entry into the cells have therapeutic potential. 
A successful example of an antiviral peptide is the human immunodeficiency virus 
(HIV) fusion inhibitor, enfuvirtide, which obtained US Food and Drug Administration 
(FDA) approval in March 2003 for treatment of patients infected with HIV resistant to 
other antiretroviral drugs. Enfuvirtide is a 36 amino acid peptide derived from the 
heptad repeat region-2 sequence of the HIV transmembrane protein gp41. Enfuvirtide 
interacts with the host CD4
+
 T cell receptor and thus blocks the HIV fusion step (Wild 
et al., 1994; Kilby et al., 1998). Screening of 441 overlapping peptides covering the 
entire hepatitis C virus (HCV) led to discovery of an 18-mer amphipathic α-helical 
peptide, designated as C5A. C5A exhibited significant antiviral activity against HCV, 
and other flaviviruses, paramyxoviruses and HIV through destabilizing the viral 
membranes (Cheng et al., 2008). A peptide derived from the pre-S1 surface protein of 
hepatitis B virus (HBV) also inhibited HBV infection (Kim et al., 2008). 
Capsid protein VP1 of enteroviruses are known to interact with cellular receptors to 
initiate infection. Site-directed mutagenesis studies on EV-A71 VP1 capsid protein 
revealed that EV-A71 interacts with SCARB2 through the cleft around EV-A71 VP1 
Q172 (Chen et al., 2012). The molecular determinant of PSGL-1 binding was also 
identified at the VP1 Q145 and K244 (Nishimura et al., 2013). Peptides targeting these 
functional receptors could potentially act as receptor antagonists and lead to new 
antiviral intervention. This study hypothesizes that screening of overlapping synthetic 
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peptides covering the entire EV-A71 VP1 capsid protein will enable identification of 
attachment or entry receptor(s) inhibitors, as well as to identify unknown receptors. 
Cell surface carbohydrates such as glycosaminoglycans (GAGs) and sialic acid are 
often targeted by pathogens as attachment factors or co-receptors (Bergstrom et al., 
1997; Liu and Thorp, 2002; Oh et al., 2010). These cell surface carbohydrates are 
abundantly expressed in most cell types. GAGs such as heparin, heparan sulfate, and 
chondroitin sulfate are negatively-charged linear polysaccharides composed of 
hexosamine/hexuronic acid repeats (Kjellen et al., 1980; Kjellen and Lindahl, 1991). 
Viruses like herpes simplex virus  (HSV) (WuDunn and Spear, 1989; Spear et al., 1992), 
dengue virus (DENV) (Chen et al., 1997), HIV (Vives et al., 2005), human 
papillomavirus (HPV) (Giroglou et al., 2001), echovirus (Goodfellow et al., 2001), 
coxsackievirus B3 (CV-B3) (Zautner et al., 2006) and foot-and-mouth disease virus 
(FMDV) (Jackson et al., 1996; O'Donnell et al., 2008) are known to utilize cell surface 
heparan sulfate as an attachment receptor. As EV-A71 has been shown to be inhibited 
by heparin mimetics (Pourianfar et al., 2012) and an antiviral peptide with a heparan 
sulfate binding domain (Tan et al., 2012), this study further hypothesized that EV-A71 
could utilize cell surface heparan sulfate as an attachment receptor.  
Other than receptor antagonists, antisense-mediated mechanism antiviral agents have 
been under investigation and promising outcomes have been demonstrated (Kole et al., 
2012). The first and only antisense-mediated antiviral agent that has received US FDA 
approval is a 21-mer phosphorothioate oligonucleotide (PTO) known as fomivirsen. 
Fomivirsen is approved for intravitreal treatment of cytomegalovirus retinitis in patients 
with acquired immunodeficiency syndrome (AIDS) (Perry and Balfour, 1999). The use 
of antisense-mediated short interfering RNA (siRNA) or short hairpin RNA (shRNA) 
targeting various regions of the EV-A71 genome have also shown promising outcomes 
(Sim et al., 2005; Tan et al., 2007a; Tan et al., 2007b; Wu et al., 2009; Yang et al., 
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2012). However, the major limitations of these antisense molecules are that they require 
a delivery agent which may be toxic to the cells, as well as having a very short half-life 
in plasma. To overcome these limitations, this study involved the use of 
phosphorodiamidate morpholino oligomers (PMOs) which are highly resistant to 
nuclease degradation and coupled with a non-peptide cell-penetrating moiety known as 
octaguanidinium dendrimer (Moulton and Jiang, 2009). The use of peptide-conjugated 
PMOs (PPMOs) targeting multiple picornaviruses, including PV, CVB3, rhinovirus and 
FMDV, showed significant antiviral effects (Yuan et al., 2006; Vagnozzi et al., 2007; 
Stone et al., 2008). This study further hypothesized that the use of translational 
suppressing vivo-morpholino oligomers (vivo-MOs) targeting EV-A71 internal 
ribosome entry site (IRES) stem-loop structures in the 5’ untranslated region (UTR) and 
EV-A71 RNA-dependent RNA polymerase (RdRP) gene could efficiently inhibit EV-
A71 infection in a tissue culture system.  
With the advancement in recombinant DNA technology which allows modification of 
genomic DNA through mutagenesis, understanding of virus pathogenesis and virulence 
can be achieved through infectious cDNA clones construction. This allows genetic 
manipulation of viral RNA genomes which facilitates the investigation of viral 
virulence determinants and characterization of antiviral drug resistance mechanisms 
(Wimmer et al., 2009; Hall et al., 2012). Infectious cDNA clones of multiple 
enteroviruses have been constructed (Racaniello and Baltimore, 1981; Kraus et al., 
1995; Martino et al., 1999; Harvala et al., 2002; Liu et al., 2011). Several infectious 
cDNA clones of EV-A71 have been previously constructed using different EV-A71 
genotypes (Arita et al., 2005; Chua et al., 2008; Han et al., 2010; Phuektes et al., 2011; 
Yeh et al., 2011; Zaini et al., 2012). Multiple EV-A71 infectious clones have been 
constructed to study the virulence determinants of EV-A71 either in vitro or in vivo 
through site-directed mutagenesis (Arita et al., 2007; Phuektes et al., 2011; Yeh et al., 
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2011; Kok et al., 2012). Infectious cDNA clones tagged with reporter genes offer a 
rapid platform for drug screening and detailed study of the mechanistic action of the 
drug. This study involved construction of EV-A71 strain 41 (genotype B4) clones with 
and without the reporter gene, enhanced green fluorescence protein (EGFP). The EV-
A71 infectious cDNA clone constructed in this study allowed detailed analysis of the 
drug mechanistic action using a reporter assay, and drug resistance through site-directed 
mutagenesis. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 The virology of enterovirus A71  
2.1.1 Classification of enteroviruses 
Human enteroviruses are members of the Enterovirus genus in the Picornaviridae 
family. Picornaviridae family is divided into 26 genera which consist of Aphthovirus, 
Aquamavirus, Avihepatovirus, Avisivirus, Cardiovirus, Cosavirus, Dicipivirus, 
Enterovirus, Erbovirus, Gallivirus, Hepatovirus, Hunnivirus, Kobuvirus, Megrivirus, 
Mischivirus, Mosavirus, Oscivirus, Parechovirus, Pasivirus, Passerivirus, Rosavirus, 
Salivirus, Sapelovirus, Senecavirus, Teschovirus and Tremovirus (Adams et al., 2013) 
(http://www.picornaviridae.com).  
Initially, the human enteroviruses were classified into four main groups based on 
pathogenicity in man and suckling mice, which were polioviruses (types 1-3), 
coxsackieviruses group A (types 1-22, 24), coxsackieviruses group B (types 1-6) and 
echoviruses (types 1-7, 11-27, 29-34) (Nasri et al., 2007). As sequence data increases, 
these subgroups did not match the observed phylogenetic relationships. Furthermore, 
each observed type was associated with a wide spectrum of disease, and therefore 
classification on the basis of clinical terms was impossible.  
As a result of this limitation, human enteroviruses have been classified into four species 
(A-D) on the basis of sequence identity and phylogenetic relationships. However, 
classification based on the phylogenetic relationships and sequence identity has led to 
the recognition that many animal viruses fall within the genus of Enterovirus, such as 
simian enteroviruses in enterovirus A, B and D. This resulted in the recent proposal to 
remove the host species from the enterovirus nomenclature. To date, the genus of 
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Enterovirus consists of 12 species, which are enterovirus A-H, enterovirus J and 
rhinovirus A-C (Table 2.1). Human rhinoviruses were classified under the Enterovirus 
genus on the basis of the similarities in genome organization, life cycle and 
phylogenetic relationships (Laine et al., 2005). EV-A71 is classified as a member of the 
species of enterovirus A (Brown and Pallansch, 1995; Pallansch and Roos, 2007; 
Racaniello, 2007).  
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Table 2.1: Current genetic classifications of enteroviruses 
Species Serotypes Name of members 
Enterovirus A 24 Coxsackieviruses A2-A8, A10, A12, A14, A16, 
enteroviruses A71, A76, A89-92, A114, A119, 
A120, simian enteroviruses SV19, SV43, SV46, 
baboon enterovirus BA13 
Enterovirus B 61 Coxsackieviruses A9, B1-B6, echoviruses 1-7, 11-
21, 24-27, 29-33, enteroviruses B69, B73-75, B77-
88, B93, B97, B98, B100, B101, B106, B107, B110, 
B111, simian enterovirus SA5 
Enterovirus C 23 Polioviruses 1-3, coxsackieviruses A1, A11, A13, 
A17, A19-22, A24, enteroviruses C95, C96, C99, 
C102, C104, C105, C109, C113, C116, C117,C118.  
Enterovirus D 5 Enteroviruses D68, D70, D94, D111, D120 
Enterovirus E 4 Enteroviruses E1-4 
Enterovirus F 6 Enteroviruses F1-6 
Enterovirus G 11 Enteroviruses G1-11 
Enterovirus H 1 Enterovirus H1 
Enterovirus J 6 Simian enterovirus SV6, enteroviruses J103, J108, 
J112, J115, J121 
Rhinovirus A 80 Rhinoviruses A1-2, A7-13, A15-16, A18-25, A28-
34, A36, A38-41, A43, A45-51, A53-68, A71, A73-
78, A80-82, A85, A88-90, A94, A96, A100-109 
Rhinovirus B 32 Rhinoviruses B3-6, B14, B17, B26-27, B35, B37, 
B42, B48, B52, B69, B70, B79, B83-84, B86, B91, 
B93, B97, B99-106 
Rhinovirus C 54 Rhinoviruses C1-54 
Information included in this table is adapted from information available on the 
Picornavirus Study Group website (www.picornaviridae.com; 
www.picornastudygroup.com). 
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2.1.2 Genomic and structural components of enterovirus A71 
EV-A71 consists of a single-stranded, positive-sense ribonucleic acid (RNA) genome of 
approximately 7411 nucleotides (Brown and Pallansch, 1995). EV-A71 is a small, non-
enveloped virus with a diameter of approximately 30 nm. The genome is enclosed 
within the icosahedral viral capsid (Plevka et al., 2012; Wang et al., 2012b). The EV-
A71 genome has a single open reading frame (ORF) encoding a polyprotein, flanked by 
5’ and 3’ untranslated regions (UTRs). As shown in Figure 2.1, the polyprotein is 
cleaved into four structural proteins (VP1, VP2, VP3 and VP4) and seven non-structural 
proteins (2A, 2B, 2C, 3A, 3B, 3C and 3D) (Brown and Pallansch, 1995). The 5’ UTR of 
EV-A71 contains six putative stem-loop structures. The stem-loop I (cloverleaf) is 
involved in viral RNA synthesis and stem-loops II-VI make up the EV-A71 internal 
ribosome entry site (IRES) involved in cap-independent viral RNA translation 
(Thompson and Sarnow, 2003). The 3’UTR of picornavirus RNA contains three 
putative stem-loop structures followed by a poly(A) tail which is required for genome 
replication (Rohll et al., 1995).  
With the recent availability of the crystal structure of EV-A71 at 3.8 Å resolution, EV-
A71 capsid has been shown to have quasi-T=3 symmetry with 60 identical units each 
consisting of four structural proteins VP1, VP2, VP3 and VP4 arranged in an 
icosahedral shape (Figure 2.2). VP1-VP3 capsid proteins are the main structural 
components of the virion, whereas VP4 is located internally. The surface loops of VP1 
are located around the icosahedral 5-fold axis and the canyon of EV-A71 was found to 
be shallower than most of the other enteroviruses. Thus, it cannot provide 
immunological seclusion for the residues located at the bottom of the canyon and hence 
it is not likely to serve as a binding site for receptors (Plevka et al., 2012).  
 
 10 
 
Figure 2.1: Schematic illustration of EV-A71 genomic RNA, translation and 
polyprotein processing. The EV-A71 genome consists of a single ORF 
flanked by 5’ UTR and 3’ UTR. The roman numerals (I-VI) refer to the 
six putative IRES stem-loop structures. The IRES-dependent translation 
of EV-A71 positive-sense RNA produces a polyprotein, which is then 
cleaved into individual products by EV-A71 2A and 3C proteases. VP1-
VP4 are structural proteins, while 2A-2C and 3A-3D are non-structural 
proteins. The figure was adapted with modifications from Brown and 
Pallansch (1995) and Solomon et al. (2010).  
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Figure 2.2: Crystal structure of EV-A71. (A) The mature EV-A71 virion, looking 
down an icosahedral two-fold axis, with VP1, VP2, VP3 and VP4 drawn 
in blue, green, red and yellow, respectively. The 5-fold axis of the EV-
A71 virion in top view (B) and side view (C). This figure was adapted 
with modification from Wang et al. (2012b). 
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2.1.3 Life cycle of enterovirus A71 
The EV-A71 life cycle involves viral attachment, entry, uncoating, IRES-dependent 
translation, polyprotein processing, genomic RNA replication, and finally maturation 
and release (Figure 2.3). Details on the EV-A71 life cycle are explained in the sub-
sections below.  
2.1.3.1 Enterovirus A71 attachment, entry and uncoating 
Virus infection is initiated by attachment of the virus to a cellular receptor at the surface 
of a susceptible cell which then initiates a chain of dynamic events to enable viral 
internalization and uncoating. Multiple attachment receptors may be used sequentially, 
or in a cell-specific manner, and co-receptors may be involved (Tuthill et al., 2010; 
Bergelson and Coyne, 2013). Cellular receptors determine tissue tropism and 
pathogenicity of the viruses (Haywood, 1994). To date, five EV-A71 receptors have 
been discovered, including PSGL-1 (Nishimura et al., 2009), SCARB2 (Yamayoshi et 
al., 2009), sialic acid (Yang et al., 2009), annexin II (Yang et al., 2011) and vimentin 
(Du et al., 2014). However, none of the receptors reported are members of the 
immunoglobulin superfamily, unlike other reported enteroviruses receptors, such as 
poliovirus receptor, intracellular adhesion molecule-1 and coxsackievirus-adenovirus 
receptor (Tuthill et al., 2010). 
Human P-selectin glycoprotein ligand-1 (PSGL-1) is a sialomucin leukocyte membrane 
protein that is expressed as a homodimer of disulfide-linked subunits. It is expressed as 
a dimeric mucin-like glycoprotein that is N-glycosylated and contains both sialylated 
and fucosylated O-linked oligosaccharides (Laszik et al., 1996; Somers et al., 2000). 
PSGL-1 is involved in the entering and rolling of leukocytes on vascular endothelium. 
PSGL-1 is a type I transmembrane receptor found on the surface of neutrophils, 
monocytes and most lymphocytes. However, PSGL-1 receptor is not expressed in 
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neuroepithelial (SK-N-MC) and rhabdomyosarcoma (RD) cells which support the 
production of EV-A71 infection. PSGL-1 is only expressed on the dendritic cells of 
lymph nodes and on macrophages in the intestinal mucosa, which could be the primary 
site of EV-A71 replication after viral ingestion. PSGL-1 is proposed to be involved in 
the viremic phase of EV-A71 infection in which induction of apoptosis in the infected 
leukocytes results in the depletion of T cells, and changes in cytokine levels observed in 
severe encephalitis cases with pulmonary edema (Nishimura et al., 2009). In another 
recent study, transgenic mice expressing human PSGL-1 alone did not enhance EV-A71 
infection (Liu et al., 2012). Therefore, PSGL-1 is not considered a major EV-A71 
receptor. A study using the EV-A71 strain 1095 revealed that VP1-145Q regulates the 
molecular switch of PSGL-1 binding, and VP1-244K interacts with PSGL-1 (Nishimura 
et al., 2013). The tyrosine sulfation sites at the amino terminus of PSGL-1 interact with 
EV-A71 (Nishimura et al., 2010).  
Besides PSGL-1, human scavenger receptor class B, member 2 (SCARB2) (also known 
as lysosomal integral membrane protein II, LGP85 and CD36b like-2) was identified as 
an EV-A71 functional receptor. SCARB2 is a heavily N-glycosylated type III 
transmembrane protein with a large extracellular domain (with ~ 400 amino acids) and 
short cytoplasmic domain at the amino and carboxyl-terminus (Fujita et al., 1992). 
SCARB2 is the most abundant protein in the lysosomal membrane, and is involved in 
enlargement of early endosomes and late endosomes or lysosomes, and impairs 
endocytic membrane traffic out from the enlarged compartments (Kuronita et al., 2002). 
SCARB2 was previously implicated in the endocytosis of high-density lipoprotein and 
the internalization of pathogenic bacteria. SCARB2-deficient mice have ureteropelvic 
junction obstruction, deafness and peripheral neuropathy (Gamp et al., 2003). Although 
SCARB2 is primarily located in endosomes, surface expression of SCARB2 has also 
been demonstrated. SCARB2 is ubiquitously expressed in various cell types (Eskelinen 
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et al., 2003) and has been suggested to be the major receptor of EV-A71 (Yamayoshi et 
al., 2009). Recent study has demonstrated that SCARB2, but not PSGL-1 is required for 
EV-A71 entry and uncoating (Lin et al., 2012b; Yamayoshi et al., 2013). Other 
enteroviruses including coxsackievirus A7, coxsackievirus A14 and coxsackievirus A16 
(CV-A16) also use SCARB2 as a receptor (Yamayoshi et al., 2012). Comparison of 
human SCARB2 and mouse SCARB2 revealed that amino acid residues 142-204 of the 
human SCARB2 are critical for EV-A71-SCARB2 interaction (Yamayoshi and Koike, 
2011). The cleft around Q172 of the EV-A71 VP1 capsid protein was further deduced to 
interact with the variable region of the SCARB2 amino acid residues 144-151 (Chen et 
al., 2012).  
The third receptor reported for EV-A71 is cell surface sialylated glycan (Yang et al., 
2009). Glycans make up the major part of the cell surface and extra-cellular matrix of 
epithelial cells. A number of microbial pathogens utilize glycans on the host cell surface 
as attachment sites to invade host epithelial cells (Olofsson and Bergstrom, 2005). Sialic 
acids are found as terminal monosaccharides on the glycan chains of glycoproteins 
(Varki and Varki, 2007). Several viruses, including EV-A70 (Alexander and Dimock, 
2002) and CV-A24 (Nilsson et al., 2008) utilize cell surface sialylated glycan as an 
attachment receptor. Removal of cell surface sialic acid residues by neuraminidase was 
able to protect DLD-1, RD and SK-N-SH cells from EV-A71 infection (Yang et al., 
2009, Su et al., 2012). Furthermore, pre-treatment of RD and SK-N-SH cells with α2-3 
or α2-6 sialic acid binding lectin was found to inhibit EV-A71 infection. A recent study 
revealed that sialic acid present on SCARB2 is critical for EV-A71 infection. EV-A71 
binding to SCARB2 was abolished after removal of the sialic acids present on SCARB2 
(Su et al., 2012).  
Annexin II is also another functional receptor for EV-A71. Annexin II is a member of 
the annexin family, which are multifunctional phospholipid binding proteins. Annexin 
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II on the endothelial cells acts as a pro-fibrinolytic co-receptor for both plasminogen 
and tissue plasminogen activator facilitating the generation of plasmin (Kim and Hajjar, 
2002). Previous work has found that annexin II could be the receptor of respiratory 
syncytial virus on epithelial cells (Malhotra et al., 2003). Pre-incubation of EV-A71 
viral particles with annexin II or pre-incubation of RD cells with anti-annexin II 
antibody resulted in reduced viral attachment. The authors suggested that binding of 
EV-A71 to annexin II could enhance viral entry and infectivity (Yang et al., 2011).  
Recently, vimentin has been reported as EV-A71 attachment receptor (Du et al., 2014). 
Vimentin is a 53 kDa polypeptide comprised of 466 amino acids, with a α-helical rod 
domain that is flanked by non-α-helical N- and C-terminal. Vimentin is widely 
expressed and a highly conserved protein of type III microfilament (Satelli and Li, 
2011). Vimentin and other cytoskeletal filaments have been reported to play critical 
roles in attachment, entry and infection for many viruses including cowpea mosaic virus 
(Koudelka et al., 2009), HIV (Shoeman et al., 1990), Japanese encephalitis virus (Das et 
al., 2011) and FMDV (Gladue et al., 2013). Soluble vimentin and anti-vimentin 
antibodies could inhibit EV-A71 binding to host cells. Knockdown of vimentin 
expression on the cell surface remarkably reduced EV-A71 binding (Du et al., 2014).  
EV-A71 infection is initiated by attachment to the EV-A71 functional receptors and 
internalization through the clathrin-mediated endocytosis pathway (Hussain et al., 2011). 
A few EV-A71 VP1 capsid protein domains such as Q172 were critical for SCARB2 
interactions (Chen et al., 2012). EV-A71-SCARB2 complexes are internalized through 
clathrin-mediated endocytosis and viral uncoating occurs within the acidified endosome 
(Lin et al., 2012b). Eight amino acid residues from positions 144-151 on SCARB2 are 
critical for interaction with EV-A71. However, seven out of the eight residues are 
different from murine SCARB2, which explains why EV-A71 infects human cell lines 
but not murine cell lines (Chen et al., 2012). Interestingly, the caveolar-mediated 
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endocytosis pathway is utilized when EV-A71 interacts with PSGL-1 receptor (Lin et 
al., 2013a). The involvement of annexin II and sialylated glycan in viral entry are not 
well defined.  
Upon attachment to the entry receptor, a series of conformations are triggered, resulting 
in formation of an “A-particle” that is primed for genome release. Formation of the “A-
particle” is the first essential event during picornavirus uncoating. Both VP4 capsid 
protein and the lipid moiety (pocket factor) resides in the hydrophobic pocket within the 
VP1 may be expelled out. The second uncoating event occurs after endocytosis; an 
unknown trigger causes RNA expulsion from the “A-particle”, leaving behind an empty 
capsid (Rossmann, 1989; Rossmann et al., 2002; Shingler et al., 2013). The formation 
of the 135S “A-particle” results in the presence of both SCARB2 entry receptor and an 
acidic pH environment, implying that “A-particle” formation happens after endocytosis 
in the early endosomes (Chen et al., 2012b). 
2.1.3.2 Enterovirus A71 translation and polyprotein processing 
EV-A71 protein synthesis commences in a cap-independent manner which depends on 
the IRES element at the 5’ UTR of the EV-A71 genome (Thompson and Sarnow, 2003). 
The IRES is a cis-acting element that forms secondary and tertiary RNA structures with 
the assistance of IRES-specific trans-acting factors (ITAFs). This recruits cellular 
translation machinery such as ribosomes to the viral RNA for initiation of translation.  
EV-A71 type I IRES requires eIF4A, eIF2, eIF3 and ATP to assemble the 48S complex 
for translation initiation (Thompson and Sarnow, 2003). Heterogeneous nuclear 
ribonucleoprotein (hnRNP) A1 interacts with the IRES; and either hnRNP A1 or 
hnRNP A2, but not both, are essential for IRES-directed translation (Lin et al., 2009c). 
Far upstream element binding proteins (FBPs) are also involved in EV-A71 translation. 
FBP-1 enhances the IRES activity of EV-A71 RNA, while FBP-2 down-regulates IRES 
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activity. FBPs are well-known to interact with certain mRNA and participate at various 
steps in transcription, RNA processing, RNA transport and RNA catabolism. However, 
involvement of FBPs in viral translation remains largely unexplored (Lin et al., 2009b).  
The EV-A71 ORF is translated into a single polyprotein, which is subsequently 
processed by virus-encoded proteases 2A and 3C into the structural capsid proteins and 
the nonstructural proteins involved mainly in the replication of viral RNA (Lin et al., 
2009a). Picornavirus 2A protease cleavage sites were found at the C-terminus of capsid 
protein precursor P1 and within the 3CD fragment which generates 3C protease and 
RdRP (Yu and Lloyd, 1991). The 2A protease also cleaves eukaryotic initiation factor 
4G (eIF4G) and therefore shuts off host cap-dependent translation to permit IRES-
dependent translation of viral RNA (Thompson and Sarnow, 2003). The picornavirus 
3C protease cleaves Gln-Gly pairs in the P2-P3 regions during proteolytic maturation of 
the viral proteins (Kitamura et al., 1981).  
2.1.3.3 Enterovirus A71 genome replication 
The positive-sense RNA genome must be first transcribed into negative-sense RNA 
which is then used as a template for synthesis of new genomic positive-sense RNA. 
Enterovirus genome replication occurs in the cytoplasm. Two cellular pathways 
contribute to viral RNA replication, are membranous vesicles derived from membranes 
of endoplasmic reticulum (ER) and/or Golgi complex and autophagosome-like vesicles 
(Belov and Ehrenfeld, 2007). Coat protein complex 1 (COPI) and COPII vesicles are 
essential components of the trafficking machinery cycling between ER and the Golgi 
complex. COPI and COPII are involved in the formation of picornavirus-induced 
vesicles for several enteroviruses including PV and echovirus 11. Recently, Wang et al. 
(2012a) demonstrated that COPI, but not COPII is required for EV-A71 replication. 
EV-A71 replication is inhibited when brefeldin A and golgicide A inhibits COPI 
 18 
activity. Co-localization of viral non-structural protein 2C with COPI subunits was 
demonstrated. Like other picornaviruses, EV-A71 infection also induces membranous 
vesicles derived from ER and Golgi complex for replication (Wang et al., 2012a).  
Co-localization of viral proteins and microtubule-associated protein 1 light chain 3 
(LC3) has been reported in PV (Jackson et al., 2005). Like PV, Huang et al. (2009) has 
established that EV-A71 infection of RD and SK-N-SH cells induces autophagy. Co-
localization of autophagosome-like vesicles with EV-A71 VP1 or LC3 protein in 
neurons of the cervical spinal cord of ICR mice was shown. EV-A71 replication was 
also inhibited by the autophagic inhibitor 3-methyladenine, suggesting that autophagy 
induced by EV-A71 is crucial for virus replication.  
Viral replication requires both cellular and viral factors which include viral non-
structural proteins (2B, 3A and 3D), cellular RNA binding proteins and cis-acting RNA 
secondary structures (Lin et al., 2008). The viral RdRP plays a key role in synthesis of 
both negative and positive strands (Neufeld et al., 1994). Destabilization of the 3’ UTR 
stem-loop structures interaction by site-directed mutagenesis severely suppressed viral 
RNA synthesis (van Ooij et al., 2006).   
2.1.3.4 Enterovirus A71 packaging and release from cells 
The assembly and virion secretion of enteroviruses is a multi-step process (Racaniello, 
2007). Recently, the structure of the procapsid of EV-A71 was resolved by cryo-
electron microscopy (cryo-EM) and the virion assembly has been postulated (Cifuente 
et al., 2013). Similar to other picornaviruses, the protomer (5S) is first assembled from 
VP1, VP3 and VP0 proteins and subsequently five promoters are self-assembled into a 
pentamer (14S). The newly synthesized RNA is packaged into the empty capsid by 
unknown mechanism, with 12 pentamers assembling into a procapsid (Jacobson and 
Baltimore, 1968; Jacobson et al., 1970). Alternatively, the RNA may recruit the 
 19 
pentamers which are subsequently packed into a capsid around the genome (Ghendon et 
al., 1972; Marongiu et al., 1981). These events produce the provirion (150S) and 
maturation occurs when VP0 is cleaved into VP2 and VP4, and the virions finally 
develop into infectious viruses (160S). Viruses are released from the cytoplasm when 
the cells lyse.  
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Figure 2.3: Intracellular replication of EV-A71. The EV-A71 replication life cycle 
involves nine critical steps: (1) attachment, (2) entry, (3) uncoating, (4) 
translation, (5) polyprotein processing, (6) replication, (7) packaging, (8) 
maturation and (9) release. 
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2.1.4 Epidemiology of enterovirus A71 
2.1.4.1 Outbreaks of enterovirus A71 
EV-A71 was first isolated from the stool of a 9-month-old child with encephalitis in 
1969, in California (Schmidt et al., 1974). In the 1970s, two large EV-A71 epidemics 
occurred in Europe. In Bulgaria in 1975, the neurovirulence of EV-A71 was manifested 
during a large EV-A71 outbreak and resulted in 44 fatalities among 451 children 
(Chumakov et al., 1979). The second epidemic happened in Hungary in 1978 with 1550 
cases (826 aseptic meningitis, 724 encephalitis) and 47 fatalities reported (Nagy et al., 
1982). Epidemics of HFMD and EV-A71 were also reported in Sweden and Japan in 
1973 (Blomberg et al., 1974; Hagiwara et al., 1978). 
In Sarawak, Malaysia in 1997, a large outbreak of EV-A71 with 2618 HFMD cases and 
34 deaths was reported. In Peninsular Malaysia, 4 fatalities were reported in 1997 
(Cardosa et al., 1999; Chan et al., 2000). In 1998, 129,106 estimated cases with 78 
fatalities were reported in Taiwan. In 1999, 6,000 HFMD cases were reported and 29 
infected patients died from the disease in Taiwan (Ho et al., 1999). Small sporadic 
outbreaks occurring every 2 to 3 years were also reported in Australia, Korea, Japan, 
Vietnam and Singapore (Bible et al., 2007).  Large outbreaks of HFMD were reported 
in 2006 in Sarawak, Malaysia with 13 deaths (Chua and Kasri, 2011). The largest EV-
A71 epidemics occurred in China and the number of cases grew from 489,000 cases and 
126 deaths in 2008 to 1,775,000 cases and 905 deaths in 2010 (Tan et al., 2011; Mao et 
al., 2012). In addition, more than 137 fatal cases have been reported in Vietnam during 
2011(Khanh et al., 2012). The emergence of EV-A71 in recent years in Asia showed 
that EV-A71 will continue to be a global threat.  
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2.1.4.2 Molecular epidemiology of enterovirus A71 
EV-A71 is further classified into 11 subgenotypes within 3 genotypes,  A, B (B1-B5) 
and C (C1-C5), based on sequence comparison of VP1 genes, and each group has at 
least 15% nucleotide divergence from the others (Brown et al., 1999; Cardosa et al., 
2003; Bible et al., 2007; Chan et al., 2010; Tee et al., 2010) (Figure 2.4). Genotype A 
consists of the prototype BrCr strain which was first identified in California, USA in 
1969 (Schmidt et al., 1974). Since then, no circulation has been reported, till recently, 
when genotype A was isolated in five out of 22 children with HFMD in Anhui province 
of China in 2008 (Yu et al., 2010).  
The molecular epidemiology of EV-A71 in the Asia-Pacific region between 1973 and 
2010 is summarized in Table 2.2. Genotype B was predominant in Malaysia and 
Singapore. Subgenotypes B1 and B2 were predominantly circulating in 1970s and 
1980s in Japan, Taiwan and United States (Brown et al., 1999; Chu et al., 2001). EV-
A71 subgenotypes B3 and B4 have been circulating since 1997 in Singapore, Malaysia 
and Japan; and subgenotype B5 has been circulating since 1999 in Malaysia, 2001 in 
Thailand and Singapore, 2003 in Japan and Taiwan, and 2006 in Brunei (Cardosa et al., 
1999; Shimizu et al., 1999; Cardosa et al., 2003; AbuBakar et al., 2009; Chan et al., 
2012; Zaini and McMinn, 2013; Linsuwanon et al., 2014).  
Genotype C is predominant in East Asia including China (Ooi et al., 2010). 
Subgenotypes C1 and C2 were initially reported in 1980s and subgenotype C3 was 
reported in Korea in 2003 (Cardosa et al., 2003). Subgenotype C4 has caused major 
outbreaks in China since 2000, and has also been reported in Japan, Vietnam, Thailand 
and Taiwan in recent years (Lin et al., 2006; Tu et al., 2007; Zhang et al., 2010b). 
Subgenotype C5 has been reported in southern Vietnam and Taiwan (Tu et al., 2007; 
Huang et al., 2008b).  
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Molecular epidemiology studies have improved the understanding of the evolution of 
EV-A71. Genetic diversity of the virus can influence its pathogenic properties and 
circulation. As a result of a lack of proof-reading ability in the RdRP, EV-A71 is 
genetically diverse with an estimated evolution rate of 4.5 x 10
-3
 substitutions per 
nucleotide per year (Tee et al., 2010).  Molecular epidemiological analysis revealed that 
each genotype either circulates predominantly or co-circulates with other genotypes 
within the same epidemic region. Co-circulation of four distinct subgenotypes has been 
reported in Malaysia between 1997 and 2000 (Herrero et al., 2003). Currently, only 
subgenotype B5 circulates in Malaysia (Chan et al., 2012). 
Other than a high error rate in replication, recombination contributes to genetic diversity 
and evolution of EV-A71. Intertypic recombination between EV-A71 and other 
Enterovirus A including CV-A16 has been demonstrated. Multiple recombination 
breakpoints were reported in EV-A71 non-structural genes (Yoke-Fun and AbuBakar, 
2006). Intratypic recombination between EV-A71 genotype B and genotype C has also 
been demonstrated and the recombinant breakpoints were located at the 3’ end of the 2A 
and 3D non-structural protein genes (Huang et al., 2008a).  
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Figure 2.4: Phylogenetic analysis of EV-A71 VP1 gene sequences. The neighbor-
joining tree was constructed with the Kimura-2 parameter as a model 
for nucleotide substitution using MEGA 5 software. The robustness of 
the tree was determined by bootstrapping with 1000 pseudoreplicates.  
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2.1.5 Clinical manifestations of enterovirus A71 infections 
EV-A71 first appeared in 1969 and since then has caused outbreaks with clinical 
manifestations ranging from hand, foot and mouth disease (HFMD), herpangina, aseptic 
meningitis and encephalitis (Schmidt et al., 1974; Liu et al., 2000). HFMD is a common 
childhood exanthema characterized by a mild febrile illness with papulovesicular rash 
on the palms and soles, and multiple oral ulcers (Liu et al., 2000). Other frequently 
encountered symptoms include poor appetite, vomiting and lethargy. EV-A71 also 
causes herpangina, an illness characterized by an abrupt onset of fever and sore throat, 
associated with development of raised papular lesions on the mucosa of the anterior 
pharyngeal folds, tonsils and soft palate. HFMD and herpangina are common clinical 
syndromes of EV-A71 infection, but they are usually mild and self-limiting. HFMD can 
be caused by other enteroviruses such as coxsackievirus (CV) A5, A10, A16 and 
echovirus 7. However, unlike these enteroviruses, EV-A71 infections are more 
commonly associated with neurological complications such as aseptic meningitis, acute 
flaccid paralysis and brainstem encephalitis (McMinn, 2002). Table 2.3 summarizes 
various neurological syndromes associated with EV-A71 infection. Similar to 
poliomyelitis EV-A71 infection can also present as severe cardiorespiratory symptoms, 
due to neurogenic cardiac failure and pulmonary edema (Chang et al., 1999). Several 
epidemics have occurred in Sarawak, and approximately 10-30% of children 
hospitalized with EV-A71-related HFMD also developed central nervous system 
complications, which were not present in children with CV-A16 infections (Ooi et al., 
2007).   
EV-A71-infected patients with aseptic meningitis generally have a complete recovery. 
However, patients with acute flaccid paralysis frequently have permanent weakness or 
paralysis (McMinn et al., 1999). Radiological and histopathological evidence suggests 
that acute flaccid paralysis occurs when EV-A71 establishes a lytic infection in anterior 
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horn motor neurons of the spinal cord, similar to the pathogenesis of poliomyelitis 
(Shen et al., 2000; Wong et al., 2008; Li et al., 2012). Brainstem encephalitis is the 
most severe neurological complications of EV-A71 infections. Extensive inflammation 
develops in the hypothalamus, brainstem, spinal cord and cerebellar dentate nucleus 
(Lum et al., 1998b; Huang et al., 1999; Wang et al., 1999). The onset of brainstem 
encephalitis is characterized by rapidly progressive cardio-respiratory failure, which 
leads to shock and pulmonary edema or hemorrhage with death (Lum et al., 1998a). 
Children occasionally recover fully from brainstem encephalitis, but may have 
permanent neurological sequelae with delayed neurodevelopment and reduced cognitive 
function (Huang et al., 2006; Chang et al., 2007).  
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Table 2.3: Neurological syndromes associated with EV-A71 infection 
Neurological manifestations 
Encephalitis 
Acute flaccid paralysis 
Encephalomyelitis 
Aseptic meningitis 
Cerebellar ataxia 
Transverse myelitis 
Neurological and systemic manifestations 
Brainstem encephalitis with cardiorespiratory failure 
Manifestations indicative of immune-mediated mechanisms  
Guillain-Barré syndrome 
Opsoclonus-myoclonus syndrome 
Benign intracranial hypertension 
Modified from Ooi et al. (2010). 
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2.1.6 Development of therapeutics against enterovirus A71 infection 
To date, no antiviral agents are currently licensed for clinical use. The only treatment 
option for EV-A71-infected patients is symptomatic relief. A number of antiviral agents 
have been developed to target different EV-A71 life cycles, including viral attachment, 
entry, uncoating, RNA translation, polyprotein processing, RNA replication and virus 
maturation. However, only a few of these antiviral agents are currently in clinical trials. 
Figure 2.5 summarizes all the antiviral agents discussed in this section.   
2.1.6.1 Therapeutics targeting viral attachment and entry  
Virus-host receptor interaction is the first essential event during virus infection. The 
ability to recognize and bind to specific receptors determines host range and tissue 
tropism (Haywood, 1994). Since virus-host receptor interactions are the first event 
during infection, inhibitors that block this event could act as potential therapeutics. The 
soluble form of cellular receptors could act as molecular decoys of cell-associated 
receptors. Soluble SCARB2, PSGL-1, sialic acid and heparin or heparin mimetics 
exhibit inhibitory effects against EV-A71 infection in vitro (Nishimura et al., 2009; 
Yamayoshi et al., 2009; Yang et al., 2009; Pourianfar et al., 2012). Highly sulfated 
suramin and its analog, NF449, exhibited antiviral activity against EV-A71 infection 
(Arita et al., 2008b; Wang et al., 2013b). NF449-resistant mutants consist of two 
mutations in VP1, E98Q and K244R, implying that NF449 inhibited EV-A71 infection 
by binding to the VP1 protein (Arita et al., 2008b). Similarly, kappa carrageenan, a 
sulfated polysaccharide from seaweed, also exhibited significant antiviral activity 
through targeting EV-A71 attachment and entry (Chiu et al., 2012). The possible 
mechanism of these soluble decoys is through disruption of the integrity of the EV-A71 
capsid structure or steric hindrance of receptor interactions.  
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Receptor antagonists could also be developed as potential antiviral agents. An 
antimicrobial peptide, lactoferrin, also exhibited anti-EV-A71 properties in vitro and in 
vivo through blocking viral attachment to the cell surface (Lin et al., 2002; Weng et al., 
2005; Chen et al., 2008a).  
2.1.6.2 Therapeutics targeting viral uncoating  
Uncoating inhibitors (pocket binders) have been intensively studied as antiviral agents 
against many picornaviruses, including rhinovirus (Fox et al., 1986), PV (Fox et al., 
1986), echovirus (McKinlay et al., 1986) and coxsackievirus (See and Tilles, 1992). 
The complex of WIN51711 with the EV-A71 hydrophobic pocket underneath the 
canyon depression has recently been resolved by X-ray crystallography (Plevka et al., 
2013). The key success factor of these uncoating inhibitors is their ability to fit into the 
VP1 hydrophobic pocket, stabilize the capsid structure, and therefore block the 
receptor-induced uncoating mechanism (Plevka et al., 2013).  
A series of modified WIN compounds including BPROZ-194, BPROZ-112, BPROZ-
284, BPROZ-103, BPROZ-299, BPROZ-101, BPROZ-033, and BPROZ-074 were 
effective against EV-A71 infection with IC50 values ranging from 0.8 nM to 1550 nM 
(Shia et al., 2002; Chern et al., 2004; Shih et al., 2004a; Shih et al., 2004b; Chang et al., 
2005; Chen et al., 2008b). However, a single point mutation in VP1 V192M was 
sufficient to confer resistance to BPROZ-194 (Shih et al., 2004b). Other than modified 
WIN compounds, the broad spectrum enterovirus inhibitor pleconaril also inhibited EV-
A71 infection in vitro and in vivo (Pevear et al., 1999; Zhang et al., 2012). However, 
pleconaril failed to inhibit the cytopathic effect (CPE) induced by a Taiwan 1998 EV-
A71 isolate (Shia et al., 2002). Another group of capsid binders, pyridazinyl oxime 
ethers chemically derived from pirodavir such as BTA39 and BTA188, significantly 
inhibited EV-A71 infection (Barnard et al., 2004). Crystallographic studies showed the 
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pirodavir predecessor R61837 complexed with rhinovirus 14 by binding to the 
hydrophobic pocket underneath the canyon floor, similar to the mechanism of WIN 
compounds (Chapman et al., 1991). 4’,6-Dichloroflavan (BW683C), previously 
identified as an anti-rhinovirus compound, was also effective against EV-A71 infection 
(Genovese et al., 1995; Conti et al., 1998). Mechanistic studies demonstrated that 
BW683C binds to and stabilizes rhinovirus against heat or acid inactivation, implying 
that BW682C acts as a viral uncoating inhibitor (Bauer et al., 1981; Tisdale and Selway, 
1983; Tisdale and Selway, 1984).  
2.1.6.3 Therapeutics targeting viral RNA translation 
The antisense-mediated mechanism consists of oligonucleotides (8-50 nucleotides in 
length) that bind to RNA through Watson-Crick base pairing and modulate the function 
of the targeted RNA (Kole et al., 2012). RNA interference (RNAi) involves the 
cleavage of targeted mRNA through the RNA-induced silencing complex. Small 
interfering RNA (siRNA) targeting highly conserved regions of 5’UTR (Deng et al., 
2012), VP1, VP2 (Wu et al., 2009), 2C, 3C, 3D (Sim et al., 2005; Tan et al., 2007b), 
and 3’UTR (Sim et al., 2005) significantly inhibited EV-A71 infection in a dose-
dependent manner. In addition, short hairpin RNA (shRNA) was effective against EV-
A71 infection in vitro and in vivo (Lu et al., 2004; Tan et al., 2007a; Tan et al., 2007b). 
The use of siRNA in clinical settings is hampered by its short half-life in plasma. 
Improved siRNA with 2’O methylation and 2’ fluoro modifications have recently been 
demonstrated against EV-A71 infection (Deng et al., 2012). However, siRNA also has 
poor endosomal uptake which limits the clinical application of these siRNAs. Other 
translation-suppressing nucleotides, for example, PPMO, showed promising results in 
inhibiting PV and CV-B3 (Yuan et al., 2006; Stone et al., 2008). Unlike siRNA or 
shRNA, PPMO interacts with targeted RNA, especially the IRES region, and blocks 
 32 
ribosome recruitment and therefore inhibits viral translation (Kole et al., 2012). PPMO 
readily penetrates the cells and is resistant to nuclease degradation.  
Compounds that down-regulate the activity of IRES-dependent translation could 
potentially be developed into antiviral agents. Quinacrine, which impairs IRES-
dependent translation by preventing the interaction between polypyrimidine-tract 
binding protein and IRES, has been demonstrated to act against EV-A71 infection 
(Wang et al., 2013a). Kaempferol, a flavonoid, was found to inhibit EV-A71 IRES 
activity by altering the composition of ITAFs (Tsai et al., 2011). Geniposide derived 
from Fructus gardeniae inhibited EV-A71 replication via inhibition of viral IRES 
activity (Lin et al., 2013b). Amantadine, a tricyclic symmetric amine previously used 
against influenza A virus infection, was found to suppress EV-A71 IRES-dependent 
translation (Davies et al., 1965; Hoffmann et al., 1965; Chen et al., 2008c). 
2.1.6.4 Therapeutics targeting viral polyprotein processing 
Since EV-A71 2A and 3C proteases are involved in multiple roles in EV-A71 infection 
and evasion of host innate immunity, they are important targets for development of 
antiviral therapeutics. A pseudosubstrate, LVLQTM peptide, could inhibit EV-A71 
infection through binding to the active site of 2A protease (Falah et al., 2012). 
Rupintrivir (AG7088) is an irreversible peptidomimetic inhibitor of human rhinovirus 
3C protease which has reached phase 2 clinical trials with promising outcomes (Patick 
et al., 1999; Witherell, 2000; Binford et al., 2005; Patick, 2006; Binford et al., 2007). 
Rupintrivir showed significant inhibition of EV-A71 infection in vitro and in vivo but 
with reduced efficacy as compared with human rhinoviruses (Zhang et al., 2010a; Hung 
et al., 2011; Lu et al., 2011; Zhang et al., 2013). X-ray crystallography of the complex 
of EV-A71 3C protease with rupintrivir revealed that the half-closed S2 sub-site and the 
size reduced S1’ pocket of EV-A71 3C protease limits the access of the rupintrivir’s P1’ 
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group which contains a lactam ring (Wang et al., 2011).  A series of 3C protease 
rupintrivir analogues were designed based on AG7088, with an aldehyde replacement of 
the α,β-unsaturated ester. Compound 10b significantly inhibited EV-A71 infection (Kuo 
et al., 2008). An orally bioavailable 3C protease inhibitor, designated as compound 1, 
also exhibited antiviral activities against multiple rhinovirus serotypes and enteroviruses 
in vitro (Patick et al., 2005). Flavonoids such as fisetin and rutin, have also been 
identified as EV-A71 3C protease inhibitors (Lin et al., 2012a). 
2.1.6.5 Therapeutics targeting viral genomic RNA replication 
Viral non-structural proteins such as 2C, 3A and RdRP play important roles in viral 
replication. Hence, inhibitors that inactivate viral replication proteins or interrupt virus 
protein-host protein interactions could potentially be developed as effective antiviral 
agents.  
Picornavirus 2C protein possesses nucleoside triphosphatase activity and is involved in 
the synthesis of the viral negative strand RNA and encapsidation of progeny virions in 
PV. Metrifudil (N-[2-methylphenyl]methyl-adenosine) and N
6
 benzyladenosine, both 
adenosine receptor agonists, were reported to have inhibitory effects against EV-A71 
infection with IC50 values of 1.3 µM and 0.1 µM, respectively. EV-A71 2C protein with 
a single mutation E325G or double mutations H118Y and I324M were resistant to 
metrifudil and N
6
 benzyladenosine, respectively (Arita et al., 2008b). Guanidine 
hydrochloride is one of the most extensively studied picornavirus inhibitors (Caliguiri 
and Tamm, 1968a; Caliguiri and Tamm, 1968b). This inhibitor blocks the replication of 
PVs (Rightsel et al., 1961; Loddo et al., 1962), coxsackieviruses (Herrmann et al., 
1982), echoviruses, and FMDV (Saunders et al., 1985). Interestingly, guanidine 
hydrochloride also inhibited EV-A71 infection and analysis of guanidine-resistant 
mutants revealed that a single mutation at the 2C protein (M193L) was sufficient to 
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confer resistance (Sadeghipour et al., 2012). The non-structural protein 2C was 
identified as the guanidine hydrochloride target, hence guanidine was likely to prevent 
the association of 2C/2BC with host membrane structures during viral replication 
(Bienz et al., 1990). 
Picornavirus 3A protein has been shown to modulate the host cell’s intracellular 
membrane transport. Protein 3AB, the precursor form of 3A, has RNA-binding 
properties and stimulates the cleavage of 3CD protease and the activity of RdRP in PV. 
Enviroxime is an anti-enterovirus compound that targets viral proteins 3A and 3AB and 
suppresses the replication of enterovirus by an unknown mechanism. Recently, 
phosphatidylinositol 4-kinase III beta (PI4KIIIβ) was identified as a target of 
enviroxime-like compounds (T-00127-HEV1 and GW5074) for anti-PV activity (Arita 
et al., 2011), and  by anti-enterovirus compounds including PI4KIIIβ inhibitor, PIK93 
(Hsu et al., 2010). Enviroxime is reported to have strong antiviral effects against EV-
A71 with an IC50 of 0.15 µM (de Palma et al., 2008). A functional analog of enviroxime, 
GW5074 (3-3,5-dibromo-4-hydroxybenzylidine-5-iodo-1,3-dihydro-indol-2-one), is a 
Raf-1 inhibitor and inhibited EV-A71 infections with an IC50 of 2.0 µM. GW5074-
resistant mutants carried similar mutations at 3A protein as enviroxime-resistant 
mutants (Arita et al., 2008b; Arita et al., 2009). The enviroxime mimetic compound 
AN-12-H5 was found to have strong inhibitory activity against EV-A71 and PV 
infections. However, AN-12-H5-resistant mutants carried mutations on the viral capsid 
protein (VP1 A224T and VP3 R227K). The authors suggested that AN-12-H5 could act 
as a bifunctional inhibitor targeting EV-A71 replication and an early stage of infection 
after the binding step (Arita et al., 2010). Interestingly, a recent study of an siRNA 
sensitization assay targeting PI4Kβ-related genes has identified oxysterol-binding 
protein (OSBP) as a target of AN-12-H5 (Arita et al., 2013). A compound designated as 
compound 1, 2-fluoro-4-(-methyl-8-(3-(methylsulfony)benzylamino)imidazo[1,2-
 35 
a]pyrazin-3-yl)phenol, was found to exhibit broad-spectrum antiviral activity against 
multiple enteroviruses with IC50 ranging between 4 to 71 nM. Resistant mutant analysis 
revealed substitutions in the 3A protein at the position which interacts with PI4KIIIβ 
(van der Schaar, et al., 2013).  
Picornavirus RdRP is involved in incorporation of nucleotides during the synthesis of 
negative and positive viral RNA strands and other activities such as uridylation of VPg 
during RNA replication. DTriP-22 (4-1-phenyl-1H-pyr-azolo [3,4-d]pyrimidine) is a 
novel class of compounds with anti-EV-A71 activity with IC50 values of 0.15 – 0.98 µM 
against EV-A71 strains from all genotypes. DTriP-22-resistant mutants showed 
mutations in the RdRP implying that DTriP-22 interacts with RdRP and inhibits poly (U) 
elongation activity, but not VPg uridylylation activity (Chen et al., 2009).   
Unlike DNA polymerase, RdRP lacks 3’ 5’ proofreading ability. Ribavirin (1-β-D-
ribofuranosyl-1,2,4-triazole-3-carboxyamine) is an antiviral compound used in the 
treatment of infections with HCV and respiratory syncytial viruses. Ribavirin causes 
transition mutations because of its ability to pair with both uracil and cytosine. Thus, 
ribavirin exerts its antiviral activity by increasing the “error rate” of viral genome 
replication past the point of “error catastrophe” whereby the fitness of all members of 
the viral population is reduced (Airaksinen et al., 2003). Ribavirin inhibited EV-A71 
infection with IC50 of 266 µM and prevented EV-A71-induced paralysis and death in 
mice (Li et al., 2008).  
2.1.6.6 Other antiviral agents 
The type 1 interferon (IFNs) system responds to viral infection and triggers first line 
antiviral defenses in cells (Basler and Garcia-Sastre, 2002). Type I IFNs including IFN-
α4, IFN-α6, IFN-α14 and IFN-α16, provide a protective effect in EV-A71-infected 
human cell lines and mice (Liu et al., 2005; Yi et al., 2011). However, EV-A71 2A 
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protease has been shown to play a crucial role in antagonizing the IFN response, which 
limits the IFN clinical application for treatment of EV-A71 infection (Lu et al., 2012).  
Chloroquine (4-aminoquinoline) is an anti-malarial agent in clinical use. The antiviral 
property of chloroquine has been demonstrated against HIV infection, through 
prevention of glycosylation of the viral envelope protein gp120 occurring in the Golgi 
apparatus (Savarino et al., 2001a; Savarino et al., 2001b; Savarino et al., 2004; Savarino, 
2011). Interestingly, treatment of EV-A71-infected human glioblastoma cells with 
chloroquine significantly prevented viral-induced apoptosis and resulted in more than a 
100-fold reduction of EV-A71 RNA synthesis at 1.2 µM (Shih et al., 2008).  
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Figure 2.5: Schematic illustration of EV-A71 intracellular infection and summary of  
the antiviral agents classified according to the mechanisms of action, 
which include molecular decoys, receptor antagonists, uncoating 
inhibitors, translation inhibitors, polyprotein processing inhibitors and 
replication inhibitors.  
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2.2 Antiviral drug discovery 
2.2.1 Antiviral peptides as therapeutics 
2.2.1.1 Therapeutic peptides – an overview 
Natural and synthetic peptides are promising pharmaceutics with the potential to treat a 
wide variety of diseases. Peptides are usually composed of up to 50 amino acids that are 
covalently linked by amide bonds between the amino group of one amino acid and the 
carboxyl group of another amino acid. Because of their regulatory role and extreme 
diversity coupled with highly specificity of molecular recognition, peptides are also 
attractive tools in drug discovery and are making their way into clinical applications. 
Due to the selective nature and efficacy of the peptide-target interaction, only low 
concentrations of the peptides are sufficient. The metabolism of peptides is superior to 
small chemical molecules due to the limited possibility for accumulation and relative 
non-toxicity to the host. These properties contribute towards a minimal risk of adverse 
effects. The peptide-based drugs can be receptor agonists or antagonists derived from 
natural peptides, as well as pathogen proteins. However, the potential of peptides as 
therapeutics is often hampered by the inability of the peptides to reach the targeted site 
in its active form in vivo, due to inadequacy of absorption through the mucosa and rapid 
degradation by proteolytic enzymes (Goodwin et al., 2012).  
The most important classes of therapeutic peptides that have been investigated include 
insulin, hormone analogs and antimicrobial peptides. Antimicrobial peptides are 
typically relatively short with a positive charge (net charge of +2 to +9) and are 
amphiphilic. To date, hundreds of antimicrobial peptides have been identified. Many 
antimicrobial peptides are derived from single-cell microorganisms, insects and other 
invertebrates, plants, amphibians, birds, fishes and mammals including humans (Wang 
and Wang, 2004). Examples of these antimicrobial peptides are human β-defensin-2, 
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human lactoferricin, cathelicidin (LL-37) and protegrin (Jenssen et al., 2004b; Jenssen 
et al., 2006).  
2.2.1.2 Antiviral applications of therapeutic peptides 
Peptides that can block viral attachment or entry into host cells have therapeutic 
potential. Enfuvirtide (Fuzeon, Roche) is the first peptide-based inhibitor of viral fusion 
approved by the FDA in March 2003 for clinical use. Enfuvirtide is a 36 amino acid 
peptide derived from the HR2 sequence of the transmembrane protein gp41 of HIV-1.  
It interacts with the CD4
+
 T-cell receptor and inhibits 6-helix bundle formation required 
for fusion of viral and cellular membranes. Enfuvirtide is used in combination with 
other antiretroviral agents in the treatment of patients with resistant HIV (Wild et al., 
1994; Kilby et al., 1998). Due to its low bioavailability, short plasma half-life 
(approximately 2 hours) and easily induced drug resistance, second and third generation 
peptide-based fusion inhibitors were developed (Ruxrungtham et al., 2004; Zhang et al., 
2004). Sifuvirtide was designed to overcome the limitation of enfuvirtide, with a stable 
secondary structure of the α-helix structure, and increased the plasma half-life up to 22 
hours (Wang et al., 2009). To overcome acquired resistance to enfuvirtide, Dwyer et al. 
(2007) synthesized a series of C-peptides with enhanced helical structures, from T2410 
to T2635. T2635 was 3,600-fold more active than enfuvirtide and did not generate 
resistant virus even after more than 70 days in culture (Dwyer et al., 2007). Another 
anti-HIV peptide was designed according to the α-helical region of the C-terminal 
domain of HIV-1 capsid, which acts as a molecular decoy to prevent C-terminal domain 
dimer formation. The α-helical structure of the peptide was stabilized using 
hydrocarbon stapling technique. In vitro assembly assays revealed that the peptide 
inhibited mature-like virus particle formation and specifically inhibited HIV-1 
production in cell-based analysis (Zhang et al., 2011).  
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An amphipathic 18-mer α-helical peptide (C5A) derived from the membrane anchor 
domain of the HCV NS5A protein was found to be virucidal for HCV and other 
flaviviruses, paramyxoviruses and HIV by destabilizing viral membranes (Cheng et al., 
2008). Structure activity analysis suggested that C5A permeabilizes viral liposome 
membranes and leads to release of viral capsids, and exposes the viral genome to 
nuclease degradation (Cheng et al., 2008). Screening of overlapping peptides covering 
the HCV E1E2 envelope proteins led to identification of a 16-mer peptide (peptide 75) 
that exhibited antiviral activities against HCV infection with an IC50 of 0.3 µM. 
Temperature shift experiments suggested that peptide 75 inhibited HCV at the post-
binding step (Liu et al., 2010).  
A few anti-flavivirus peptides were identified using physio-chemical algorithms and in 
combination with the Wimley-White interfacial hydrophobicity scale. One of them is 
DN59, a peptide corresponding to the stem domain of DENV that inhibits DENV and 
West Nile virus (WNV) at low micromolar concentrations (Hrobowski et al., 2005). 
Screening of a phage display library derived from murine brain cDNA against WNV 
envelope protein led to identification of a peptide, designated as peptide 9, that 
exhibited antiviral activity against WNV and DENV in vitro. Mice challenged with 
WNV that had been pre-incubated with peptide 9 had reduced viremia and fatality (Bai 
et al., 2007).  
A 21-mer synthetic peptide derived from the pre-S1 surface protein of HBV exhibited 
antiviral activity against HBV at picomolar concentrations. The IC50 reported was 
approximately 20 nM. This peptide is believed to interact with the hepatocyte receptor 
and therefore blocks HBV binding (Kim et al., 2008). Another study by Zheng et al. 
(2005) identified four 20-mer synthetic peptides derived from the severe acute 
respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) S protein with 
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significant antiviral activity against SARS-CoV infection. Pre-incubation with the P8 
peptide resulted in over 10,000-fold reduction of SARS-CoV infectivity.  
Peptide 6 derived from the Zn
2+
 finger region of the M1 sequence of influenza virus 
strain A/PR/8/34 centered around amino acids residues 148 to 166 was shown to 
significantly inhibit multiple influenza viruses at concentrations as low as 0.1 nM. The 
peptide 6 inhibited influenza viruses infection by inhibiting polymerase activity (Nasser 
et al., 1996). EB peptide, a 20-mer peptide derived from fibroblast growth factor 4, 
exhibited significant antiviral activity against influenza viruses including the highly 
pathogenic H5N1. EB peptide binds to the viral hemagglutinin protein and therefore 
inhibits viral attachment to the cellular receptor. In vivo studies demonstrated that pre-
treatment of HK/156 virus with 2 mM EB peptide resulted in 100% survival of infected 
mice (Jones et al., 2006; Jones et al., 2011). Interestingly, EB peptide also exhibited 
antiviral activity against multiple viruses including herpes simplex virus type 1 (HSV-1), 
vaccinia virus, and poxviruses (Bultmann et al., 2001; Altmann et al., 2009; Altmann et 
al., 2012). 
Screening of 138 15-mer peptides covering the ectodomain of the HSV-1 glycoprotein 
B (gB) identified three peptides (gB94, gB122 and gB131) with 50% effective 
concentration (EC50) below 20 µM. Studies revealed that gB131 is an entry inhibitor, 
and gB122 inhibits HSV-1 entry and also causes viral inactivation. The viral 
inactivation activity was probably a result of either premature triggering or inhibition of 
conformational change in the gB-1 molecule required for entry. The gB122 or gB131 
may be acting by blocking a protein-protein interaction, in particular, inhibiting gB 
binding to paired immunoglobulin-like type 2 receptor-alpha, gD or gH-gL 
(Akkarawongsa et al., 2009). Interestingly, highly cationic α-helical peptides that 
interact with heparan sulfate significantly inhibited HSV-1 and HSV-2 infection. These 
peptides blocked HSV attachment to the cell surface heparan sulfate. Increasing the net 
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positive charge of the peptides significantly increased the antiviral activities against 
HSV-1 infection (Jenssen et al., 2004a). A recent study by Tiwari et al. (2011) 
identified two anti-heparan sulfate peptides, G1 and G2 that exhibited significant anti-
HSV-1 activities. These peptides were isolated through phage display peptide library 
screening by using heparan sulfate as the target. G2 peptide exhibited broad spectrum 
antiviral activity, as well as inhibitory activity in vivo (Tiwari et al., 2011).  
2.2.2 Antisense-mediated morpholino oligomers as therapeutics 
2.2.2.1 Antisense-mediated mechanism – an overview 
The use of a synthetic oligonucleotide to inhibit pathogen replication through an 
antisense-mediated mechanism was first reported by Zamecnik and Stephenson (1978), 
using a tridecamer oligodeoxyribonucleotide complementary to Rous sarcoma virus 
RNA to inhibit production of virus in chick embryo fibroblast cells. The 
oligodeoxyribonucloetide likely hybridized with the viral RNA and blocked viral 
protein translation (Zamecnik and Stephenson, 1978). However, unmodified 
oligodeoxynucleotides are highly susceptible to degradation by endogenous nucleases. 
Phosphorothioate oligonucleotides (PTOs) were the first oligonucleotide analog 
derivatives developed to resist nuclease degradation. The only antisense drug that has 
received approval from FDA for therapeutic application is fomivirsen, a 21-nucleotide 
PTO antisense drug for intravitreal treatment of cytomegalovirus retinitis in AIDS 
patients (de Smet et al., 1999; Perry and Balfour, 1999).  
In general, antisense-mediated mechanisms can be divided into two categories, targeting 
RNA cleavage and non-cleavage (Bennett and Swayze, 2010). RNA interference (RNAi) 
and antisense gapmer oligonucleotides target RNA cleavage while translation-
suppressing oligonucleotides do not (Kole et al., 2012). RNAi is a form of post-
transcriptional gene silencing.  
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Small interferencing RNAs (siRNA) are short synthetic double stranded RNAs of 21-22 
nucleotide length, which interact with a multi-protein RNA-induced silencing complex 
(RISC) and hybridize to the targeted mRNA, subsequently leading to mRNA 
degradation by nucleases. In contrast, antisense gapmer oligonucleotides are modified 
single-stranded DNA that bind to complementary mRNA by base pairing and induce 
cleavage of targeted mRNA by ribonuclease H (Kole et al., 2012). Translation-
suppressing oligonucleotides are oligonucleotides that pair with mRNA sequences near 
the translation initiation site and block binding of ribosomes to mRNA, thereby 
inhibiting translation of the undesirable proteins. Translation-suppressing 
oligonucleotide-mRNA duplexes are recognized by neither ribonuclease H nor RISC, 
therefore the mRNA is not cleaved (Kole et al., 2012). The major limitations of these 
translation-suppressing oligonucleotides include the low knock-down efficacies and off-
target effects. 
2.2.2.2 Phosphorodiamidate morpholino oligomers 
Phosphorodiamidate morpholino oligomers (PMOs) are steric-blocking translation-
suppressing oligonucleotides which bind to RNA and block RNA translation. In PMOs, 
the deoxyribose rings of DNA are replaced with 6-membered morpholine rings, and the 
phosphodiester linkages are replaced with phosphorodiamidate linkages. PMOs have no 
electrical charge, do not interact strongly with proteins, and do not require the activity 
of RNase-H for their activities (Summerton and Weller, 1997; Summerton, 1999). Like 
siRNA antisense molecules, PMOs do not readily cross cell membranes without 
delivery techniques, which have prevented their efficacious use in animals. Although 
the unmodified PMOs are endocytosed, uptake by endocytosis does not mean the PMOs 
reach the cytoplasm or nucleus of the cell. The PMOs are retained within endosomes 
with few PMOs escaping from the endosomes to the cytosol or nuclear compartment 
(Partridge et al., 1996). With the recent identification of cell-penetrating peptide 
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sequences, PMOs can be easily taken up into cells if conjugated with cell-penetrating 
peptides. This technology is known as peptide-linked PMOs (PPMOs) (Abes et al., 
2006; Abes et al., 2008).  
In PPMOs, the PMO is covalently linked with arginine-rich cell-penetrating peptides, 
which include (RXR)4B-, (RXR)4XB-, (RXRRBR)2XB- and (RX)8B-, with R 
representing arginine, B representing β-alanine, and X representing 6-aminohexanoic 
acid (Abes et al., 2006, Moulton and Jiang, 2009). PPMOs are taken up by endocytosis 
and a fraction of endocytosed PPMOs escape from the endosome, entering the cytosol 
and nuclear compartment where they can block mRNA translation. Besides PPMOs, 
vivo-morpholino oligomers (vivo-MOs) are antisense PMO that are covalently linked to 
a molecular scaffold, a guanidium group at each of its eight tips. Vivo-MOs have been 
effective in mice, rats, adult zebrafish and various organ explants (Moulton and Jiang, 
2009). A schematic illustration of vivo-MOs and PPMOs is shown in Figure 2.6. 
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Figure 2.6: Molecular structures of morpholino oligomers: (A) Phosphorodiamidate 
morpholino oligomer (PMO), (B) octaguanidinium-conjugated 
morpholino oligomer (vivo-MO) and (C) 5’ cell-penetrating peptide-
conjugated phosphorodiamidate morpholino oligomer (PPMO). This 
figure was adapted with modifications from Moulton and Jiang (2009). 
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2.2.2.3 Antiviral applications of morpholino oligomers 
In recent years, PPMOs and vivo-MOs have been shown to be effective antiviral 
therapeutics. PPMOs are found to inhibit various viruses in vitro and in vivo, including 
DENV (Kinney et al., 2005; Holden et al., 2006; Stein et al., 2008), Ebola virus 
(Enterlein et al., 2006; Warfield et al., 2006; Swenson et al., 2009), influenza virus (Ge 
et al., 2006; Gabriel et al., 2008; Lupfer et al., 2008; Bottcher-Friebertshauser et al., 
2011), coronavirus (Neuman et al., 2004; Neuman et al., 2005; Burrer et al., 2007; 
Moulton et al., 2007), PV (Stone et al., 2008), FMDV (Vagnozzi et al., 2007), CV-B3 
(Yuan et al., 2006) and rhinovirus (Stone et al., 2008). These PPMOs are designed as 
antisense drugs against positive-sense viruses, often targeting the viral mRNA sequence 
involved in one or more of the major early events in viral translation.  
Antisense-mediated PPMOs targeting several positive-sense picornaviruses have been 
demonstrated recently. PPMOs targeting type I IRES picornaviruses, including PV, 
rhinovirus, CV-B2, and CV-B3 IRES stem-loop structures IV-VI caused significant 
inhibition of viral infection in tissue culture as well as in animal models (Yuan et al., 
2006; Stone et al., 2008). In contrast to type I IRES picornaviruses, only PPMOs 
targeting the AUG start site, but not IRES structure of type II IRES picornaviruses 
including FMDV, exhibited significant antiviral properties (Vagnozzi et al., 2007). The 
antisense PPMOs are known to complement the RNA target, either preventing the 48S 
ribosome formation or disrupting the integrity of the RNA structures required for 
translation initiation. Viruses acquired resistance to the PPMOs after serial passage in 
the presence of the PPMOs. Sequence analysis of the mutant viruses revealed a single 
mutation was sufficient to confer PPMO resistance (Vagnozzi et al., 2007; Stone et al., 
2008).  
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Antisense-mediated PPMOs have also been developed for flaviviruses. PPMOs 
targeting the DENV 5’UTR stem-loop, 3’UTR cyclization sequence and 3’UTR stem-
loop inhibited DENV replication, presumably by blocking critical RNA-RNA or RNA-
protein interactions involved in viral translation and replication (Holden et al., 2006). In 
a different study, PPMOs targeting the DENV 3’UTR cyclization sequences exhibited 
broad-spectrum antiviral activity against DENV serotypes 1-4 (Kinney et al., 2005). 
PPMOs targeting the DENV AUG translation start site region have moderate efficacies 
when compared to those targeting the 5’UTR stem loop or 3’UTR cyclization sequences 
(Kinney et al., 2005). Both PPMOs targeting the 5’UTR stem-loop and 3’UTR 
cyclization sequences of DENV-2 increased the average survival time of up to 8 days in 
DENV-2-infected AG129 mice (Stein et al., 2008). PPMOs targeting the 5’ end, the 
AUG translation start site region, 5’UTR stem-loop and 3’UTR cyclization sequence 
were found to inhibit WNV infection in BHK-21 cells (Deas et al., 2007). PPMO 
targeting Japanese encephalitis virus 3’UTR cyclization sequence exhibited significant 
antiviral activity in tissue culture and mice (Anantpadma et al., 2010). 
The inhibitory effects of PPMOs against multiple influenza viruses in vitro and in vivo 
have been demonstrated. The (RXR)4XB-conjugated PMOs targeting the start site of 
viral polymerase subunit PB1 mRNA and the 3’ end of the NP virion RNA significantly 
inhibited viral replication in Balb/c mice when administered through the intranasal route 
(Gabriel et al., 2008). The PPMO targeting these two regions also inhibited many 
influenza A virus subtypes, including H1N1, H3N2, H3N8, H7N7 and highly 
pathogenic H5N1 (Ge et al., 2006).  
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2.3 Glycosaminoglycans as virus receptors 
2.3.1 Heparan sulfate glycosaminoglycan – an overview 
Heparin and heparan sulfate are structurally the most complex members of the 
glycosaminoglycan (GAG) family. Heparin and heparan sulfate are linear 
polysaccharides that are composed of repeating units of uronic acid (D-glucuronic acid 
and L-iduronic acid) and D-glucosamine (Kjellen et al., 1980; Kjellen and Lindahl, 
1991). Heparin is mainly present in mast cells while heparan sulfate exists in all cell 
types. Both are predominantly present on the cell surface and in the extracellular matrix 
(ECM) in the form of proteoglycans. Heparin is highly sulfated whereas heparan sulfate 
is a low-sulfated chain. Heparan sulfate is negatively-charged through sulfate groups in 
different positions.  
The heparan sulfate chains rarely occur as free entities but are attached to various core 
proteins. The heparan sulfate-protein conjugate is known as heparan sulfate 
proteoglycan. There are two major subfamilies of plasma membrane-bound heparan 
sulfate proteoglycans, syndecans and glypicans (Bernfield et al., 1999). Heparan sulfate 
is structurally diverse in different cell types. The diversities arise from the disaccharide 
composition which differs by the presence of variably sulfated or non-sulfated uronic 
acid and D-glucosamine. Endothelial cells and connective tissue mast cells are rich in 
D-glucuronic acid-D-glucosamine while kidney is rich in L-iduronic acid-D-
glucosamine (Edge and Spiro, 1990; Bourin and Lindahl, 1993; Rosenberg et al., 1997).  
The biosynthesis of heparan sulfate involves three basic steps: chain initiation, 
polymerization and modification (Figure 2.7). During chain initiation, linkage 
tetrasaccharides are assembled on the serine residues in the core protein. After addition 
of an N-acetylglucosamine residue, polymerization takes place by alternate addition of 
glucuronic acid and N-acetylglucosamine residues. As the chain grows, modifying 
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enzymes introduce sulfate groups at various positions, and some of the glucuronic acid 
residues are converted into iduronic acid. Glucosaminyl N-deacetylase/N-
sulfotransferase (NDST) is the first modifying enzyme that replaces the acetyl group in 
N-acetylglucosamine residues with a sulfate group. Other modifying enzymes include 
2-O-sulfotransferase, 6-O-sulfotransferase and 3-O-sulfotransferase which add 2-O-
sulfate, 6-O-sulfate and 3-O-sulfate groups, respectively. The final heparan sulfate 
biosynthesis product has a cluster of N- and O-sulfated sugar residues separated by non-
sulfated regions (Esko and Zhang, 1996; Esko and Lindahl, 2001; Forsberg and Kjellen, 
2001; Sugahara and Kitagawa, 2002).  
As a result of its diverse structures, heparan sulfate is known to interact with a wide 
variety of proteins, including growth factors, chemokines, morphogens and enzymes. 
Many signaling molecules, such as fibroblast growth factor, vascular endothelial growth 
factor, transforming growth factor-β1 and –β2 bind to cell surface heparan sulfate 
(Bernfield et al., 1999). Importantly, heparan sulfate serves as an attachment factor for 
many pathogens.  
2.3.2 Heparan sulfate as virus attachment receptors 
Heparan sulfate plays its role as a receptor through three major characteristics. First, 
heparan sulfate is a linear negatively-charged carbohydrate polymer. Most of the 
heparan sulfate interactions are mediated by electrostatic interactions between clusters 
of basic amino acids and concentrated negative charges on the sulfated heparan sulfate 
chain. Second, the domain organization of heparan sulfate places relatively flexible N-
acetyl-rich domains adjacent to relatively rigid N-sulfated domains, thus facilitating 
protein interactions with the sulfate residues. Finally, the micro-sequence diversity and 
macro-organization are cell type-specific, and do not appear to be core protein-specific, 
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presumably the result of the cell type-specific repertoires of heparan sulfate chain-
modifying enzymes (Zhu et al., 2011).  
Besides its functional roles in embryo development and homeostasis, heparan sulfate 
proteoglycans have been found to serve as receptors for a growing number of viruses 
from many different families, which include HSV (WuDunn and Spear, 1989; Mardberg 
et al., 2001; Ali et al., 2012), HPV (Giroglou et al., 2001; Bousarghin et al., 2003; 
Johnson et al., 2009), HBV (Cooper et al., 2005; Schulze et al., 2007) and HIV 
(Roderiquez et al., 1995). A summary list of the viruses that utilize cell surface heparan 
sulfate as an attachment receptor is shown in Table 2.6. 
Most of the virus-heparan sulfate binding is mediated by electrostatic interactions 
between a cluster of basic amino acids arranged in a three-dimensional array on the 
surface of the virus capsid or envelope protein, and concentrated negative charges on 
the heparan sulfate polysaccharides chain (McLeish et al., 2012). A stretch of 
positively-charged amino acids (lysine and arginine) present on the viral envelope or 
capsid protein is associated with heparan sulfate binding (Roderiquez et al., 1995; 
Mardberg et al., 2001; Knappe et al., 2007). Cardin and Weintraub (1989) identified 
two consensus motifs associated with heparan sulfate binding, XBBXBX and 
XBBBXXBBX, where B represents a basic amino acid, and X represents any amino 
acid.  
2.3.3 Heparan sulfate binding and neurovirulence 
Heparan sulfate binding has been postulated to be associated with neurovirulence of a 
number of viruses. In the case of HIV, involvement of heparan sulfate in HIV infection 
improves the efficiency of virus binding to brain microvascular endothelial cells and is 
postulated to facilitate CNS infection (Banks et al., 2004; Bobardt et al., 2004). 
Heparan sulfate-binding Sindbis virus showed low neurovirulence after subcutaneous 
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inoculation, but high neurovirulence when inoculated directly into the brain of the mice 
(Ryman et al., 2007). Highly neurovirulent Theiler’s murine encephalomyelitis virus 
(TMEV) GDVII was associated with heparan sulfate binding. A non-heparan sulfate-
binding GDVII mutant with R3126L and N1051S mutations was attenuated in mice, 
implying that heparan sulfate is associated with neurovirulence of GDVII virus (Reddi 
and Lipton, 2002; Reddi et al., 2004).  
Other than Sindbis virus, natural circulating alphaviruses eastern equine encephalitis 
virus (EEEV) was found to utilize cell surface heparan sulfate. Ablation of positive 
charge amino acids in the E2 71-77 region significantly reduced heparan sulfate binding 
and neurovirulence. The heparan sulfate binding phenotypes were associated with 
increased EEEV brain replication and neurological disease, but reduced lymphoid tissue 
replication, signs of illness and cytokine/chemokine induction in mice (Gardner et al., 
2011). 
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Figure 2.7:  Schematic illustration of heparan sulfate chain biosynthesis, modified 
from Esko and Lindahl (2001).  
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2.4 Specific aims 
As a result of the high morbidity and possible neurological complications of EV-A71 
infection, development of effective antiviral agents to counter EV-A71 infection is 
urgently needed. This study hypothesized that synthetic peptides derived from the EV-
A71 capsid protein VP1 can exhibit antiviral activity against EV-A71 attachment or 
entry, and can eventually lead to discovery of an unknown attachment or entry receptor. 
With the results of the antiviral peptide work, this study further hypothesized that cell-
surface heparan sulfate glycosaminoglycan is used by EV-A71 as an attachment 
receptor. As an alternative to the antiviral peptide, this thesis also hypothesized that 
DNA-like morpholino oligomers conjugated with cell-penetrating octaguanidinium 
dendrimer could act against EV-A71 infection. To test these hypotheses, the specific 
objectives of this study were as follows:  
i. To construct and characterize EV-A71 infectious cDNA clones with and without 
EGFP gene between the EV-A71 5’UTR and VP4 capsid gene; 
ii. To screen overlapping synthetic peptides covering the entire EV-A71 VP1 
capsid protein for antiviral peptide(s) against viral attachment during EV-A71 
infection in vitro;  
iii. To investigate and elucidate the role of cell surface heparan sulfate 
glycosaminoglycan in EV-A71 infection;  
iv. To develop antisense-mediated translation-suppressing oligomers targeting the 
EV-A71 5’UTR IRES stem-loop structure as antiviral inhibiting viral RNA 
translation; and 
v. To isolate vivo-MO-resistant EV-A71 mutants and characterize the degree of 
tolerance of mismatches by the antisense-mediated translation-suppressing 
oligomers. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Microbiology 
3.1.1 Bacterial work 
3.1.1.1 Bacterial strains and plasmids 
Bacterial strains involved in this study include E. coli TOP10 (Invitrogen, USA) (F-
mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 nupG recA1 araD139 Δ(ara-
leu)7697 galE15 galK16 rpsL(Str
R) endA1 λ-) and E. coli XL10-Gold (Agilent 
Technologies, USA) (endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac Hte Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 tetR F'[proAB lacIqZΔM15 Tn10(TetR Amy CmR)]). The 
plasmids involved in this study were pCR-XL-TOPO (Invitrogen, USA), pCR-XL-
TOPO-EV-A71, pCR-XL-TOPO-EV-A71_EGFP and pET-30a-VP1 (a gift from Dr. 
Tan Eng Lee, Singapore Polytechnic, Singapore). The restriction map of pCR-XL-
TOPO vector is shown in Figure 3.1. 
3.1.1.2 Culture and storage of bacterial cells 
Luria Bertani (LB) broth was prepared according to Miller (1972). LB broth and agar 
were autoclaved for 20 minutes at 121°C. E. coli strains with recombinant plasmids 
containing a kanamycin resistance gene were grown and maintained in LB broth or agar 
supplemented with 50 µg/ml kanamycin. E. coli on plates were stored at 4°C up to 1 
month. For long-term storage, bacterial strains were maintained in LB broth 
supplemented with 20% glycerol (v/v) and stored at -80°C. To revive the bacterial strain 
from the glycerol stock, a sterile wire loop was placed into the glycerol stock and 
aseptically streaked on the LB agar plate containing the appropriate antibiotic. The plate 
was then incubated at 37°C overnight until colonies were observed.  
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3.1.1.3 Transformation of competent Escherichia coli  
E. coli TOP10 and XL10-Gold competent cells were thawed on ice. An aliquot of 1 µl 
of β-mercaptoethanol was added into 20 µl XL10-Gold competent cells. Two 
microliters of recombinant plasmids were added to the competent cells, which were then 
incubated on ice for 30 minutes. The competent cells-plasmid mix was heated at 42°C 
for 45s and immediately placed on ice for at least 2 minutes. An aliquot of 250 µl of 
super optimal broth with catabolite repression (SOC) medium was added to the 
transformed E. coli strains and the suspension was shaken at 225 rpm for 1 hour at 37°C. 
Approximately 100 µl of transformed E. coli was spread on LB agar plate supplemented 
with 50 µg/ml kanamycin. The plate was incubated overnight at 37°C and stored at 4°C.  
Blue white screening was not necessary as the transformed bacteria without the insert of 
interest were eventually killed by the toxic product expressed by the ccdB lethal gene. 
The recombinant plasmid with the insert of interest was confirmed by both restriction 
enzyme digestion analysis and colony PCR. The confirmed colonies were then kept as 
glycerol stock for long-term storage and further downstream analysis.  
 
 
 
 
 
 
    
    57 
 
Figure 3.1: Schematic illustration of pCR-XL-TOPO and the restriction 
endonuclease recognition sites. The pCR-XL-TOPO allows cloning of  
DNA fragments of up to 11 kbp using the TA cloning method. This 
figure is adapted from pCR-XL-TOPO (Invitrogen, USA) user’s manual. 
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3.1.2 Virus work 
3.1.2.1 Virus strains  
The virus strains used in this study were EV-A71 strain 41 (GenBank accession number 
AM396587), EV-A71 prototype strain BrCr (GenBank accession number AB204852), 
EV-A71 strain UH1/PM/1997 (GenBank accession number AM396587), EV-A71 strain 
SHA66/97 (GenBank accession number AM396586), EV-A71 strain SHA52/97 
(GenBank accession number AM396584), PV vaccine strain, CV-A16 strain 22159 
(GenBank accession number JN248387), and chikungunya virus (CHIKV) strain 
MY/08/065 (GenBank accession number FN295485). EV-A71 clinical isolates with 
minimal passage history (strain names 14716, 35017, 1657640 and 1687413) were all 
obtained from the Diagnostic Virology Laboratory, University Malaya Medical Center, 
Kuala Lumpur, Malaysia. 
3.1.2.2 Virus propagation and storage 
A 75cm
2
 tissue culture flask (TPP, Switzerland) with 70-80% confluent 
rhabdomyosarcoma (RD) cells was infected with 100 µl of virus supernatant. The flask 
was incubated at room temperature for an hour and replaced with fresh Dulbecco’s 
modification Eagle medium (DMEM) supplemented with 2% fetal bovine serum (FBS). 
The flask was incubated at 37°C in 5% CO2 and observed for CPE, seen as round and 
shrunken cells which eventually dislodged from the flask surface (Lennette, 1969). The 
culture supernatants were harvested and freeze-thawed twice, then clarified to remove 
cell debris by centrifugation at 14,000 x g for 10 minutes at 4°C. The supernatants were 
then kept at -80°C until use.  
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3.1.2.3 Plaque assay 
A 24-well plate with 1.5 x 10
5
 RD cells/well or a 6-well plate with 6 x 10
5
 RD cells/well 
were prepared and incubated overnight at 37°C in 5% CO2. Prior to virus infection, the 
complete growth medium (DMEM supplemented with 10% FBS) was removed, and 
appropriate amount of serum-free DMEM was added. An aliquot of 100 µl of virus 
inoculum was added to the cells for an hour at room temperature with gentle rocking to 
allow virus attachment. After 1 hour incubation, the inocula were removed and 
immediately replaced with 500 µl and 2 ml plaque medium (DMEM supplemented with 
2% FBS and 1.2% w/v carboxylmethylcellulose) for 24-well plates and 6-well plates, 
respectively. After 48 to 72 hours incubation, the plaque medium was removed; the 
cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet. The 
plaques were visualized against a white background. The plaque forming unit per 
milliliter (PFU/ml) was calculated with the following formula:  
   PFU/ml = Number of plaques x dilution factor 
     Volume of inoculum (ml) 
3.1.2.4 Immunofluorescence assay 
Approximately 1.5 x 10
4
 cells/well were seeded in chamber slides (Lab-Tek, USA) and 
CellCarrier-96 black plates (Perkin-Elmer, USA) and incubated overnight at 37°C in     
5% CO2. EV-A71 at multiplicity of infection (MOI) of 100 was added into each well 
and incubated at 4°C for an hour to allow virus to attach. After 1 hour incubation, the 
inocula were removed and the cells were fixed with 4% formaldehyde and 
permeabilized using 0.25% Triton X-100 (Sigma, USA) for 5 minutes. The cells were 
subsequently blocked with Image-iT FX signal enhancer (Invitrogen, USA) for 1 hour. 
EV-A71 particles were immunostained with mouse anti-EV-A71 monoclonal antibodies 
(Millipore, USA) as the primary antibodies and 1:200 diluted Alexa Fluor 488 labeled 
    
    60 
anti-mouse IgG (Invitrogen, USA) as the secondary antibody for an hour at 37°C. For 
nuclear visualization, cells were treated with 0.01% 4’,6’-diamidino-2-phenylindole 
(DAPI; Sigma, USA) for 7 minutes at room temperature. Immunofluorescence was 
detected with Leica TCS SP5 confocal microscope (Leica Microsystems, Germany) and 
Nikon Eclipse TE2000-E fluorescence microscope. The CellCarrier-96 black plate 
(PerkinElmer, USA) was evaluated using Cellomics ArrayScan VTI high content 
screening reader with Spot Detector Bio-application software (Thermo Scientific, USA).  
3.2 Cell biology 
3.2.1 Mammalian cell lines 
3.2.1.1 Cell lines 
Human rhabdomyosarcoma cells (RD, ATCC # CCL-136), African green monkey 
kidney cells (Vero, ATCC # CCL-81), human colon adenocarcinoma cells (HT-29, 
ATCC # HTB-38), human cervical adenocarcinoma epithelial cells (HeLa, ATCC # 
CCL-2) and Chinese hamster ovary cells (CHO-K1, ATCC # CCL-61; CHO-pgsD677, 
ATCC # CRL-2244 and CHO-pgsA745, ATCC # CRL-2242) were used in this study. 
CHO-pgsD677 cells are deficient in N-acetylglucosaminyltransferase and 
glucuronosyltransferase activities required for heparan sulfate polymerization and thus 
completely lack heparan sulfate, but produce 3- to 4-fold higher levels of chondroitin 
sulfate than wild-type CHO-K1 (Lidholt et al., 1992). CHO-pgsA745 cells are deficient 
in the enzyme UDP-D-xylose:serine-1,3-D-xylosyltransferase which catalyzes the first 
sugar transfer reaction in GAG formation, and thus completely lack GAGs (Esko et al., 
1985), including heparan sulfate and chondroitin sulfate. 
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3.2.1.2 Propagation and maintenance 
RD and CHO-K1 cells were propagated in DMEM. HeLa and Vero cells were 
propagated in Eagle minimum essential medium (EMEM). HT-29 cells were propagated 
in McCoy’s medium. CHO-pgsD677 and CHO-pgsA745 were propagated in Kaighn’s 
modification of Ham’s F-12 (F-12K) medium. All media were supplemented with 10% 
FBS, 1% L-glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin, 
except growth media for CHO-K1 cells which require 1% sodium pyruvate. All cell 
lines were grown at 37°C in 5% CO2 until 80-90% confluency. 
To passage the cells, growth medium was removed and the cells were rinsed with      
0.12% trypsin-EDTA. An aliquot of 2 ml of 0.12% trypsin-EDTA was added to the 
cells and incubated for 5 minutes at 37°C. Upon complete detachment, an equal volume 
of complete growth medium was added to the trypsinized cells. The cell suspension was 
split with a ratio of 1:4 to 1:6 into a new 75 cm
2
 tissue culture flask and topped up with 
10 ml of complete growth medium, followed by incubation in a 37°C incubator in 5% 
CO2. 
3.2.1.3 Cell seeding 
A confluent monolayer of cells in a 75 cm
2
 tissue culture flask was rinsed with 0.12% 
trypsin-EDTA and treated with 2 ml of 0.12% trypsin-EDTA to detach the cells from 
the flask. An aliquot of cell suspension was mixed with an equal volume of 0.4% trypan 
blue solution, and the number of cells was enumerated using a hemocytometer or 
automated cell counter. The cells were added to the desired volume of complete growth 
medium in a petri dish and resuspended gently. Respective volumes of 100 µl, 500 µl, 
or 2 ml were added to each well of a 96-well plate, 24-well plate or 6-well plate. The 
plate was then incubated at 37°C in 5% CO2.  
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3.2.1.4 Cell freezing and storage 
A confluent monolayer of either RD, CHO-K1, CHO-pgsD677 and CHO-pgsA745 cells 
in 75 cm
2
 tissue culture flasks was washed with 0.12% trypsin-EDTA. The cell 
monolayer was then treated with 2 ml of trypsin-EDTA for 5 minutes at 37°C to detach 
the cells from the flask, followed by the addition of 2 ml of growth media. Then, the 
cells were pelleted through centrifugation at 150 x g for 5 minutes and the supernatant 
was discarded. The cell pellet was then resuspended gently in 2 ml of freezing media 
containing 5% DMSO (Sigma, USA) and an aliquot of 1 ml of cell suspension was 
transferred into a cryovial (Nunc, USA). The cryovial was then kept in Nalgene Mr. 
Frosty container (Nalgene, USA) at -80°C for a day and then transferred into either 
liquid or vapor phase of liquid nitrogen for long-term storage. The cooling rate of          
-1°C/minute is the optimal rate for cell preservation.  
3.2.1.5 Cell reconstitution 
When required, each cryovial of cells was retrieved from the liquid nitrogen and thawed 
immediately in a 37°C water bath. When thawed, the cell suspension was transferred 
slowly into a 25 cm
2
 culture flask containing 5 ml of pre-warmed reviving medium 
(DMEM supplemented with 20% of FBS, 1% L-glutamine, 1% NEAA and 1% 
penicillin/streptomycin) and the cells were allowed to attach onto the culture flask for 
not more than 4 hours. After 2 hours incubation at 37°C in 5% CO2, the reviving media 
was removed to eliminate the toxic effects of DMSO present in the freezing media and 
immediately replaced with fresh reviving media. The cells were allowed to grow to 
confluency and subsequently maintained in growth medium supplemented with 10% 
FBS. The cells were subjected to at least two passages before being used for further 
studies.  
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3.2.1.6 Cell viability assay 
Cell viability analysis was performed using CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay reagent (Promega, USA) according to the manufacturer’s 
instructions. Briefly, overnight incubated RD cells (1.5 x 10
4
 cells/well) were prepared 
and an aliquot of 100 µl of the medium containing peptide or inhibitors was added to 
each well. After overnight incubation, an aliquot of 20 µl of the cell viability assay 
reagent was added to each well, and the plate was incubated for 2 hours at 37°C. The 
absorbance reading at 490 nm was obtained using the microplate reader and the 
percentage of cell viability was calculated.  
3.3 Molecular biology 
3.3.1 Design and synthesis of enterovirus A71 primers and TaqMan probe 
The primers and TaqMan probe used for TaqMan real-time PCR were adapted from Tan 
et al. (2008) and shown in Table 3.1. All the primers and TaqMan probe were 
synthesized by Integrate DNA Technology (IDT, USA). The TaqMan probe with 
double quenchers was designed with 6-carboxyfluorescein (6-FAM) at the 5’ end and 
Iowa Black fluorescence quencher at the 3’ end. An internal ZEN quencher (IDT, USA) 
reduced the background fluorescence and improved the sensitivity of the TaqMan probe 
to detect the targeted viral RNA. The TaqMan real-time PCR was used to quantitate 
virus titer based on RNA copy numbers.  
3.3.2 Design and synthesis of synthetic peptides 
All synthetic peptides were produced by Mimotopes Pty Ltd (Australia). A set of 95 
overlapping peptides spanning the entire sequence of the VP1 capsid protein of EV-A71 
strain 41 was synthesized (Appendix IV). Each peptide contained 15 amino acid 
residues with 12 residues overlapping with the adjacent peptides. Synthetic peptide 
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SP40, SP40X, G1 and G2 (Table 3.2) were synthesized with >95% purity assessed by 
high performance liquid chromatography (HPLC). In alanine scanning analysis, a set of 
13 peptides with alanine substitution of each amino acid of the SP40 peptide was also 
synthesized. All the peptides were dissolved in 100% DMSO to achieve a final 
concentration of 10 mM. The peptides were further diluted to the desired final 
concentration using serum-free DMEM.  
3.3.3 Design and synthesis of morpholino oligomers 
All the octaguanidinium-conjugated morpholino oligomers (vivo-MOs) were 
synthesized by Gene Tools LLC (USA). The 23-mers vivo-MOs were designed to 
complement the EV-A71 strain 41 5’ UTR IRES stem-loop structure V-VI and RdRP. 
A control vivo-MO with a nonsense sequence was synthesized and used as a negative 
control throughout the experiment (Table 3.3). All the vivo-MOs were dissolved in 
phosphate buffer saline (PBS) to a final concentration of 0.5 mM with maintenance 
medium (DMEM supplemented with 2% FBS) or serum-free DMEM, depending on the 
time of addition of vivo-MOs. 
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Table 3.2:  Synthetic peptide sequences  
Peptide Sequence pI Net charge GRAVY* 
SP40 Ac-QMRRKVELFTYMRFD-NH2 9.98 +2 -0.833 
SP40X Ac-REFTMKRMVLFRQDY-NH2 9.98 +2 -0.833 
G1 Ac-LRSRTKIIRIRH-NH2 12.48 +5 -0.775 
G2 Ac-MPRRRRIRRRQK-NH2 12.78 +8 -2.842 
*Grand average of hydropathicity index (GRAVY) indicates the solubility of protein; a 
positive GRAVY indicates hydrophobicity and a negative GRAVY indicates 
hydrophilicity. 
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Table 3.3:  The 23-mers vivo-MOs sequences and target locations in EV-A71 RNA 
Vivo-MO Sequence (5’- 3’) Target location in EV-A71 
RNA (nucleotide positions) 
Vivo-MO-1 CAGAGTTGCCCATTACGACACAC IRES core (512-534) 
Vivo-MO-2 GAAACACGGACACCCAAAGTAGT IRES core (546-568) 
Vivo-MO-3 AAACAATTCGAGCCAATTTCTTC RdRP gene (7303-7325) 
Vivo-MO-C CCTACTCCATCGTTCAGCTCTGA - 
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3.3.4 DNA work 
This section describes the methodology involved in plasmid DNA extraction, PCR, 
DNA purification and cloning. These techniques are required for infectious cDNA 
clones construction.  
3.3.4.1 Plasmid extraction  
The Hybrid Q mini spin purification kit (GeneAll, Korea) was used for small scale 
plasmid DNA isolation. This method was based on the alkaline lysis method with an 
additional column purification step. The anion exchange resin within the column allows 
the negatively-charged plasmid DNA to bind while the contaminants are washed away 
by wash buffer. The plasmid DNA purification was carried out according to the 
manufacturer’s instructions. Five mililiters of overnight bacterial culture was pelleted 
by centrifugation for 5 minutes at 14,000 x g and the pellet was resuspended with 250 µl 
S1 buffer supplemented with RNase. The bacterial cells were then lysed with 250 µl of 
S2 lysis buffer and incubated for 5 minutes. The cleared lysate was then neutralized 
with 350 µl of G3 buffer. The resulting precipitate containing proteins and cellular 
debris were then removed through centrifugation for 10 minutes at 17,000 x g. The 
plasmid-containing supernatant was then applied to the DNA binding column and then 
washed twice with 500 µl of AW buffer, followed by 700 µl of PW buffer. The plasmid 
DNA was eluted from the column with 40 µl of pre-warmed EB buffer through 
centrifugation for 2 minutes at 17,000 x g. The plasmid concentration was quantitated 
using a nano-drop spectrophotometer based on absorbance readings of 260 nm and 280 
nm. The integrity of the plasmid DNA was then verified by agarose gel electrophoresis.  
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3.3.4.2 Restriction endonuclease digestion of DNA 
Digestion of DNA was carried out with specific restriction endonuclease (NEB, USA) 
according to the manufacturer’s instructions. In brief, the reaction was carried out in 
thin-wall PCR tubes with 1-5 µg of DNA, restriction enzyme in the 1X digestion buffer 
and bovine serum albumin (BSA). All reactions were incubated for at least 1 hour and 
up to 16 hours at optimal temperatures suggested by the manufacturer.  
3.3.4.3   DNA agarose gel electrophoresis 
DNA fragments were screened by horizontal gel electrophoresis.  The electrophoresis 
was performed in agarose gel pre-stained with GelRed nucleic acid stain (Biotium, USA) 
prepared in 0.5X TAE buffer. DNA products were mixed with a gel loading buffer and 
loaded into the wells. The size of the DNA fragment in the gel was determined based on 
a 1 kb DNA ladder. Electrophoresis was carried out at 80 V and the DNA bands were 
visualized under the UV illumination.  
3.3.4.4 DNA gel purification  
Digested DNA fragments and the PCR products were purified using Expin mini spin 
purification kit (GeneAll, Korea) according to the manufacturer’s instructions. Briefly, 
the desired DNA fragments were carefully excised from the agarose gel using a clean 
scalpel blade. An aliquot of GB buffer was added to the excised gel (300 µl per 100 mg 
of gel) which was then incubated for 10 minutes at 50°C. For DNA fragments larger 
than 5 kbp, an aliquot of isopropanol was added to the mixture at a ratio of 100 µl to 
100 mg of gel. The DNA-containing mixture was then added to the column, which was 
then washed with 700 µl NW buffer. The DNA was eluted from the column using 40 µl 
of EB buffer and stored at -20°C.  
 
    
    70 
3.3.4.5 Phenol chloroform purification of DNA and DNA precipitation 
The DNA-containing solution was mixed with an equal volume of phenol/chloroform 
/isoamyl alcohol (25:24:1, pH 8) (Amresco, USA) and vortexed for 1 minute. The 
solvent and aqueous phases were separated through centrifugation at 17,000 x g for 10 
minutes. The aqueous phase was carefully removed and mixed with an equal volume of 
chloroform/isoamyl alcohol (24:1) (Sigma, USA). This step was necessary to remove 
the remaining phenol residues. After 10 minutes centrifugation at 17,000 x g, the 
aqueous phase was removed, 1/10 volume of 3 M sodium acetate (pH 5.5) was added 
and mixed well. An aliquot of 2.5 volume of absolute ethanol or 1 volume of isopropyl 
alcohol was added to the mixture, which was then and incubated at -80°C or -20°C, 
respectively, for 1 hour to precipitate the DNA. The precipitated DNA was pelleted by 
centrifugation at 17,000 x g for 20 minutes at 4°C and the DNA pellet was washed with 
70% ethanol to remove the remaining salts. After air-drying, the pellet was dissolved 
with TE buffer or nuclease free water.  
3.3.4.6 A-tailing of purified PCR product 
The gel purified blunt end PCR products were subject to A-tailing using GoTaq DNA 
polymerase (Promega, USA) according to the manufacturer’s instructions. A single A 
residue overhang at the 3’ end was added to the DNA fragment. Briefly, approximately 
500 ng of DNA template was added into GoTaq Green master mix containing 0.2 mM 
dNTP, 1.5 mM MgCl2 and 1.25 U of GoTaq DNA polymerase. The reaction mix was 
incubated for 30 minutes at 70°C. The A-tailed products were then purified by 
phenol/chloroform/isoamyl alcohol, reconstituted with TE buffer and kept at -20°C until 
use.  
 
 
    
    71 
3.3.4.7 TA cloning  
The plasmid vector (pCR-XL-TOPO) was supplied as linear form with a single 3’ 
thymidine (T) overhang. The PCR products carrying 3’ deoxyadenosine (A) overhangs 
were cloned into the pCR-XL-TOPO vector according to the manufacturer’s 
instructions. This technology involves the topoisomerase from vaccinia virus. 
Approximately 10-100 ng/ul of the DNA template was prepared. An aliquot of 4 µl of 
the DNA template in TE buffer was mixed with 1 µl (10 ng/µl) of plasmid DNA and 
incubated at room temperature for 30 minutes. Thereafter, the reaction was stopped by 
adding 1 µl 6X TOPO stop solution. The recombinant plasmid DNA was then 
transformed into E. coli TOP10 competent cells as previously described.  
3.3.5 RNA work 
This section describes the steps involved in RNA quantification using TaqMan real-time 
PCR and RNA gel electrophoresis.  
3.3.5.1 Viral genomic RNA extraction 
EV-A71 RNA genome was extracted from infected tissue culture using QIAamp viral 
RNA mini kit (QIAGEN, Germany) according to the manufacturer’s instructions. 
Briefly, 140 µl of the virus-containing supernatant was lysed with 560 µl of AVL buffer 
containing the recommended amount of carrier RNA, followed by addition of 560 µl of 
absolute ethanol. The viral RNA-containing mixture was then added to the column and 
washed twice with 500 µl of AW1 and AW2. The viral RNA was eluted with 60 µl 
AVE buffer and kept at -80°C.  
 
 
    
    72 
3.3.5.2 TaqMan real-time PCR 
The TaqMan real-time PCR was performed using TaqMan Fast Virus 1-Step Master 
Mix (ABI, USA) with the primers and TaqMan probe as stated in Table 3.1. The 
reaction mix was prepared (Table 3.4). The PCR reaction was performed with a 
StepOne Plus real-time PCR system (ABI, USA) with cDNA synthesis by reverse 
transcription for 5 minutes at 50°C, and subsequent amplification for 40 cycles at 95°C 
for 3 s and 60°C for 30 s. Plasmid DNA containing the EV-A71 VP1 gene was used as 
the standard to determine the samples copy numbers. The RNA copy number was 
determined using StepOne Plus software v2.2.  
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Table 3.4: Master mix preparation for TaqMan real-time PCR. 
Reagent Volume Final concentration 
VP1-F (10 µM) 0.25 µl 0.25 µM 
VP1-R (10 µM)   0.25 µl 0.25 µM 
TaqMan probe (5 µM) 1.0 µl 2.0 µM 
TaqMan Fast Virus 1-Step Master Mix (4X) 2.5 µl 1X 
RNA template  1.0 µl - 
PCR grade water  5.0 µl - 
Total 10.0 µl  
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3.3.5.3 RNA non-denaturing agarose gel electrophoresis 
RNA fragments were screened by horizontal gel electrophoresis.  The electrophoresis 
was performed in agarose gel pre-stained with GelRed nucleic acid stain (Biotium, USA) 
prepared in 1X TAE buffer. RNA products were mixed with a 2X RNA loading buffer 
(NEB, USA) and loaded into the wells. The size of the RNA fragment in the gel was 
determined based on the standard 0.5-10 kb RNA ladder (Invitrogen, USA). 
Electrophoresis was carried out at 80 V for 1 hour and the RNA bands were visualized 
under UV illumination.  
3.3.6  Protein work 
Protein work is necessary for determination of the protein expression with SDS-PAGE 
and western blot analysis.  
3.3.6.1 Total protein extraction and quantification 
The infected RD cells in the 24-well plate were lysed with 100 µl of ReadyPrep 
Sequential Extraction Kit Reagent 2 (BioRad, USA). The lysate was then clarified by 
centrifugation at 14,000 x g for 10 minutes at 4°C to remove the cell debris. The protein 
concentration of the cell lysate was quantitated using MicroBCA Protein Assay (Pierce 
Biotechnology, USA) according to the manufacturer’s instructions. In brief, the 
microBCA working reagent was prepared accordingly (25:24:1, reagent MA:MB:MC). 
An aliquot of 150 µl of the standard or unknown sample was mixed with 150 µl of the 
working reagent and incubated at 37°C for 2 hours. Bovine serum albumin with known 
concentration was used as the standard. The absorbance reading was measured at 562 
nm using a microplate reader. The concentration of the sample was calculated based on 
the standard curve.  
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3.3.6.2 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using a vertical slab gel unit in a Mini-Protean tetra cell 
(Bio-Rad, USA) according to the manufacturer’s instructions. The slab gel was cast 
between two grease-free glass plates, with a 12% (w/v) polyacrylamide separating gel 
and a 5% (w/v) polyacrylamide stacking gel. The separating gel mixture was poured to 
1.5 cm below the bottom of the comb and then carefully overlaid with absolute ethanol 
to ensure the formation of a straight meniscus. After the separating gel was well 
polymerized, the ethanol overlay was removed. Thereafter, the stacking gel mixture was 
layered over the separating gel and the comb was placed in position. The compositions 
of separating gel and stacking gel are shown in Appendix II. After the gel was 
polymerized, the comb was removed and the wells were flushed with SDS running 
buffer. An aliquot of 20 µl of the sample with SDS loading dye was boiled at 100°C for 
5 minutes and added into each well. The samples were electrophoresed at 120 V for 2 
hours. The gels were then soaked in Coomassie blue staining solution (Appendix II) for 
1 hour with constant shaking. The stained gels were soaked in destaining solution 
(Appendix II) with constant shaking until protein bands could be visualized as blue 
bands against a clear background.  
3.3.6.3 Western blot analysis 
The proteins in the resolved SDS-PAGE gel were transferred onto a PVDF membrane 
(Millipore, USA) using a Trans-Blot SD semi-dry transfer cell (Bio-Rad, USA) 
according to the manufacturer’s instructions. Briefly, the transfer was prepared by 
assembling the following components from the bottom: two layers of ice-cold anode I 
buffer-treated filter papers, a layer of ice-cold anode II buffer-treated filter paper, ice-
cold anode II buffer-treated PVDF membrane, ice-cold cathode buffer-treated SDS-
PAGE gel and three layer of ice-cold cathode buffer-treated filter papers. The buffer 
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ingredients are shown in Appendix III. The transfer was carried out at 15V for 15 
minutes and 10V for 30 minutes for the 0.75 mm and 1.5 mm gels respectively. The 
membrane was subsequently blocked with 5% skimmed milk in PBS for 1 hour. The 
membrane was then incubated with 1:100 diluted anti-EV-A71 monoclonal antibodies 
(Millipore, USA) or 1:5000 diluted β-actin antibodies (Sigma, USA) for 1 hour at room 
temperature. Thereafter, the membrane was washed twice with PBS-0.05% Tween-20 to 
remove unbound antibodies. The membrane was then incubated with 1:2000 diluted of 
HRP-conjugated goat anti-mouse antibody (Gene Tex, USA) for 1 hour at room 
temperature. The immunoblots were developed with DAB substrate in stable peroxide 
substrate solution (Pierce Biotechnology, USA). The size of the desired protein bands 
were determined based on the PageRuler prestained protein marker (Thermo Scientific, 
USA).  
3.3.6.4 Chemiluminescence analysis 
For chemiluminescence analysis, the protein resolved in the SDS-PAGE gel was 
transferred to a nitrocellulose membrane using a Trans-Blot SD semi-dry transfer cell 
according to the manufacturer’s instructions. All the filter papers, nitrocellulose 
membrane and the SDS-PAGE gel were soaked in transfer buffer (24 mM Tris, 77 mM 
glycine, 20% methanol) for 15 minutes at 4°C. The transfer was prepared by assembling 
three layers of filter papers, followed by a nitrocellulose membrane, SDS-PAGE gel and 
three layers of filter papers. The transfer was performed at 15 V for 15 minutes. The 
membrane was then blocked with 5% skimmed milk in PBS-0.05% Tween-20 for 1 
hour. The membrane was then incubated with 1:100 diluted anti-EV-A71 monoclonal 
antibodies (Millipore, USA) for an hour. Thereafter, the membrane was washed twice 
with PBS-0.05% Tween-20 to remove unbound antibodies. The membrane was then 
incubated with 1:2000 diluted HRP-conjugated goat anti-mouse antibody (Gene Tex, 
USA) for 1 hour at room temperature. The immunoblot was developed with Amersham 
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ECL Prime Western Blotting Detection Reagent (GE Healthcare, UK) and detected by 
chemiluminescence. The protein size was determined using Precise Plus Protein 
WesternC Standard (Bio-Rad, USA).  
3.3.7  Construction of enterovirus A71 infectious cDNA clones 
3.3.7.1 Design and synthesis of primers  
The primers involved in EV-A71 infectious cDNA clone are shown in Table 3.5. The 
forward primer (EV-A71_MluI/SP6_F) was designed with a restriction enzyme MluI 
cutting site (5’ ACGCGT 3’) and a SP6 promoter sequence (5’ 
ATTTAGGTGACACTATAG 3’, with transcription start site underlined). The reverse 
primer (EV-A71_polyA/EagI_R) was designed with poly(T)50 followed by an EagI 
restriction enzyme cutting site.  
3.3.7.2 Reverse transcription  
The EV-A71 genomic RNA was reverse transcribed into cDNA using Superscript III 
reverse transcriptase (Invitrogen, USA) according to the manufacturer’s instructions. In 
brief, the reaction mix was set up with 100 ng of RNA, 2 pmol of EV-
A71_polyA/EagI_R and 1 mM dNTP mix in 10 µl reactions. Thereafter, the reaction 
mix was incubated at 65°C for 5 minutes and immediately placed on ice for at least 1 
minute. The remaining components were then added into the reaction mix (1X RT 
buffer, 0.01 M DTT, 40 U RNaseOUT and 400 U SuperScript III reverse transcriptase) 
and incubated at 55°C for 60 minutes followed by reverse transcriptase inactivation at 
70°C for 15 minutes. The RNA that hybridized to the cDNA was removed by addition 
of 2 U RNase H and incubated for 20 minutes at 37°C. The cDNA was kept in -80°C 
until further experiments.  
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3.3.7.3 Full-length PCR of enterovirus A71 genome 
Full genome PCR was performed using iProof high fidelity DNA polymerase (Bio-Rad, 
USA) according to the manufacturer’s instructions. Briefly, PCR reaction mix was 
prepared with 0.5 µM of pEV-A71_MluI/SP6_F, pEV-A71_PolyA/EagI_R, and 2 µl of 
cDNA in 1X high fidelity buffer containing 0.2 mM dNTP and 1 unit of iProof DNA 
polymerase. The PCR was performed with initial denaturation of 2 minutes at 98°C, 
followed by 25 cycles of 98°C for 10 s, 60°C for 20 s and 72°C for 4 minutes.  
3.3.8  Construction of enhanced green fluorescence protein (EGFP)-expressing 
enterovirus A71 infectious cDNA clone 
3.3.8.1 Design and synthesis of primers 
The three sets of primers involved in EV-A71_EGFP infectious cDNA clone 
construction are shown in Table 3.5. Primer set I was designed to amplify the EV-A71 
5’UTR region, flanked by BstB1, SP6 promoter site at the 5’ end and EGFP sequence at 
the 3’ end. Primer set II was designed to amplify the EGFP gene, flanked by EV-A71 
5’UTR and VP4. Primer set III amplified the EV-A71 P1 region. Primer set IV 
specifically amplified EV-A71 P2 to the poly(A) tail. Each fragment had at least 30 
nucleotides of overlapping sequences.  
3.3.8.2 Overlapping extension PCR  
Overlapping extension PCR was performed using Q5 high fidelity DNA polymerase 
(NEB, USA) according to the manufacturer’s instructions. The PCR reaction mix was 
set up with 0.5 µM of each of forward and reverse primers, 1X high fidelity buffer, 0.2 
mM dNTP, 1 unit of Q5 DNA polymerase and 10 ng of plasmid DNA containing either 
EV-A71 full genomic sequence or EGFP gene. The PCR was performed with initial 
denaturation of 2 minutes at 98°C, followed by 25 cycles of 98°C for 10 s, 70-72°C for 
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20 s and 72°C for 1-2 minutes. Approximately 100 ng of the gel purified fragments 
were then overlapped through 15 cycles of 98°C for 10 s and 72°C for 1-2 minutes. The 
fused products were then amplified using pEV-A71_BstBI/SP6_1F and pEV-
A71_PolyA/AgeI_4R for 25 cycles of 98°C for 10 s and 72°C for 5 minutes.  
    
    80 
 
T
ab
le
 3
.5
: 
 
P
ri
m
er
s 
in
v
o
lv
ed
 i
n
 E
V
-A
7
1
 i
n
fe
ct
io
u
s 
cD
N
A
 c
lo
n
es
 c
o
n
st
ru
ct
io
n
 
P
ri
m
er
 
S
eq
u
en
ce
 (
5
’ 

 3
’)
 
p
E
V
-A
7
1
_
M
lu
/S
P
6
_
F
 
G
T
A
A
C
G
C
G
T
A
G
C
G
A
T
T
T
A
G
G
T
G
A
C
A
C
T
A
T
A
G
T
T
A
A
A
A
C
A
G
C
T
G
T
G
G
G
T
T
G
 
p
E
V
-A
7
1
_
P
o
ly
A
/E
ag
I_
R
 
C
C
T
A
C
G
G
C
C
G
T
5
0
G
C
T
A
T
T
C
C
G
G
T
T
A
T
A
A
C
A
A
A
T
T
T
A
C
 
p
E
V
-A
7
1
_
B
st
B
1
/S
P
6
_
1
F
 
G
C
T
T
C
G
A
A
G
C
G
A
T
T
T
A
G
G
T
G
A
C
A
C
T
A
T
A
G
T
T
 
p
E
V
-A
7
1
_
E
G
F
P
/5
U
T
R
_
1
R
 
G
A
A
C
A
G
C
T
C
C
T
C
G
C
C
C
T
T
G
C
T
C
A
C
T
G
A
G
C
C
C
A
T
G
T
T
T
G
A
T
T
G
T
A
T
T
G
  
p
E
V
-A
7
1
_
5
U
T
R
/E
G
F
P
_
2
F
 
C
A
A
T
A
C
A
A
T
C
A
A
A
C
A
T
G
G
G
C
T
C
A
G
T
G
A
G
C
A
A
G
G
G
C
G
A
G
G
A
G
C
T
G
T
T
C
  
p
E
V
-A
7
1
_
V
P
4
/E
G
F
P
_
2
R
 
T
G
T
G
A
G
C
C
A
A
G
G
G
T
A
G
T
A
A
T
G
G
C
C
T
T
G
T
A
C
A
G
C
T
C
G
T
C
C
A
T
G
C
C
G
A
G
  
p
E
V
-A
7
1
_
E
G
F
P
/V
P
4
_
3
F
 
G
T
A
C
A
A
G
G
C
C
A
T
T
A
C
T
A
C
C
C
T
T
G
G
C
T
C
A
C
A
G
G
T
G
T
C
T
A
C
T
C
A
G
C
G
A
T
 
p
E
V
-A
7
1
_
P
2
_
3
R
 
C
C
C
T
C
A
C
A
T
C
A
G
C
A
A
A
A
C
C
A
A
C
G
A
G
  
p
E
V
-A
7
1
_
P
2
_
4
F
 
C
A
T
G
G
T
G
T
A
G
T
T
G
G
T
A
T
A
G
T
G
T
C
C
A
C
  
p
E
V
-A
7
1
_
A
g
e
I/
P
o
ly
A
_
4
R
 
G
A
C
C
G
G
T
5
0
G
C
T
A
T
T
C
C
G
G
 
 
    
    81 
3.3.9 In vitro transcription of SP6 promoter 
In vitro transcription was performed using RiboMAX large scale RNA production 
system (Promega, USA) according to the manufacturer’s instructions. In brief, 1-5 µg of 
the linearized DNA template was added to the reaction mix containing 1X SP6 
transcription buffer, 25 mM of each of the rNTP and 2 µl of the enzymes mix. In vitro 
transcription was carried out at 37°C for 4-6 hours. Thereafter, the DNA template was 
removed by DNase treatment for 15 minutes at 37°C at the concentration of 1 U/µg of 
DNA.  
3.3.10 RNA purification  
Prior to transfection, the unincorporated free rNTP and the digested DNA was removed 
using Illustra Microspin G-50 column (GE Healthcare, UK) according to the 
manufacturer’s instructions. The column was prepared by centrifugation at 800 x g for 1 
minute to remove the excess storage buffer. An aliquot of 20-50 µl of the in vitro 
transcribed RNA was added to the resin which was then centrifuged at 800 x g for 2 
minutes. Purified RNA was collected and stored at -80°C till use. 
3.3.11 Transfection of infectious RNA  
Overnight grown RD cells (1.5 x 10
5
 cells/well in a 24-well plate or 6 x 10
5
 cells/well in 
a 6-well plate) were prepared and used for transfection. Approximately 1µg and 5 µg of 
RNA was transfected into a 24-well and 6-well plate, respectively. Prior to transfection, 
the growth medium was removed and replaced with Opti-MEM (Invitrogen, USA). 
Transfection mix was prepared with a ratio of 1 µl of Lipofectamine 2000 reagent to 1 
µg of RNA. The RNA-containing Opti-MEM was mixed with the Lipofectamine 2000 
reagent containing Opti-MEM and incubated at room temperature for 20 minutes. 
Thereafter, the RNA-lipofectamine mixture was added to the cells drop-by-drop. Two 
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hours after transfection, the transfection medium was removed and replaced with fresh 
maintenance medium.  
3.3.12 Rescue of infectious viral particles 
Infectious RNA-transfected RD cells were harvested 72 hours post-transfection. The 
harvested cells were freeze-thawed twice. The cell debris was removed through 
centrifugation at 17,000 x g for 10 minutes at 4°C. The virus-containing supernatant 
was kept in -80°C and the virus titers were determined by plaque assay.   
3.3.13 Construction of enterovirus A71 mutants 
In this study, site-directed mutagenesis is performed to introduce mutations into EV-
A71 infectious clone, to study the degree of tolerance of the vivo-MO-1 towards the 
number and positions of the mutations. 
3.3.13.1 Design and synthesis of primers 
The primers involved in site-directed mutagenesis are listed in Table 3.6. The primers 
were designed to carry the desired point mutation flanked by at least 15 nucleotides. 
Each primer set was complementary to each other. The melting temperature (Tm) of 
each of the primers was designed to be more than 78°C, determined using the following 
calculation: 
Tm = 81.5 + 0.41(%GC) – (675/N) - %mismatch 
Where N is the primer length in bases and the values for %GC and %mismatch are 
whole numbers.  
3.3.13.2 Site-directed mutagenesis 
The QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, 
USA) was used according to the manufacturer’s instructions. The pCR-XL-TOPO-EV-
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A71 recombinant plasmid was used. The basic procedure utilizes a plasmid DNA vector 
and the two primers containing the desired mutation. The primers complementary to the 
opposite strands of the vector were extended during temperature cycling by Pfu Ultra 
HF DNA polymerase without primer displacement. The PCR cycles included initial 
denaturation for 2 minutes at 95°C, and 18 cycles of denaturation at 95°C for 20 s, 
annealing at 60°C for 10 s and extension at 68°C for 4 minutes, followed by a final 
extension at 68°C for 2 minutes. The extension of the oligonucleotide primers generated 
a mutated plasmid containing staggered nicks. After the temperature cycling, the 
parental unmutated plasmid DNA template was removed using DpnI for 30 minutes at 
37°C, which specifically cleaved the methylated and hemimethylated targeted sequence 
5’ Gm6ATC 3’. An aliquot of 2-3 µl of the mutated plasmid containing the staggered 
nicks was transformed into E. coli XL10-Gold ultracompetent cells (Agilent 
Technologies, USA) as previously described in section 3.1.1.3. 
3.3.14 In vitro translation assay 
In order to test whether the antisense-mediated morpholino oligomers inhibit viral RNA 
translation, a cell-free translation assay was performed. In vitro translation assay was 
performed using Human Coupled 1-step In Vitro Translation Kit (Pierce Biotechnology, 
USA) according to the manufacturer’s instructions. This kit has been optimized for 
encephalomyocarditis virus IRES-dependent translation. In brief, approximately 1 µg of 
in vitro transcribed infectious RNA was added to a reaction mix containing HeLa lysate 
and accessory proteins. In vitro translation was carried out at 30°C for 6 hours. 
Thereafter, the protein fragments were resolved by SDS-PAGE and EV-A71 proteins 
were detected through chemiluminescence analysis as previously described in section 
3.3.6.4.  
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Table 3.6: Primers involved in site-directed mutagenesis 
Primer  Sequence (5’  3’)a 
pMO-1-mutant 1F CGTAATGGGCAACTCCGCAGCGGAACCGAC 
pMO-1-mutant 1R GTCGGTTCCGCTGCGGAGTTGCCCATTACG 
pMO-1-mutant 2F GGTAGTGTGTCGTAACGGGCAACTCTGCAG 
pMO-1-mutant 2R CTGCAGAGTTGCCCGTTACGACACACTACC 
pMO-1-mutant 3F GTAGTGTGTCGTAACGGGTAACTCTGCAGCGGAAC 
pMO-1-mutant 3R GTTCCGCTGCAGAGTTACCCGTTACGACACACTAC 
pMO-1-mutant 4F ATCCAGAGGGTAGTGCGTCGTAACGGGTAAC 
pMO-1-mutant 4R GTTACCCGTTACGACGCACTACCCTCTGGAT 
a 
Underlined nucleotides indicate substitution mutations. 
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3.3.15 Small interference RNA transient knockdown 
Small interference RNA (siRNA) targeting heparan sulfate modifying enzyme N-
deacetylase/N-sulfotransferase-1 (NDST-1) and the heparan sulfate polymerase 
exostosin-1 (EXT-1) were purchased from Santa Cruz Biotechnology (USA). Different 
concentrations of siRNAs were incubated with Lipofectamine 2000 reagent in Opti-
MEM (Invitrogen, USA) for 20 minutes. The siRNAs were then transfected into 1 x 10
4
 
RD cells for 24 hours. Before infection, the transfection medium was removed, and 
washed twice with serum-free DMEM. Thereafter, the cells were infected with EV-A71 
at a MOI of 0.1.   
3.4 Biochemistry  
3.4.1 Heparinase I/II/III and chondroitinase ABC preparation 
Heparinase I, II, III, I/III blend from Flavobacterium heparinum and chondroitinase 
ABC from Proteus vulgaris were all purchased from Sigma (USA). Heparinase I from 
recombinant Bacteroides thetaiotaomicron was supplied by R&D Systems (USA). 
Heparinase I, II, III were reconstituted in digestion buffer I (pH 7.5) containing 
phosphate buffered saline (PBS), 0.05 M sodium acetate and 0.02% bovine serum 
albumin (BSA). Chondroitinase ABC was reconstituted in digestion buffer II (pH 7.5) 
containing PBS, 0.5 mM MgCl2, 0.9 mM CaCl2 and 0.1% BSA.  
3.4.2 Removal of cell surface heparan sulfate and chondroitin sulfate using enzymatic 
treatment 
Overnight cultured RD cells were pre-treated with various concentrations of heparinase 
I/II/III and chondroitinase ABC in the respective digestion buffers for an hour at 37°C. 
Prior to infection, the cells were washed twice with ice cold serum-free DMEM. 
Thereafter, the treated cells were infected with EV-A71 for an hour at 4°C. After an 
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hour of infection, the inoculum was removed and the cells were washed twice with ice 
cold serum-free DMEM. The cells were either replenished with maintenance medium 
and the viral titers were determined 24 hours post-infection or fixed with 4% 
formaldehyde for immunofluorescence analysis.   
3.5 Antiviral inhibition assay 
3.5.1 Cell protection inhibition assay 
Approximately 1.5 x 10
4
 cells/well of the RD cells were prepared and incubated 
overnight at 37°C in 5% CO2. The growth medium was removed and replaced with 
serum-free DMEM containing peptides, vivo-MOs and glycosaminoglycans for 1-4 
hours. Prior to infection, the cells were washed with serum free DMEM and EV-A71 at 
a MOI of 0.1 was added to the cells. After 1 hour incubation, the inoculum was 
removed, the cells were washed with serum-free DMEM and replaced with fresh 
maintenance medium. The virus was harvested 24 hours post-infection and the titers 
were determined by plaque assay and TaqMan real-time PCR. 
3.5.2 Virus inactivation assay 
EV-A71 virus supernatant at MOI of 10 or 0.1 was pre-incubated with peptide or 
glycosaminoglycans for an hour at 37°C before infection. For peptide work, the virus-
peptide mixture was then diluted 200-fold and added to overnight grown RD cells. For 
the glycosaminoglycan (GAG) work, the GAG-treated virus was then added to 
overnight grown RD cells. After 1 hour of incubation, the inoculum was removed and 
replenished with fresh maintenance medium. The virus was harvested 24 hours post-
infection and the titers were determined by plaque assay and TaqMan real-time PCR. 
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3.5.3 Comprehensive inhibition assay 
In the comprehensive inhibition assay, both cells and virus were treated with peptides. 
In brief, RD cells were pre-treated with various concentrations of peptide for 1 hour at 
room temperature. At the same time, virus at a MOI of 0.1 was pre-treated with the 
same amount of peptide for 1 hour at 37°C. After incubation, the peptide-containing 
supernatant was removed from the cells and the peptide-treated virus was added to the 
cells. After 1 hour of incubation, the inoculum was removed and replaced with 
maintenance medium. The virus titers were quantitated 24 hours post-infection by 
TaqMan real-time PCR and plaque assay.  
3.5.4 Virus attachment inhibition assay 
In the virus attachment inhibition assay, RD cells were pre-treated with peptide for an 
hour before infection. A MOI of 100 of ice-cold EV-A71 was added to the pre-cold RD 
cells and incubated at 4°C for an hour.  After incubation, the inoculum was removed 
and the cells were washed twice with ice-cold serum-free DMEM. Thereafter, the cells 
were either fixed with 4% formaldehyde for immunofluorescence assay or replaced with 
maintenance medium. Virus was harvested 24 hour post-infection and the virus titers 
were determined by plaque assay and TaqMan real-time PCR.  
3.6 Three-dimensional structure and sequence analysis 
The crystal structure of EV-A71 with protein data bank (PDB) identification code 
4AED was downloaded from the PDB (http://www.rcsb.org/pdb). The three-
dimensional structure of EV-A71 was built using the Deep-View Swiss PDB viewer, 
version 4.0.4 (Swiss Institute of Bioinformatics). For sequence analysis, VP1 sequences 
from different genotypes were downloaded from GenBank 
(http://www.ncbi.nlm.nih.gov) and were aligned using ClustalW2 software 
(http://www.ebi.ac.uk/tools/msa/clustalw2/) (Larkin et al., 2007).  
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3.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5 (GraphPad software Inc., 
USA). Means ± standard deviations were obtained from at least two independent 
biological replicates. Statistical significance was calculated using the Mann-Whitney 
test. A P value of < 0.05 was considered as statistically significant.  
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CHAPTER 4  
RESULTS 
4.1  Construction of enterovirus A71 and enhanced green fluorescence protein-
expressing enterovirus A71 cDNA infectious clones 
In this study, infectious clone of EV-A71 was constructed either with or without the 
enhanced green fluorescence protein (EGFP) reporter gene. These constructs are 
required to understand the mechanism of antiviral resistance, as well as to characterize 
the mechanism of action of an antiviral. In this study, EV-A71 infectious cDNA clone is 
utilized to characterize the degree of mismatch tolerance of the vivo-MO-1 against EV-
A71. Desired mutations are introduced into vivo-MO-1 targeted region through site-
directed mutagenesis. EV-A71_EGFP is used to study the mechanism of action of vivo-
MOs against EV-A71 infection.  
4.1.1 Construction and characterization of the enterovirus A71 cDNA clone 
4.1.1.1 Amplification and cloning of the full-length enterovirus A71 genome 
EV-A71 viral RNA was extracted using QIAamp viral RNA mini kit and subjected to 
cDNA synthesis. As shown in the agarose gel electrophoresis in Figure 4.1A, the full-
length EV-A71 genome size of approximately 7.5 kb was successfully amplified using 
iProof high fidelity DNA polymerase. The PCR product was then gel purified and 
subjected to A-tailing using GoTaq DNA polymerase. The product with single 3’ 
adenosine (A) was then cloned into pCR-XL-TOPO plasmid vector and the recombinant 
plasmid was then transformed into E. coli TOP10. The recombinant plasmid was then 
linearized by EagI. The electrophoresed intact recombinant plasmid pCR-TOPO-XL-
EV-A71 is shown in Figure 4.1B.  
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4.1.1.2 Characterization of enterovirus A71 infectious cDNA clone 
The schematic illustration of EV-A71 infectious cDNA clone in pCR-XL-TOPO vector 
is shown in Figure 4.2. The EV-A71 genome was cloned downstream of the SP6 
promoter. Upstream of the SP6 promoter was a MluI restriction site and downstream of 
the poly(A) tail was an EagI restriction site. Infectious EV-A71 genomic RNA was 
synthesized using SP6 RNA polymerase. The in vitro transcribed RNA contains an 
additional G residue at the 5’ end and CGGCC residues at the 3’ end. As depicted in 
Figure 4.1C, the size of the in vitro transcribed RNA was approximately 7.5 kb. 
Smearing after the expected band was observed, which was likely due to some RNA 
degradation occurring during in vitro transcription or incomplete denaturation. The 
presence of non-viral residues at the 5’ and 3’ ends were found to reduce viral 
replication efficacy. This correlated well with the results demonstrated in this study. RD 
cells transfected with the purified viral RNA developed CPE faster than the RD cells 
transfected with in vitro transcribed RNA. The CPE was usually observed 48 to 72 
hours post-transfection of the in vitro transcribed RNA. Characterization of the plaque 
morphology and the replication kinetics of the cDNA-derived EV-A71 and the wild-
type virus are shown in Figure 4.3. There were no differences in the plaque morphology 
and the replication kinetics between the viruses produced from the infectious cDNA 
clone and the wild-type virus.  
4.1.2 Construction and characterization of the enterovirus A71 enhanced green 
fluorescence protein (EGFP) reporter virus 
4.1.2.1 Amplification and cloning of full-length enterovirus A71 EGFP genome 
In order to avoid alteration of the EV-A71 genome through addition of restriction 
enzyme cutting sites, overlapping extension PCR was used to fuse the EGFP gene into 
the EV-A71 genome. The recombinant plasmid pCR-XL-TOPO-EV-A71 and pEGFP-
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N1 (Clonetech, USA) were used as the backbone for EV-A71_EGFP construction. The 
primers were designed with at least 15 nucleotides overlap. A total of four DNA 
fragments were fused together. Fragment 1 (808 bp) covered the EV-A71 5’UTR which 
was flanked by the SP6 promoter and part of the EGFP gene. Fragment 2 (777 bp) 
covered the EGFP gene and was flanked by part of the EV-A71 5’UTR and VP4. 
Fragment 3 (3037 bp) covered the EV-A71 P1 region which was flanked by part of the 
EGFP gene and the EV-A71 2A gene. Fragment 4 (3783 bp) covered the entire EV-A71 
P2 and P3 regions and was flanked by part of the EV-A71 2A region and a poly(A) tail. 
The fragments were then fused fragment-by-fragment using overlapping extension PCR 
(Figure 4.4A). The final full-length EV-A71 genome with EGFP gene (8.2 kb) was then 
gel purified and cloned into a pCR-XL-TOPO vector. All the PCRs were performed 
using Q5 high fidelity DNA polymerase, which has > 100X fidelity compared to normal 
Taq polymerase.  
4.1.2.2 Characterization of enterovirus A71 EGFP-expressing infectious cDNA clone 
The schematic illustration of EV-A71_EGFP-expressing infectious cDNA clone is 
depicted in Figure 4.5. The EGFP gene was fused between 5’UTR and VP4 followed by 
a 2A cleavage site (with amino acid sequence of –AITTL-). After viral polyprotein 
synthesis, the EGFP which was fused with VP4 will be cleaved off by EV-A71 2A 
proteases to produce a functional EGFP. The EV-A71_EGFP-expressing infectious 
cDNA clone was flanked by restriction sites BstB1 upstream of the SP6 promoter 
sequence and AgeI located downstream of the poly(A) tail. The in vitro transcribed 
RNA contains an additional G residue at the 5’ end and CCGG residues at the 3’ end. 
The in vitro transcribed RNA was about 8 kb in length (Figure 4.4B). The GFP signal 
could be detected 24 hours post-transfection and the CPE was observed 72 days post-
transfection. The replication kinetics and the plaque morphology were determined using 
the P1 stock. As shown in Figure 4.6, EV-A71 expressing EGFP has a smaller plaque 
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size with a diameter of 1 mm and less well-defined edges compared to wild type EV-
A71 with an average 1.5 mm diameter. EV-A71_EGFP infectious virus had slower 
replication kinetics compared to the wild type EV-A71, which could be a result of 
inefficiency in RNA genome packaging. 
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Figure 4.1: Agarose gel electrophoresis of full-length EV-A71 genome. Agarose gel 
electrophoresis images of (A) full-length EV-A71genomic PCR product 
(lane 1), (B) purified plasmid pCR-TOPO-XL-EV-A71 from E.coli 
TOP10 (lane 2) and (C) SP6 in vitro transcribed RNA (lane 3). Lane M1 
contains VC 1 kb DNA ladder and lane M2 contains 0.5-10 kb RNA 
ladder. The sizes of the DNA and RNA ladders are indicated as base 
pairs (bp) and bases (b).  
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Figure 4.2: Schematic illustration of EV-A71 infectious cDNA clone in pCR-XL-
TOPO. EV-A71 genomic cDNA was cloned downstream of a SP6 RNA 
polymerase promoter. The in vitro transcribed positive-sense RNA 
carried an additional G residue at the 5’ end and a poly(A)50 tail followed 
by additional CGGCC residues at the 3’ end. The arrow indicates the 
transcription start site.  
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Figure 4.3: Replication kinetics of the EV-A71 infectious cDNA clone. Phenotypic 
characterization of wild-type EV-A71 and clone-derived EV-A71 based 
on the (A) plaque morphology after 48 hours post-infection and (B) 
replication kinetics in RD cells. At each time point, titers are the average 
of two biological replicates; error bars represent the standard deviation of 
the mean. 
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Figure 4.4: Agarose gel electrophoresis of overlapping PCR DNA fragments and in 
vitro transcribed RNA. Agarose gel electrophoresis images of (A) 
overlapping extension PCR products and (B) SP6 in vitro transcribed 
RNA. Lane M1, 1 kb DNA ladder; Lane 1, fragment 1; lane 2, 
overlapped product of fragments 1 and 2; lane 3, overlapped product of 
fragments 1, 2 and 3; lane 4, full-length EV-A71_EGFP; lane M2, 0.5-10 
kb RNA ladder; and lane 6, in vitro transcribed RNA.  
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Figure 4.5:  Schematic illustration of EV-A71_EGFP-expressing cDNA clone in 
pCR-XL-TOPO. The EV-A71_EGFP genome was located downstream 
of bacteriophage SP6 RNA polymerase promoter sequence and upstream 
of a poly(A)50 tail. The EGFP gene was fused in between the EV-A71 
5’UTR and VP4 gene, followed by a 2A cleavage site using overlapping 
extension PCR. The positive-sense RNA derived from the SP6 RNA 
polymerase consists of an additional G residue at the 5’ end and CCGG 
residues at the 3’ end. The arrow indicates the transcription start site. 
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Figure 4.6: Characterization of EV-A71_EGFP-expressing clone. (A) RD cells were 
infected with rescued EV-A71_EGFP at a MOI of 0.1. The viral-induced 
CPE and the EGFP expression was observed 24 hours post-infection. 
The EGFP signal (green) was detected using a fluorescence microscope 
at an excitation wavelength of 488 nm. Phenotypic characterization of 
EV-A71 and EV-A71_EGFP based on the (B) plaque formation size 
after 72 hours post-infection and (C) replication kinetics in RD cells. At 
each time point, titers are the average of two biological replicates; error 
bars represent the standard deviation of the mean. 
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4.2 Inhibition of enterovirus A71 infections by a novel antiviral peptide derived 
from enterovirus A71 capsid protein VP1 
Virus-host receptor interaction is an essential event during virus infection. EV-A71 VP1 
is known to carry multiple receptors recognition sites. Therefore, screening of synthetic 
peptides covering the entire VP1 capsid protein could lead to novel antiviral peptides 
discovery as well as discovery of an unknown receptor. A library of 95 overlapping 
peptides was synthesized and screened for potential anti-EV-A71 activity. The 
following sub-sections describe the outcomes of the antiviral peptides screening, which 
led to a novel antiviral peptide discovery. 
4.2.1 Screening of 95 overlapping peptides against enterovirus A71 infection 
In this study, 95 synthetic peptides covering the entire EV-A71 VP1 were synthesized 
with overlapping 12 residues (6 residues at the C terminal and 6 residues at the N 
terminal). The peptides used for the initial screening had 60 – 65% purity. All synthetic 
peptides were dissolved in 100% DMSO followed by dilution using serum-free DMEM. 
The synthetic peptides were diluted to a final concentration of approximately 100 µM 
and the inhibitory effects against 100 plaque forming units (PFU) of EV-A71 were 
evaluated in RD cells using a comprehensive inhibitory assay. A peptide was considered 
to have antiviral effect if it inhibited at least 80% of plaque formation at a concentration 
of 100 µM. Of the 95 overlapping synthetic peptides used, four peptides, designated as 
SP40, SP45, SP81 and SP82, exhibited significant antiviral activity against EV-A71 
infection (Figure 4.7). SP40, SP45, SP81 and SP82 reduced plaque formation by 89.3%, 
83.7%, 83.7%, and 82.5%, respectively. This study further focused on the SP40 peptide, 
as it exhibited the highest inhibitory activity. The amino acid sequence of the SP40 
peptide (Ac-QMRRKVELFTYMRFD-NH2) was highly conserved across all EV-A71 
genotypes, implying that this region plays a critical role in EV-A71 infection.  
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Figure 4.7: Identification of antiviral peptides. A library containing 95 overlapping 
synthetic peptides (15-mers) covering the entire EV-A71 capsid protein 
VP1 was synthesized. Each peptide was screened at a concentration of 
100 µM for its ability to inhibit EV-A71 infection in a plaque reduction 
assay. A schematic representation of the EV-A71 genome is shown; and 
the percentage of EV-A71 infectivity following treatment with each 
peptide is shown in the bar graph. Arrows denote the four peptides that 
inhibited > 80% of plaques.  
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4.2.2 Antiviral analysis of the SP40 peptide 
To further investigate the antiviral activities of SP40 peptide, the peptide was re-
synthesized at a higher purity of > 95% by HPLC. A scrambled peptide, SP40X (Ac-
REFTMKRMVLFRQDY-NH2) was synthesized and used as a control throughout the 
experiment. The inhibitory effect of SP40 peptide against EV-A71 at a MOI of 0.1 was 
determined using a comprehensive inhibition assay. SP40 peptide significantly reduced 
EV-A71-induced CPE (Figure 4.8A), plaque formation (Figure 4.8B) and viral protein 
expression (Figure 4.8C). The results also confirmed that SP40 peptide inhibited EV-
A71 infection in RD cells, with reduction of viral plaques by 96.3% ± 0.8 (Figure 4.9A) 
and viral RNA level by 92.0% ± 9.3 (Figure 4.9B). The inhibition concentration 50% 
(IC50) for SP40 peptide was 7.9 µM ± 3.5. The scramble SP40X did not inhibit EV-A71 
infection, except at higher concentration. This is likely due to the accumulation of 
positively-charged amino acids. Taken together, these data suggests that the amino acid 
sequence of SP40 is critical for its antiviral activity.  
To verify whether the antiviral activity of SP40 peptide was cell-specific, the SP40 
peptide was tested against EV-A71 infection in HeLa, Vero and HT-29 cell lines. As 
depicted in Figure 4.10A and B, SP40 peptide greatly inhibited EV-A71 infection in 
HeLa, Vero and HT-29 cells in a dose-dependent manner, as determined by CPE 
observation and TaqMan real-time PCR. However, SP40 peptide exhibited reduced 
efficacy in HT-29 cells as compared to the HeLa or Vero cells.  
This study also further investigated whether SP40 peptide inhibited different EV-A71 
genotypes as well as other enteroviruses. As shown in Table 4.1, SP40 peptide also 
exhibited antiviral activity against EV-A71 BrCr (genotype A), EV-A71 SHA66/97 
(genotype B3), EV-A71 SHA52/97 (genotype C2), CV-A16 strain 22159 and PV 
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vaccine strain. However, reduced antiviral activity was observed against the PV vaccine 
strain (IC50 of 18.2 µM ± 10.4).  
4.2.3 Cytotoxicity analysis of the SP40 peptide 
To evaluate whether SP40 peptide was cytotoxic to cells, RD cells were treated with 
increasing concentrations of SP40 peptide from 0 µM to 280 µM. The cell viability was 
then determined. As depicted in Figure 4.11, SP40 peptide was not toxic to cells when 
tested up to 280 µM.   
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Figure 4.8: Inhibitory effects of SP40 and SP40X peptides on CPE, plaque formation 
and protein synthesis. (A) For CPE, EV-A71 at a MOI of 0.1 was pre-
incubated with peptides for 1 hour before infection of peptide-treated RD 
cells. The images were taken at 24 hours post-infection. CPE was seen as 
round and shrunken cells, which eventually dislodged from the surface. 
(B) For the plaque reduction assay, approximately 100 PFU of EV-A71 
were pre-incubated with peptides for 1 hour before infection of the 
peptide-treated RD cells. The cells were fixed with 4% formaldehyde 
and stained with 0.5% crystal violet at 48 hours post-infection. (C) 
Western blot analysis of total protein isolated from virus-infected cells 
using the anti-EV-A71 monoclonal antibodies and monoclonal anti-β-
actin antibodies. The molecular weights of the EV-A71 protein and β-
actin are 36 kDa and 42 kDa, respectively. 
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Figure 4.9: Antiviral activities of the SP40 and SP40X peptides. Both RD cells and 
EV-A71 were separately pre-incubated with increasing concentrations of 
each peptide for 1 hour before viral inoculation. The inhibitory levels of 
the peptide were evaluated at 24 hours post-infection by (A) plaque assay 
and (B) TaqMan real-time PCR. At each peptide concentration, titers are 
the average of two biological replicates; error bars represent the standard 
deviation of the mean.  
 
105 
 
Figure 4.10:  The antiviral activities of the SP40 peptide in various cell lines. Vero, 
HeLa and HT-29 cell lines were pre-treated with the SP40 peptide at 
various concentrations for 1 hour at room temperature before infection 
with EV-A71 at a MOI of 0.1. (A) The viral-induced CPE in various cell 
lines were observed 24 hours post-infection. CPE was seen as round and 
shrunken cells, which eventually dislodged from the surface. (B) Viral 
RNA inhibition was quantitated by TaqMan real-time PCR. At each 
peptide concentration, percentages of inhibition are the average of two 
biological replicates; error bars represent the standard deviation of the 
mean. 
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Table 4.1: Inhibition concentration 50% (IC50) of the SP40 peptide against various 
enteroviruses 
Enterovirus Genotype Clinical manifestations IC50 (µM)
a 
EV-A71 BrCr A Aseptic meningitis 9.3 ± 2.5 
EV-A71 SHA66/97 B3 HFMD
 
6 ± 0.7 
EV-A71 41 B4 Fatal 7.9 ± 3.5 
EV-A71 SHA52/97 C2 HFMD 8.5 ± 2.8 
CV-A16 - HFMD 6 ± 0.8 
PV vaccine strain - - 18.22 ± 10.4 
a
The IC50s are presented as mean ± standard deviation determined from at least two 
independent experiments 
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Figure 4.11: Cytotoxicity assay. RD cell monolayers in a 96-well plate were treated 
with increased concentrations of SP40 peptide. Cell viability was 
assayed as an absorbance reading at 490 nm. At each peptide 
concentration, the absorbance readings are averages of two biological 
replicates; error bars represent the standard deviation of the mean. 
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4.2.4 Mechanism of action of the SP40 peptide 
Since the amino acid sequence of SP40 peptide was critical for its antiviral activity, 
further understanding of the mechanism of action is required. The data from the 
comprehensive assay suggests that the SP40 peptide could exert its antiviral activity 
through inhibition of the viral binding step or inactivation of the virus. To further 
elucidate the mechanism, either cells or viruses were pre-treated with SP40 peptide 
before infection. When the viruses at a MOI of 10 were pre-treated with the SP40 
peptide, followed by 200-fold dilution prior to infection, the SP40 peptide lost its 
antiviral activity against EV-A71, and this implied that SP40 peptide did not inactivate 
the virus (Figure 4.12).  
When only the cells were pre-treated with SP40 peptide, significant inhibition of EV-
A71 infection was observed with an IC50 value of 15 µM. This result suggests that the 
SP40 peptide could either inhibit EV-A71 at the pre-binding step or post-binding step. 
To address this, RD cells were pre-treated with various concentrations of the SP40 
peptide at 4°C for 1 hour, followed by EV-A71 at a MOI of 100 at 4°C for 1 hour. The 
EV-A71 viral particles that attached to the cells surface were then determined by 
immunofluorescence assay and further quantitated by high content screening analysis. 
As shown in Figure 4.13A, the number of EV-A71 viral particles (with Alexa Fluor 488 
green fluorescence) attached to the SP40 peptide-treated cell surface was significantly 
lower compared to the untreated cells. This result was further verified by Cellomics 
HCS ArrayScan Spot Detector Bio-Application and TaqMan real-time PCR. As shown 
in Figure 4.13B, the number of spots per field for SP40 peptide-treated RD cells (68 ± 
20 spots/field) was lower compared to the untreated cells (210 ± 39 spots/fields). The 
results correlated well with TaqMan real-time PCR (Figure 4.13C). To investigate if 
SP40 peptide inhibited the EV-A71 post-binding step, RD cells were pre-treated with 
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EV-A71 at 4°C for 1 hour to allow the virus to bind to the cells, followed by addition of 
SP40 peptide. The cells were washed and then immediately shifted to 37°C for 1 hour to 
allow the virus to enter the cells. However, SP40 peptide lost its antiviral activity, which 
implies that SP40 peptide blocked EV-A71 infection at the pre-binding step. These 
findings suggest that SP40 peptide could interact with the attachment receptor targeted 
by EV-A71 and hence block the attachment event.  
To further verify whether the SP40 peptide still inhibits EV-A71 infection in the post-
infection event, SP40 peptide was administered 1 hour after EV-A71 infection. The 
SP40 peptide was found to be non-inhibitory when added 1 hour after infection, with an 
IC50 value of 200 µM (Figure 4.12).  
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Figure 4.12: Mechanism of action studies of SP40 peptide. The SP40 peptide was 
administered at different time points relative to viral inoculation, and 
plaque assay was performed 24 hours post-infection. In the 
comprehensive assay, both RD cells and EV-A71 were pre-treated with 
the SP40 peptide for an hour before infection. In the cell protection assay, 
RD cells were pre-treated with the peptide for an hour before virus 
inoculation. In the post-infection assay, RD cells were infected with EV-
A71 for an hour before addition of the peptide-containing media. In the 
virus inactivation assay, EV-A71 was pre-treated with the peptide for an 
hour, and diluted 200-fold before infection of RD cells. At each peptide 
concentration, percentages of plaque inhibition are the average of two 
biological replicates; error bars represent the standard deviation of the 
mean
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Figure 4.13: Effect of SP40 peptide on EV-A71 attachment. (A) Immunofluorescence 
analysis of EV-A71 viral particles attached on the RD cell surface. EV-
A71 viral particles were probed with anti-EV-A71 antibodies and Alexa 
Fluor 488; and cell nuclei were stained with DAPI. EV-A71 viral 
particles and nuclei are shown in green and blue fluorescence, 
respectively. The number of virus particles attached to the cell surface 
were quantified by (B) TaqMan real-time PCR assay and (C) Cellomics 
HCS ArrayScan Spot Detector Bio-Application. At each peptide 
concentration, titers are the average of two biological replicates; error 
bars represent the standard deviation of the mean. 
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4.2.5 Alanine scanning analysis 
Identification of the amino acids critical for the antiviral activity of SP40 peptide can 
determine the mechanism of action, and identify the potential receptor binding site. 
Alanine scanning is the most common method used to identify the amino acid residues 
critical for activities. Thirteen peptides with alanine substitutions in each amino acid 
position of the 15-mer SP40 peptide were synthesized. The inhibitory effects in RD 
cells at 200 µM of all peptides were evaluated. Reduction of viral RNA levels by each 
of the peptides were evaluated and are summarized in Figure 4.14. Substitution of an 
arginine residue at position 3 (P3) with alanine significantly reduced the antiviral 
activity from 95.9% to 60.8%. Substitution of other positively-charged amino acids 
(lysine and arginine) at positions 4, 5 and 13 (P4, P5 and P11) of the SP40 peptide with 
alanine caused a moderate reduction of antiviral activity, from 95.9% to 74.3%, 70.9% 
and 70.6%, respectively. Substitution of a polar amino acid, methionine, at position 12 
(P10) with alanine also reduced the antiviral activity moderately to 74.7%. Alanine 
substitution of other amino acids at other positions of the SP40 peptide did not alter its 
antiviral activity. These results indicated that the positively-charged amino acids of 
SP40 peptide were critical for its antiviral properties. Substitution of a polar methionine 
also reduced the antiviral properties.  
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Figure 4.14: Alanine scanning analysis of SP40 peptide. Thirteen different peptides 
(P1-P13) were synthesized by replacing one residue at a time with an 
alanine and their inhibitory effect was determined, compared with the 
original SP40 represented by the red line. SP40X, a scrambled peptide, 
was used as a negative control. Percentages higher than the red line 
showed a gain of antiviral activity whereas a lower number represented a 
loss of antiviral activity. Data presented are mean of two biological 
replicates; error bars represent the standard deviation of the mean. 
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4.2.6 Three-dimensional structure analysis 
With the recent available crystal structure of EV-A71, the position of the SP40 peptide 
was located and characterized (Figure 4.15). The SP40 peptide was not positioned on 
the surface, but the lysine residues of SP81 and SP82, which also exhibited antiviral 
activity (see section 4.2.1) were highly exposed on the surface.  
4.2.7 Synergistic antiviral activities of the SP40 peptide with SP81 
To investigate whether the SP40 peptide exhibited synergistic antiviral activities with 
other peptides, the SP40 peptide was combined with SP45 and SP81 (> 70% purity by 
HPLC) to a final concentration of 200 µM. The SP40 peptide exhibited synergistic 
antiviral activity with SP81 peptide to achieve a total viral RNA inhibition of 99.7% 
when compared to 92.0% inhibition by the SP40 peptide alone. However, the SP40 
peptide had less synergistic effect when combined with the SP45 peptide, with viral 
RNA inhibition of 94.3%. When all the three peptides were combined, viral RNA 
inhibition achieved was 98.8%. There were only few amino acids difference between 
SP81 and SP82 peptides, implying that these two peptides could share similar 
mechanism in action. Therefore, synergistic antiviral activities of SP40 and SP82 
peptides were not included in this study. These data suggest that all these peptides could 
potentially target different host factors that are important for EV-A71 infection.  
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Figure 4.15: Proposed location of the SP40 peptide based on the recently determined 
EV-A71 crystal structure (PDB accession number 4AED). The molecular 
structures of EV-A71 VP1, VP2, VP3, and VP4 are represented by red, 
blue, green and grey, respectively. The SP40 peptide sequence is 
indicated in yellow. 
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4.3 Enterovirus A71 uses cell surface heparan sulfate glycosaminoglycan as an 
attachment receptor 
The previous section describes the discovery of an antiviral peptide, SP40 peptide, 
which exhibited significant antiviral activity against EV-A71 infection. Alanine 
scanning analysis revealed that the positively-charged amino acids were critical for the 
antiviral activity. This implies that SP40 peptide may interact with a highly negatively-
charged attachment factor present on the cell surface, and block viral attachment. 
Interestingly, SP40 peptide also carries a heparan sulfate mimetic-binding domain (-
RRK-). These findings led to the postulation that EV-A71 may utilize highly 
negatively-charged cell surface heparan sulfate as an attachment receptor. The 
following sub-sections provide evidence to support this hypothesis. 
4.3.1 Inhibitory effects of heparin, dextran sulfate, chondroitin sulfate and suramin 
against enterovirus A71 infection 
To characterize whether cell surface GAGs play a significant role in viral receptor 
interaction, various concentrations of heparin and chondroitin sulfate were pre-
incubated with EV-A71 at a MOI of 0.1 for 1 hour at 37˚C before infection of RD cells. 
The viral titers were quantified 24 hours post-infection using quantitative TaqMan real-
time PCR and plaque assay. Of the two GAGs evaluated, significant inhibition of EV-
A71 by heparin and chondroitin sulfate was observed only at concentrations higher than 
500 µg/ml (Figure 4.16A). The inhibitory effect of heparin was most significant at 79.4 
± 2.9% compared to chondroitin sulfate (38.5 ± 6.4%) when tested at a concentration of 
1000 µg/ml (P < 0.05). A similar inhibitory trend was observed in the plaque assay 
(Table 4.2).  
To further investigate the significance of the carbohydrate backbone on the inhibition of 
EV-A71, polyanions dextran sulfate (2.3 sulfate groups/glucosyl group) and 
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polysulfonate suramin (6.0 sulfate groups/molecule) were used. Previous studies have 
shown that suramin inhibits viruses such as DENV and HBV virus which bind to cell 
surface heparan sulfate (Chen et al., 1997; Schulze et al., 2007). Viral inhibition 
increased with concentration of the tested inhibitors, and at 1000 µg/ml the inhibition 
was 65.8 ± 6.7% for dextran sulfate and 63.4 ± 6.1% for suramin (Table 4.2). However, 
suramin was more effective as it was able to inhibit EV-A71 infection at a concentration 
as low as 20 µg/ml (Figure 4.16A). Inhibition of EV-A71 infection by the suramin 
analog NF449 was previously demonstrated by Arita et al. (2008b). 
Pre-incubation of RD cells with heparin and dextran sulfate at concentrations from 100-
1000 µg/ml before viral infection had no inhibitory effect, but enhanced the virus 
infectivity. The results demonstrated that the inhibitory effect was due to direct 
interaction of these compounds with the virus and not to the target cells (Figure 4.16A 
and 4.16B).  
4.3.2 Inhibitory effects of anti-heparan sulfate peptide and poly-D-lysine peptide 
against enterovirus A71 infection 
To assess the important role of negative charges carried on the cell surface in the 
binding of EV-A71, RD cells were pre-incubated with poly-D-lysine to neutralize cell 
surface negative charges before EV-A71 infection at a MOI of 0.1. As shown in Figure 
4.16C, poly-D-lysine strongly decreased EV-A71 infection in a dose-dependent manner 
when applied from 1 to 5 µg/ml. At 5 µg/ml, the inhibition was significant, with viral 
RNA inhibition of 99.1 ± 0.2%. Concentrations higher than 5 mg/ml were found to be 
cytotoxic to RD cells. To ascertain whether the negative charge carried by heparan 
sulfate present on the cell surface plays a significant role in viral attachment, two anti-
heparan sulfate peptides identified by Tiwari et al. (2011), G1 (LRSRTKIIRIRH) and 
G2 (MPRRRRIRRRQK) were evaluated for their inhibitory effects. The inhibitory 
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effect of G2 was significant with viral RNA inhibition of 76.5 ± 26.8% at 1000 µg/ml. 
The G1 peptide did not inhibit EV-A71 infection (Figure 4.16C). These data confirmed 
that EV-A71 binds to cell surface heparan sulfate.  
4.3.3 Inhibitory effect of heparin against enterovirus A71 clinical isolates 
Heparan sulfate binding phenotype is often acquired through tissue culture adaptation as 
previously observed in Sindbis virus and FMDV (Jackson et al., 1996; Klimstra et al., 
1998). To verify that the heparan sulfate binding phenotype of EV-A71 is not a result of 
tissue culture adaptation, the inhibitory effects of heparin against various laboratory EV-
A71 strains (BrCr, 41, UH1/97 and SHA66/97) and low passage clinical EV-A71 
isolates from the Diagnostic Virology Laboratory, University Malaya Medical Center 
(EV-A71 strains 14716, 35017, 1657640 and 1687413) was evaluated. Heparin at 2500 
µg/ml was observed to have an inhibitory effect on both laboratory strains and low 
passage EV-A71 isolates (Figure 4.17). The inhibitory effects varied between strains. 
The inhibition of the laboratory strains ranged from 61.4-98.0%, while inhibition of the 
low passage isolates ranged from 30.4-78.4%. Interestingly, heparin failed to inhibit the 
PV vaccine strain even when tested at 2500 µg/ml, implying that PV does not use 
heparan sulfate as attachment receptor. The data suggested that the heparan sulfate-
binding phenotypes were not likely acquired through tissue culture adaptation. 
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Figure 4.16: Inhibitory effects of GAGs and inhibitors. For the viral inactivation assay, 
various concentrations of (A) GAGs, polyanionic dextran sulfate and 
suramin were pre-incubated with EV-A71 for 1 hour at 37°C before 
infection of RD cells at room temperature. For the cell protection assay, 
various concentrations of (B) GAGs, (C) poly-D-lysine and anti-heparan 
sulfate peptides, designated as G1 and G2 peptides, were pre-incubated 
with RD cells for 1 hour at 37°C before EV-A71 infection. The viral 
RNA was extracted and quantified by TaqMan real-time PCR 24 hours 
post-infection. The data were obtained from at least two biological 
replicates and the error bars indicate the standard deviation of the mean. 
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Figure 4.17: Inhibitory effect of heparin against EV-A71 isolates and the PV vaccine 
strain. EV-A71 and PV viral particles were pre-treated with heparin at a 
final concentration of 2500 µg/ml for 1 hour at 37°C before RD cell 
infections. The low passage EV-A71 isolates (14716, 35017, 1657640 
and 1687413) and the PV vaccine strain were obtained from the 
Diagnostic Virology Laboratory, University Malaya Medical Center. The 
viral titers of EV-A71 and the PV vaccine strain were quantified 24 
hours post-infection by TaqMan real-time PCR and plaque assays, 
respectively. The data were obtained from at least two biological 
replicates and the error bars indicate the standard deviation of the mean. 
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Table 4.2: Effect of GAGs, GAG variants and inhibitors tested on EV-A71 
infection
 
 
Inhibitors 
a
 Inhibition (%) 
Viral plaque reduction  Viral RNA reduction 
Heparin 95.5 ± 0.7 79.4 ± 2.9 
Chondroitin sulfate 52.4 ± 16.4 38.4 ± 6.4 
De-N-sulfated heparin 70.0 ± 1.1 39.7 ± 15.6 
Dextran sulfate 95.2 ± 0.7 65.8 ± 6.7 
Suramin 76.3 ± 2.4 63.4 ± 6.1 
a
 The concentration of inhibitors used was 1000 µg/ml.  
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4.3.4 Characterization of the residues critical for the inhibitory properties 
To establish if the degree of sulfation of heparin is critical for viral inhibition, different 
sulfated heparin variants were investigated. N-acetyl-de-O-sulfated heparin, which is 
completely de-sulfated (0 sulfate group/disaccharide), failed to abolish EV-A71 
infection (Figure 4.18A). In contrast, de-N-sulfated heparin (0.8-1.2 sulfate 
group/disaccharide) showed moderate inhibition (39.7 ± 15.6%) and the wild-type 
heparin (2.4 sulfate group/disaccharide) exhibited the most significant inhibition (79.4 ± 
2.9%) at 1000 µg/ml, indicating that the degree of sulfation within the GAG 
carbohydrate structure is functionally important. Inhibition of viral plaque formation by 
these GAGs and inhibitors are shown in Table 4.2. 
To further confirm the role of sulfation of heparan sulfate in EV-A71 attachment, EV-
A71 infection of RD cells grown in medium containing 0-50 mM of sodium chlorate 
was carried out. Sodium chlorate inhibits cellular adenosine triphosphate sulfurylase, 
which reduces sulfation of heparan sulfate by up to 60% (Giroglou et al., 2001; 
Guibinga et al., 2002). As shown in Figure 4.18B, RD cells treated overnight with 
sodium chlorate had significantly reduced EV-A71 infection in a dose-dependent 
manner in all the EV-A71 strains tested. Sodium chlorate inhibited EV-A71 strains 41, 
UH1, SHA66 and BrCr infections at 50 mM with viral RNA inhibition of 92.7 ± 2.7%, 
79.0 ± 3.3%, 83.2 ± 4.2%, and 61.5 ± 5.5%, respectively. To rule out the possibility that 
the reduction of EV-A71 was due to the cytotoxicity of sodium chlorate, cytotoxicity of 
sodium chlorate was evaluated by the commercially available MTT assay. Sodium 
chlorate showed no toxicity at 10 mM and 30 mM, and minimal cytotoxicity at 50 mM 
(data not shown).  
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Figure 4.18: Identification of residues critical for the inhibitory effect. (A) EV-A71 
was pre-incubated with various concentrations of heparin and heparin 
variants for 1 hour at 37 °C before infection of RD cells. N-acetyl-de-O-
sulfated heparin is completely desulfated, and de-N-sulfated heparin is 
partially desulfated compared to heparin. (B) Inhibitory effect of sodium 
chlorate on RD cells against different EV-A71 strains. RD cells were 
pre-treated with increasing concentrations (0 mM, 10 mM, 30 mM and 
50 mM) of sodium chlorate for 24 hours before EV-A71 (strains BrCr, 
41, UH1 and SHA66) infection at a MOI of 0.1. Data presented are 
obtained from at least two biological replicates. Error bars indicate 
standard deviation of the mean. 
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4.3.5 Removal of cell surface heparan sulfate using enzymatic treatment 
To identify the type of GAG which is responsible for EV-A71 binding to RD cells, the 
binding of EV-A71 to cells after enzymatic removal of cell surface GAGs with 
chondroitinase ABC and heparinase I/II/III digestion was examined. Heparinase I 
degrades heparin and highly sulfated domains in heparan sulfate (relative activity about 
3:1) at the linkages between hexosamines and O-sulfated iduronic acids. Heparinase II 
cleaves heparan sulfate, and to a lesser extent heparin (relative activity about 2:1) at the 
1-4 linkages between hexosamines and uronic acid residues. Heparinase III specifically 
degrades heparan sulfate (Ernst et al., 1995; Chen et al., 1997). Treatment of RD cells 
with each of the heparinases at 2.5 mIU/ml and 5.0 mIU/ml for 1 hour at 37˚C was 
found to significantly reduce the viral RNA (Figure 4.19A) 24 hours post-infection in a 
dose-dependent manner. Treatment of RD cells with heparinase I, II and III at 5.0 
mIU/ml significantly inhibited EV-A71 viral RNA by 68.6 ± 6.2%, 91.7 ± 4.1% and 
82.2 ± 11.7%, respectively (Figure 4.19A). Removal of cell surface chondroitin sulfate 
by chondroitinase ABC failed to inhibit EV-A71 infection (Figure 4.19A), even when 
tested at concentrations as high as 20 mIU/ml (data not shown). Removal of cell surface 
heparan sulfate significantly reduced the infectivity of the different EV-A71 strains 
tested, but not the PV vaccine strain (Figure 4.19B). Removal of surface heparan sulfate, 
but not chondroitin sulfate, significantly reduces EV-A71 attachment to the surface of 
RD cells (Figure 4.19C). 
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Figure 4.19, continued 
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Figure 4.19: Effect of heparinases and chondroitinase ABC treatment on EV-A71 
infection. (A) Inhibitory effect of heparinase I, II, III and chondroitinase 
ABC on EV-A71 infection. RD cells were pre-treated with heparinases 
or chondroitinase ABC for 1 hour at 37˚C before EV-A71 infection at a 
MOI of 0.1. The viral RNA was extracted and evaluated by TaqMan 
real-time PCR. (B) Inhibitory effect of heparinase I against different EV-
A71 strains and PV vaccine strain. PV vaccine strain was used as a 
control virus. (C) Confocal microscopy analysis (40X magnification) of 
EV-A71 binding assay after heparinase I and chondroitinase ABC 
treatments. EV-A71 viral particles were stained with monoclonal anti-
EV-A71 antibody and subsequently stained with Alexa Fluor 488 anti-
mouse IgG. Nuclei were stained with DAPI. EV-A71 viral particles and 
nuclei are shown in green and blue, respectively. 
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4.3.6 Knockdown of heparan sulfate biosynthesis expression using small interference 
RNA  
To further confirm that heparan sulfate plays an important role in EV-A71 infection, 
expression of the NDST-1 and EXT-1 genes were transiently knocked down using 
siRNA. NDST-1 is a heparan sulfate modification enzyme which removes N-acetyl 
groups from the selected N-acetylglucosamine (GlcNAc) residues and replaces them 
with sulfate groups (Presto et al., 2008). EXT-1 is a heparan sulfate polymerase that 
adds alternating units of glucuronic acid (GlcA) and GlcNAc to the non-reducing end of 
the chain. RD cells were transfected with various concentrations of NDST-1 and EXT-1 
siRNAs for 24 hours using Lipofectamine 2000 reagent before infection with EV-A71 
at a MOI of 0.1. As shown in Figure 4.20, transient knockdown of both NDST-1 and 
EXT-1 expression in RD cells significantly reduced EV-A71 infection with inhibition 
up to 80.1 ± 7.7% and 57.2 ± 19.1% at 20 nM, respectively. However, the scrambled 
negative control siRNA did not reduce EV-A71 infection.  
4.3.7 Binding of enterovirus A71 to Chinese hamster ovary (CHO) cells that are 
variably deficient in glycosaminoglycan biosynthesis 
CHO cells with defects in the biosynthesis of GAGs have been extensively used to 
demonstrate the involvement of heparan sulfate as the receptor for binding of various 
viruses (Summerford and Samulski, 1998; Goodfellow et al., 2001; Guibinga et al., 
2002; Vlasak et al., 2005; Schulze et al., 2007). The mutant CHO-pgsD677 cells are 
deficient in N-acetylglucosaminyltransferase and glucuronosyltransferase activities 
required for heparan sulfate polymerization, and thus completely lack heparan sulfate. 
These cells also produce three- to four-fold higher levels of chondroitin sulfate when 
compared to the wild-type CHO-K1 cells (Lidholt et al., 1992). The mutant CHO-
pgsA745 cells are deficient in the enzyme UDP-D-xylose:serine-1,3-D-
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xylosyltransferase, which catalyses the first sugar transfer reaction in GAG formation, 
and thus completely lack GAGs (Esko et al., 1985).  
To investigate whether EV-A71 binds differently in these cell lines, cells were seeded in 
CellCarrier-96 and chamber slides, and infected with EV-A71 at an MOI of 100 for 1 
hour at 4°C. As shown in Figure 4.21, significantly lower numbers of viral particles 
were attached to the CHO-pgsD677 and CHO-pgsA745 cells when compared to the 
wild-type CHO-K1 which expressed normal levels of heparan sulfate (P <0.001). 
Results from Cellomics HCS VTI array scaning demonstrated that CHO-pgsD677 and 
CHO-pgsA745 cells showed reduced binding of 46.7% and 41.6%, respectively when 
compared to CHO-K1 cells. Interestingly, more viral particles were bound to RD when 
compared to CHO-K1 cells. This could result from the different levels of heparan 
sulfate expression or the sulfation phenotypes in RD and CHO-K1 cells.  
4.3.8 Binding of enterovirus A71 to immobilized heparin sepharose beads 
To characterize the interaction of EV-A71 particles to GAGs, virus-containing 
supernatant was applied to a heparin affinity chromatography column under normal 
physiological salt conditions (0.14 M NaCl) and eluted with 2M NaCl. The virus in 
each fraction collected was quantified by TaqMan real-time PCR and plaque assay for 
EV-A71 and PV, respectively. As depicted in Figure 4.22A, most of the EV-A71 viral 
particles were detected in all the eluates following application of 2M NaCl. The EV-
A71 viral particles present in eluate 1 were concentrated by up to 4.1-fold. In a control 
experiment, a column packed with sepharose alone showed no binding of EV-A71 viral 
particles to the column (Figure 4.22B). The results confirm that the EV-A71 particles 
bind to heparin and were eluted by high salt concentrations. In contrast to EV-A71, the 
PV vaccine strain did not interact with heparin sepharose and most of the PV viral 
particles were detected in the flow-through fraction (Figure 4.22A). This result 
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confirmed that EV-A71 binds to cell surface heparan sulfate, and PV does not.  
4.3.9 Enterovirus A71 three-dimensional structuring and prediction of heparan sulfate 
binding domains 
To determine the possible heparan sulfate binding site(s) on the EV-A71 viral particles, 
the three-dimensional crystal structure of EV-A71 was built using DeepView Swiss 
PDB viewer (Guex and Peitsch, 1997). As shown in Figure 4.23A, amino acids Arg166, 
Lys242 and Lys244 are arranged symmetrically in the 5-fold axis of the EV-A71 
pentamer structure. These amino acids are also located at positions which are highly 
exposed on the surface of the EV-A71 viral particle (Figure 4.23B). All these amino 
acids were highly conserved across all EV-A71 genotypes with the exception of Lys244, 
where lysine (K) was substituted with glutamic acid (E) in genotype A (Figure 4.23C). 
These symmetrically arranged clusters of positively-charged amino acids could serve as 
the major binding site for heparan sulfate.  
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Figure 4.20: Effect of transient siRNA knockdown of NDST-1 and EXT-1 expression 
on EV-A71 infection. The NDST-1 and EXT-1 siRNA in lipofectamine 
2000 reagent was transfected into RD cells for 24 hours before EV-A71 
infection. The viral load was determined 24 hours post-infection by 
TaqMan real-time PCR. An siRNA with a nonsense sequence was used 
as a control. The data presented are means obtained from at least two 
biological replicates. Error bars indicate standard deviation of the mean. 
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Figure 4.21: Binding of EV-A71 to CHO-K1 and CHO mutant cells. CHO-K1 cells 
and CHO mutants defective in proteoglycan synthesis were assessed for 
their ability to bind to EV-A71. Cell line CHO-pgsA745 lacks heparan 
sulfate and chondroitin sulfate proteoglycans, while CHO-pgsD677 lacks 
heparan sulfate proteoglycan but produces 15% of normal proteoglycans. 
Binding of EV-A71 to parental and mutant CHO cells was assayed using 
(A) confocal microscopic analysis (40X magnification) and (B) 
Cellomics HCS ArrayScan VTI SpotDetector BioApplication and 
verified by TaqMan real-time PCR. EV-A71 viral particles and nuclei 
are shown in green and blue, respectively. The data presented are means 
obtained from at least two biological replicates. Error bars indicate 
standard deviation of the mean. 
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Figure 4.22: Binding of EV-A71 and PV to immobilized heparin-sepharose column. 
(A) EV-A71 and PV supernatants were passed through a column of 
immobilized heparin-sepharose and eluted with 2M NaCl. The viral titers 
of EV-A71 and PV vaccine strain from each fraction were quantified by 
TaqMan real-time PCR and plaque assay, respectively. EV-A71 is 
presented as viral RNA/ml and the PV vaccine strain was presented as 
PFU/ml. (B) Binding of EV-A71 to the sepharose beads. Error bars 
represent means ± SD of each fraction. 
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Figure 4.23: Three-dimensional pentameric structure and sequence alignment of EV-
A71. The structure of the EV-A71 pentamer was generated using 
DeepView Swiss PDB viewer. The molecular structure of EV-A71 VP1, 
VP2, VP3 and VP4 is represented by blue, green, red and purple, 
respectively. The amino acids Arg166, Lys242 and Lys244 are indicated 
in yellow, white and light blue, respectively. (A) Top view and (B) side 
view of the EV-A71 pentamer. (C) Histogram showing sequence 
consensus in the VP1 region of EV-A71. A total of 174 sequences were 
aligned and analyzed using ClustalW2. The arbitrary scale is depicted to 
the left of the histogram and 1.0 denotes perfect consensus at a given 
amino acid site across all entries. The alignment of Arg166, Lys242 and 
Lys244 of representative EV-A71 strains from genotypes A, B and C are 
shown above the histogram. 
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4.3.10 Enterovirus A71 receptors analysis 
Multiple receptors have been discovered for EV-A71 infection, which include human 
SCARB2, PSGL-1, sialic acid, annexin II and vimentin (Nishimura et al., 2009; 
Yamayoshi et al., 2009; Yang et al., 2009; Yang et al., 2011; Du et al., 2014). In this 
study, the sequential events of the SCARB2 and heparan sulfate usage were investigated. 
RD cells in a chamber slide were incubated with EV-A71 viral particles at an MOI of 
100 at 4°C for an hour. The cells were either immediately fixed or shifted to 37°C for 
15 minutes before being fixed with 4% formaldehyde. The cells were then stained with 
anti-EV-A71 monoclonal antibodies and either anti-heparan sulfate monoclonal 
antibodies or anti-SCARB2 monoclonal antibodies. The nuclei were visualized by 
DAPI stain. At 4°C, most of the virus particles were co-localized with the heparan 
sulfate receptor (Figure 4.24A). However, when the temperature was shifted to 37°C for 
15 minutes, most of the virus particles were now co-localized with SCARB2 receptor 
(Figure 4.24B). These results indicated that cell surface heparan sulfate serves as an 
attachment receptor and virus entry required further interactions with the SCARB2 
entry receptor.  
Cell surface sialic acid and heparan sulfate were removed using neuraminidase V and 
heparinase I/III blend, respectively, leading to the reduction of EV-A71 infection 
(Figure 4.25). Interestingly, the inhibition of EV-A71 infection was higher when cell 
surface heparan sulfate was removed, suggesting that heparan sulfate is more important 
compared to sialic acid. When both cell surface sialic acid and heparan sulfate were 
removed, a greater reduction of EV-A71 infection was observed. This data suggests that 
EV-A71 selectively binds to cell surface heparan sulfate and sialic acid, and heparan 
sulfate is functionally more important than sialic acid. 
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Figure 4.24: Colocalization analyses of EV-A71 receptor interactions. Confocal 
microscopy analysis (40X magnification) of EV-A71 binding to the RD 
cells was performed at the (A) attachment stage and (B) entry stage. EV-
A71 was allowed to attach to the cell surface at 4°C for an hour, and 
viral entry was stimulated at 37°C. EV-A71 viral particles, heparan 
sulfate and SCARB2 were bound to their respective monoclonal 
antibodies and stained with the appropriate Alexa Fluor-conjugated IgG 
antibodies. Nuclei were stained with DAPI. EV-A71 viral particles and 
nuclei are stained green and blue, respectively. Both heparan sulfate and 
SCARB2 are stained red. Co-localization is indicated in yellow. 
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Figure 4.25: Effect of heparinase I/III and neuraminidase V treatment on EV-A71 
infection. RD cells were pre-treated with heparinase I/III, neuraminidase 
V or both for 1 hour before infection of EV-A71 at a MOI of 0.1. The 
virus titers were determined 24 hours post-infection by plaque assay. The 
data presented are means of two biological replicates. Error bars indicate 
standard deviation of mean.  
  
 
137 
4.4 Inhibition of enterovirus A71 infections by octaguanidinium-conjugated 
morpholino oligomers 
The absence of effective antiviral agents remains a major challenge in treatment of viral 
infection. The previous section describes the use of SP40 peptide as a receptor 
antagonist to inhibit EV-A71 infection. Other compounds including suramin and 
dextran sulfate which serve as molecular decoys also block EV-A71 infection. This 
study also further characterizes the use of antisense-mediated morpholino oligomers as 
translation inhibitors. Since the efficacy of the antisense-mediated agent is limited by 
poor uptake by cells, this study used a morpholino oligomer conjugated with a cell-
penetrating molecule, octaguanidinium (Figure 4.26A), as an anti-EV-A71 agent.  
4.4.1 Design of octaguanidinium-conjugated morpholino oligomers (vivo-MOs) 
Three antisense vivo-MOs were designed to pair with complementary sequences in the 
IRES regions of the 5’ UTR and RdRP gene of EV-A71 positive-sense RNA (Figure 
4.26B and Table 4.3). Since EV-A71 translation is highly dependent on the IRES 
structure, two vivo-MOs (vivo-MO-1 and vivo-MO-2) were designed to target the IRES 
domains V-IV of 522-577, which are highly conserved across all EV-A71 genotypes. 
PPMOs targeting these regions were previously shown to be effective against other 
picornaviruses including PV and CV-B3 (Yuan et al., 2006; Stone et al., 2008). This 
IRES region was also previously found to interact with important translational factors 
(Lin et al., 2009b; Huang et al., 2011; Shih et al., 2011), and hence these vivo-MOs 
were likely to interfere with these interactions. The vivo-MO-3 targeting EV-A71 RdRP 
was designed according to the siRNA which was previously shown to be effective 
against EV-A71 infection in vitro and in vivo (Tan et al., 2007b). A vivo-MO with a 
nonsense sequence with no homology to any EV-A71 genome was used as a control. 
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Figure 4.26: Schematic illustrations of vivo-MO and the EV-A71 genomic structure. 
(A) vivo-MO is an antisense structural type in which each subunit 
consists of a purine or pyrimidine base attached to a morpholino ring 
with a unique covalently-linked delivery moiety comprised of an 
octaguanidinium dendrimer (Moulton and Jiang, 2009). (B) Three 
genomic vivo-MOs target sequences (5’ to 3’), labeled (1), (2) and (3), 
are indicated within the proposed secondary structures of the IRES 
region and RdRP of EV-A71 RNA (upper part). The sequences of these 
three targeted regions were aligned across all EV-A71 genotypes, CV-
A16 and PV (bottom part). Mismatched nucleotides are shown in red. 
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Table 4.3: The 23-mers vivo-MOs sequences and target locations in EV-A71 RNA 
Vivo-MO Sequence (5’- 3’) Target location in EV-A71 
RNA (nucleotide position) 
Vivo-MO-1 CAGAGTTGCCCATTACGACACAC IRES core (512-534) 
Vivo-MO-2 GAAACACGGACACCCAAAGTAGT IRES core (546-568) 
Vivo-MO-3 AAACAATTCGAGCCAATTTCTTC RdRP (7303-7325) 
Vivo-MO-C CCTACTCCATCGTTCAGCTCTGA - 
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4.4.2 Inhibitory effects of vivo-MOs against enterovirus A71 infection  
To evaluate the effects of vivo-MOs on EV-A71 infectivity in RD cells, RD cells were 
treated with vivo-MOs an hour after infection. As shown in Figure 4.27, both vivo-MOs 
targeting the EV-A71 IRES stem-loop region exhibited significant antiviral activity 
against EV-A71 infection with reduction of virus-induced CPE (Figure 4.27A), viral 
plaque formation (Figure 4.27B), RNA (Figure 4.27C) and protein expression (Figure 
4.27D) in a dose-dependent manner. Vivo-MO-1 and vivo-MO-2 significantly reduced 
EV-A71 plaque formation by up to 2.7 and 3.5 log10 PFU/ml at 10 µM, respectively. 
Significant inhibition was observed at concentrations higher than 1 µM. The IC50 values 
of vivo-MO-1 and vivo-MO-2 reported in this study were 1.5 µM and 1.2 µM, 
respectively. However, vivo-MO-3 exhibited less inhibitory effect against EV-A71 
infection in RD cells with a plaque reduction of only 1.2 log10 PFU/ml. 
Besides RD cells, vivo-MOs also inhibited EV-A71 in neuroepithelial SK-N-MC cells, 
but with reduced activity when compared to RD cells. This confirms that the antiviral 
effects are not cell-specific.  
4.4.3 Cytotoxicity analysis of vivo-MOs in tissue culture  
To measure the effects of vivo-MOs on cell viability, non-infected RD cells were 
treated with various concentrations of vivo-MOs for 24 hours in maintenance medium. 
None of the three vivo-MOs caused more than 20% reduction of cell viability at 
concentrations less than 5 µM as measured by the MTS assay. Overall, vivo-MOs 
concentrations up to 5 µM showed minimal cytotoxicity to cells (Figure 4.28).  
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Figure 4.27, continued 
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Figure 4.27: Inhibitory effects of vivo-MOs in RD cells. Various concentrations of 
vivo-MOs were applied to RD cells after 1 hour post-infection and (A) 
virus-induced CPE (20 × magnification) was observed 24 hours post-
infection. CPE was seen as round and shrunken cells, which eventually 
dislodged from the surface. The total infectious particles or total viral 
proteins were harvested 24 hours post-infection and evaluated by (B) 
plaque assay, (C) TaqMan real-time PCR and (D) western blot analysis. 
EV-A71 viral capsid protein was detected by mouse anti-EV-A71 
monoclonal antibody and cellular β-actin was detected using mouse anti-
β-actin monoclonal antibody. Vivo-MO-C is the negative control with 
nonsense sequence. 
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Figure 4.28: Cell viability analysis of vivo-MOs. Various concentrations of vivo-MOs 
were incubated with RD cells for 24 hours in maintenance medium 
followed by MTS assay. The absorbance reading at 490 nm was obtained. 
The percentage of cell viability (%) was determined by dividing the 
absorbance readings obtained from vivo-MO-treated over non-treated 
cells. The data presented are means of two biological replicates. Error 
bars indicate the standard deviation of mean. 
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4.4.4 Time of addition analysis 
To further characterize the efficacy of vivo-MOs at multiple time points relative to EV-
A71 infection, vivo-MOs were applied for 4 hours before, or at 0, 1, 2, 4, or 6 hours 
after EV-A71 infection. Both vivo-MO-1 and vivo-MO-2 remained effective when 
administered before or after EV-A71 infection. When vivo-MOs and EV-A71 were 
added together into the RD cells for 1 hour, the inhibitory effect was reduced, which 
could have resulted from the incomplete uptake of the vivo-MOs by the cells. However, 
the efficacies of vivo-MO-1 and vivo-MO-2 were reduced when treatments were 
delayed. Nonetheless, the antiviral effects were retained with 92.8% plaque inhibition, 
for both vivo-MO-1 and vivo-MO-2 even when administered 6 hours post-infection. 
Vivo-MO-3 had no observable inhibitory effects on EV-A71 infection when 
administered 4 hours before infection and 2, 4, or 6 hours after EV-A71 infection 
(Figure 4.29).  
4.4.5 Inhibitory effects of vivo-MOs against other enteroviruses 
Next, the ability of the vivo-MOs to inhibit different EV-A71 strains and other 
picornaviruses were investigated. Each of the vivo-MOs was tested at a final 
concentration of 5 µM against two other EV-A71 strains (BrCr and UH1/97), PV, CV-
A16 and CHIKV as the control virus. The vivo-MO-2 which targets the highly 
conserved region of the IRES stem-loop structure exhibited significant inhibitory 
activity against EV-A71 strains BrCr and UH1/97, PV and CV-A16 with viral plaque 
reduction ranging from 1.8 - 3.1 log10 PFU/ml (Figure 4.30). However, vivo-MO-1 only 
exhibited antiviral activities against EV-A71 strains BrCr and UH1/97, and CV-A16, 
but not against PV (Figure 4.30). EV-A71 strain BrCr which has a single nucleotide 
mismatch in the middle of the vivo-MO-1 targeted site (Figure 4.26B) remained 
sensitive to the vivo-MO-1 treatment. The efficacy of vivo-MO-1 against CV-A16 (0.95 
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log10PFU/ml reduction) was significantly lower when compared to EV-A71 (1.86 
log10PFU/ml reduction). This could be due to CV-A16 having three nucleotide 
mismatches with the vivo-MO-1. PV with five nucleotide mismatches was completely 
resistant to the inhibitory effect of vivo-MO-1. The vivo-MO-C, which has no 
homologous sequence to the EV-A71 genome, was not inhibitory at all against all EV-
A71 strains tested. All the vivo-MOs did not show any inhibition of CHIKV infection. 
Thus, the antiviral activities of vivo-MOs were sequence-specific. 
4.4.6 Mechanism of action analysis of vivo-MOs 
To investigate the mechanism of action of the antiviral vivo-MOs, cell-free translation 
analysis was used. In cell-free analysis, 1 µg of infectious RNA was in vitro translated 
either in the presence or absence of 10 µM of vivo-MOs. The presence of either vivo-
MO-1 or vivo-MO-2 significantly blocked the in vitro translation of EV-A71 viral 
capsid proteins when compared to the control without vivo-MOs (Figure 4.31A). Vivo-
MO-3 exhibited reduced efficacies as compared to IRES-targeting vivo-MOs (Figure 
4.31A). In the EGFP reporter translation inhibition assay, the presence of vivo-MO-1 or 
vivo-MO-2 greatly reduced EGFP expression in RD cells 6 hours post-infection with 
EV-A71_EGFP (Figure 4.31B).  
4.4.7 Isolation and characterization of vivo-MO-resistant mutants 
Enteroviruses may escape antiviral effects through mutations (Shih et al., 2004b, de 
Palma et al., 2009). To determine whether EV-A71 could become resistant to vivo-MO 
treatments, EV-A71 was serially passaged in the presence of increasing concentrations 
of either vivo-MO-1 or vivo-MO-2. Interestingly, only EV-A71 mutants resistant to 
vivo-MO-1 were isolated after eight passages. EV-A71 mutants that were resistant to 
vivo-MO-2 could not be isolated, suggesting that the region targeted by vivo-MO-2 is 
critical for EV-A71 translation initiation. 
 146 
4.4.8 Characterization of degree of tolerance of vivo-MO mismatches against 
enterovirus A71 infection 
To investigate the determinant(s) of resistance, viral RNA was isolated from the 
resistant population and the 5’ UTR was sequenced. A single point mutation from T to 
C at position 533 was sufficient to confer resistance to vivo-MO-1 (Figure 4.32A). To 
characterize the loss of inhibitory activity by vivo-MO-1, EV-A71 mutants carrying 
various mismatches at the vivo-MO-1 target site were constructed (Table 4.4), and the 
inhibitory effects of vivo-MO-1 against each of the mutants were evaluated. The 
mismatched RNA target sequences were designed to reflect the most likely natural 
variations that would arise in the EV-A71 sequence. As shown in Figure 4.32B, the EV-
A71 MO-1-mutant-1, which carried a single point mutation at position 533 (T to C 
substitution), required higher vivo-MO-1 concentrations to achieve a similar inhibitory 
effect when compared to the wild type. The EV-A71 MO-1-mutant-2 with a single point 
mutation in the middle of the targeted sequence (a T to C substitution at position 523) 
remained sensitive to vivo-MO-1, but vivo-MO-1 had reduced inhibitory efficacy when 
compared with the wild type. Increasing the number of mutations on the targeted 
sequence significantly reduced the inhibitory efficacy of vivo-MO-1. The viral plaque 
inhibition at 2 µM of vivo-MO-1 against EV-A71 MO-1-WT was 98.9% ± 0.1, and 
reduced to 89.6% ± 3.4 for the MO-1-mutant-1 that carried a point mutation at the 3’ 
end of the target sequence. The viral plaque inhibition by vivo-MO-1 reduced to 78.0% 
when the number of nucleotide mismatches increased to three.  
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Figure 4.29: The effect of time of addition on the antiviral properties of vivo-MOs. 
Vivo-MOs at the final concentration of 5 µM were applied to RD cells at 
4 hours before or 0, 1, 2, 4, 6 hours after EV-A71 infection at MOI of 0.1. 
The data presented were obtained from at least two independent 
biological replicates. Error bars indicate standard deviation of the mean. 
Percentage of inhibition at the time points -4, +1, and +6 are shown 
above the respective bars. Asterisks indicate statistically significant 
differences compared to the control, with p < 0.05. 
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Figure 4.30: The antiviral activities of vivo-MOs against multiple enteroviruses. RD 
cells were pre-treated with each of the vivo-MOs at a final concentration 
of 5 µM for 4 hours at 37°C before infection with various enteroviruses 
(EV-A71 strains BrCr and UH1/97, PV and CV-A16) and CHIKV at 
MOI of 0.1. The inhibitory effects of each of the vivo-MOs were 
evaluated by plaque assay 24 hours post-infection. The data presented 
were obtained from at least two independent biological replicates. Error 
bars indicate standard deviation of the mean. Asterisks indicate 
statistically significant differences compared to the control, with p < 0.05. 
 
 
 
 
 
 
 
149 
 
Figure 4.31: Translation inhibition assay. (A) In vitro translation was performed with 
1 µg of RNA using the 1-Step Human Coupled IVT Kit either in the 
presence or absence of vivo-MOs at a final concentration of 10 µM. 
Aliquots of 15 µl of the translated product was subjected to SDS-PAGE 
and western blot analysis. A 36 KDa band indicates expression of EV-
A71 capsid protein. (B) EV-A71_EGFP expression assay. RD cells were 
infected with EV-A71 at a MOI of 1 for an hour at 37°C, followed by 
treatment of vivo-MOs at the final concentration of 2.5 µM.  The EGFP 
signal was detected 6 hours post-infection using a fluorescence 
microscope. EGFP expression and cell nuclei are presented as green and 
blue, respectively. 
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Table 4.4: The vivo-MO-1 sequence (3’ to 5’) and the in vitro transcribed infectious 
RNA with target sequences (5’ to 3’) 
Target Sequence Mismatch(es) 
Vivo-MO-1 3’-CACACAGCATTACCCGTTGAGAC-5’ - 
MO-1-WT 5’-GTGTGTCGTAATGGGCAACTCTG-3’ 0 
MO-1-mutant-1 5’-*********************C*-3’ 1 
MO-1-mutant-2 5’-***********C***********-3’ 1 
MO-1-mutant-3 5’-***********C***T*******-3’ 2 
MO-1-mutant-4 5’-***C*******C***T*******-3’ 3 
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Figure 4.32: Vivo-MO-1 resistant mutant analysis. EV-A71 was serially passaged in 
the presence of vivo-MO-1 from 1 µM to 5 µM. EV-A71 populations 
that were resistant to vivo-MO-1 were plaque purified, and subjected to 
DNA sequencing. (A) The DNA sequences targeted by vivo-MO-1 are 
shown in the sequencing chromatograms. The arrow indicates the T to C 
substitution at position 533 of the vivo-MO-1 resistant mutant. (B) The 
effect of sequence mismatches between vivo-MO-1 and target RNA on 
the inhibition assay. Several in vitro transcribed RNA, each having a 
different number of nucleotide mismatches in the target region were 
analyzed. Viral titers were quantitated 24 hours post-infection by plaque 
assay. The data presented were obtained from at least two independent 
biological replicates. 
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CHAPTER 5 
DISCUSSION 
5.1 Construction of enterovirus A71 infectious cDNA clone  
Development of cDNA-derived infectious viruses allows rapid characterization of the 
molecular biology of a virus (Evans, 1999). This approach is based on the infectious 
nature of the viral RNA genome in permissive host cells. An infectious cDNA clone of 
a picornavirus was first demonstrated by Racaniello and Baltimore (1981). 
Subsequently, infectious cDNA clones of coxsackievirus, hepatitis A virus and other 
enteroviruses were also constructed (Gow et al., 1996; Tellier et al., 1996a; Tellier et al., 
1996b; Martino et al., 1999). In the current study, the full-length infectious cDNA clone 
of EV-A71 strain 41 was constructed using a long distance RT-PCR technique with 
high fidelity DNA polymerase. The long distance RT-PCR approach has been 
implemented to rapidly amplify the full-length cDNA of different enteroviruses (Gow et 
al., 1996; Leister and Thompson, 1996; Cameron-Wilson et al., 2002). Combination of 
cDNA fragments into a full-length clone can be technically challenging due to the lack 
of appropriate restriction enzyme sites. The method could also easily fail due to the 
combination of cDNA fragments from incompatible quasispecies (Gow et al., 1996). 
However, a few EV-A71 infectious cDNA clones have been constructed using this 
approach (Arita et al., 2005; Chua et al., 2008; Phuektes et al., 2011). Construction of 
EV-A71 infectious cDNA clones using full genome PCR technique have also been 
previously reported (Han et al., 2010; Yeh et al., 2011). The product was then cloned 
into the high copy number vector pCR-XL-TOPO and transformed into E. coli TOP10. 
To avoid incorporation of mutations during PCR, iProof high fidelity DNA polymerase 
was used in this study, which has 52X more fidelity than normal Taq polymerase (4.4 x 
10
-7
 vs 2.28 x 10
-5 
error rate). Initially, the infectious clone was constructed using 
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Platinum Taq high fidelity polymerase which has 3X greater fidelity than normal Taq 
polymerase. However, none of the clones generated were infectious. The loss of 
infectivity could be a result of generation of lethal mutations during PCR (Yanagi et al., 
1997). 
The EV-A71 genome was cloned downstream of an SP6 bacteriophage promoter. The 
SP6 promoter-driven transcription yielded a positive-sense RNA with an additional G 
residue at the 5’ end of EV-A71 RNA. Most enterovirus infectious cDNA clones 
contain an additional 1, 2 or 3 G residues at the 5’ end of the cDNA-derived viral RNA 
and no alteration of viral infectivity has been reported (Kraus et al., 1995; Martino et al., 
1999; Arita et al., 2005). A previous study by Phuektes et al. (2011) reported that the 
infectious EV-A71 strain 6F clone with two G residues at the 5’ end was infectious. 
However, an additional G residue at the 5’ end of the in vitro transcribed RNA yielded 
substantially lower rescue viral titers compared to transfection of the purified viral RNA 
(van der Werf et al., 1986; Boyer and Haenni, 1994).  
The length of the poly(A) tail at the 3’ end plays a critical role in cDNA-derived 
enterovirus infectivity and viral RNA replication, allowing poly(A) binding protein 
interaction and initiation of VPg uridylation (Silvestri et al., 2006). Silvestri et al. (2006) 
demonstrated that increasing the length of poly(A) tail of PV significantly increased PV 
negative strand RNA synthesis. PV RNA with poly(A)11 and poly(A)12 had 1-3% of the 
level of negative-strand RNA synthesis of PV with poly(A)80. PV RNA with poly(A)20 
had a similar level of negative-strand RNA synthesis to poly(A)80. Previous studies by 
Phuektes et al. (2011) and Arita et al. (2005) demonstrated that EV-A71 infectious 
cDNA clones with poly(A)25 could produce infectious viral particles. The infectious 
cDNA clone constructed in this study carried poly(A)50 which was similar to the EV-
A71 infectious cDNA clone constructed by Yeh et al. (2011).  
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The fluorescence protein-based reporting viruses allow high content image-based assays, 
which allow rapid evaluation of the antiviral activity and cytotoxicity of compounds 
simultaneously in living cells (Shum et al., 2010). EV-A71 expressing GFP has been 
constructed previously by Yamayoshi et al. (2009) and Shang et al. (2013). The EV-
A71_EGFP-expressing infectious cDNA clone developed in this study was constructed 
using the overlapping extension PCR technique, which was simpler than restriction 
digestion and cloning, and which also allows incorporation of the desired gene into 
regions lacking suitable restriction digestion sites. With Q5 high fidelity DNA 
polymerase that has 100X greater fidelity then normal Taq polymerase, incorporation of 
undesired mutations into the EV-A71 genome during PCR was minimized.  
The phenotype of the clone-derived virus was compared with the parental virus. 
Although transfection of the in vitro transcribed RNA produced lower virus yield 
compared to the purified viral RNA, the rescued EV-A71 had similar plaque 
morphology and replication kinetics as the parental virus. This could be a result of the 
restoration of the wild type 5’ and 3’ ends of the viral genomes after transfection (Eggen 
et al., 1989; Tacahashi and Uyeda, 1999; Kusov et al., 2005; Liu et al., 2008). The in 
vitro transcribed RNA can be repaired before replication depending on the availability 
of host enzymes (Kusov et al., 2005). The EGFP-expressing EV-A71 had smaller 
plaque sizes and lower viral titers compared to the parental virus. Although producing 
lower titers, the EV-A71_EGFP RNA genome (of 8.2 kb length) remained infectious. A 
similar observation has been reported by Shang et al. (2013). Incorporation of larger 
foreign genes such as Renilla and firefly luciferase (1 kb and 1.6 kb, respectively) in PV 
infectious cDNA led to low stability and very low viral titers (Song et al., 2012).  
In conclusion, full-length infectious cDNA clones of EV-A71 strain 41 (genotype B4) 
as well as EGFP-expressing EV-A71 were successfully constructed. The availability of 
such infectious cDNA clones allows study of the pathogenesis of EV-A71 at a 
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molecular level (Arita et al., 2005; Arita et al., 2008a; Chua et al., 2008; Kung et al., 
2010; Yeh et al., 2011; Huang et al., 2012). In the current study, EV-A71 infectious 
cDNA clones were used to investigate the degree of tolerance of mismatches of vivo-
MO-1 towards its targeted sequence within the EV-A71 RNA genome.  
5.2 Development of an antiviral peptide against enterovirus A71 infections 
EV-A71 infections are not limited to mild HFMD, but in some cases, may lead to severe 
neurological complications with high mortality rates, and yet treatment remains limited 
by a lack of effective antivirals (Wu et al., 2010).  
Inhibition of viral attachment provides an option for therapeutic intervention. 
Therapeutic peptides have become an attractive tool in drug discovery due to their 
active regulatory role in biological systems and their high specificity of recognition. The 
best characterized therapeutic peptide inhibitor is enfuvirtide, a fusion inhibitor which 
mimics the N terminal sequence in the HIV fusion protein, gp41 (Kilby et al., 1998). 
Using peptides offers significant advantages over small chemical molecules or large 
therapeutic antibodies. Major advantages of peptides are their small size and their high 
activity and specificity when compared to antibodies. Peptides are better candidates to 
inhibit protein-protein interactions over a surface area often too large to be inhibited by 
small chemical molecules. Peptides accumulate in lesser quantities in tissues, and have 
very low cell toxicity compared to small synthetic molecules (Huther and Dietrich, 
2007). Antimicrobial peptides such as lactoferrin, human β-defensin-2 and dermaseptins 
have been reported to exhibit antiviral properties against various viruses (Gropp et al., 
1999; Andersen et al., 2001; Bastian and Schafer, 2001; Belaid et al., 2002; Andersen et 
al., 2003; Jenssen et al., 2006).  
Peptides derived from virus envelope or capsid that play significant roles in surface 
protein-protein interactions can exert inhibitory activities against viruses like influenza 
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virus (Jones et al., 2006), HSV-1 (Akkarawongsa et al., 2009; Tiwari et al., 2011), 
HBV (Kim et al., 2008), HCV (Cheng et al., 2008; Liu et al., 2010), HIV-1 (Kilby et al., 
1998), DENV and WNV (Hrobowski et al., 2005). Although the EV-A71 capsid protein 
VP1 has been reported to be responsible in mediating viral adsorption and the uncoating 
process, little information is available about the molecular interactions of EV-A71 and 
cell receptors (Li et al., 2007). Recently, Chen et al. (2012) identified several amino 
acid residues present within position 152-236 in the EV-A71 capsid protein VP1 that 
were critical for the molecular interaction between EV-A71 and the SCARB2 receptor.  
A Pepscan strategy was employed to screen 95-overlapping synthetic peptides 
corresponding to the VP1 capsid protein for antiviral activity against EV-A71. Four 
peptides SP40, SP45, SP81 and SP82 were found to exhibit significant antiviral 
activities. The SP40 peptide was selected for further investigation as the amino acid 
sequence of SP40 is highly conserved across all EV-A71 genotypes and subgenotypes. 
The results demonstrated that the SP40 peptide inhibited EV-A71 infection in a dose-
dependent manner corresponding to the reduction of viral RNA, viral protein and plaque 
formation. The IC50 values ranged from 6-9.3 µM against all representative strains of 
EV-A71 genotypes A, B and C. Interestingly, the SP40 peptide also inhibited CV-A16 
and PV1 infection in vitro, implying that the SP40 peptide could function as a broad-
spectrum antiviral agent. However, a higher concentration of SP40 peptide was required 
to block PV1 infection. This could be due to the high degree of dissimilarity of the 
amino acid sequences of EV-A71 and PV. 
The possible mechanism of action of the SP40 peptide could be either through direct 
virus inactivation or blocking of viral attachment and entry. This study confirmed that 
the SP40 peptide was not virucidal, but that it blocked viral attachment to the cell 
surface and hence prevented EV-A71 infection. Immunofluorescence assay showed the 
number of viral particles attached to the cell surface was reduced significantly when the 
 
157 
RD cells were pre-treated with the SP40 peptide before addition of virus at 4˚C. This 
indicated that the SP40 peptide probably first interacted with a cell surface receptor and 
subsequently prevented EV-A71-cellular receptor interactions. However, the SP40 
peptide lost its antiviral activity when the peptide was added 1 hour after EV-A71 
infection.  
Results also demonstrated the importance of the SP40 amino acid sequence for its 
antiviral activity. The inhibitory effect of the scrambled peptide SP40X, was 
significantly lower (42.5%) than the effect observed with the SP40 peptide. The SP40 
peptide could prevent viral attachment by interacting with cell receptors present on the 
surface of RD cells, thereby blocking the availability of receptors for attachment of the 
EV-A71 viral particles. The observation of a significantly reduced IC50 value when RD 
cells were pre-treated with SP40 before EV-A71 infection strongly supported this view. 
The cellular receptor that the SP40 peptide interacted with remained unknown. None of 
the amino acids identified that interact with SCARB2 (Chen et al., 2012) was mapped 
within the SP40 peptide amino acid sequence. This suggested that the SP40 peptide 
probably did not interact with the SCARB2 receptor. The SP40 peptide could also 
inhibit CV-A16 and PV1 infections in vitro, indicating that it could interact with a 
common receptor shared by these viruses.  
Since the positively-charged amino acids were critical for antiviral activities, the SP40 
peptide could interact with cell surface receptors through electrostatic charge 
interactions. The antiviral activity of the SP40 peptide was not restricted to a specific 
cell type, but it could block EV-A71 infection in different cell lines. This indicated that 
the SP40 peptide was probably interacting with a receptor that was commonly 
expressed in most cell types. Cell surface GAGs are present ubiquitously on the surface 
of most animal cells and in the extracellular matrix (Liu and Thorp, 2002). The presence 
of several arginine residues in SP40 showed similarity to an antiviral peptide against 
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HSV-1 which bore positively-charged poly-arginine residues, and which was found to 
interact with heparan sulfate (Tiwari et al., 2011). Sequence analysis of the SP40 
peptide revealed that it contained heparan sulfate GAG-specific binding domains 
(G1RRRRS6 and R28KVR31) present in bovine and human lactoferrins (Mann et al., 
1994; Shimazaki et al., 1998; Jenssen et al., 2006). Several studies have reported that 
lactoferrin was able to bind to ligands such as heparan sulfate and chondroitin sulfate 
(van der Strate et al., 2001; Marchetti et al., 2004; Jenssen et al., 2006). It is possible 
that through this interaction, lactoferrin was able to inhibit EV-A71 infection (Weng et 
al., 2005). These findings suggest that the SP40 peptide could interact with cell surface 
GAGs to prevent EV-A71 attachment. The SP40 peptide reported in this study had an 
even lower IC50 value at 15 µg/ml when compared to the IC50 value of bovine 
lactoferrin at 34.5 µg/ml (Weng et al., 2005) or human lactoferrin at 103.3-185.0 µg/ml 
(Lin et al., 2002; Wu et al., 2010).  
Interestingly, the amino acid domains in VP1 that are critical for SCARB2 binding were 
found in the SP45, SP55, and SP81 peptides. These peptides were able to inhibit EV-
A71 infections in a dose-dependent manner with no cytotoxicity to the RD cells. Strong 
synergistic antiviral activities were observed between the SP40 and the SP81 peptides in 
RD cells. The additive effects of these two peptides could have significantly reduced the 
availability of receptors for viral attachment.  
Since the SP40 peptide works at a very low micromolar concentrations, is non-cytotoxic 
to RD cells, and has activity against multiple EV-A71 genotypes, it is potentially an 
excellent candidate for further development as an antiviral agent. The SP40 peptide was 
effective when administered before EV-A71 infection and may be of particular use for 
prophylactic intervention, for example to contacts of a case of neurological EV-A71 
disease. The exact cellular receptor(s) that the SP40 peptide interacts with still remains 
unknown, but it was postulated to interact with cell surface negatively-charged GAGs 
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such as heparan sulfate. Further in vivo studies are needed for development of SP40 as 
an antiviral agent. Although a major disadvantage of peptides is their low bioavailability 
due to their rapid degradation in the gastrointestinal system, new formulations, such as 
the D-isomer peptide and other delivery options are being developed (Huther and 
Dietrich, 2007).  
5.3 Cell surface heparan sulfate as an enterovirus A71 attachment receptor 
Virus receptors are one of the determinants of virus host range and tissue tropism 
(Haywood, 1994). Receptors that are known to bind to EV-A71 have been identified 
over the past few years. PSGL-1 was the first to be discovered as an EV-A71 receptor. 
However, PSGL-1 is selectively expressed only in neutrophils, monocytes and most 
lymphocytes (Nishimura et al., 2009). The second receptor, reported by Yamayoshi et 
al. (2009), was human SCARB2 which is expressed on most types of cells (Yamayoshi 
et al., 2012).  EV-A71 binds to the SCARB2 receptor, and is then internalized through 
clathrin-mediated endocytosis (Hussain et al., 2011; Lin et al., 2013a). However, 
blocking of these receptors did not abolish EV-A71 infection and this led to discovery 
of a third receptor, annexin II. Pre-treatment of host cells with anti-annexin II antibody 
was found to reduce viral attachment. Pre-incubation of EV-A71 with annexin II also 
reduced EV-A71 infection (Yang et al., 2011).  
Besides these known receptors for EV-A71, Yang et al. (2009) reported sialylated 
glycans as a receptor for EV-A71. Treatment of RD, SK-N-SH and DLD-1 cells with 
neuraminidase was found to reduce the ability of EV-A71 to bind to the cell surface, 
confirming that EV-A71 utilizes sialylated glycans as attachment factors (Yang et al., 
2009; Su et al., 2012). Recently, vimentin, a type III microfilament, was reported as an 
EV-A71 attachment receptor. Treatment of EV-A71 with soluble vimentin as molecular 
decoys or blocking of cell surface with anti-vimentin antibodies reduced EV-A71 
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binding to the cells (Du et al., 2014). Other than these five known receptors, this current 
study has demonstrated that cell surface heparan sulfate is required for EV-A71 
attachment. In this study, EV-A71 infection of RD cells was significantly reduced when 
EV-A71 viral particles were pre-treated with soluble heparin, dextran sulfate and 
suramin. However, pre-incubation of RD cells with heparin and dextran sulfate did not 
inhibit, but unexpectedly enhanced EV-A71 infection. This could be caused by the 
creation of additional artificial binding sites through accumulation of heparin and 
dextran sulfate on the surface of cells (Hilgard and Stockert, 2000; Schulze et al., 2007). 
These findings imply that heparin or dextran sulfate could bind to the positively-
charged surface of viral particles, and prevent interaction of viral particles with the cell 
surface as demonstrated in FMDV (Fry et al., 1999). Removal of cell surface heparan 
sulfate using each of the heparinases (I, II, III) also reduced the ability of EV-A71 to 
bind to and infect RD cells which further confirmed the important role of heparan 
sulfate in EV-A71 infection. The involvement of chondroitin sulfate as a receptor for 
attachment was excluded as enzymatic removal of chondroitin sulfate did not impair 
EV-A71 infection.  
The present study demonstrated that EV-A71 could bind to CHO cells. However, CHO 
cells defective in the biosynthesis of heparan sulfate and chondroitin sulfate exhibited a 
reduced ability to bind to EV-A71, which further supports the role of heparan sulfate in 
EV-A71 infection. No infection was observed since CHO cells are not susceptible to 
EV-A71 infection in nature. The inability of EV-A71 to infect CHO cells is likely due 
to its failure to internalize and initiate infection. In TMEV GDVII, viruses bound to 
heparan sulfate were postulated to use protein entry receptors for virus internalization 
(Reddi and Lipton, 2002). A similar mechanism could be utilized by EV-A71. EV-A71 
viral particles bound to heparan sulfate may need to interact with known entry receptors 
such as SCARB2 and PSGL-1, or with an unknown protein entry receptor to gain entry 
 
161 
into the cells. CHO cells of hamster origin may have different SCARB2 since it has 
been reported that the EV-A71 binding domains in human SCARB2 and murine 
SCARB2 are different (Chen et al., 2012). Results also showed that EV-A71 was still 
able to bind to the CHO mutant completely lacking in heparan sulfate and chondroitin 
sulfate, which further suggests that multiple attachment receptors are involved during 
EV-A71 infection. This view is similar to what has been reported for several viruses 
that use heparan sulfate (Delputte et al., 2002; Reddi and Lipton, 2002; Misinzo et al., 
2006).  
Heparan sulfate is expressed by all cell types. However, they show variations in 
structure with differences in the degrees of sulfation, modification in chain length and 
the position of the sulfate group (Shi and Zaia, 2009). The data demonstrated that highly 
sulfated heparin could inhibit EV-A71 infection whereas decreased sulfation in heparin 
led to a progressive loss of EV-A71 inhibition. Completely de-sulfated heparin was 
found to have no inhibitory effect. This suggests that structural variations of heparan 
sulfate present in different cell types could lead to differences in susceptibility to 
infection, and may explain the selective tropism of EV-A71 (Jackson et al., 1996).  
Heparan sulfate binding could arise from adaptation to the cells in which isolates were 
propagated. Culture adaptations of heparan sulfate usage in picornaviruses (Sa-Carvalho 
et al., 1997; Escarmis et al., 1998), flaviviruses (Lee et al., 2004) and alphaviruses 
(Klimstra et al., 1998) have been demonstrated. In vitro cultivation of viruses was 
shown to rapidly select amino acid substitutions that increase the net positive charge of 
the envelope protein (Lee and Lobigs, 2002). However, the ability to bind to heparan 
sulfate was also documented for clinical isolates of porcine circoviruses (Misinzo et al., 
2006) and echoviruses (Goodfellow et al., 2001). The present study showed that heparin 
was able to inhibit clinical isolates of EV-A71 with low passage history, hence the 
heparan sulfate binding phenotype was not likely due to culture adaptation of EV-A71.  
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Furthermore, this study has shown that EV-A71 binds to heparin sepharose under 
physiological salt concentrations, and that the interaction could be disrupted by high salt 
concentrations. This suggests that EV-A71-heparin interactions involve mainly 
electrostatic charge interactions. Substitution of a single positively-charged amino acid 
with another amino acid is sufficient to abolish the heparin-binding phenotype in 
TMEV GDVII virus and CV-A9 (Reddi and Lipton, 2002; Reddi et al., 2004; McLeish 
et al., 2012). Thus, positively-charged amino acids present on the surface of viral 
particles are critical for heparin binding. Sequence analysis of the VP1 capsid protein 
revealed two possible heparan sulfate mimic binding domains, from residues 120-123 (-
RRKV-) and residues 241-244 (-SKSK-). Peptides with these heparan sulfate binding 
domains exhibited significant antiviral activity against EV-A71 infection in RD cells, 
suggesting that the inhibitory effect could have resulted from direct binding to heparan 
sulfate and blocking of viral attachment (Tan et al., 2012). Heparan sulfate-interacting 
regions could be linear heparan sulfate-binding domains, or are more often formed from 
clusters of basic residues that are displayed on the three-dimensional crystal structure as 
shown in FMDV and CV-A9 (Fry et al., 1999; McLeish et al., 2012). With the recent 
available crystal structure of EV-A71, the electrostatic surface of EV-A71 was 
determined (Wang et al., 2012b). A few conserved positively-charged amino acids 
(Arg166, Lys242 and Lys244) were clustered symmetrically at the 5-fold axis of the 
EV-A71 pentamer. These amino acids were also located on the surface of EV-A71 viral 
particles. These findings suggests that the interaction could be due to the electrostatic 
interactions between these clusters of basic amino acids arranged in a three-dimensional 
array on the virions and concentrated negative charges on the sulfated heparan sulfate 
chain.  
This study demonstrated that EV-A71 viral particles utilized cell surface heparan sulfate 
as an attachment receptor. Although the exact mechanism of how EV-A71 viral 
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particles interact with cell surface negatively-charged heparan sulfate remains unclear, 
determination of the molecular basis of the viral-receptor interaction within target cells 
will be useful towards understanding the pathogenicity of EV-A71 and development of 
antiviral agents against EV-A71.  
5.4 Development of an antisense-mediated translation inhibitor of enterovirus 
A71 infections 
The use of antisense mechanisms to inhibit pathogen replication has showed promising 
results. Fomivirsen, used for intravitreal treatment of cytomegalovirus retinitis, is the 
only antisense agent approved by the FDA to date (de Smet et al., 1999; Perry and 
Balfour, 1999). Various antisense molecules, mainly siRNA targeting different regions 
of the EV-A71 RNA genome, have been described (Sim et al., 2005; Tan et al., 2007a; 
Tan et al., 2007b; Deng et al., 2012; Yang et al., 2012). However, the major limitations 
of RNA-based antiviral therapeutics are short half-lives in plasma and the need for a 
delivery reagent which might be cytotoxic to cells (Song et al., 2003; Kole et al., 2012). 
To overcome these limitations, phosphorodiamidate morpholino oligomers (PMOs), 
which are highly resistant to nuclease degradation, coupled with a non-peptide cell-
penetrating molecule known as octaguanidinium dendrimer was used in this study 
(Moulton and Jiang, 2009).  These have an advantage over peptide-based cell-
penetrating molecules, which are susceptible to protease degradation that can impact the 
effectiveness of PPMOs (Youngblood et al., 2007).  
The present study examined the effects of vivo-MOs designed to interfere with the 
initiation of translation and expression of EV-A71 RdRP in RD cells. Among the three 
vivo-MOs examined, the two vivo-MOs targeting the EV-A71 IRES stem-loop region 
exhibited significant antiviral activity. The vivo-MOs blocked EV-A71 viral protein 
synthesis in a cell-free inhibition assay using HeLa cell extracts, as well as in a cell-
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based EV-A71_EGFP inhibition assay. Previous studies have also reported that only 
PMOs targeting positive strand IRES regions or the AUG start codon sites were 
effective when compared to the PMOs targeting other regions of the viral RNA (Yuan 
et al., 2006; Vagnozzi et al., 2007; Stone et al., 2008). The PMO may bind with 
complementary viral RNA and disrupt the integrity of the IRES stem-loop secondary 
structures or tertiary structures, hence arresting IRES-dependent translation. These 
PMOs were likely to block 40S ribosomal subunit binding the viral RNA in the vicinity 
of stem-loop V in the picornavirus type I IRES. Furthermore, it has been suggested that 
the IRES stem-loop V-VI of EV-A71 interacts with ITAF such as FBP and hnRNP A1 
(Lin et al., 2009b; Lin et al., 2009c; Shih et al., 2011). The mechanism of action of 
vivo-MOs was likely to be disruption of RNA structure integrity and blocking of the 
interaction between translational factors and viral RNA. Unlike synthetic double-
stranded siRNA or antisense oligonucleotides which involve cleavage of mRNA, PMOs 
are translation-suppressing oligonucleotides which are not recognized by the RNA-
induced silencing complex (RISC) or RNase H and therefore do not lead to RNA 
degradation (Kole et al., 2012). This could explain why siRNA targeting the same 
sequence as vivo-MO-3 was effective, not by acting as a translation suppression 
oligonucleotide, but by down-regulating gene expression via steric hindrance of 
ribosome access to mRNA (Tan et al., 2007b).  
The timing of treatment with vivo-MOs affects their antiviral efficacies. Vivo-MOs 
retained their antiviral activity when administered either before or shortly after EV-A71 
infection. The antiviral properties dropped significantly if the treatment was delayed in 
a time-dependent manner. These data suggest that delayed treatment may allow viral 
replication to a level that the vivo-MOs were unable to effectively interfere with viral 
translation. The cytotoxicity effects of vivo-MOs were observed at concentrations 
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higher than 5 µM, which could have resulted from the delivery moiety octaguanidinium 
dendrimer.  
Previous studies have shown that many EV-A71 subgenotypes co-circulate during 
outbreaks in Asia (Chan et al., 2012). The data presented in this study showed that vivo-
MO-1 exhibited broad-spectrum antiviral activity against different EV-A71 strains from 
different subgenotypes, and vivo-MO-2 was found to exhibit broad-spectrum antiviral 
activities against different enteroviruses, including CV-A16, another common 
etiological agent of HFMD.   
Previous studies have also demonstrated that a single nucleotide mismatch or more were 
sufficient for PPMO resistance. In this study, an EV-A71 mutant that was resistant to 
vivo-MO-1 carried a single nucleotide substitution (Vagnozzi et al., 2007; Stone et al., 
2008) of T to C at the position 533. This study failed to isolate any EV-A71 resistant to 
vivo-MO-2 even after eight passages in vitro, implying that the vivo-MO-2 targeted 
region was intolerable to any mutation in nature. Interestingly, vivo-MO-1 remained 
highly inhibitory even with a single mismatch in the middle of the target RNA of the 
EV-A71 BrCr strain, but more than one mismatch in the targeted sequence resulted in a 
substantial loss of inhibition, as seen with CV-A16 and PV. The mutagenesis studies 
further confirmed that the positions and number of mutations affect the antiviral 
efficacy in RD cells. A single mismatch present in the middle of the targeted sequence 
(T to C substitution at position 523) was more tolerable than a mutation appearing at the 
end of the targeted site (T to C substitution at position 533). These findings correlated 
well with previous findings that PV and FMDV which showed resistance to PPMO also 
carried a single point mutation at the extreme end of the PPMO-targeted sequence 
(Vagnozzi et al., 2007; Stone et al., 2008). A similar observation has been demonstrated 
in influenza virus as the degree of inhibition was associated with the number of 
mismatches (Ge et al., 2006). Unlike RNAi machinery that is extremely sensitive to 
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mutations within the central region and the 3’ end of the target sequence (Gitlin et al., 
2005), PMOs remained active even with mismatches at the central region of the targeted 
region. 
In summary, we have established two critical locations that are involved in viral 
translation initiation in the EV-A71 genome as targets for vivo-MO antiviral 
intervention. The vivo-MOs worked well at low micromolar concentrations to inhibit 
EV-A71 infection and showed little cytotoxicity in RD cells. The potent inhibition of 
several enteroviruses by vivo-MO-2 raises the possibility that it could be developed as a 
broad-spectrum antiviral agent. Furthermore, the degree of tolerance of mismatches by 
vivo-MOs is a favorable characteristic for their use as a potential antiviral agent.  
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CHAPTER 6 
CONCLUSION 
In this study, screening of 95 overlapping synthetic peptides covering the entire EV-
A71 VP1 capsid protein led to discovery of an attachment inhibitor known as SP40 
peptide, which could potentially be developed as an antiviral. The SP40 peptide 
functions as a receptor antagonist, which blocks viral attachment to the targeted receptor. 
This led to the finding of the role of cell surface heparan sulfate as an EV-A71 
attachment receptor. EV-A71 interacts with heparan sulfate via electrostatic interaction. 
Clustering of positively-charged amino acids at the 5-fold axis of EV-A71 pentamer 
may be responsible for the heparan sulfate interactions. The outcomes of this study 
support the hypothesis that screening of overlapping peptides covering the VP1 capsid 
protein could lead to identification of a viral attachment inhibitor and a previously 
unknown receptor. This study also identified two antisense-mediated vivo-MOs 
targeting two highly conserved EV-A71 IRES sites which significantly inhibited EV-
A71 infection by arresting IRES-dependent translation. Serial passaging of EV-A71 in 
the presence of increasing concentrations of the vivo-MOs led to isolation of vivo-MO-
1 resistant mutants with a single mutation at the 3’ end of the targeted site. No vivo-
MO-2 resistant mutant was isolated after 8 passages, implying that the vivo-MO-2 
targeted site is intolerant of any mutation. Overall, the attachment receptor antagonist 
and antisense-mediated translation-suppressing inhibitors could be developed into 
potential anti-EV-A71 agents.  
  
 
168 
REFERENCES 
Abes R, Moulton HM, Clair P, Yang ST, Abes S, Melikov K, Prevot P, Youngblood DS, 
Iversen PL, Chernomordik LV, Lebleu B. Delivery of steric block morpholino 
oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids 
Research. 2008; 36(20): 6343-54. 
Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B. 
Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows 
efficient splicing correction in the absence of endosomolytic agents. Journal of 
Controlled Release. 2006; 116(3): 304-13. 
Abubakar S, Chan YF, Lam SK. Outbreaks of enterovirus 71 infection. New England 
Journal of Medicine. 2000; 342(5): 355-6. 
Abubakar S, Sam IC, Yusof J, Lim MK, Misbah S, Matrahim N, Hooi PS. Enterovirus 
71 outbreak, Brunei. Emerging Infectious Diseases. 2009; 15(1): 79-82. 
Adams MJ, King AM, Carstens EB. Ratification vote on taxonomic proposals to the 
International Committee on Taxonomy of Viruses (2013). Archives of Virology. 
2013; 158(9): 2023-30. 
Airaksinen A, Pariente N, Menendez-Arias L, Domingo E. Curing of foot-and-mouth 
disease virus from persistently infected cells by ribavirin involves enhanced 
mutagenesis. Virology. 2003; 311(2); 339-49. 
Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR. Multiple peptides 
homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. 
Antimicrobial Agents and Chemotherapy. 2009; 53(3): 987-96. 
Akula SM, Wang FZ, Vieira J, Chandran B. Human herpesvirus 8 interaction with 
target cells involves heparan sulfate. Virology. 2001; 282(2): 245-55. 
Alexander DA, Dimock K. Sialic acid functions in enterovirus 70 binding and infection. 
Journal of Virology. 2002; 76(22): 11265-72. 
Ali MM, Karasneh GA, Jarding MJ, Tiwari V, Shukla D. A 3-O sulfated heparan sulfate 
binding peptide preferentially targets herpes simplex virus type-2 infected cells. 
Journal of Virology. 2012; 86(12): 6434-43. 
Altmann SE, Brandt CR, Jahrling PB, Blaney JE. Antiviral activity of the EB peptide 
against zoonotic poxviruses. Virology Journal. 2012; 9: 6. 
Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR. Inhibition of vaccinia virus entry 
by a broad spectrum antiviral peptide. Virology. 2009; 388(2): 248-59. 
Anantpadma M, Stein DA, Vrati S. Inhibition of Japanese encephalitis virus replication 
in cultured cells and mice by a peptide-conjugated morpholino oligomer. Journal 
of Antimicrobial Chemotherapy. 2010; 65(5): 953-61. 
Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit herpes 
simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. 
Antiviral Research. 2003; 58(3): 209-15. 
 
169 
Andersen JH, Osbakk SA, Vorland LH, Traavik T, Gutteberg TJ. Lactoferrin and cyclic 
lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. 
Antiviral Research. 2001; 51(2): 141-9. 
Arita M, Ami Y, Wakita T, Shimizu H. Cooperative effect of the attenuation 
determinants derived from poliovirus sabin 1 strain is essential for attenuation of 
enterovirus 71 in the NOD/SCID mouse infection model. Journal of Virology. 
2008a; 82(4): 1787-97. 
Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Phosphatidylinositol 4-
kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. 
Journal of Virology. 2011; 85(5): 2364-72. 
Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. Oxysterol-binding 
protein family is the target of minor enviroxime-like compounds. Journal of 
Virology. 2013; 87(8): 4252-60. 
Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, 
Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype a 
showed a broad spectrum of antigenicity with attenuated neurovirulence in 
cynomolgus monkeys. Journal of Virology. 2007; 81(17): 9386-95. 
Arita M, Shimizu H, Nagata N, Ami Y, Suzaki Y, Sata T, Iwasaki T, Miyamura T. 
Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus 
monkeys. Journal of General Virology. 2005; 6(Pt 5): 1391-401. 
Arita M, Takebe Y, Wakita T, Shimizu H. A bifunctional anti-enterovirus compound 
that inhibits replication and the early stage of enterovirus 71 infection. Journal of 
General Virology. 2010; 91(Pt 11): 2734-44. 
Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active 
compounds that inhibit poliovirus and enterovirus 71 infectivity. Journal of 
General Virology. 2008b; 89(Pt 10): 2518-30. 
Arita M, Wakita T, Shimizu H. Cellular kinase inhibitors that suppress enterovirus 
replication have a conserved target in viral protein 3A similar to that of 
enviroxime. Journal of General Virology. 2009; 90(Pt 8): 1869-79. 
Bai F, Town T, Pradhan D, Cox J, Ashish, Ledizet M, Anderson JF, Flavell, RA, 
Krueger JK, Koski RA, Fikrig E. Antiviral peptides targeting the West Nile virus 
envelope protein. Journal of Virology. 2007; 81(4): 2047-55. 
Banks WA, Robinson SM, Wolf KM, Bess JW Jr, Arthur LO. Binding, internalization, 
and membrane incorporation of human immunodeficiency virus-1 at the blood-
brain barrier is differentially regulated. Neuroscience. 2004; 128(1): 143-53. 
Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. 
In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to 
pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. 
Antimicrobial Agents and Chemotherapy. 2004; 48(5): 1766-72. 
 
 
170 
Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, 
Toida T, van Kuppevelt TH, Depla E, von Weizsacker F, Blum HE, Baumert, T. F. 
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell 
surface heparan sulfate. Journal of Biological Chemistry. 2003; 278(42): 41003-
12. 
Basler CF, Garcia-Sastre A. Viruses and the type I interferon antiviral system: induction 
and evasion. International Reviews of Immunology. 2002; 21(4-5): 305-37. 
Bastian A, Schafer H. Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in 
vitro. Regulatory Peptides. 2001; 101(1-3): 157-61. 
Bauer DJ, Selway JW, Batchelor JF, Tisdale M, Caldwell IC, Young DA. 4',6-
Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature. 1981; 
292(5821): 369-70. 
Belaid A, Aouni M, Khelifa R, Trabelsi A, Jemmali M, Hani K. In vitro antiviral 
activity of dermaseptins against herpes simplex virus type 1. Journal of Medical 
Virology. 2002; 66(2): 229-34. 
Belov GA, Ehrenfeld E. Involvement of cellular membrane traffic proteins in poliovirus 
replication. Cell Cycle. 2007; 6(1): 36-8. 
Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of 
antisense oligonucleotides as a therapeutic platform. Annual Review of 
Pharmacology and Toxicology. 2010; 50: 259-93. 
Bergelson JM, Coyne CB. Picornavirus entry. Advance in Experimental Medicine and 
Biology. 2013; 790: 24-41. 
Bergstrom T, Trybala E, Spillmann D. Heparan sulfate and viral tropism. Nature 
Medicine. 1997; 3: 1177. 
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 
Functions of cell surface heparan sulfate proteoglycans. Annual Reviews of 
Biochemistry. 1999; 68: 729-77. 
Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: 
epidemiological and pathological implications. Reviews in Medical Virology. 
2007; 17(6): 371-9. 
Bienz K, Egger D, Troxler M, Pasamontes L. Structural organization of poliovirus RNA 
replication is mediated by viral proteins of the P2 genomic region. Journal of 
Virology. 1990; 64(3): 1156-63. 
Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW 3rd, 
Matthews DA, Patick AK. Conservation of amino acids in human rhinovirus 3C 
protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel 
human rhinovirus 3C protease inhibitor. Antimicrobial Agents and Chemotherapy. 
2005; 49(2): 619-26. 
Binford SL, Weady PT, Maldonado F, Brothers MA, Matthews DA, Patick AK. In vitro 
resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. 
Antimicrobial Agents and Chemotherapy. 2007; 51(12): 4366-73. 
 
171 
Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, von Zeipel G. New 
enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, 
and mouth disease. Lancet. 1974; 304(7872): 112. 
Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, van der 
Schueren B, David G, Gallay PA. Contribution of proteoglycans to human 
immunodeficiency virus type 1 brain invasion. Journal of Virology. 2004; 78(12): 
6567-84. 
Bose S, Banerjee AK. Role of heparan sulfate in human parainfluenza virus type 3 
infection. Virology. 2002; 298(1): 73-83. 
Bottcher-Friebertshauser E, Stein DA, Klenk HD, Garten W. Inhibition of influenza 
virus infection in human airway cell cultures by an antisense peptide-conjugated 
morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. 
Journal of Virology. 2011; 85(4): 1554-62. 
Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. 
Biochemical Journal. 1993; 289(2): 313-30. 
Bousarghin L, Touze A, Combita-Rojas AL, Coursaget P. Positively charged sequences 
of human papillomavirus type 16 capsid proteins are sufficient to mediate gene 
transfer into target cells via the heparan sulfate receptor. Journal of General 
Virology. 2003; 84(Pt 1): 157-164. 
Boyer JC, Haenni AL. Infectious transcripts and cDNA clones of RNA viruses. 
Virology. 1994; 198(2): 415-26. 
Brown BA, Oberste MS, Alexander JP Jr, Kennett ML, Pallansch MA. Molecular 
epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. 
Journal of Virology. 1999; 73(12): 9969-75. 
Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct 
from poliovirus. Virus Research. 1995; 39(2-3): 195-205. 
Bultmann H, Busse JS, Brandt CR. Modified FGF4 signal peptide inhibits entry of 
herpes simplex virus type 1. Journal of Virology. 2001; 75(6): 2634-45. 
Burrer R, Neuman BW, Ting JP, Stein DA, Moulton HM, Iversen PL, Kuhn P, 
Buchmeier MJ. Antiviral effects of antisense morpholino oligomers in murine 
coronavirus infection models. Journal of Virology. 2007; 81(11): 5637-48. 
Byrnes AP, Griffin DE. Binding of Sindbis virus to cell surface heparan sulfate. Journal 
of Virology. 1998; 72(9): 7349-56. 
Caliguiri LA, Tamm I. Action of guanidine on the replication of poliovirus RNA. 
Virology. 1968a; 35(3): 408-17. 
Caliguiri LA, Tamm I. Distribution and translation of poliovirus RNA in guanidine-
treated cells. Virology. 1968b; 36(2): 223-31. 
 
 
172 
Cameron-Wilson CL, Zhang H, Zhang F, Buluwela L, Muir P, Archard LC. A vector 
with transcriptional terminators increases efficiency of cloning of an RNA virus 
by reverse transcription long polymerase chain reaction. Journal of Molecular 
Microbiology and Biotechnology. 2002; 4(2): 127-31. 
Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan 
interactions. Arteriosclerosis. 1989; 9(1): 21-32. 
Cardosa MJ, Krishnan S, Tio PH, Perera D, Wong SC. Isolation of subgenus B 
adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and 
mouth disease in Sibu, Sarawak. Lancet. 1999; 354(9183): 987-91. 
Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, Cho H, McMinn P. 
Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in 
the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. 
Emerging Infectious Diseases. 2003; 9(4): 461-8. 
Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and 
mouth disease caused by human enterovirus 71, Singapore. Emerging Infectious 
Diseases. 2003; 9(1): 78-85. 
Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, 
Pallansch MA, Suleiman AB, Jegathesan M, Anderson LJ. Deaths of children 
during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: 
clinical and pathological characteristics of the disease. Clinical Infectious 
Diseases. 2000; 31(3): 678-83. 
Chan YF, Abubakar S. Phylogenetic evidence for inter-typic recombination in the 
emergence of human enterovirus 71 subgenotypes. BMC Microbiology. 2006; 6: 
74. 
Chan YF, Sam IC, Abubakar S. Phylogenetic designation of enterovirus 71 genotypes 
and subgenotypes using complete genome sequences. Infection, Genetics and 
Evolution. 2010; 10(3): 404-12. 
Chan YF, Wee KL, Chiam CW, Khor CS, Chan SY, Wan Nor Amalina WMZ, Sam IC. 
Comparative genetic analysis of VP4, VP1 and 3D gene regions of enterovirus 71 
and coxsackievirus A16 circulating in Malaysia between 1997-2008. Tropical 
Biomedicine. 2012; 28(3): 451-66. 
Chang CS, Lin YT, Shih SR, Lee CC, Lee YC, Tai CL, Tseng SN, Chern JH. Design, 
synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-
ylimidazolidin-2-one derivatives. Journal of Medicinal Chemistry. 2005; 48(10): 
3522-35. 
Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, Lin KL, Huang YC, Lu CY, 
Lin TY. Neurodevelopment and cognition in children after enterovirus 71 
infection. New England Journal of Medicine. 2007; 356(12): 1226-34. 
Chang LY, Lin TY, Hsu KH, Huang YC, Lin KL, Hsueh C, Shih SR, Ning HC, Hwang 
MS, Wang HS, Lee CY. Clinical features and risk factors of pulmonary oedema 
after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999; 
354(9191): 1682-6. 
 
173 
Chapman MS, Minor I, Rossmann MG, Diana GD, Andries K. Human rhinovirus 14 
complexed with antiviral compound R 61837. Journal of Molecular Biology. 1999; 
217(3): 455-63. 
Chen HL, Wang LC, Chang CH, Yen CC, Cheng WT, Wu SC, Hung CM, Kuo MF, 
Chen CM. Recombinant porcine lactoferrin expressed in the milk of transgenic 
mice protects neonatal mice from a lethal challenge with enterovirus type 71. 
Vaccine. 2008a; 26(7): 891-8. 
Chen KT, Chang HL, Wang ST, Cheng YT, Yang JY. Epidemiologic features of hand-
foot-mouth disease and herpangina caused by enterovirus 71 in Taiwan, 1998-
2005. Pediatrics. 2007; 120(2): e244-52. 
Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li X, Dong W, 
Wan X, Huang N, Shen X, Liang Z, Li W. Molecular determinants of enterovirus 
71 viral entry: a cleft around Q172 on VP1 interacts with a variable region on 
scavenge receptor B2. Journal of Biological Chemistry. 2012; 287(9): 6406-20. 
Chen TC, Chang HY, Lin PF, Chern JH., Hsu JT, Chang CY, Shih SR. Novel antiviral 
agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. 
Antimicrobial Agents and Chemotherapy. 2009; 53(7): 2740-7. 
Chen TC, Liu SC, Huang PN, Chang HY, Chern JH, Shih SR. Antiviral activity of 
pyridyl imidazolidinones against enterovirus 71 variants. Journal of Biomedical 
Science. 2008b; 15(3): 291-300. 
Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM.  
Dengue virus infectivity depends on envelope protein binding to target cell 
heparan sulfate. Nature Medicine. 1997; 3(8): 866-71. 
Chen YJ, Zeng SJ, Hsu JT, Horng JT, Yang HM, Shih SR, Chu YT, Wu TY. 
Amantadine as a regulator of internal ribosome entry site. Acta Pharmacologica 
Sinica. 2008c; 29(11): 1327-33. 
Cheng G, Montero A, Gastaminza P, Whitten-Bauer C, Wieland SF, Isogawa M, 
Fredericksen B, Selvarajah S, Gallay PA, Ghadiri MR, Chisari FV. A virocidal 
amphipathic -helical peptide that inhibits hepatitis C virus infection in vitro. 
Proceedings of the National Academy of Science U S A. 2008; 105(8): 3088-93. 
Chern JH, Shia KS, Hsu TA, Tai CL, Lee CC, Lee YC, Chang CS, Tseng SN, Shih SR. 
Design, synthesis, and structure-activity relationships of pyrazolo[3,4-
d]pyrimidines: a novel class of potent enterovirus inhibitors. Bioorganic and 
Medicinal Chemistry Letters. 2004; 14(19): 2519-25. 
Chiu YH, Chan YL, Tsai LW, Li TL, Wu CJ. Prevention of human enterovirus 71 
infection by kappa carrageenan. Antiviral Research. 2012; 95(2): 128-34. 
Chu PY, Lin KH, Hwang KP, Chou LC, Wang CF, Shih SR, Wang JR, Shimada Y, 
Ishiko H. Molecular epidemiology of enterovirus 71 in Taiwan. Archives of 
Virology. 2001; 146(3): 589-600. 
Chua BH, Phuektes P, Sanders SA, Nicholls PK, McMinn PC. The molecular basis of 
mouse adaptation by human enterovirus 71. Journal of General Virology. 2008; 
89(Pt 7): 1622-32. 
 
174 
Chua KB, Kasri AR. Hand foot and mouth disease due to enterovirus 71 in Malaysia. 
Virologica Sinica. 2011; 26(4): 221-28. 
Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, 
Vasilenko S, Brodvarova I, Nikolova M, Gyurova S, Gacheva M, Mitov G, Ninov 
N, Tsylka E, Robinson I, Frolova M, Bashkirtsev V, Martiyanova L, Rodin V. 
Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in 
Bulgaria. Archives of Virology. 1979; 60(3-4): 329-40. 
Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus 
interaction with cell surface heparan sulfate. Journal of Virology. 1998; 72(2): 
1577-85. 
Cifuente JO, Lee H, Yoder JD, Shingler KL, Carnegie MS, Yoder JL, Ashley RE, 
Makhov AM, Conway JF, Hafenstein S. Structures of the procapsid and mature 
virion of enterovirus 71 strain 1095. Journal of Virology. 2013; 87(13): 7637-45. 
Conti C, Mastromarino P, Sgro R, Desideri N. Anti-picornavirus activity of synthetic 
flavon-3-yl esters. Antiviral Chemistry and Chemotherapy. 1998; 9(6): 511-15. 
Cooper A, Tal G, Lider O, Shaul Y.  Cytokine induction by the hepatitis B virus capsid 
in macrophages is facilitated by membrane heparan sulfate and involves TLR2. 
Journal of Immunology. 2005; 175(5): 3165-76. 
Das S, Ravi V, Desai A. Japanese encephalitis virus interacts with vimentin to facilitate 
its entry into porcine kidney cell line. Virus Research. 2011; 160(1-2): 404-8. 
Davies WL, Grunert RR, Hoffmann CE. Influenza virus growth and antibody response 
in amantadine-treated mice. Journal of Immunology. 1965; 95(6): 1090-4. 
de Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, 
Andrews R, Arimilli M, Al-Tel TH, de Clercq E, van Kuppeveld F, Neyts J. 
Mutations in the nonstructural protein 3A confer resistance to the novel 
enterovirus replication inhibitor TTP-8307. Antimicrobial Agents and 
Chemotherapy. 2009; 53(5): 1850-7. 
de Palma AM, Vliegen I, de Clercq E, Neyts J. Selective inhibitors of picornavirus 
replication. Medicinal Research Reviews. 2008; 28(6): 823-84. 
de Smet MD, Meenken CJ, van den Horn GJ. Fomivirsen - a phosphorothioate 
oligonucleotide for the treatment of CMV retinitis. Ocular Immunology and 
Inflammation. 1999; 7(3-4): 189-98. 
Deas TS, Bennett CJ, Jones SA, Tilgner M, Ren P, Behr MJ, Stein DA, Iversen PL, 
Kramer LD, Bernard KA, Shi PY. In vitro resistance selection and in vivo 
efficacy of morpholino oligomers against West Nile virus. Antimicrobial Agents 
and Chemotherapy. 2007; 51(7): 2470-82. 
Delputt PL, Vanderheijden N, Nauwynck HJ,  Pensaert MB. Involvement of the matrix 
protein in attachment of porcine reproductive and respiratory syndrome virus to a 
heparin-like receptor on porcine alveolar macrophages. Journal of Virology. 2002; 
76(9): 4312-20. 
 
175 
Deng JX, Nie XJ, Lei YF, Ma CF, Xu DL, Li B, Xu ZK, Zhang GC. The highly 
conserved 5' untranslated region as an effective target towards the inhibition of 
enterovirus 71 replication by unmodified and appropriate 2'- modified siRNAs. 
Journal of Biomedical Science. 2012; 19(1): 73. 
Du N, Cong H, Tian H, Zhang H, Zhang W, Song L, Tien P. Cell surface vimentin is an 
attachment receptor for enterovirus 71. Journal of Virology. 2014; 88(10): 5816-
33. 
Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, 
Matthews TJ, Greenberg ML, Delmedico MK. Design of helical, oligomeric HIV-
1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. 
Proceedings of the National Academy of Science U S A. 2007; 104(31). 12772-7. 
Edge AS, Spiro RG. Characterization of novel sequences containing 3-O-sulfated 
glucosamine in glomerular basement membrane heparan sulfate and localization 
of sulfated disaccharides to a peripheral domain. Journal of Biological Chemistry. 
1990; 265(26): 15874-81. 
Eggen R, Verver J, Wellink J, De Jong A, Goldbach R, van Kammen A. Improvements 
of the infectivity of in vitro transcripts from cloned cowpea mosaic virus cDNA: 
impact of terminal nucleotide sequences. Virology. 1989; 173(2): 447-55. 
Enterlein S, Warfield KL, Swenson DL, Stein DA, Smith JL, Gamble CS, Kroeker AD, 
Iversen PL, Bavari S, Muhlberger E. VP35 knockdown inhibits Ebola virus 
amplification and protects against lethal infection in mice. Antimicrobial Agents 
and Chemotherapy. 2006; 50(3): 984-93. 
Ernst S, Langer R, Cooney CL, Sasisekharan R. Enzymatic degradation of 
glycosaminoglycans. Critical Reviews in Biochemistry and Molecular Biology. 
1995; 30(5): 387-444. 
Escarmis C, Carrillo EC, Ferrer M, Arriaza JF, Lopez N, Tami C, Verdaguer N, 
Domingo E, Franze-Fernandez MT. Rapid selection in modified BHK-21 cells of 
a foot-and-mouth disease virus variant showing alterations in cell tropism. Journal 
of Virology. 1998; 72(12): 10171-9. 
Escribano-Romero E, Jimenez-Clavero MA, Gomes P, Garcia-Ranea JA, Ley V. 
Heparan sulphate mediates swine vesicular disease virus attachment to the host 
cell. Journal of General Virology. 2004; 85(Pt 3): 653-63. 
Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal 
membrane proteins. Trends in Cell Biology. 2003; 13(3): 137-45. 
Esko JD, Lindahl U. Molecular diversity of heparan sulfate. Journal of Clinical 
Investigation. 2001; 108(2): 169-73. 
Esko JD, Stewart TE, Taylor WH. Animal cell mutants defective in glycosaminoglycan 
biosynthesis. Proceedings of the National Academy of Science U S A. 1985; 
82(10): 3197-201. 
Esko JD, Zhang L. Influence of core protein sequence on glycosaminoglycan assembly. 
Current Opinion in Structural Biology. 1996; 6(5): 663-70. 
 
176 
Evans DJ. Reverse genetics of picornaviruses. Advances in Virus Research. 1999; 53: 
209-228. 
Falah N, Montserret R, Lelogeais V, Schuffenecker I, Lina B, Cortay JC, Violot S. 
Blocking human enterovirus 71 replication by targeting viral 2A protease. Journal 
of Antimicrobial Chemotherapy. 2012; 67(12): 2865-69. 
Feldman SA, Audet S, Beeler JA, The fusion glycoprotein of human respiratory 
syncytial virus facilitates virus attachment and infectivity via an interaction with 
cellular heparan sulfate. Journal of Virology. 2000; 74(14): 6442-7. 
Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. Journal of Clinical 
Investigation. 2001; 108(2): 175-80. 
Fox MP, Otto MJ, Mckinlay MA. Prevention of rhinovirus and poliovirus uncoating by 
WIN 51711, a new antiviral drug. Antimicrobial Agents and Chemotherapy. 1986; 
30(1): 110-6. 
Fry EE, Lea SM, Jackson T, Newman JW, Ellard FM, Blakemore WE, Abu-Ghazaleh R, 
Samuel A, King AM, Stuart DI. The structure and function of a foot-and-mouth 
disease virus-oligosaccharide receptor complex. EMBO Journal. 1999; 18(3): 
543-54. 
Fujita H, Takata Y, Kono A, Tanaka Y, Takahashi T, Himeno M, Kato K. Isolation and 
sequencing of a cDNA clone encoding the 85 kDa human lysosomal 
sialoglycoprotein (hLGP85) in human metastatic pancreas islet tumor cells. 
Biochemical and Biophysical Research Communications. 1992; 184(2): 604-11. 
Gabriel G, Nordmann A, Stein DA, Iversen PL, Klenk HD. Morpholino oligomers 
targeting the PB1 and NP genes enhance the survival of mice infected with highly 
pathogenic influenza A H7N7 virus. Journal of General Virology. 2008; 89(Pt 4): 
939-48. 
Gamp AC, Tanaka Y, Lullmann-Rauch R, Wittke D, D'hooge R, De Deyn PP, Moser T, 
Hartmann D, Reiss K, Illert AL, Von Figura K, Saftig P. LIMP-2/LGP85 
deficiency causes ureteric pelvic junction obstruction, deafness and peripheral 
neuropathy in mice. Human Molecular Genetics. 2003; 12(6): 631-46. 
Gardner CL, Ebel GD, Ryman KD, Klimstra WB. Heparan sulfate binding by natural 
eastern equine encephalitis viruses promotes neurovirulence. Proceedings of the 
National Academy of Science U S A. 2011; 108(38): 16026-31. 
Ge Q, Pastey M, Kobasa D, Puthavathana P, Lupfer C, Bestwick RK, Iversen PL, Chen 
J, Stein DA. Inhibition of multiple subtypes of influenza A virus in cell cultures 
with morpholino oligomers. Antimicrobial Agents and Chemotherapy. 2006; 
50(11): 3724-33. 
Genovese D, Conti C, Tomao P, Desideri N, Stein ML, Catone S, Fiore L. Effect of 
chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in 
vitro. Antiviral Research. 1995; 27(1-2): 123-36. 
Ghendon Y, Yakobson E, Mikhejeva A. Study of some stages of poliovirus 
morphogenesis in MiO cells. Journal of Virology. 1972; 10(2): 261-6. 
 
177 
Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. Human papillomavirus infection 
requires cell surface heparan sulfate. Journal of Virology. 2001; 75(3): 1565-70. 
Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short 
interfering RNA-target recognition and implications for therapeutic approaches. 
Journal of Virology. 2005; 79(2): 1027-35. 
Gladue DP, O’Donnel V, Baker-Branstetter R, Holinka LG, Pacheco JM, Fernandez 
sainz I, Lu Z, Ambroggio X, Rodriguez L, Borca MV. Foot-and-mouth disease 
virus modulates cellular vimentin for virus survival. Journal of Virology. 2013; 
87(12): 6794-803. 
Goodfellow IG, Sioofy AB, Powell RM, Evans DJ. Echoviruses bind heparan sulfate at 
the cell surface. Journal of Virology. 2001; 75(10): 4918-21. 
Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. 
Current Medicinal Chemistry. 2012; 19(26): 4451-61. 
Gow JW, Mcgill MM, Behan WM, Behan PO. Long RT-PCR amplification of full-
length enterovirus genome. Biotechniques. 1996; 20(4): 582-4. 
Gropp R, Frye M, Wagner TO, Bargon J. Epithelial defensins impair adenoviral 
infection: implication for adenovirus-mediated gene therapy. Human Gene 
Therapy. 1999; 10(6): 957-64. 
Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for 
comparative protein modeling. Electrophoresis. 1997; 18(15): 2714-23. 
Guibinga GH, Miyanohara A, Esko JD, Friedmann T. Cell surface heparan sulfate is a 
receptor for attachment of envelope protein-free retrovirus-like particles and 
VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Molecular 
Therapy. 2002; 5(5): 538-46. 
Hagiwara A, Tagaya I, Yoneyama T. Epidemic of hand, foot and mouth disease 
associated with enterovirus 71 infection. Intervirology. 1978; 9(1): 60-3. 
Hall RN, Meers J, Fowler E, Mahony T. Back to BAC: the use of infectious clone 
technologies for viral mutagenesis. Viruses. 2012; 4(2): 211-35. 
Han JF, Cao RY, Tian X, Yu M, Qin ED, Qin CF. Producing infectious enterovirus type 
71 in a rapid strategy. Virology Journal. 2010; 7: 116. 
Harvala H, Kalimo H, Dahllund L, Santti J, Hughes P, Hyypia T, Stanway G. Mapping 
of tissue tropism determinants in coxsackievirus genomes. Journal of General 
Virology. 2002; 83(Pt 7): 1697-706. 
Haywood AM. Virus receptors: binding, adhesion strengthening, and changes in viral 
structure. Journal of Virology. 1994; 68(1): 1-5. 
Herrero LJ, Lee CS, Hurrelbrink RJ, Chua BH, Chua KB, McMinn PC. Molecular 
epidemiology of enterovirus 71 in peninsular Malaysia, 1997-2000. Archives of 
Virology. 2003; 148(7): 1369-85. 
 
178 
Herrmann EC Jr, Herrmann JA, Delong DC. Prevention of death in mice infected with 
coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles. 
Antiviral Research. 1982; 2(6): 339-46. 
Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of 
hepatocytes. Hepatology. 2000; 32(5): 1069-77. 
Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic 
of enterovirus 71 infection in Taiwan. New England Journal of Medicine. 1999; 
341(13): 929-35. 
Hoffmann CE, Neumayer EM, Haff RF, Goldsby RA. Mode of action of the antiviral 
activity of amantadine in tissue culture. Journal of Bacteriology. 1965; 90(3): 623-
8. 
Holden KL, Stein DA, Pierson TC, Ahmed AA, Clyde K, Iversen PL, Harris E. 
Inhibition of dengue virus translation and RNA synthesis by a morpholino 
oligomer targeted to the top of the terminal 3' stem-loop structure. Virology. 2006; 
344(2): 439-52. 
Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West 
Nile virus infectivity. Virology Journal. 2005; 2: 49. 
Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der 
Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld 
FJM, Altan-Bonnet N. Viral reoganization of the secretory pathway generates 
distinct organelles for RNA replication. Cell. 2010; 141(5); 799-811.  
Huang CC, Liu CC, Chang YC, Chen CY, Wang ST, Yeh TF. Neurologic 
complications in children with enterovirus 71 infection. New England Journal of 
Medicine. 1999; 341(13): 936-42. 
Huang MC, Wang SM, Hsu YW, Lin HC, Chi CY, Liu CC.Long-term cognitive and 
motor deficits after enterovirus 71 brainstem encephalitis in children. Pediatrics. 
2006; 118(6): e1785-8. 
Huang PN, Lin JY, Locker N, Kung YA, Hung CT, Huang HI, Li ML, Shih SR. Far 
upstream element binding protein 1 binds the internal ribosomal entry site of 
enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids 
Research. 2011; 39(22): 9633-48. 
Huang SC, Chang CL, Wang PS, Tsai Y, Liu HS. Enterovirus 71-induced autophagy 
detected in vitro and in vivo promotes viral replication. Journal of Medical 
Virology. 2009; 81(7): 1241-52. 
Huang SC, Hsu YW, Wang HC, Huang SW, Kiang D, Tsai HP, Wang SM, Liu CC, Lin 
KH, Su IJ, Wang JR. Appearance of intratypic recombination of enterovirus 71 in 
Taiwan from 2002 to 2005. Virus Research. 2008a; 131(2): 250-9. 
Huang SW, Wang YF, Yu CK, Su IJ, Wang JR. Mutations in VP2 and VP1 capsid 
proteins increase infectivity and mouse lethality of enterovirus 71 by virus 
binding and RNA accumulation enhancement. Virology. 2012; 422(1): 132-43. 
 
179 
Huang YP, Lin TL, Kuo CY, Lin MW, Yao CY, Liao HW, Hsu LC, Yang CF, Yang JY 
Chen PJ, Wu HS. The circulation of subgenogroups B5 and C5 of enterovirus 71 
in Taiwan from 2006 to 2007. Virus Research. 2008b; 137(2): 206-12. 
Hulst MM, van Gennip HG, Moormann RJ. Passage of classical swine fever virus in 
cultured swine kidney cells selects virus variants that bind to heparan sulfate due 
to a single amino acid change in envelope protein E(rns). Journal of Virology. 
2000; 74(20): 9553-61. 
Hung HC, Wang HC, Shih SR, Teng IF, Tseng CP, Hsu JT. Synergistic inhibition of 
enterovirus 71 replication by interferon and rupintrivir. Journal of Infectious 
Diseases. 2011; 203(12): 1784-90. 
Hussain KM, Leong KL, Ng MM, Chu JJ. The essential role of clathrin-mediated 
endocytosis in the infectious entry of human enterovirus 71. Journal of Biological 
Chemistry. 2011; 286(1): 309-21. 
Huther A, Dietrich U. The emergence of peptides as therapeutic drugs for the inhibition 
of HIV-1. AIDS Reviews. 2007; 9(4): 208-17. 
Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE, Corteyn AH, Stuart 
DI, Newman JW, King AM. Efficient infection of cells in culture by type O foot-
and-mouth disease virus requires binding to cell surface heparan sulfate. Journal 
of Virology. 1996; 70(8): 5282-7. 
Jackson WT, Giddings TH Jr, Taylor MP, Mulinyawe S, Rabinovitch M, Kopito RR, 
Kirkegaard K. Subversion of cellular autophagosomal machinery by RNA viruses. 
PLoS Biology. 2005: 3: e156. 
Jacobson MF, Asso J, Baltimore D. Further evidence on the formation of poliovirus 
proteins. Journal of Molecular Biology. 1970; 49(3): 657-69. 
Jacobson MF, Baltimore D. Morphogenesis of poliovirus. I. Association of the viral 
RNA with coat protein. Journal of Molecular Biology. 1968; 33(2): 369-78. 
Jacquet A, Haumont M, Chellun D, Massaer M, Tufaro F, Bollen A, Jacobs P. The 
varicella zoster virus glycoprotein B (gB) plays a role in virus binding to cell 
surface heparan sulfate proteoglycans. Virus Research. 1998; 53(2): 197-207. 
Jenssen H, Andersen JH, Mantzilas D, Gutteberg TJ. A wide range of medium-sized, 
highly cationic, alpha-helical peptides show antiviral activity against herpes 
simplex virus. Antiviral Research. 2004a; 64(2): 119-26. 
Jenssen H, Andersen JH, Uhlin-Hansen L, Gutteberg TJ, Rekdal O. Anti-HSV activity 
of lactoferricin analogues is only partly related to their affinity for heparan sulfate. 
Antiviral Research. 2004b; 61(2): 101-9. 
Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clinical Microbiology 
Reviews. 2006; 19(3): 491-511. 
Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM. Role of heparan 
sulfate in attachment to and infection of the murine female genital tract by human 
papillomavirus. Journal of Virology. 2009; 83(5): 2067-74. 
 
180 
Jones JC, Settles EW, Brandt CR, Schultz-Cherry S. Identification of the minimal active 
sequence of an anti-influenza virus peptide. Antimicrobial Agents and 
Chemotherapy. 2011; 55(4): 1810-3. 
Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of 
influenza virus infection by a novel antiviral peptide that targets viral attachment 
to cells. Journal of Virology. 2006; 80(24): 11960-7. 
Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW. Heparan sulfate 
proteoglycans mediate attachment and entry of human T-cell leukemia virus type 
1 virions into CD4+ T cells. Journal of Virology. 2005; 79(20): 12692-702. 
Kapusinszky B, Szomor KN, Farkas A, Takacs M, Berencsi G. Detection of non-polio 
enteroviruses in Hungary 2000-2008 and molecular epidemiology of enterovirus 
71, coxsackievirus A16, and echovirus 30. Virus Genes. 2010; 40(2): 163-73. 
Khanh TH, Sabanathan S, Thanh TT, Thoa Le PK, Thuong TC, Hang V, Farrar J, Hien 
TT, Chau NV, Van Doorn HR. Enterovirus 71-associated hand, foot, and mouth 
disease, Southern Vietnam, 2011. Emerging Infectious Diseases. 2012; 18(12): 
2002-5. 
Kilby JM, Hopkins S, Venetta TM, Dimassimo B, Cloud GA, Lee JY, Alldredge L, 
Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw 
GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a 
peptide inhibitor of gp41-mediated virus entry. Nature Medicine. 1998; 4(11): 
1302-7. 
Kim DH, Ni Y, Lee SH, Urban S, Han KH. An anti-viral peptide derived from the 
preS1 surface protein of hepatitis B virus. BMB Reports. 2008; 41(9): 640-4. 
Kim J, Hajjar KA. Annexin II: a plasminogen-plasminogen activator co-receptor. 
Frontiers in Bioscience. 2002; 7: d341-8. 
Kinney RM, Huang CY, Rose BC, Kroeker AD, Dreher TW, Iversen PL, Stein DA. 
Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino 
oligomers. Journal of Virology. 2005; 79(8): 5116-28. 
Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, 
Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E. Primary structure, 
gene organization and polypeptide expression of poliovirus RNA. Nature. 1981; 
291(5816): 547-53. 
Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annual Review of 
Biochemistry. 1991; 60: 443-475. 
Kjellen L, Oldberg A, Hook M. Cell-surface heparan sulfate. Mechanisms of 
proteoglycan-cell association. Journal of Biological Chemistry. 1980; 255(21): 
10407-13. 
Klimstra WB, Ryman KD, Johnston RE. Adaptation of Sindbis virus to BHK cells 
selects for use of heparan sulfate as an attachment receptor. Journal of Virology. 
1998; 72(9): 7357-66. 
 
181 
Knappe M, Bodevin S, Selinka HC, Spillmann D, Streeck RE, Chen XS, Lindahl U, 
Sapp M. Surface-exposed amino acid residues of HPV16 L1 protein mediating 
interaction with cell surface heparan sulfate. Journal of Biological Chemistry. 
2007; 282(38): 27913-22. 
Kok CC, Phuektes P, Bek E, McMinn PC. Modification of the untranslated regions of 
human enterovirus 71 impairs growth in a cell-specific manner. Journal of 
Virology. 2012; 86(1): 542-52. 
Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and 
antisense oligonucleotides. Nature Reviews Drug Discovery. 2012; 11(2): 125-40. 
Koudelka KJ, Destito G, Plummer EM, Trauger SA, Siuzdak G, Manchester M. 
Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin. PLoS 
Pathogens. 2009; 5(5): e1000417. 
Kraus W, Zimmermann H, Zimmermann A, Eggers HJ, Nelsen-Salz B. Infectious 
cDNA clones of echovirus 12 and a variant resistant against the uncoating 
inhibitor rhodanine differ in seven amino acids. Journal of Virology. 1995; 69(9): 
5853-8. 
Kung YH, Huang SW, Kuo PH, Kiang D, Ho MS, Liu CC, Yu CK, Su IJ, Wang JR. 
Introduction of a strong temperature-sensitive phenotype into enterovirus 71 by 
altering an amino acid of virus 3D polymerase. Virology. 2010; 396(1): 1-9. 
Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JT, Liu HG, Tseng SN, Chang SC, Lee CY, 
Shih SR, Liang PH. Design, synthesis, and evaluation of 3C protease inhibitors as 
anti-enterovirus 71 agents. Bioorganic and Medicinal Chemistry. 2008; 16(15): 
7388-98. 
Kuronita T, Eskelinen EL, Fujita H, Saftig P, Himeno M, Tanaka Y. A role for the 
lysosomal membrane protein LGP85 in the biogenesis and maintenance of 
endosomal and lysosomal morphology. Journal of Cell Science. 2002; 115(21): 
4117-31. 
Kusov YY, Gosert R, Gauss-Muller V. Replication and in vivo repair of the hepatitis A 
virus genome lacking the poly(A) tail. Journal of General Virology. 2005; 86(Pt 
5): 1363-8. 
Laine P, Savolainen C, Blomqvist S, Hovi T. Phylogenetic analysis of human rhinovirus 
capsid protein VP1 and 2A protease coding sequences confirms shared genus-like 
relationships with human enteroviruses. Journal of General Virology. 2005; 86(Pt 
3): 697-706. 
Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, 
Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins D 
G. Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21): 2947-8. 
Laszik Z, Jansen PJ, Cummings RD, Tedder TF, Mcever RP, Moore KL. P-selectin 
glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and 
dendritic lineage and in some nonhematopoietic cells. Blood. 1996; 88(8): 3010-
21. 
 
182 
Lee E, Hall RA, Lobigs M. Common E protein determinants for attenuation of 
glycosaminoglycan-binding variants of Japanese encephalitis and West Nile 
viruses. Journal of Virology. 2004; 78(15): 8271-80. 
Lee E, Lobigs M. Mechanism of virulence attenuation of glycosaminoglycan-binding 
variants of Japanese encephalitis virus and Murray Valley encephalitis virus. 
Journal of Virology. 2002; 76(10): 4901-11. 
Leister D, Thompson R. Production of full-length cDNA from a picornaviral genome by 
RT-PCR. Trends in Genetics. 1996; 12(1): 11. 
Li C, Wang H, Shih SR, Chen TC, Li ML. The efficacy of viral capsid inhibitors in 
human enterovirus infection and associated diseases. Current Medicinal 
Chemistry. 2007; 14(8): 847-56. 
Li J, Chen F, Liu T, Wang L. MRI Findings of neurological complications in hand-foot-
mouth disease by enterovirus 71 infection. International Journal of Neuroscience. 
2012; 122(7): 338-44. 
Li ZH, Li CM, Ling P, Shen FH, Chen SH, Liu CC, Yu CK. Ribavirin reduces mortality 
in enterovirus 71-infected mice by decreasing viral replication. Journal of 
Infectious Diseases. 2008; 197(6): 854-7. 
Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S, Massague J, 
Lindahl U, Esko JD. A single mutation affects both N-
acetylglucosaminyltransferase and glucuronosyltransferase activities in a Chinese 
hamster ovary cell mutant defective in heparan sulfate biosynthesis. Proceedings 
of the National Academy of Science U S A. 1992; 89(6): 2267-71. 
Lin HY, Yang YT, Yu SL, Hsiao KN, Liu CC, Sia C, Chow YH. Caveolar endocytosis 
is required for human PSGL-1-mediated enterovirus 71 infection. Journal of 
Virology. 2013a; 87(16): 9064-76. 
Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR. Viral and host proteins 
involved in picornavirus life cycle. Journal of Biomedical Science. 2009a; 16: 103. 
Lin JY, Li ML, Huang PN, Chien KY, Horng JT, Shih SR. Heterogeneous nuclear 
ribonuclear protein K interacts with the enterovirus 71 5' untranslated region and 
participates in virus replication. Journal of General Virology. 2008; 89(Pt 10): 
2540-9. 
Lin JY, Li ML, Shih SR. Far upstream element binding protein 2 interacts with 
enterovirus 71 internal ribosomal entry site and negatively regulates viral 
translation. Nucleic Acids Research. 2009b; 37(1): 47-59. 
Lin JY, Shih SR, Pan M, Li C, Lue CF, Stollar V, Li ML. hnRNP A1 interacts with the 
5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required 
for viral replication. Journal of Virology. 2009c; 83(12): 6106-14. 
Lin KH, Hwang KP, Ke GM, Wang CF, Ke LY, Hsu YT, Tung YC, Chu PY, Chen BH, 
Chen HL, Kao CL, Wang JR, Eng HL, Wang SY, Hsu LC, Chen HY. Evolution 
of EV71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup 
C4 of EV71. Journal of Medical Virology. 2006; 78(2): 254-62. 
 
183 
Lin TY, Chu C, Chiu CH. Lactoferrin inhibits enterovirus 71 infection of human 
embryonal rhabdomyosarcoma cells in vitro. Journal of Infectious Diseases. 2002; 
186(8): 1161-4. 
Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, Kung SH, Tsai FJ, Lan YC, Lin 
CW. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. Journal of 
Virological Methods. 2012a; 182(1-2): 93-8. 
Lin YJ, Lai CC, Lai CH, Sue SC, Lin CW, Hung CH, Lin TH, Hsu WY, Huang SM, 
Hung YL, Tien N, Liu X, Chen CL, Tsai FJ. Inhibition of enterovirus 71 
infections and viral IRES activity by Fructus gardeniae and geniposide. European 
Journal of Medicinal Chemistry. 2013b; 62: 206-13. 
Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, Liu CC, Sia C, Chong P, 
Chow YH. Human SCARB2-mediated entry and endocytosis of EV71. PLoS 
ONE. 2012b; 7: e30507. 
Linsuwanon P, Puenpa J, Huang SW, Wang YF, Mauleekoonphairoj J, Wang JR, 
Poovorawan Y. Epidemiology and seroepidemiology of human enterovirus 71 
among Thai populations. Journal of Biomedical Science. 2014; 21:16. 
Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ. An outbreak of enterovirus 71 
infection in Taiwan, 1998: epidemiologic and clinical manifestations. Journal of 
Clinical Virology. 2000; 17(1): 23-30. 
Liu F, Liu Q, Cai Y, Leng Q, Huang Z. Construction and characterization of an 
infectious clone of coxsackievirus A16. Virology Journal. 2011; 8: 534. 
Liu GQ, Ni Z, Yun T, Yu B, Zhu JM, Hua JG, Chen JP. Rabbit hemorrhagic disease 
virus poly(A) tail is not essential for the infectivity of the virus and can be 
restored in vivo. Archives of Virology. 2008; 153(5): 939-44. 
Liu J, Dong W, Quan X, Ma C, Qin C, Zhang L. Transgenic expression of human P-
selectin glycoprotein ligand-1 is not sufficient for enterovirus 71 infection in mice. 
Archives of Virology. 2012; 157(3): 539-43. 
Liu J, Thorp SC. Cell surface heparan sulfate and its roles in assisting viral infections. 
Medicinal Research Reviews. 2002; 22(1): 1-25. 
Liu ML, Lee YP, Wang YF, Lei HY, Liu CC, Wang SM, Su IJ, Wang JR, Yeh TM, 
Chen SH, Yu CK. Type I interferons protect mice against enterovirus 71 infection. 
Journal of General Virology. 2005; 86(Pt 12): 3263-9. 
Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. A peptide derived from 
hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. 
Antiviral Research. 2010; 86(2): 172-9. 
Loddo B, Ferrari W, Brotzu G, Spanedda A. In vitro inhibition of infectivity of polio 
viruses by guanidine. Nature. 1962; 193: 97-8. 
Lu G, Qi J, Chen Z, Xu X, Gao F, Lin D, Qian W, Liu H, Jiang H, Yan  J, Gao GF. 
Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and 
their substrates and anti-hand, foot, and mouth disease virus drug design. Journal 
of Virology. 2011; 85(19): 10319-31. 
 
184 
Lu J, Yi L, Zhao J, Yu J, Chen Y, Lin MC, Kung HF, He ML. Enterovirus 71 disrupts 
interferon signaling by reducing the level of interferon receptor 1. Journal of 
Virology. 2012; 86(7): 3767-76. 
Lu WW, Hsu YY, Yang JY, Kung SH. Selective inhibition of enterovirus 71 replication 
by short hairpin RNAs. Biochemical and Biophysical Research Communications. 
2004; 325(2): 494-9. 
Lum LC, Wong KT, Lam SK, Chua KB, Goh AY. Neurogenic pulmonary oedema and 
enterovirus 71 encephalomyelitis. Lancet. 1998a; 352(9137): 1391. 
Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, Ong BB, Paul G, 
AbuBakar S, Lambert M. Fatal enterovirus 71 encephalomyelitis. Journal of 
Pediatrics. 1998b; 133(6): 795-8. 
Lupfer C, Stein DA, Mourich DV, Tepper SE, Iversen PL, Pastey M. Inhibition of 
influenza A H3N8 virus infections in mice by morpholino oligomers. Archives of 
Virology. 2008; 153(5): 929-37. 
Malhotra R, Ward M, Bright H, Priest R, Foster MR, Hurle M, Blair E, Bird M. 
Isolation and characterisation of potential respiratory syncytial virus receptor(s) 
on epithelial cells. Microbes and Infection. 2003; 5(2): 123-33. 
Mandl CW, Kroschewski H, Allison SL, Kofler R, Holzmann H, Meixner T, Heinz FX. 
Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the 
formation of multiple heparan sulfate binding sites in the envelope protein and 
attenuation in vivo. Journal of Virology. 2001; 75(12): 5627-37. 
Mann DM, Romm E, Migliorini M. Delineation of the glycosaminoglycan-binding site 
in the human inflammatory response protein lactoferrin. Journal of Biological 
Chemistry. 1994; 269(38): 23661-7. 
Mao Q, Li N, Yu X, Yao X, Li F, Lu F, Zhuang H, Liang Z, Wang J. Antigenicity, 
animal protective effect and genetic characteristics of candidate vaccine strains of 
enterovirus 71. Archives of Virology. 2012; 157(1): 37-41. 
Marchetti M, Trybala E, Superti F, Johansson M, Bergstrom T. Inhibition of herpes 
simplex virus infection by lactoferrin is dependent on interference with the virus 
binding to glycosaminoglycans. Virology. 2004; 318(1): 405-13. 
Mardberg K, Trybala E, Glorioso JC, Bergstrom T. Mutational analysis of the major 
heparan sulfate-binding domain of herpes simplex virus type 1 glycoprotein C. 
Journal of General Virology. 2001; 82(Pt 8): 1941-50. 
Marongiu ME, Pani A, Corrias MV, Sau M, La Colla P. Poliovirus morphogenesis. I. 
Identification of 80S dissociable particles and evidence for the artifactual 
production of procapsids. Journal of Virology. 1981; 39(2): 341-7. 
Martino TA, Tellier R, Petric M, Irwin DM, Afshar A, Liu PP. The complete consensus 
sequence of coxsackievirus B6 and generation of infectious clones by long RT-
PCR. Virus Research. 1999; 64(1): 77-86. 
 
185 
McKinlay MA, Frank JA Jr, Benziger DP, Steinberg BA. Use of WIN 51711 to prevent 
echovirus type 9-induced paralysis in suckling mice. Journal of Infectious 
Diseases. 1986; 154(4): 676-81. 
McLeish NJ, Williams CH, Kaloudas D, Roivainen M, Stanway G. Symmetry-related 
clustering of positive charges is a common mechanism for heparan sulfate binding 
in enteroviruses. Journal of Virology. 2012; 86(20): 11163-70. 
McMinn PC, Stratov I, Dowse G. Enterovirus 71 outbreak in Western Australia 
associated with acute flaccid paralysis. Communicable Diseases Intelligence. 
1999; 23(7): 199. 
McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public 
health significance. FEMS Microbiology Reviews. 2002; 26(1): 91-107. 
Misinzo G, Delputte PL, Meerts P, Lefebvre DJ, Nauwynck HJ. Porcine circovirus 2 
uses heparan sulfate and chondroitin sulfate B glycosaminoglycans as receptors 
for its attachment to host cells. Journal of Virology. 2006; 80(7): 3487-94. 
Moulton HM, Fletcher S, Neuman BW, Mcclorey G, Stein DA, Abes S, Wilton SD, 
Buchmeier MJ, Lebleu B, Iversen PL. Cell-penetrating peptide-morpholino 
conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and 
inhibit murine coronavirus replication in vivo. Biochemical Society Transactions. 
2007; 35(4): 826-8. 
Moulton JD, Jiang S. Gene knockdowns in adult animals: PPMOs and vivo-
morpholinos. Molecules. 2009; 14(3): 1304-23. 
Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus 
type 71 infections: experiences gained during an epidemic of acute CNS diseases 
in Hungary in 1978. Archives of Virology. 1982; 71(3): 217-27. 
Nasri D, Bouslama L, Pillet S, Bourlet T, Aouni M, Pozzetto B. Basic rationale, current 
methods and future directions for molecular typing of human enterovirus. Expert 
Review of Molecular Diagnostics. 2007; 7(4): 419-34. 
Nasser EH, Judd AK, Sanchez A, Anastasiou D, Bucher DJ. Antiviral activity of 
influenza virus M1 zinc finger peptides. Journal of Virology. 1996; 70(12): 8639-
44. 
Neufeld KL, Galarza JM, Richards OC, Summers DF, Ehrenfeld E. Identification of 
terminal adenylyl transferase activity of the poliovirus polymerase 3Dpol. Journal 
of Virology. 1994; 68(9): 5811-8. 
Neuman BW, Stein DA, Kroeker AD, Churchill MJ, Kim AM, Kuhn P, Dawson P, 
Moulton HM, Bestwick RK, Iversen PL, Buchmeier MJ. Inhibition, escape, and 
attenuated growth of severe acute respiratory syndrome coronavirus treated with 
antisense morpholino oligomers. Journal of Virology. 2005; 79(15): 9665-76. 
Neuman BW, Stein DA, Kroeker AD, Paulino AD, Moulton HM, Iversen PL, 
Buchmeier MJ. Antisense morpholino-oligomers directed against the 5' end of the 
genome inhibit coronavirus proliferation and growth. Journal of Virology. 2004; 
78(11): 5891-9. 
 
186 
Nilsson EC, Jamshidi F, Johansson SM, Oberste MS, Arnberg N. Sialic acid is a cellular 
receptor for coxsackievirus A24 variant, an emerging virus with pandemic 
potential. Journal of Virology. 2008; 82(6): 3061-8. 
Nishimura Y, Lee H, Hafenstein S, Kataoka C, Wakita T, Bergelson JM, Shimizu H. 
Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular 
switch to control receptor interaction. PLoS Pathogens. 2013; 9: e1003511. 
Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-
selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nature 
Medicine. 2009; 15(7): 794-7. 
Nishimura Y, Wakita T, Shimizu H. Tyrosine sulfation of the amino terminus of PSGL-
1 is critical for enterovirus 71 infection. PLoS Pathogens. 2010; 6: e1001174. 
O'Donnell V, Larocco M, Baxt B. Heparan sulfate-binding foot-and-mouth disease virus 
enters cells via caveola-mediated endocytosis. Journal of Virology. 2008; 82(18): 
9075-85. 
Oh MJ, Akhtar J, Desai P, Shukla D. A role for heparan sulfate in viral surfing. 
Biochemical and Biophysical Research Communications. 2010; 391(1): 176-81. 
Olofsson S, Bergstrom T. Glycoconjugate glycans as viral receptors. Annals of 
Medicine. 2005; 37(3): 154-72. 
Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, 
diagnosis, and management of enterovirus 71. Lancet Neurology. 2010; 9(11): 
1097-105. 
Ooi MH, Wong SC, Podin Y, Akin W, Del Sel S, Mohan A, Chieng CH, Perera D, 
Clear D, Wong D, Blake E, Cardosa MJ, Solomon T. Human enterovirus 71 
disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular 
epidemiological study. Clinical Infectious Diseases. 2007; 44(5): 646-56. 
Pallansch MA, Roos RP. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses and 
newer enteroviruses. In Knipe DM, Howley PM, Griffin RA, Martin MA, 
Roizman B, Straus SE, editors. Fields Virology. 5th ed. Philadelphia: Lippincott 
Williams & Wilkins; 2007. P. 840-893. 
Partridge M, Vincent A, Matthews P, Puma J, Stein D, Summerton J. A simple method 
for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense 
and Nucleic Acid Drug Development. 1996; 6(3): 169-75. 
Patick AK. Rhinovirus chemotherapy. Antiviral Research. 2006; 71(2-3): 391-6. 
Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD., Maldonado F, 
Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Mathews 
DA, Worland ST. In vitro antiviral activity of AG7088, a potent inhibitor of 
human rhinovirus 3C protease. Antimicrobial Agents and Chemotherapy. 1999; 
43(10): 2444-50. 
Perry CM, Balfour JA. Fomivirsen. Drugs. 1999; 57(3): 375-80. 
 
187 
Pevear DC, Tull TM, Seipel ME, Groarke, J. M. Activity of pleconaril against 
enteroviruses. Antimicrobial Agents and Chemotherapy. 1999; 43(9): 2109-15. 
Phuektes P, Chua BH, Sanders S, Bek EJ, Kok  CC, McMinn PC. Mapping genetic 
determinants of the cell-culture growth phenotype of enterovirus 71. Journal of 
General Virology. 2011; 92(Pt 6): 1380-90. 
Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal structure of human 
enterovirus 71. Science. 2012; 336(6086): 1274. 
Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG. Structure of human 
enterovirus 71 in complex with a capsid-binding inhibitor. Proceedings of the 
National Academy of Science U S A. 2013; 110(14): 5463-7. 
Plochmann K, Horn A, Gschmack E, Armbruster N, Krieg J, Wiktorowicz T, Weber C, 
Stirnnagel K, Lindemann D, Rethwilm A, Scheller C. Heparan sulfate is an 
attachment factor for foamy virus entry. Journal of Virology. 2012; 86(18): 
10028-35. 
Pourianfar HR, Poh CL, Fecondo J, Grollo L. In vitro evaluation of the antiviral activity 
of heparan sulphate mimetic compounds against enterovirus 71. Virus Research. 
2012; 169(1): 22-9. 
Presto J, Thuveson M, Carlsson P, Busse M, Wilen M, Eriksson I, Kusche-Gullberg M, 
Kjellen L. Heparan sulfate biosynthesis enzymes EXT1 and EXT2 affect NDST1 
expression and heparan sulfate sulfation. Proceedings of the National Academy of 
Science U S A. 2008; 105(12): 4751-6. 
Racaniello VR. Picornaviridae: The viruses and their replication. In Knipe DM, Howley 
PM, Griffin RA, Martin B, Roizman B, Straus SE, editors. 5th ed. Fields virology. 
Philadelphia: Lippincott Williams & Wilkins; 2007. P. 795-834. 
Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in 
mammalian cells. Science. 1981; 214(4523): 916-9. 
Reddi HV, Kumar AS, Kung AY, Kallio PD, Schlitt BP, Lipton HL. Heparan sulfate-
independent infection attenuates high-neurovirulence GDVII virus-induced 
encephalitis. Journal of Virology. 2004; 78(16): 8909-16. 
Reddi HV, Lipton HL. Heparan sulfate mediates infection of high-neurovirulence 
Theiler's viruses. Journal of Virology. 2002; 76(16): 8400-7. 
Rightsel WA, Dice JR, McAlpine RJ, Timm EA, McLean IW Jr, Dixon GJ, Schabel FM 
Jr. Antiviral effect of guanidine. Science. 1961; 134(3478): 558-9. 
Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski H, Norcross MA. 
Mediation of human immunodeficiency virus type 1 binding by interaction of cell 
surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. 
Journal of Virology. 1995; 69(4): 2233-9. 
Rohll JB, Moon DH, Evans DJ, Almond JW. The 3' untranslated region of picornavirus 
RNA: features required for efficient genome replication. Journal of Virology. 
1995; 69(12): 7835-44. 
 
188 
Rosenberg RD, Shworak NW, Liu J, Schwartz JJ, Zhang L. Heparan sulfate 
proteoglycans of the cardiovascular system. Specific structures emerge but how is 
synthesis regulated? Journal of Clinical Investigation. 1997; 100(11): S67-75. 
Rossmann MG. The canyon hypothesis. Viral Immunology. 1989; 2(3): 143-61. 
Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions. Trends in 
Microbiology. 2002; 10(7): 324-31. 
Ruxrungtham K, Boyd M, Bellibas SE, Zhang X, Dorr A, Kolis S, Kinchelow T, Buss 
N, Patel IH. Lack of interaction between enfuvirtide and ritonavir or ritonavir-
boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology. 
2004; 44(7): 793-803. 
Ryman KD, Gardner CL, Burke CW, Meier KC, Thompson JM, Klimstra WB. Heparan 
sulfate binding can contribute to the neurovirulence of neuroadapted and 
nonneuroadapted Sindbis viruses. Journal of Virology.2007;  81(7): 3563-73. 
Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. Tissue culture 
adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and 
are attenuated in cattle. Journal of Virology. 1997; 71(7): 5115-23. 
Sadeghipour S, Bek EJ, McMinn PC. Selection and characterisation of guanidine-
resistant mutants of human enterovirus 71. Virus Research. 2012; 169(1): 72-9. 
Satelli A, Li S. Vimentin as potential molecular target in cancer therapy or vimentin, an 
overview and its potential as a molecular target for cancer therapy. Cellular and 
Molecular Life Sciences. 2011; 68(18): 3033-48.  
Saunders K, King AM, Mccahon D, Newman JW, Slade WR, Forss S. Recombination 
and oligonucleotide analysis of guanidine-resistant foot-and-mouth disease virus 
mutants. Journal of Virology. 1985; 56(3): 921-9. 
Savarino A. Use of chloroquine in viral diseases. The Lancet Infectious Diseases. 2011; 
11(9): 653-4. 
Savarino A, Gennero L, Chen HC, Serrano D, Malavasi F, Boelaert JR, Sperber K. 
Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of 
activity. AIDS. 2001a; 15(17): 2221-9. 
Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. 
Journal of Clinical Virology. 2001b; 20(3): 131-5. 
Savarino A, Lucia MB, Rastrelli E, Rutella S, Golotta C, Morra E, Tamburrini E, Perno 
CF, Boelaert JR, Sperber K, Cauda R. Anti-HIV effects of chloroquine: inhibition 
of viral particle glycosylation and synergism with protease inhibitors. Journal of 
Acquired Immune Deficiency Syndromes. 2004; 35(3): 223-32. 
Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from 
patients with disease of the central nervous system. Journal of Infectious Diseases. 
1974; 129(3): 304-9. 
 
189 
Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface 
protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007; 
46(6): 1759-68. 
See DM, Tilles JG. Treatment of coxsackievirus A9 myocarditis in mice with WIN 
54954. Antimicrobial Agents and Chemotherapy. 1992; 36(2): 425-8. 
Shang B, Deng C, Ye H, Xu W, Yuan Z, Shi PY, Zhang B. Development and 
characterization of a stable eGFP enterovirus 71 for antiviral screening. Antiviral 
Research. 2013; 97(2): 198-205. 
Shen WC, Tsai C, Chiu H, Chow K. MRI of enterovirus 71 myelitis with monoplegia. 
Neuroradiology. 2000; 42(2): 124-7. 
Shi X, Zaia J. Organ-specific heparan sulfate structural phenotypes. Journal of 
Biological Chemistry. 2009; 284(18): 11806-14. 
Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee 
YC, Chen SJ, Peng KC, Tseng HY, Chang YL, Tai CL, Shih SR. Design, 
synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel 
class of potent and selective human enterovirus 71 inhibitors. Journal of 
Medicinal Chemistry. 2002; 45(8): 1644-55. 
Shih SR, Chen SJ, Hakimelahi GH, Liu HJ, Tseng CT, Shia KS. Selective human 
enterovirus and rhinovirus inhibitors: an overview of capsid-binding and protease-
inhibiting molecules. Medicinal Research Reviews. 2004a; 24(4): 449-74. 
Shih SR, Stollar V, Li ML. Host factors in enterovirus 71 replication. Journal of 
Virology. 2011; 85(19): 9658-66. 
Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, 
Lee YC, Peng KC, Chao YS. Mutation in enterovirus 71 capsid protein VP1 
confers resistance to the inhibitory effects of pyridyl imidazolidinone. 
Antimicrobial Agents and Chemotherapy. 2004b; 48(9): 3523-9. 
Shih SR, Weng KF, Stollar V, Li ML. Viral protein synthesis is required for enterovirus 
71 to induce apoptosis in human glioblastoma cells. Journal of Neurovirology. 
2008; 14(1): 53-61. 
Shimazaki K, Tazume T, Uji K, Tanaka M, Kumura H, Mikawa K, Shimo-Oka T. 
Properties of a heparin-binding peptide derived from bovine lactoferrin. Journal of 
Dairy Science. 1998; 81(11): 2841-9. 
Shimizu H, Utama A, Yoshii K, Yoshida H, Yoneyama T, Sinniah M, Yusof MA, 
Okuno Y, Okabe N, Shih SR, Chen HY, Wang GR, Kao CL, Chang KS, 
Miyamura T, Hagiwara A. Enterovirus 71 from fatal and nonfatal cases of hand, 
foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. 
Japanese Journal of Infectious Diseases. 1999; 52(1): 12-5. 
Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF,  
Hafenstein S. The enterovirus 71 A-particle forms a gateway to allow genome 
release: a cryoEM study of picornavirus uncoating. PLoS Pathogens. 2013; 9: 
e1003240. 
 
190 
Shoeman RL, Honer B, Stoller TJ, Kesselmeier C, Miedel MC, Traub P, Graves MC. 
Human immunodeficiency virus type 1 protease cleaves the intermediate filament 
proteins vimentin, desmin, and glial fibrillary acidic protein. Proceedings of the 
National Academy of Sciences of U S A. 1990; 87(16): 6336-40. 
Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, Nelson JA, Fruh K, 
Djaballah H. High-content assay to identify inhibitors of dengue virus infection. 
Assay and Drug Development Technologies.2010; 8(5): 553-70. 
Silvestri LS, Parilla JM, Morasco BJ, Ogram SA, Flanegan JB. Relationship between 
poliovirus negative-strand RNA synthesis and the length of the 3' poly(A) tail. 
Virology. 2006; 345(2): 509-19. 
Sim AC, Luhur A, Tan TM, Chow VT, Poh CL. RNA interference against enterovirus 
71 infection. Virology. 2005; 341(1): 72-9. 
Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn PC, Ooi MH. Virology, 
epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious 
Diseases. 2010; 10(11): 778-90. 
Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of 
leukocyte tethering and rolling revealed by structures of P- and E-selectin bound 
to SLe(X) and PSGL-1. Cell. 2000; 103(3): 467-79. 
Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J. 
RNA interference targeting Fas protects mice from fulminant hepatitis. Nature 
Medicine. 2003; 9(3): 347-51. 
Song Y, Paul AV, Wimmer E. Evolution of poliovirus defective interfering particles 
expressing Gaussia luciferase. Journal of Virology. 2012; 86(4): 1999-2010. 
Spear PG, Shieh MT, Herold BC, Wudunn D, Koshy TI. Heparan sulfate 
glycosaminoglycans as primary cell surface receptors for herpes simplex virus. 
Advances in Experimental Medicine and Biology. 1992; 313: 341-53. 
Stein DA, Huang CY, Silengo S, Amantana A, Crumley S, Blouch RE, Iversen PL, 
Kinney RM. Treatment of AG129 mice with antisense morpholino oligomers 
increases survival time following challenge with dengue 2 virus. Journal of 
Antimicrobial Chemotherapy. 2008; 62(3): 555-65. 
Stone JK, Rijnbrand R, Stein DA, Ma Y, Yang Y, Iversen PL, Andino R. A morpholino 
oligomer targeting highly conserved internal ribosome entry site sequence is able 
to inhibit multiple species of picornavirus. Antimicrobial Agents and 
Chemotherapy. 2008; 52(6): 1970-81. 
Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR, Chang CF. Cell 
surface sialylation affects binding of enterovirus 71 to rhabdomyosarcoma and 
neuroblastoma cells. BMC Microbiology. 2012; 12(1): 162. 
Sugahara K, Kitagawa H. Heparin and heparan sulfate biosynthesis. IUBMB Life. 2002; 
54(4): 163-75. 
 
191 
Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a 
receptor for adeno-associated virus type 2 virions. Journal of Virology. 1998; 
72(2): 1438-45. 
Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent 
structural type. Biochimica Biophysica Acta. 1999; 1489(1): 141-58. 
Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and 
properties. Antisense and Nucleic Acid Drug Development. 1997; 7(2): 187-95. 
Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch 
RE, Moulton HM, Weller DD, Iversen PL, Bavari S. Chemical modifications of 
antisense morpholino oligomers enhance their efficacy against Ebola virus 
infection. Antimicrobial Agents and Chemotherapy. 2009; 53(5): 2089-99. 
Tacahashi Y, Uyeda I. Restoration of the 3' end of potyvirus RNA derived from 
poly(A)-deficient infectious cDNA clones. Virology. 1999; 265(1): 147-52. 
Tan CW, Chan YF, Sim KM, Tan EL, Poh CL. Inhibition of enterovirus 71 (EV-71) 
infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. 
PLoS ONE. 2012;  7: e34589. 
Tan EL, Tan TM, Chow VT, Poh CL. Enhanced potency and efficacy of 29-mer 
shRNAs in inhibition of enterovirus 71. Antiviral Research. 2007a; 74(1): 9-15. 
Tan EL, Tan TM, Chow VT, Poh, CL. Inhibition of enterovirus 71 in virus-infected 
mice by RNA interference. Molecular Therapy. 2007b; 15(11): 1931-8. 
Tan EL, Yong LL, Quak SH, Yeo WC, Chow VT, Poh CL. Rapid detection of 
enterovirus 71 by real-time TaqMan RT-PCR. Journal of Clinical Virology. 2008; 
42(2): 203-6. 
Tan X, Huang X, Zhu S, Chen H, Yu Q, Wang H, Huo X, Zhou J, Wu Y, Yan D, Zhang 
Y, Wang D, Cui A, An H, Xu W. The persistent circulation of enterovirus 71 in 
People's Republic of China: causing emerging nationwide epidemics since 2008. 
PLoS ONE. 2011; 6: e25662. 
Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, Tong CY, Takebe Y, Pybus 
OG. Evolutionary genetics of human enterovirus 71: origin, population dynamics, 
natural selection, and seasonal periodicity of the VP1 gene. Journal of Virology. 
2010; 84(7): 3339-50. 
Tellier R, Bukh J, Emerson SU, Miller RH, Purcell RH. Long PCR and its application 
to hepatitis viruses: amplification of hepatitis A, hepatitis B, and hepatitis C virus 
genomes. Journal of Clinical Microbiology. 1996a; 34(12): 3085-91. 
Tellier R, Bukh J, Emerson SU, Purcell RH. Amplification of the full-length hepatitis A 
virus genome by long reverse transcription-PCR and transcription of infectious 
RNA directly from the amplicon. Proceedings of the National Academy of 
Science U S A. 1996b; 93(9): 4370-3. 
 
 
192 
Thoa Le PK, Chiang PS, Khanh TH, Luo ST, Dan TN, Wang YF., Thuong TC, Chung 
WY, Hung NT, Wang JR, Nhan Le NT, Thinh Le Q, Su IJ, Dung TD, Lee MS. 
Genetic and antigenic characterization of enterovirus 71 in Ho Chi Minh city, 
Vietnam, 2011. PLoS ONE. 2013; 8: e69895. 
Thompson SR, Sarnow P. Enterovirus 71 contains a type I IRES element that functions 
when eukaryotic initiation factor eIF4G is cleaved. Virology. 2003; 315(1): 259-
66. 
Tisdale M, Selway JW. Inhibition of an early stage of rhinovirus replication by 
dichloroflavan (BW683C). Journal of General Virology. 1983; 64 (Pt 4): 795-803. 
Tisdale M, Selway JW. Effect of dichloroflavan (BW683C) on the stability and 
uncoating of rhinovirus type 1B. Journal of Antimicrobial Chemotherapy. 1984; 
14 Suppl A: 97-105. 
Tiwari V, Liu J, Valyi-Nagy T, Shukla D. Anti-heparan sulfate peptides that block 
herpes simplex virus infection in vivo. Journal of Biological Chemistry. 2011; 
286(28): 25406-25415. 
Trybala E, Bergstrom T, Spillmann D, Svennerholm B, Olofsson S, Flynn SJ,  Ryan P. 
Mode of interaction between pseudorabies virus and heparan sulfate/heparin. 
Virology. 1996; 218(1): 35-42. 
Tsai FJ, Lin CW, Lai CC, Lan YC, Lai CH, Hung CH, Hsueh KC, Lin TH, Chang HC, 
Wan L, Sheu JJC, Lin YJ. Kaempferol inhibits enterovirus 71 replication and 
internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. 
Food Chemistry. 2011; 128(2): 312-22. 
Tu PV, Thao NT, Perera D, Truong KH, Tien NTK., Thuong TC, Ooi MH, Cardosa MJ, 
McMinn PC. Epidemiological and virological investigation of hand, foot and 
mouth disease, Southern Vietnam, 2005. Emerging Infectious Diseases. 2007; 
13(11): 1733-41. 
Tuthill TJ, Groppelli E, Hogle JM, Rowlands DJ. Picornaviruses. Current Topics in 
Microbiology and Immunology. 2010; 343: 43-89. 
Vagnozzi A, Stein DA, Iversen PL, Rieder E. Inhibition of foot-and-mouth disease virus 
infections in cell cultures with antisense morpholino oligomers. Journal of 
Virology. 2007; 81(21): 11669-80. 
van der Schaar HM, Leyssen P, Thibaut HJ, de Palma A, Van der Linden L, Lanke 
KHW, Lacroix C, Verbeken E, Conrath K, MacLeod AM, Mitchell DR, Palmer 
NJ, van de Poel H, Andrews M, Neyts J, van Kuppeveld FJ. A novel, broad-
spectrum inhibitor of enterovirus replication that targets host cell factor 
phosphatidylinositol 4-kinase IIIβ. Antimicrobial Agents and Chemotherapy. 
2013; 57(10): 4971-81. 
van der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK. Antiviral 
activities of lactoferrin. Antiviral Research. 2001; 52(3): 225-39. 
van der Werf S, Bradley J, Wimmer E, Studier FW, Dunn JJ. Synthesis of infectious 
poliovirus RNA by purified T7 RNA polymerase. Proceedings of the National 
Academy of Science U S A. 1986; 83(8): 2330-4. 
 
193 
van Ooij MJ, Polacek C, Glaudemans DH, Kuijpers J, van Kuppeveld FJ, Andino R, 
Agol VI, Melchers WJ. Polyadenylation of genomic RNA and initiation of 
antigenomic RNA in a positive-strand RNA virus are controlled by the same cis-
element. Nucleic Acids Research. 2006; 34(10): 2953-65. 
Varki NM, Varki A. Diversity in cell surface sialic acid presentations: implications for 
biology and disease. Laboratory Investigation. 2007; 87(9): 851-7. 
Vives RR, Imberty A, Sattentau QJ, Lortat-Jacob H. Heparan sulfate targets the HIV-1 
envelope glycoprotein gp120 coreceptor binding site. Journal of Biological 
Chemistry. 2005; 280(22): 21353-7. 
Vlasak M, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate 
proteoglycan for cell attachment. Journal of Virology. 2005; 79(10): 5963-70. 
Wang J, Du J, Wu Z, Jin Q. Quinacrine impairs enterovirus 71 RNA replication by 
preventing binding of polypyrimidine-tract binding protein with internal ribosome 
entry sites. PLoS ONE. 2013a; 8: e52954. 
Wang J, Fan T, Yao X, Wu Z, Guo L, Lei X, Wang M, Jin Q, Cui S. Crystal structures 
of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of 
catalytically important residues. Journal of Virology. 2011; 85(19): 10021-30. 
Wang J, Wu Z, Jin Q. COPI is required for enterovirus 71 replication. PLoS ONE. 
2012a; 7: e38035. 
Wang RR, Yang LM, Wang YH, Pang W, Tam SC, Tien P, Zheng YT. Sifuvirtide, a 
potent HIV fusion inhibitor peptide. Biochemical and Biophysical Research 
Communications. 2009; 382(3): 540-4. 
Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, Chen YJ, Yang YJ, Lin SJ, Yeh 
TF. Clinical spectrum of enterovirus 71 infection in children in Southern Taiwan, 
with an emphasis on neurological complications. Clinical Infectious Diseases. 
1999; 29(1): 184-90. 
Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, Walter TS, 
Evans G, Axford D, Owen R, Rowlands DJ, Wang J, Stuart DI, Fry EE, Rao Z. A 
sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. 
Nature Structural and Molecular Biology. 2012b; 19(4) 424-9. 
Wang Y, Qing J, Sun Y, Rao Z. Suramin inhibits EV71 infection. Antiviral Research. 
2013b; 103C: 1-6. 
Wang Z, Wang G. APD: the Antimicrobial Peptide Database. Nucleic Acids Research. 
2004; 32: D590-2. 
Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, Blouch R, Stein DA, 
Aman MJ, Iversen PL, Bavari S. Gene-specific countermeasures against Ebola 
virus based on antisense phosphorodiamidate morpholino oligomers. PLoS 
Pathogens. 2006; 2: e1. 
Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh TM. 
Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host 
cells. Antiviral Research. 2005; 67(1): 31-7. 
 
194 
Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides 
corresponding to a predictive alpha-helical domain of human immunodeficiency 
virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the 
National Academy of Science U S A. 1994; 91(21): 9770-4. 
Wimmer E, Mueller S, Tumpey TM, Taubenberger JK. Synthetic viruses: a new 
opportunity to understand and prevent viral disease. Nature Biotechnology. 2009; 
27(12): 1163-72. 
Witherell G. AG-7088 Pfizer. Current Opinion in Investigational Drugs. 2000; 1(3): 
297-302. 
Wong KT, Munisamy B, Ong KC, Kojima H, Noriyo N, Chua KB, Ong BB, Nagashima 
K. The distribution of inflammation and virus in human enterovirus 71 
encephalomyelitis suggests possible viral spread by neural pathways. Journal of 
Neuropathology and Experimental Neurology. 2008; 67(2): 162-9. 
Wu KX, Ng MM, Chu JJ. Developments towards antiviral therapies against enterovirus 
71. Drug Discovery Today. 2010; 15(23-24): 1041-1051. 
Wu Z, Yang F, Zhao R, Zhao L, Guo D, Jin Q. Identification of small interfering RNAs 
which inhibit the replication of several enterovirus 71 strains in China. Journal of 
Virological Methods. 2009; 159(2): 233-8. 
WuDunn D, Spear PG. Initial interaction of herpes simplex virus with cells is binding to 
heparan sulfate. Journal of Virology. 1989; 63(1): 52-8. 
Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto M, Nishimura 
H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K, Koike S. Human 
SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and 
enterovirus 71. Journal of Virology. 2012; 86(10): 5686-96. 
Yamayoshi S, Koike S. Identification of a human SCARB2 region that is important for 
enterovirus 71 binding and infection. Journal of Virology. 2011; 85(10): 4937-46. 
Yamayoshi S, Ohka S, Fujii K, Koike S. Functional comparison of SCARB2 and 
PSGL1 as receptors for enterovirus 71. Journal of Virology. 2013; 87(6): 3335-47. 
Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, Koike S. 
Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nature Medicine. 
2009; 15(7): 798-801. 
Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length 
cDNA clone of hepatitis C virus are infectious when directly transfected into the 
liver of a chimpanzee. Proceedings of the National Academy of Science U S A. 
1997; 94(16): 8738-43. 
Yang B, Chuang H, Yang KD. Sialylated glycans as receptor and inhibitor of 
enterovirus 71 infection to DLD-1 intestinal cells. Virology Journal. 2009; 6: 141. 
Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of 
enterovirus 71 and enhances viral infectivity. Journal of Virology. 2011; 85(22): 
11809-20. 
 
195 
Yang Z, Li G, Zhang Y, Liu X, Tien P. A novel minicircle vector based system for 
inhibiting the replication and gene expression of enterovirus 71 and 
coxsackievirus A16. Antiviral Research. 2012; 96(22): 234-44. 
Yeh MT, Wang SW, Yu CK, Lin KH, Lei HY, Su IJ, Wang JR. A single nucleotide in 
stem loop II of 5'-untranslated region contributes to virulence of enterovirus 71 in 
mice. PLoS ONE. 2011; 6: e27082. 
Yi L, He Y, Chen Y, Kung HF, He ML. Potent inhibition of human enterovirus 71 
replication by type I interferon subtypes. Antiviral Therapy. 2011; 16(1): 51-8. 
Yoke-Fun C, AbuBakar S. Recombinant human enterovirus 71 in hand, foot and mouth 
disease patients. Emerging Infectious Diseases. 2004; 10(8): 1468-70. 
Youngblood DS, Hatlevig SA, Hassinger JN, Iversen PL, Moulton HM. Stability of 
cell-penetrating peptide-morpholino oligomer conjugates in human serum and in 
cells. Bioconjugate Chemistry. 2007; 18(1): 50-60. 
Yu H, Chen W, Chang H, Tang R, Zhao J, Gan L, Liu B, Chen J, Wang M. Genetic 
analysis of the VP1 region of enterovirus 71 reveals the emergence of genotype A 
in Central China in 2008. Virus Genes. 2010; 41(1): 1-4. 
Yu SF, Lloyd RE. Identification of essential amino acid residues in the functional 
activity of poliovirus 2A protease. Virology. 1991; 182(2): 615-25. 
Yuan J, Stein DA, Lim T, Qiu D, Coughlin S, Liu Z, Wang Y, Blouch R, Moulton HM, 
Iversen PL, Yang D. Inhibition of coxsackievirus B3 in cell cultures and in mice 
by peptide-conjugated morpholino oligomers targeting the internal ribosome entry 
site. Journal of Virology. 2006; 80(23): 11510-9. 
Zaini Z, McMinn P. Complete genome sequence of a human enterovirus 71 strain 
isolated in Brunei in 2006. Genome Announcements. 2013; 1(4): e00522-13. 
Zaini Z, Phuektes P, McMinn P. A reverse genetic study of the adaptation of human 
enterovirus 71 to growth in Chinese hamster ovary cell cultures. Virus Research. 
2012; 165(2): 151-6. 
Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell 
transformation by a specific oligodeoxynucleotide. Proceedings of the National 
Academy of Science U S A. 1978; 75(1): 280-4. 
Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M. N- and 6-O-sulfated 
heparan sulfates mediate internalization of coxsackievirus B3 variant PD into 
CHO-K1 cells. Journal of Virology. 2006; 80(13): 6629-36. 
Zhang G, Zhou F, Gu B, Ding C, Feng D, Xie F, Wang J, Zhang C, Cao Q, Deng Y, Hu 
W, Yao K. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral 
activity against enterovirus 71 infection. Archives of Virology. 2012; 157(4): 669-
79. 
Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A, Cowburn D, 
Freed EO, Debnath AK. Antiviral activity of alpha-helical stapled peptides 
designed from the HIV-1 capsid dimerization domain. Retrovirology. 2011; 8: 28. 
 
196 
Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, Patel IH. 
Assessment of drug-drug interaction potential of enfuvirtide in human 
immunodeficiency virus type 1-infected patients. Clinical Pharmacology and 
Therapeutics. 2004; 75(6): 558-68. 
Zhang X, Song Z, Qin B, Chen L, Hu Y, Yuan Z. Rupintrivir is a promising candidate 
for treating severe cases of enterovirus-71 infection: evaluation of antiviral 
efficacy in a murine infection model. Antiviral Research. 2013; 97(3): 264-9. 
Zhang XN, Song ZG, Jiang T, Shi BS, Hu YW, Yuan ZH. Rupintrivir is a promising 
candidate for treating severe cases of enterovirus-71 infection. World Journal of 
Gastroenterology. 2010a; 16(2): 201-9. 
Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, Mao N, Xu S, Zhu S, Cui A, Yan D, 
Li Q, Dong X, Zhang J, Zhao Y, Wan J, Feng Z, Sun J, Wang S, Li D, Xu W. An 
emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of 
hand foot and mouth disease in Fuyang city of China. Virology Journal. 2010b; 7: 
94. 
Zheng BJ, Guan Y, Hez ML, Sun H, Du L, Zheng Y, Wong KL, Chen H, Chen Y, Lu L, 
Tanner JA, Watt RM, Niccolai N, Bernini A, Spiga O, Woo PC, Kung HF, Yuen 
KY, Huang JD. Synthetic peptides outside the spike protein heptad repeat regions 
as potent inhibitors of SARS-associated coronavirus. Antiviral Therapy. 2005; 
10(3): 393-403. 
Zhu W, Li J, Liang G. How does cellular heparan sulfate function in viral pathogenicity? 
Biomedical and Environmental Sciences. 2011; 24(1): 81-7. 
 
 
 
 
  
 
197 
APPENDICES 
 
Appendix I Reagents for growth media 
 
DMEM growth medium 
2X DMEM   500 ml 
FBS    100 ml 
Penicillin/streptomycin 10 ml 
NEAA    10 ml 
L-glutamine   10 ml 
MiliQ H2O   370 ml 
 
The media was stored at 4°C until use.  
 
DMEM maintenance medium 
 2X DMEM   500 ml 
FBS    20 ml 
Penicillin/streptomycin 10 ml 
NEAA    10 ml 
L-glutamine   10 ml 
MiliQ H2O   450 ml 
 
The media was stored at 4°C until use.  
 
Plaque medium (1.2% w/v carboxymethylcellulose) 
2X DMEM   500 ml 
FBS    20 ml 
Penicillin/streptomycin 10 ml 
NEAA    10 ml 
L-glutamine   10 ml 
MiliQ H2O   450 ml 
Carboxymethylcellulose 12 g 
 
The media was stored at 4°C until use.  
 
Super optimal broth with catabolite repression (SOC) medium 
Tryptone   2 % 
Yeast extract   0.5 % 
NaCl    10 mM 
KCl    2.5 mM 
MgCl2    10 mM 
MgSO4   10 mM 
Glucose   20 mM 
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Appendix II  Materials for SDS-PAGE 
 
Polyacrylamide gel 
      5% separating gel 12% resolving gel 
       (5 ml)   (8 ml) 
30% acrylamide/ 0.8% bisacrylamide  0.83 ml  3.20 ml 
1.5 M Tris-HCl, pH 8.8    -   2.00 ml 
1.0M Tris-HCl, pH 6.8    1.25 ml  - 
10% SDS      50 µl   80 µl 
10% Ammonium persulphate    50 µl   80 µl 
TEMED      5 µl   8 µl 
MiliQ H2O      2.82 ml  1.32 ml 
 
6x SDS loading buffer 
1 M Tris-HCl, pH 6.8  3.75 ml  
SDS    1.2 g 
Glycerol   6 ml 
DTT    0.93 g 
Bromophenol Blue  6 mg 
 
Top up to 25 ml with miliQ H2O and stored at -20°C until use. 
 
SDS running buffer 
Tris-Base   25 mM 
Glycine   192 mM 
SDS    0.1 % 
 
SDS staining solution 
Ethanol   40 % 
Acetic acid   10 % 
Coomassive Brilliant Blue 0.1 % 
miliQ H2O   50 % 
 
SDS destaining solution 
Ethanol   40 % 
Acetic acid    10 % 
Distilled water   50 % 
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Appendix III Material for western blot 
 
Anode buffer I 
Tris-base  0.3 M 
Methanol  10 % 
pH   10.4 
 
Anode buffer II 
Tris-base  25 mM 
Methanol  10% 
pH   10.4 
 
Cathode buffer 
Tris-base  25 mM 
Glycine  40 mM 
Methanol  10 % 
pH   9.4 
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Appendix IV List of 95 overlapping synthetic peptides covering the VP1 capsid 
protein 
 
1  : GDRVADVIESSIGDS 
2  : VADVIESSIGDSVSR 
3  : VIESSIGDSVSRALT 
4  : SSIGDSVSRALTQAL 
5  : GDSVSRALTQALPAP 
6  : VSRALTQALPAPTGQ 
7  : ALTQALPAPTGQNTQ 
8  : QALPAPTGQNTQVSS 
9  : PAPTGQNTQVSSHRL 
10 : TGQNTQVSSHRLDTG 
11 : NTQVSSHRLDTGEVP 
12 : VSSHRLDTGEVPALQ 
13 : HRLDTGEVPALQAAE 
14 : DTGEVPALQAAEIGA 
15 : EVPALQAAEIGASSN 
16 : ALQAAEIGASSNTSD 
17 : AAEIGASSNTSDESM 
18 : IGASSNTSDESMIET 
19 : SSNTSDESMIETRCV 
20 : TSDESMIETRCVLNS 
21 : ESMIETRCVLNSHST 
22 : IETRCVLNSHSTAET 
23 : RCVLNSHSTAETTLD 
24 : LNSHSTAETTLDSFF 
25 : HSTAETTLDSFFSRA 
26 : AETTLDSFFSRAGLV 
27 : TLDSFFSRAGLVGEI 
28 : SFFSRAGLVGEIDLP 
29 : SRAGLVGEIDLPLEG 
30 : GLVGEIDLPLEGTTN 
31 : GEIDLPLEGTTNPNG 
32 : DLPLEGTTNPNGYAN 
33 : LEGTTNPNGYANWDI 
34 : TTNPNGYANWDIDIT 
35 : PNGYANWDIDITGYA 
36 : YANWDIDITGYAQMR 
37 : WDIDITGYAQMRRKV 
38 : DITGYAQMRRKVELF 
39 : GYAQMRRKVELFTYM 
40 : QMRRKVELFTYMRFD 
41 : RKVELFTYMRFDAEF 
42 : ELFTYMRFDAEFTFV 
43 : TYMRFDAEFTFVACT 
44 : RFDAEFTFVACTPTG 
45 : AEFTFVACTPTGEVV 
46 : TFVACTPTGEVVPQL 
47 : ACTPTGEVVPQLLQY 
48 : PTGEVVPQLLQYMFV 
 
 
49 : EVVPQLLQYMFVPPG 
50 : PQLLQYMFVPPGAPK 
51 : LQYMFVPPGAPKPES 
52 : MFVPPGAPKPESRES 
53 : PPGAPKPESRESLAW 
54 : APKPESRESLAWQTA 
55 : PESRESLAWQTATNP 
56 : RESLAWQTATNPSVF 
57 : LAWQTATNPSVFVKL 
58 : QTATNPSVFVKLTDP 
59 : TNPSVFVKLTDPPAQ 
60 : SVFVKLTDPPAQVSV 
61 : VKLTDPPAQVSVPFM 
62 : TDPPAQVSVPFMSPA 
63 : PAQVSVPFMSPASAY 
64 : VSVPFMSPASAYQWF 
65 : PFMSPASAYQWFYDG 
66 : SPASAYQWFYDGYPT 
67 : SAYQWFYDGYPTFGE 
68 : QWFYDGYPTFGEHKQ 
69 : YDGYPTFGEHKQEKD 
70 : YPTFGEHKQEKDLEY 
71 : FGEHKQEKDLEYGAC 
72 : HKQEKDLEYGACPNN 
73 : EKDLEYGACPNNMMG 
74 : LEYGACPNNMMGTFS 
75 : GACPNNMMGTFSVRT 
76 : PNNMMGTFSVRTVGS 
77 : MMGTFSVRTVGSSKS 
78 : TFSVRTVGSSKSKYP 
79 : VRTVGSSKSKYPLVV 
80 : VGSSKSKYPLVVRIY 
81 : SKSKYPLVVRIYMRM 
82 : KYPLVVRIYMRMKHV 
83 : LVVRIYMRMKHVRAW 
84 : RIYMRMKHVRAWIPR 
85 : MRMKHVRAWIPRPMR 
86 : KHVRAWIPRPMRNQN 
87 : RAWIPRPMRNQNYLF 
88 : IPRPMRNQNYLFKAN 
89 : PMRNQNYLFKANPNY 
90 : NQNYLFKANPNYAGN 
91 : YLFKANPNYAGNSIK 
92 : KANPNYAGNSIKPTG 
93 : PNYAGNSIKPTGTSR 
94 : AGNSIKPTGTSRTAI 
95 : SIKPTGTSRTAITTL 
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Abstract
Enterovirus 71 (EV-71) is the main causative agent of hand, foot and mouth disease (HFMD). In recent years, EV-71 infections
were reported to cause high fatalities and severe neurological complications in Asia. Currently, no effective antiviral or
vaccine is available to treat or prevent EV-71 infection. In this study, we have discovered a synthetic peptide which could be
developed as a potential antiviral for inhibition of EV-71. Ninety five synthetic peptides (15-mers) overlapping the entire EV-
71 capsid protein, VP1, were chemically synthesized and tested for antiviral properties against EV-71 in human
Rhabdomyosarcoma (RD) cells. One peptide, SP40, was found to significantly reduce cytopathic effects of all representative
EV-71 strains from genotypes A, B and C tested, with IC50 values ranging from 6–9.3 mM in RD cells. The in vitro inhibitory
effect of SP40 exhibited a dose dependent concentration corresponding to a decrease in infectious viral particles, total viral
RNA and the levels of VP1 protein. The antiviral activity of SP40 peptide was not restricted to a specific cell line as inhibition
of EV-71 was observed in RD, HeLa, HT-29 and Vero cells. Besides inhibition of EV-71, it also had antiviral activities against
CV-A16 and poliovirus type 1 in cell culture. Mechanism of action studies suggested that the SP40 peptide was not virucidal
but was able to block viral attachment to the RD cells. Substitutions of arginine and lysine residues with alanine in the SP40
peptide at positions R3A, R4A, K5A and R13A were found to significantly decrease antiviral activities, implying the
importance of positively charged amino acids for the antiviral activities. The data demonstrated the potential and feasibility
of SP40 as a broad spectrum antiviral agent against EV-71.
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Introduction
Enterovirus 71 (EV-71) belongs to the Human Enterovirus A
species of the genus Enterovirus within the family Picornaviridae [1].
EV-71 is composed of a single-stranded, positive-sense RNA of
approximately 7411 nucleotides enclosed within an icosahedral
capsid assembled from 60 copies of each of the four structural
proteins, VP1–VP4 [2].
EV-71 is one of the main etiological agents of hand, foot and
mouth disease (HFMD) which is generally regarded as a mild
childhood disease. HFMD is characterized by the development of
mild febrile illness with papulovesicular lesions on the hand, foot
and mouth. Several epidemics with high mortalities have occurred
in Europe in the 1970s (Bulgaria 1975 and Hungary in 1978) [3,4].
However, in recent years, it has emerged as a pathogen capable of
causing severe neurological complications such as brain stem
encephalitis and acute flaccid paralysis in infants and young
children (,6 years old) in Asia [5–7]. The impact of high fatalities
and long-term neurological sequelae in severely infected children
isolated from large scale HFMD outbreaks in Malaysia (1997),Tai-
wan (1998) and China (2009) indicated that EV-71 should be
regarded as the most feared neurotrophic enterovirus after the
eradication of poliovirus [8–10]. Currently, there is no vaccine for
prevention or antiviral to treat EV-71 infections [6,11]. Thus,
there is a need to develop better and effective antiviral agents to
treat future EV-71 infections.
Peptides that can block viral attachment or entry into host cells
have therapeutic potentials. Enfuvirtide is the first peptide-based
inhibitor of viral fusion approved by the FDA in March, 2003 for
clinical use. Enfuvirtide is a 36-amino acid peptide derived from
the HR2 sequence of the transmembrane protein gp41 of HIV-1
and is the prototype of new antivirals [12,13]. Recent studies have
discovered potential antiviral peptides against Hepatitis C by
screening 441 overlapping peptides (18-mers) covering the entire
HCV polyprotein [14] and a peptide derived from the pre-S1
surface protein of Hepatitis B virus was able to exhibit antiviral
properties against Hepatitis B virus infection [15]. Shih et al. (2004)
showed that BPROZ-194 binds to VP1 and was effective in
inhibiting viral attachment or viral uncoating. This indicated that
VP1 is a good target to derive potentially antiviral peptide
sequences [16].
In the present study, 95-overlapping peptides (15-mers) covering
the entire EV-71 capsid protein, VP1, were chemically synthe-
sized. These peptides were screened for their ability to inhibit EV-
71 infection in Rhabdomyosarcoma (RD) cells. Four peptides were
found to inhibit EV-71 infection by more than 80% when
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e34589
screened at 100 mM. One peptide, SP40, was selected for further
studies as it was able to inhibit EV-71 infection at 89% in RD cells
and it mimics the sequence that is highly conserved in all EV-71
genotypes.
Materials and Methods
Cell and Viruses
Rhabdomyosarcoma (RD, ATCC # CCL-136) cells, African
green monkey kidney (Vero, ATCC # CCL-81) cells, human
cervical adenocarcinoma Epithelial (HeLa, ATCC # CCL-2) cells
and human colon adenocarcinoma (HT-29, ATCC # HTB-38)
cells were obtained from American Type Culture Collection
(ATCC, USA). RD cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS). Vero and HeLa cell lines were grown in Eagle
Minimal Essential Medium (EMEM) supplemented with 10%
FBS. HT-29 cells were grown in McCoy’s Medium supplemented
with 10% FBS. EV-71 strain 41 (5865/SIN/000009) (GenBank
accession number: AF316321), SHA66/97 (GenBank accession
number: AM396586); BrCr (GenBank accession number:
AB204852) and SHA52 (GenBank accession number:
AM396584) were propagated in RD cells supplemented with 2%
FBS. Coxsackievirus A16 (strain 22159) and poliovirus type 1 used
were clinical isolates and were propagated in RD and Vero cells
supplemented with 2% FBS, respectively.
Peptides
A set of 95 overlapping synthetic peptides spanning the entire
sequence of the VP1 capsid protein of Enterovirus 71 strain 41
(GenBank accession no. AF316321) was synthesized by Mimo-
topes Pty Ltd. (Clayton Victoria, Australia). Each peptide
contains 15-amino acid residues with 12 residues overlapping
with the adjacent peptides. All the peptides were reconstituted
in 100% dimethyl sulfoxide (DMSO) and stored at 280uC. The
peptide stock solution was diluted to the final concentration of
100 mM in the maintenance medium for initial screening. The
final concentration of the DMSO was less than 1%. The
peptide that showed inhibition of cytopathic effects was
identified and synthesized in larger amounts with .95% HPLC
purity grade.
In vitro EV-71 Inhibitory Assay of 95-overlapping
Synthetic Peptides
Approximately 1.56104 of RD cells were seeded into each well
of a 96-well plate and incubated overnight in a CO2 incubator
supplemented with 5% CO2. Prior to virus infection, EV-71
(100 PFU) were incubated with 100 mM of each synthetic peptide
for 1 hour at room temperature with gentle rocking and then
transferred to the plate containing RD cells. After adsorption for
1 hour, the inoculum was removed, and the cells were washed
twice with the serum free medium. An aliquot of 100 ml of the
fresh maintenance medium supplemented with 2% FBS was
added and the infected RD cells were incubated at 37uC for
24 hours. After 24-hour post infection, total infectious viral
particles were harvested and titrated with plaque assay.
EV-71 Plaque Assay
The plaque assay was carried out according to Sim et al. (2005)
with some modifications [17]. In brief, approximately 1.5X105
RD cells were seeded into each well of a 24-well plate, and
maintained in the complete growth medium. Prior to viral
infection, the complete growth medium was removed. After
adsorption for 1 hour, the inocula were removed, and the cells
were washed twice, overlaid with 500 ml plaque medium
(containing 1.2% carboxymethylcellulose and 2% FBS). After
48 hours of incubation, cells were fixed with 4% formaldehyde
and stained with 0.5% crystal violet.
Inhibition Concentration 50% (IC50) Determination
The IC50 values of SP40 against EV-71 strains, CV-A16 and
poliovirus type 1 were determined using comprehensive assay. In
brief, various concentrations of the peptide were prepared and
mixed with an equal volume of virus supernatant. The virus-
peptide mixtures were then used to infect peptide treated RD cells
at a MOI of 0.1. For EV-71, the viral titer was determined by the
plaque assay and total viral RNA was quantitated by the RT
TaqMan Real-time PCR assay. For CV-A16 and poliovirus type
1, the total infectious viral particles were harvested 24-hour post
infection and quantitated by TCID50 using Reed and Muench
method [18].
Reverse Transcription (RT) TaqMan Real-time PCR Assay
The primers and probewere designed according to Tan et al. [19].
The forward primer employed was 59-GAGCTCTATAGGAGA-
TAGTGTGAGTAGGG-39, the reverse primer was 59-AT-
GACTGCTCACCTGCGTGTT-39 and the TaqMan probe used
was 596-FAM-ACTTACCCA/ZEN/GGCCCTGCCAGCTCC-
lowa Black FQ-39. The viral RNA samples were extracted using
QIAamp Viral RNA mini kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions. The RT TaqMan
real-time PCR assay was performed with the OneStepTMPlus Real
TimeSystem (ABI,Carlsbad,USA)usingTaqManHFast virus1-step
master mix (ABI, Carlsbad, USA) with cDNA synthesis by reverse
transcription for 5 minutes at 50uC and subsequently amplified for
40 cycles at 95uC for 3 s, 60uC for 30 s.
SDS-PAGE and Western Blot Analysis
RD cells were seeded at 7.56105 cells/well in a 6-well plate and
followed by overnight incubation at 37uC in a CO2 incubator.
Prior to infection, both RD cells and virus were pre-treated with
various concentrations of the peptides for 1 hour. At 24-hour post-
infection, the cells and viruses were harvested. The cells were lysed
using 100 ml of ReadyPrep Sequential Extraction Kit Reagent 2
(Bio-Rad, USA). The protein concentration was determined using
the MicroBCA protein assay (Pierce, Rockford, USA). An aliquot
of 30 mg of each lysate was electrophoresed in a denaturing 12.5%
polyacrylamide gel. The proteins were transferred onto a PVDF
membrane (Millipore, Billerica, USA), and the membrane was
subsequently blocked in 5% skimmed milk powder in phosphate
buffered saline (PBS) with 0.05% Tween-20 for 1 hour in room
temperature. The membrane was incubated with 1:1000 diluted
anti-EV-71 monoclonal antibody (Millipore, Billerica, USA) or
1:1000 diluted b-actin antibody (Sigma, St. Louis, USA) for
1 hour at room temperature. After the membrane was washed, it
was incubated with 1:1000 diluted secondary antibody (HRP-
conjugated rabbit anti-mouse antibody, Sigma, St. Louis, USA) for
1 hour at room temperature. The immunoblots were developed
with the DAB substrate in stable peroxide substrate solution
(Pierce, Rockford, USA).
Mechanism of Action of SP40
RD cells were seeded at 1.56104 cells per well in a 96-well plate
and incubated overnight at 37uC in a CO2 incubator before EV-
71 infection with a MOI of 0.1 per well. Peptides were added at
various concentrations under the following conditions: (i) Cell
protection assay: RD cells were treated with various concentra-
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tions of peptide (50 ml/well). After 1 hour, the cells were washed
twice with serum free medium and infected with 100 ml/well of
EV-71 (1.56104 PFU/ml) for 1 hour. The medium containing
virus was replaced with fresh maintenance medium and the viral
titer was determined 24-hour post-infection using plaque assay. (ii)
Post-infection assay: RD cells were first infected with EV-71 for
1 hour before addition of the peptide. The inocula were replaced
with fresh maintenance medium containing various concentrations
of peptide (50 ml/well) and the viral titer was determined 24 hours
later. (iii) Virucidal assay: EV-71 (16106 PFU/ml) was treated
with various concentrations of peptide in 100 ml of maintenance
medium for 1 hour. The treated virus was then diluted 200-fold
and used to infect cells for 1 hour. The diluted virus-peptide
mixtures were replaced with fresh maintenance medium, and the
plaque forming unit was determined 24 hours later. (iv) Viral
attachment assay: RD cells in the chamber slide (Lab-tek,
Rochester, USA) or a 96-well plate or a CellCarrier-96 optic
black plate (Perkin-Elmer, Waltham, USA) were pre-treated with
the peptide for 1 hour at 4uC and subsequently infected with EV-
71 at the MOI of 100 for 1 hour at 4uC. The infected cells in the
96-well plate were washed twice to remove unbound viral
particles, the attached EV-71 viral RNA were extracted and
quantitated by the RT TaqMan Real-time PCR assay. The
infected cells in the chamber slide and the CellCarrier-96 optic
black plate were fixed with 4% paraformaldehyde and permea-
bilized with 0.25% Triton-X. The slide was first blocked with
Image-iTTM FX Signal Enhancer (Invitrogen, San Diego, USA)
for 1 hour. Subsequently, anti-Enterovirus 71 monoclonal anti-
body (Millipore, Billerica, USA) was added into the cell-coated
well followed by 1:200 diluted Alexa Fluor 488 anti-mouse IgG
(Invitrogen, USA) as a secondary antibody. The nuclei of the RD
cells were stained with 4,6-diamidino-2-phenylindole (DAPI). The
slide was observed under Nikon Eclipse TE2000-E Fluorescence
Microscope and the CellCarrier-96 optic black plate was analyzed
by Cellomics High Content Screening ArrayScan VTI (Thermo
Fisher Scientific, USA) using Spot Detector Bio-Application. The
number of spots per field was determined.
Cytotoxicity Assay
Peptide cytotoxicity was determined by a commercially
available assay (Celltiter 96 AQueous One Solution Cell
Proliferation Assay Reagent, Promega, Madison, WI) following
the manufacturer’s instructions. Briefly, RD cells (1.5X104 cells/
well) were seeded in a 96-well plate, and the plate was incubated
for 24 hours at 37uC. An aliquot of 20 ml of the medium
containing the desired concentration of the SP40 peptide was
added to the cells. The final concentration of DMSO for all
peptide dilutions was adjusted to 0.6% to eliminate the effect of
DMSO variation on cell cytotoxicity. After incubation of the cells
in the presence of the SP40 peptide overnight at 37uC, 20 ml of the
96 AQqueous One Solution cell proliferation assay reagent were
added to each well. The plate was then incubated for 2 hours at
37uC and the absorbance at 490 nm was determined with a 96-
well plate reader.
Sequence Alignment and Structure Homology Prediction
The genome sequences of the EV-71 strain 41 (GenBank
accession number: AAK13008) and the Mahoney poliovirus strain
(GenBank accession number:1PO2_1) were searched using the
NCBI Protein website (http://www.ncbi.nlm.nih.gov/protein/).
The sequence of the EV-71, VP1 protein was aligned using Clustal
W2 program (http://www.ebi.ac.uk/Tools/Clustalw2/index.
html). The three-dimensional structure of the VP1-VP4 protein
complex of Mahoney strain poliovirus (PDB ID: 1HXS) was
selected to predict the possible position of SP40 by homology
modeling.
Results
Screening of the VP1 Capsid Protein Peptide Library
To test the potential of using peptides as an antiviral agent, a
library of 15-mer peptides (purity at 60–65%) corresponding to
residues 1 to 297 of the VP1 capsid protein and overlapping with
each other by 12 residues (6 residues on the C-terminal and N-
terminal, respectively) were synthesized. All the 95-overlapping
peptides were evaluated for their ability to reduce cytopathic
effects caused by EV-71 in RD cells, followed by plaque reduction
assay as described in the materials and methods. The criterion for
designating a peptide as antiviral is the inhibition of at least 80% of
plaque formation at a concentration of 100 mM. Fig. 1 shows the
locations of the peptides in the EV-71 genome and their antiviral
activities in the initial screen. Of the 95-overlapping peptides in
the library, there were four peptides, designated as SP40, SP45,
SP81 and SP82 that were found to exhibit inhibitory effects
against EV-71 plaque formation at 89.3%, 83.7%, 83.7%, and
82.5%, respectively (Fig. 1). The SP40 peptide was selected for
further analysis as SP40 showed the highest inhibition of both
cytopathic effect and plaque reduction. The amino acid sequence
of the SP40 peptide was highly conserved across all genotypes of
EV-71 (Table S1). SP40 is a 15-mer peptide (Ac-QMRRKVELF-
TYMRFD-NH2) spanning from position 118 to 132 in the VP1
capsid region. A scrambled-SP40 peptide, designated as SP40X
(Ac-REFTMKRMVLFRQDY-NH2), was synthesized and used as
a control throughout the experiments.
Synergistic Antiviral Activities of the SP40 Peptide
with SP81
To investigate whether the SP40 peptide exhibited synergistic
antiviral activities with other peptides, the SP40 peptide was mixed
with SP45, SP55 and SP81 (,70% purities) to a final
concentration of 200 mM. Our results demonstrated that the
SP40 peptide could best exhibit synergistic antiviral activities with
the SP81 peptide to achieve a total viral RNA inhibition of 99.7%
when compared to 92.0% being exhibited by 200 mM of the SP40
peptide alone. However, the SP40 peptide had less synergistic
effect when combined with the SP45 peptide or the SP55 peptide,
with viral RNA inhibitions of 94.3% and 96.0%, respectively.
When all the 4 peptides were combined, viral RNA inhibition
achieved was at 98.8%.
Antiviral Properties of SP40
To further confirm that the SP40 peptide inhibited EV-71
infection in RD cells, the peptide was synthesized on a larger scale
with .95% purity. The peptide was tested in the comprehensive
assay against EV-71 at a MOI of 0.1. The results confirmed that
SP40 inhibited viral plaque formation and RNA synthesis with
inhibition levels achieved at 96.3%60.8 and 92.0%69.3,
respectively when the peptide was applied at 200 mM (Fig. 2B,
Fig.3A and 3B). The SP40 peptide also significantly reduced viral
cytopathic effect and protein synthesis when tested in RD cells
(Fig. 2A, Fig. 2C). To determine whether the amino acid sequence
of the SP40 peptide is critical for the antiviral activities, the
antiviral property of the scrambled SP40X peptide was evaluated.
The data indicated that the SP40X peptide showed no significant
inhibition of EV-71 infection at 200 mM. Two independent
experiments confirmed that the SP40 peptide inhibited EV-71
strain 41 infection with an IC50 of 7.9 mM63.5 (Table 1).
Interestingly, the SP40 peptide also inhibited all three genotypes of
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EV-71 (genotypes A, B and C) with IC50 values ranging from 6–
9.3 mM (Table 1, Fig. 3C). The SP40 peptide was found to inhibit
EV-71 induced cytopathic effects and viral RNA synthesis in Vero,
HeLa and HT-29 cell lines in a dose-dependent manner (Fig. 4A
and 4B). The SP40 peptide also exhibited antiviral activities
against CV-A16 and poliovirus type 1 with IC50 values of
6 mM60.8 and 18.22 mM610.4, respectively. However, the IC50
value against poliovirus type 1 was observed at a higher value
(Table 1). Hence, we concluded that the SP40 peptide exhibited a
broad-spectrum antiviral activity against all EV-71 genotypes as
well as other enteroviruses in various cell lines.
Mechanism of Action of SP40
We have found that the SP40 peptide exhibited the strongest
inhibitory effect when tested in the comprehensive assay with an
IC50 of 7.9 mM where both RD cells and EV-71 viral particles
were first pre-treated with the SP40 peptide separately before
infection (Fig. 3D). This suggested that the SP40 peptide could
exert its inhibition at the viral binding step in EV-71 infection or it
was virucidal to EV-71 viral particles.
To determine if the SP40 peptide could inactivate EV-71 viral
particles, viral supernatant at a MOI of 10 was incubated with the
SP40 peptide for 1 hour at room temperature, and subsequently
diluted 200-folds and viable viral particles were quantitated by the
plaque assay. The results demonstrated that the SP40 peptide
could not inactivate EV-71 even when the peptide tested was
present at a concentration as high as 200 mM. Hence, SP40
peptide was not virucidal to EV-71 viral particles (Fig. 3D).
To elucidate whether the SP40 peptide could inhibit the viral
binding step in EV-71 infection, RD cells were pre-incubated with
the SP40 peptide for 1 hour at room temperature before EV-71
infection. The IC50 value observed was 15 mM (Fig. 3D). The data
indicated that the SP40 peptide could disrupt or interfere the
binding of the EV-71 viral particles to cells or it could interfere
with post-binding steps. To address this, RD cells were pre-treated
with various concentrations of the SP40 peptide at 4uC for 1 hour,
followed by EV-71 inoculation at a MOI of 100 at 4uC. The EV-
71 viral particles that were attached to the RD cell surface were
determined by immunofluorescence assay as described in the
Materials and Methods. As shown in Fig. 5A, the number of EV-
71 viral particles (green fluorescence) attached to the RD cell
Figure 1. Identification of antiviral peptides. A library consisting of 95-overlapping peptides (15 mers) covering the entire EV-71 capsid protein,
VP1 was synthesized. Each peptide was screened at a presumptive concentration of 100 mM for its ability to inhibit EV-71 infection in plaque
reduction assay. The top line showed a schematic representation of the EV71 genome, and the activities of the peptides were shown at the bottom.
Arrows denote the four peptides that were positive in the assay.
doi:10.1371/journal.pone.0034589.g001
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surface was observed to be reduced when tested in the presence of
the SP40 peptide. The results from the Cellomics HCS ArrayScan
Spot Detector BioApplication assay showed that the number of
viral particles that were attached to the cell surface were reduced
from 210639 viral spots per field to 68620 viral spots per field in
a dose dependent manner (Fig. 5B). Total viral RNA determined
by real-time RT-PCR assay confirmed significant reduction of
viral RNA following treatment with the SP40 peptide before
infection with EV-71 at 4uC (Fig. 5C). To investigate if SP40
inhibited a post-binding step in EV-71 entry to the cells, RD cells
were incubated with EV-71 for 1 hour at 4uC, followed by the
addition of SP40. The cells were washed and immediately shifted
to 37uC for 1 hour to allow post-binding event. No inhibition of
plaque formation was observed (data not shown). The results
demonstrated that the SP40 peptide disrupted the binding of the
EV-71 viral particles to RD cells rather than at the EV-71 during
post-binding stage.
Figure 2. Inhibitory effects of SP40 and SP40X peptides in cytopathic effect, plaque formation and protein synthesis. (A) For
cytopathic effect, EV-71 at a MOI of 0.1 was pre-incubated with peptides for 1 hour before infection of peptide-treated RD cells. The images were
taken at 24-hour post-infection. (B) For plaque reduction assay, approximately 100 PFU of EV-71 were pre-incubated with peptides for 1 hour before
infection of peptide-treated RD cells. The cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet at 48-hour post-infection. (C)
Western blot analysis of total protein isolated from virus-infected cells using the EV-71 monoclonal antibody (Millipore, Billerica, USA) and monoclonal
anti b-actin antibody (Sigma, St. Louis, USA).
doi:10.1371/journal.pone.0034589.g002
Table 1. IC50 of the SP40 peptide against various
enteroviruses.
EV-71 strains Genotypes Clinical manifestations IC50 (mM)
b
BrCr A Aseptic meningitis 9.362.5
SHA66/97 B3 HFMDa 660.7
41 B4 Fatal 7.963.5
SHA52 C2 HFMD 8.562.8
Coxsackievirus A16 – HFMD 660.8
Poliovirus type 1 – – 18.22610.4
aHFMD denotes hand, foot and mouth disease.
bThe IC50s are the mean 6 standard deviations determined from at least two
independent experiments.
doi:10.1371/journal.pone.0034589.t001
Antiviral Peptide against EV-71 Infections
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e34589
The SP40 peptide was found to be non-inhibitory when added
one hour after RD cells were infected with EV-71. The IC50 of
SP40 peptide after 1 hour post-infection was established to be
200 mM (Fig. 3D).
Residues Critical for Antiviral Activity of SP40
To identify the residues in the SP40 peptide that are critical for
antiviral activity, 13 peptides with alanine substitution in each of
the amino acid position in the 15-mer SP40 peptide were
synthesized. The inhibitory effects in RD cells at 200 mM of all
peptides were evaluated. Reduction of viral RNA levels by each of
the peptides being evaluated was summarized in Fig. 6. Substi-
tution of the arginine residue at position 3 (P3) with alanine in the
SP40 peptide was found to significantly decrease the inhibitory
activity (from 95.9% to 61.8%) when compared to substitution at
other positions. When positively charged arginine or lysine
residues at positions 4, 5 and 13 (P4, P5 and P11) of the SP40
peptide were substituted with alanine, there were moderate losses
of activities (from 95.9% reduced to 74.3%, 70.9% and 70.6%,
respectively). With only one exception, substitution of the polar
methionine residue at position 12 with alanine in the SP40 peptide
also reduced the antiviral activity moderately to 74.7%. Alanine
substitutions of amino acids at other positions of the SP40 peptide
did not alter the antiviral activities when compared to the SP40
peptide. Our data indicated that the positively charged amino
acids were critical for the antiviral activities of the SP40 peptide.
Cytotoxicity Assay
To evaluate whether the SP40 peptide was cytotoxic to cells,
RD cells were treated with increasing concentrations of the SP40
peptide from 0 mM to 280 mM, and cell viability was determined
using CellTiter 96 AQueous One Solution Cell Proliferation Assay
Reagent (Promega, Madison, WI). We found that the SP40
peptide was non-cytotoxic to RD cells when tested at the
concentration of up to 280 mM. The SP40 peptide was also
non-cytotoxic to HeLa, Vero, HT-29 cell lines (data not shown).
Homology Modeling of EV-71
The EV-71 VP1 amino acid sequence was aligned with
Mahoney poliovirus using Cluster W2 program and the three
dimensional structure of the EV-71 capsid protein based on the
poliovirus model was analyzed by the NCBI Cn3D 4.3 software
(Fig. 7). The amino acid sequence of the SP40 in the 3D structure
is indicated in yellow. The 3D-homology structure of EV-71
indicated that part of the SP40 peptide was exposed on the
surface.
Discussion
A Pepscan strategy was employed to screen 95-overlapping
synthetic peptides corresponding to the VP1 capsid protein for
antiviral activity against EV-71. Four peptides SP40, SP45, SP81
and SP82 were found to exhibit significant antiviral activities. The
SP40 peptide was selected for further investigation as the amino
Figure 3. Antiviral activities of the SP40 and SP40X peptides.
Both RD cells and EV-71 were separately pre-incubated with increasing
concentrations of each peptide for 1 hour before viral inoculation. The
inhibitory levels of the peptides were evaluated at 24-hour post-
infection by (A) plaque assay and (B) RT TaqMan real-time PCR. (C)
Antiviral properties of the SP40 peptide against different EV-71 strains
in the comprehensive assay and (D) Mechanism of action studies: The
SP40 peptide was added to EV-71 infection at different time points
relative to viral inoculation as previously described in the Materials and
Methods.
doi:10.1371/journal.pone.0034589.g003
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acid sequence of SP40 is highly conserved across all EV-71
genotypes and sub-genotypes. Our results demonstrated that the
SP40 peptide inhibited EV-71 infection in a dose-dependent
manner corresponding to the reduction of viral RNA, VP1 protein
and plaque formation. The IC50 values reported in our studies
ranged from 6–9.3 mM against all representative strains of EV-71
genotypes A, B and C. Interestingly, the SP40 peptide also
inhibited CV-A16 and poliovirus type 1 infection in vitro, implying
that the SP40 peptide could function as a broad-spectrum antiviral
agent. However, a higher concentration of SP40 peptide was
required to block poliovirus type 1 infection. This could be due to
the high degree of dissimilarity of the amino acid sequence present
in EV-71 and poliovirus.
The possible mechanism of action of the SP40 peptide could be
either through direct viral inactivation or it could block viral
attachment and entry. Our data confirmed that the SP40 peptide
was not virucidal, but it blocked viral attachment to the cell-
surface and hence prevented EV-71 infection. Our immunofluo-
rescence assay and Cellomics HCS ArrayScan showed the number
of viral particles attached to the cell surface was reduced
significantly when the RD cells were pre-treated with the SP40
peptide before addition of virus at 4uC. The results indicated that
Figure 4. The antiviral activities of the SP40 peptide in various cell lines. Vero, HeLa and HT-29 cell lines were pre-treated with the SP40
peptide at various concentrations for 1 hour at room temperature before infection with EV-71 at a MOI of 0.1. (A) The viral induced cytopathic effects
in various cell lines were observed 24-hour post-infection. (B) The viral RNA inhibition that were quantitated by RT TaqMan real-time PCR assay.
doi:10.1371/journal.pone.0034589.g004
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the SP40 peptide probably first interacted with a cell-surface
receptor and subsequently prevented EV-71-cellular receptor
interactions. However, the SP40 peptide lost its antiviral activity
when the peptide was added 1 hour after EV-71 infection.
Previous studies have shown that peptides could play a
significant role in surface protein-protein interactions and could
exert inhibitory activities against viruses like influenza virus [20],
Herpes Simplex virus-1 [21,22], Hepatitis B virus [15], Hepatitis
C virus [14,23], HIV-1 [12], Dengue virus and West Nile virus
Figure 5. Viral attachment assay. (A) RD cells were grown in the chamber slides (Lab-tek, Rochester, USA) and incubated at room temperature for
1 hour with or without the SP40 peptide. This was followed by the incubation of the cells in the cold with EV-71 for 1 hour and washing off the
unbound virions with PBS. RD cell monolayers were fixed with 4% paraformaldehyde and subsequently blocked with Image-iTTM FX Signal Enhancer
(Invitrogen, San Diego, USA). The EV-71 particles were probed with anti-EV-71 monoclonal antibody (Millipore, Billerica, USA) and Alexa Fluor
488 anti-mouse IgG (Invitrogen, San Diego, USA). The nuclei were stained with DAPI for 7uminutes at room temperature. The images were obtained
from the fluorescent microscopy. EV-71 viral particles and cell nuclei were shown in green and blue fluorescence, respectively. The number of virus
particles that was attached to the cell surface were quantitated by (B) Cellomics HCS ArrayScan Spot Detector Bio-Application and (C) RT TaqMan real-
time PCR assay
doi:10.1371/journal.pone.0034589.g005
Figure 6. Alanine scanning analysis. Alanine scanning was performed on the SP40 peptide. Thirteen different peptides were synthesized by
replacing one residue at a time with an A and their inhibitory effect was determined as described above. Activity of each peptide was compared with
the wild-type SP40, which was represented by the red line. Numbers higher than the red line showed a gain of activity whereas a lower number
represented a loss of activity.
doi:10.1371/journal.pone.0034589.g006
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[24]. Although the EV-71 capsid protein VP1 has been reported to
be responsible in mediating viral adsorption and uncoating
process, little information is available about the molecular
interactions of EV-71 and cell receptors [25]. Recently, Chen et
al. [26] had identified several amino acid residues present in the
EV-71 capsid protein VP1 that were critical for the molecular
interaction between EV-71 and the SCARB2 receptor. These
amino acid residues were found within the residues 152–236 of the
VP1 protein. None of the amino acids identified was mapped
within the SP40 peptide amino acid sequence. This finding
suggested that the SP40 peptide probably did not interact with the
SCARB2 receptor.
Figure 7. Proposed locations of the SP40 peptide based on sequence alignment and molecular modeling of poliovirus structure. (A)
The EV-71 strain 41 was aligned with Mahoney poliovirus strain using Clustal W2 program and (B) The molecular structure of poliovirus VP1, VP2, VP3,
and VP4 is represented by purple, blue, brown and green, respectively. The SP40 sequence is indicated in yellow.
doi:10.1371/journal.pone.0034589.g007
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We have demonstrated the importance of the SP40 amino acid
sequence for antiviral activities by comparison with a peptide
carrying scrambled sequence. The inhibitory effect of the
scrambled peptide, SP40X, was significantly lower (at 42.5%)
than the effect observed with the SP40 peptide. Since the amino
acid sequence of the SP40 peptide was highly conserved across all
EV-71 genotypes and was exposed on the surface, this sequence
might carry important motif/domain that interacted with an
unidentified cell-surface receptor. The SP40 peptide could prevent
viral attachment by interacting with cell receptors present on
the surfaces of the RD cells, thereby blocking the availability of the
receptor for attachment of the EV-71 viral particles. The
observation of a significantly reduced IC50 value when RD cells
were pre-treated with SP40 before EV-71 infection strongly
supports this view. The cellular receptor that the SP40 peptide
interacted with remained unknown. However, the SP40 peptide
could also inhibit CV-A16 and poliovirus type 1 infections in vitro,
indicating that the SP40 peptide could interact with a common
receptor that was probably shared by these viruses.
Since the positively charged amino acids were critical for
antiviral activities, the SP40 peptide could interact with cell surface
receptors through electrostatic charge interactions. The antiviral
activity of the SP40 peptide was not restricted to a specific cell
type, but it could block EV-71 infection in different cell lines. This
indicated that the SP40 peptide was probably interacting with the
receptor that was commonly expressed in most cell types.
Interestingly, cell surface glycosaminoglycans are present ubiqui-
tously on the surface of most animal cells and in the extracellular
matrix [27]. The presence of several arginine residues in SP40
draws similarity to the antiviral peptide displaying positively
charged poly-arginine residues against herpes simplex virus-I
(HSV-I) [22]. The antiviral property of the poly-arginine peptide
against HSV-I infection in mice was due to an interaction with
heparan sulfate. Sequence analysis of the SP40 peptide revealed
that it consisted of heparan sulfate glycosaminoglycan specific
binding domains (G1RRRRS6 and R28KVR31) present in bovine
and human lactoferrins [28–30]. Several studies have reported
that lactoferrin was able to bind to ligands such as heparan sulfate
and chondroitin sulfate [28,31,32]. It is possible that through this
interaction lactoferrin was able to inhibit EV-71 infection [33].
These findings suggested that the SP40 peptide could have
interacted with cell surface glycosaminoglycans and prevented EV-
71 attachment.
This is the first time that a small novel viral-based peptide (15-
mer) derived from VP1 is reported to exhibit antiviral activities
against all genotypes and sub-genotypes of EV-71 infection in vitro.
The development and use of antivirals like enviroxime [34],
pleconaril [35], nucleoside analog ribavirin [36] and 3C protease
inhibitors [37] for treating enteroviral infection showed variable
efficacies against the neurotrophic EV-71 virus [38]. Our results
showed that some EV-71 strains were even resistant to ribavirin at
800 mM (unpublished data), this contradicts with the finding of an
IC50 of 266 mM reported by Li et al. [36]. This indicated that
ribavirin might not serve as an effective antiviral agent against all
EV-71 strains. Other antiviral agents like the viral capsid-binding
pyridyl imidazolidinones were found to be ineffective when a
single amino acid mutation occurred at position 192 of the
hydrophobic pocket of the VP1 capsid protein [16]. The SP40
peptide was found to exhibit very similar antiviral properties with
bovine and human lactoferrins which were predicted to prevent
viral attachment, possibly by blocking an unknown cellular
receptor [33,39]. However, the exact antiviral mechanism of
lactoferrin remains to be determined and the SP40 peptide
reported in our study has an even lower IC50 value at 15 mg/ml
when compared to the IC50 value of bovine lactoferrin at 34.5 mg/
ml [33] or human lactoferrin at 103.3–185.0 mg/ml [39,40]. Thus,
SP40 is a good antiviral candidate.
The peptides that blocked the SCARB2 receptor could also be
developed as antiviral agents. Chen et al. [26] have discovered the
amino acid residues in the VP1 capsid protein that are critical for
SCARB2 receptor binding. Interestingly, the amino acids in VP1
that are critical for SCARB2 binding were found in the SP45,
SP55, and SP81 peptides. The amino acid residues that are
important for SCARB2 binding in the SP45, SP55 and SP81
peptides were illustrated in Fig. S1. These peptides were able to
inhibit EV-71 infections in a dose-dependent manner with no
cytotoxicity to the RD cells (unpublished data). Strong synergistic
antiviral activities were observed between the SP40 and the SP81
peptides in RD cells. Since the amino acids critical for binding to
SCARB2 were not present in the SP40 peptide, the data suggested
that the SP40 peptide could have interacted with a different
receptor compared with the SP81 peptide. The additive effects of
these two peptides could have significantly reduced the availability
of receptors for viral attachment.
Inhibition of viruses at the stage of viral attachment provides a
target for therapeutic intervention. Therapeutic peptides have
become an attractive tool in drug discovery due to their active
regulatory role in the biological system and their extreme high
specificity of recognition. The best characterized therapeutic
peptide inhibitor is Enfuvirtide (fusion inhibitor) which mimics the
N terminal sequence in HIV fusion protein, gp41 [12]. Using
peptides as therapeutic agents offer some significant advantages
over small chemical molecules or large therapeutic antibodies. A
major advantage of peptides is their small size and their high
activity and specificity when compared to the antibodies. Peptides
are better candidates to inhibit protein-protein interactions that
comprise a surface area often too large to be inhibited by small
chemical molecules. Peptides accumulate in lesser quantity in
tissues, and have very low cell toxicity when compared to small
synthetic molecules [41]. Antimicrobial peptides such as lactofer-
rin, human b-defensin-2 and dermaseptins have been reported to
exhibit antiviral properties against various viruses [28,42–46].
Therefore, therapeutic peptides have some advantages over the
smaller chemical compounds as antiviral agents.
Since the SP40 peptide works at a very low micromolar
concentration and is non-cytotoxic to RD cells, it is potentially an
excellent candidate for further development as an antiviral agent.
The SP40 peptide was effective when administered before EV-71
infection and could be considered as an excellent candidate for
prophylactic intervention. The exact cellular receptor(s) that the
SP40 peptide interacted with still remained unknown. Further in
vivo studies are needed for development of the SP40 as an antiviral
agent. Although a major disadvantage of peptides is their low
bioavailability due to their rapid degradation in the gastrointes-
tinal system, new formulations, such as the D-isomer peptide and
other delivery options are being developed to circumvent these
disadvantages [41].
Supporting Information
Figure S1 Diagrammatic illustration of EV-71 VP1
secondary structure. Cylinder and arrow represent a-helix
structure and b-sheet, respectively. The effects of mutations
examined as to which amino acids were interacting with the
SCARB2 receptor was marked as follows: Filled circle indicates
those most effective residues for viral binding and infection; open
circle indicates partial effective residues [26]. The amino acid
sequences of SP40, SP45, SP55 and SP81-83 were shown to
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correspond to their secondary structure and location within the
VP1 capsid protein.
(TIF)
Table S1 VP1 protein sequences among enteroviruses.
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Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan
as an Attachment Receptor
Chee Wah Tan,a Chit Laa Poh,b I-Ching Sam,a,c Yoke Fun Chana,c
Department of Medical Microbiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysiaa; Faculty of Science and Technology, Sunway University, Selangor,
Malaysiab; Tropical Infectious Disease Research and Education Center (TIDREC), Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysiac
Enterovirus 71 (EV-71) infections are usually associated with mild hand, foot, andmouth disease in young children but have
been reported to cause severe neurological complications with highmortality rates. To date, four EV-71 receptors have been
identified, but inhibition of these receptors by antagonists did not completely abolish EV-71 infection, implying that there is an
as yet undiscovered receptor(s). Since EV-71 has a wide range of tissue tropisms, we hypothesize that EV-71 infections may be
facilitated by using receptors that are widely expressed in all cell types, such as heparan sulfate. In this study, heparin, polysul-
fated dextran sulfate, and suramin were found to significantly prevent EV-71 infection. Heparin inhibited infection by all the
EV-71 strains tested, including those with a single-passage history. Neutralization of the cell surface anionic charge by polyca-
tionic poly-D-lysine and blockage of heparan sulfate by an anti-heparan sulfate peptide also inhibited EV-71 infection. Interfer-
ence with heparan sulfate biosynthesis either by sodium chlorate treatment or through transient knockdown ofN-deacetylase/
N-sulfotransferase-1 and exostosin-1 expression reduced EV-71 infection in RD cells. Enzymatic removal of cell surface heparan
sulfate by heparinase I/II/III inhibited EV-71 infection. Furthermore, the level of EV-71 attachment to CHO cell lines that are
variably deficient in cell surface glycosaminoglycans was significantly lower than that to wild-type CHO cells. Direct binding of
EV-71 particles to heparin-Sepharose columns under physiological salt conditions was demonstrated. We conclude that EV-71
infection requires initial binding to heparan sulfate as an attachment receptor.
Human enterovirus 71 (EV-71) belongs to the Enterovirus ge-nus within the family Picornaviridae. The EV-71 genome is a
positive-sense, single-stranded RNA enclosed in an icosahedral
capsid assembled from 60 copies of each of the four structural
proteins, VP1 to VP4 (1).
EV-71 infections usually cause mild hand, foot, and mouth
disease (HFMD), characterized by the development of fever with
rashes on the palms and feet and with oral ulcers (2). EV-71 also
causes severe neurological manifestations, such as aseptic menin-
gitis, brain stem encephalitis, and poliomyelitis-like acute flaccid
paralysis (3). In recent years, EV-71 has emerged as an important
cause of epidemic viral encephalitis in Asia, resulting in high fa-
talities among children below the age of 6 years (3, 4).
Receptor binding is an essential event during viral infection.
The ability to recognize and interact with specific receptors is one
of the factors that contribute to the host range and tissue tropism
of a virus (5). To date, at least four EV-71 receptors have been
reported. The first receptor to be discovered was the human P-
selectin glycoprotein ligand-1 (PSGL-1). PSGL-1 is a sialomucin
membrane protein expressed mainly in leukocytes and was hy-
pothesized to facilitate the viremic phase of EV-71 infection (6).
The second receptor reported was the human scavenger receptor
class B-2 (SCARB2), a type III double-transmembrane protein
located primarily in endosomes but also expressed on the cell sur-
face (7–9). Sialylated glycan was also reported as one of the possi-
ble receptors for EV-71 infection. Removal of sialic acid residues
from plasma membranes was able to protect DLD-1, RD, and
SK-N-SH cells from EV-71 infection (10, 11). Annexin II has re-
cently been identified as another possible receptor for EV-71 in
RD cells. Pretreatment of EV-71 with soluble annexin II resulted
in reduced viral attachment to the cell surface (12). However,
inhibitors that blocked all of the receptors identified failed to in-
hibit EV-71 infection completely (13). This may imply the in-
volvement of one or more EV-71 receptors that have yet to be
discovered.
Our previous study identified a novel antiviral peptide, SP40,
derived from the VP1 capsid protein (14). This peptide was found
to contain a heparan sulfate-specific glycosaminoglycan (GAG)
binding domain (-RRKV-), and the positively charged amino ac-
idswere found to be critical for antiviral properties.Wepostulated
that SP40 interacted with heparan sulfate and blocked EV-71 at-
tachment (14). Similarly, bovine and human lactoferrin exhibited
antiviral activities against EV-71 when tested in vitro and in vivo,
possibly due to direct interactionwith heparan sulfate, resulting in
interference with EV-71 binding (15, 16). In a recent study, hep-
arin and heparan sulfate were reported to exhibit antiviral activi-
ties against EV-71 infection (17). These findings led us to hypoth-
esize that surface heparan sulfate might play an important role in
EV-71 attachment.
GAGs are negatively charged linear polysaccharides composed
of hexosamine/hexuronic acid repeats. GAGs acquire negative
charges through N- and O-sulfation of the carbohydrate moieties
(18). The types of GAG include heparin, heparan sulfate, and
chondroitin sulfate. GAG-ligand interactions are complex and are
characterized either by merely electrostatic forces or by specific
interactions (19). Many viral pathogens, such as herpes simplex
virus (20, 21), HIV (22, 23), dengue virus (24), human papilloma-
virus (25), vaccinia virus (26), Theiler’smurine encephalomyelitis
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virus (TMEV) (27), adeno-associated virus type 2 (28, 29), hepa-
titis B virus (30), hepatitis C virus (31), Sindbis virus (32), echo-
virus (33), coxsackievirus B3 and A9 (34, 35), and foot-and-
mouth disease virus (36, 37), are known to utilize cell surface
heparan sulfate as an attachment or entry receptor.
In the present study, we investigate the role of heparan sulfate
in the binding of EV-71 to the surface of rhabdomyosarcoma
(RD) cells. We provide evidence that the ability of EV-71 to bind
to RD cells was reduced after the enzymatic removal of cell surface
heparan sulfate and through the obstruction of heparan sulfate
biosynthesis. Our results show that cell surface heparan sulfate,
and not chondroitin sulfate, serves as an attachment receptor for
EV-71.
MATERIALS AND METHODS
Reagents. Soluble GAGs (heparin sodium salt from porcine intestinal
mucosa, chondroitin sulfate sodium salt from shark cartilage, N-acetyl-
de-O-sulfated heparin sodium salt, and de-N-sulfated heparin sodium
salt), dextran sulfate sodium salt from Leuconostoc mesenteroides,
suramin, heparinase I/II/III from Flavobacterium heparinum, chondroiti-
nase ABC from Proteus vulgaris, and sodium chlorate were all purchased
from Sigma.Heparinase I from recombinantBacteroides thetaiotaomicron
was supplied by R&D Systems. An anti-EV-71 monoclonal antibody and
poly-D-lysine were purchased from Millipore, and Alexa Fluor 488-la-
beled anti-mouse IgG was purchased from Invitrogen. Anti-heparan sul-
fate peptides G1 (LRSRTKIIRIRH) and G2 (MPRRRRIRRRQK) (under-
lining indicates positively charged amino acids), described previously
(38), were synthesized by Mimotopes Pty Ltd. (Australia) with 92%
purity as determined by high-performance liquid chromatography
(HPLC). All the primers and probes were synthesized by IDT.
Cell lines and viruses. All the cell lines used in this experiment were
obtained from the American Type Culture Collection (ATCC). Human
rhabdomyosarcoma (RD; ATCC no. CCL-136) and Chinese hamster
ovary (CHO-K1; ATCC no. CCL-61) cells were grown in Dulbecco’s
modified Eagle medium (DMEM) (HyClone) supplemented with 10%
fetal bovine serum (FBS). Mutant CHO-pgsD677 (ATCC no. CRL-2244)
and CHO-pgsA745 (ATCC no. CRL-2242) cells were grown in Kaighn’s
modification of Ham’s F-12 (F-12K) medium (ATCC) supplemented
with 10% FBS. All the experiments were carried out using 1.5  104 RD
cells, unless otherwise stated. EV-71 laboratory strains BrCr (GenBank
accession number AB204852), 41 (a gift from Tan Eng Lee, Singapore
Polytechnic, Singapore) (GenBank accession number AF316321), UH1/
PM/97 (GenBank accession number AM396587), and SHA66/97 (GenBank
accession number AM396586) were propagated in RD cells in mainte-
nance medium supplemented with 2% FBS. All the other EV-71 isolates
(14716, 35017, 1687413, and 1657640) and the poliovirus (PV) vaccine
strain were obtained from theDiagnostic Virology Laboratory, University
Malaya Medical Center, Kuala Lumpur, Malaysia. Isolates 14716,
1687413, and 1657640 were all passaged once in tissue culture, while iso-
late 35017 had been passaged twice. Throughout the study, EV-71 strain
41 was used, unless otherwise stated.
TaqMan quantitative real-time PCR assay. TaqMan quantitative
real-time PCR was performed as described previously (14). Forward
primer 5=-GAGCTCTATAGGAGATAGTGTGAGTAGGG-3=, reverse
primer 5=-ATGACTGCTCACCTGCGTGTT-3=, and TaqMan probe 5=-
6-carboxyfluorescein (FAM)-ACTTACCCA/ZEN/GGCCCTGCCAGCT
CC-Iowa Black FQ-3= were used. Viral RNA samples were extracted by
using a QIAamp viral RNA minikit (Qiagen, Germany) according to
the manufacturer’s instructions. The TaqMan real-time reverse tran-
scription (RT)-PCR assay was performed with the StepOnePlus real-
time system (ABI) using the TaqMan Fast Virus 1-step master mix
(ABI), with cDNA synthesis from RNA by reverse transcription for 5
min at 50°C and subsequent amplification for 40 cycles at 95°C for 3 s
and 60°C for 30 s.
Evaluation of the role of GAGs and inhibitors in EV-71 infection of
RD cells. Viral inactivation experiments were performed by preincuba-
tion of EV-71 particles with various concentrations of GAGs (heparin,
chondroitin sulfate, de-N-sulfated heparin, and N-acetyl-de-O-sulfated
heparin) and inhibitors (dextran sulfate and suramin) for 60 min at 37°C
before inoculation of the RD cells. For cell protection studies, RD cells
were preincubatedwithGAGs, poly-D-lysine, or anti-heparan sulfate pep-
tides at various concentrations for 60 min at 37°C. The cells were washed
twice andwere subsequently infectedwith various EV-71 isolates for 1 h at
amultiplicity of infection (MOI) of 0.1. Viral infectivitywas evaluated and
quantified by TaqMan real-time PCR and a plaque assay after 24 h postin-
fection.
Inhibition of cellular GAG sulfation by sodium chlorate. Sodium
chlorate inhibition experiments were carried out in DMEM supple-
mented with 10% FBS. RD cells were cultured for 24 h in the presence of
sodium chlorate at concentrations ranging from 0 mM to 50 mM, fol-
lowed by infection using different EV-71 strains at an MOI of 0.1. The
viral titers were quantified by TaqMan quantitative real-time PCR.
siRNA silencing of the gene involved in heparan sulfate biosynthe-
sis. Small interfering RNAs (siRNAs) targeting the heparan sulfate-mod-
ifying enzyme N-deacetylase/N-sulfotransferase 1 (NDST-1) and the
heparan sulfate polymerase exostosin-1 (EXT-1) were purchased from
Santa Cruz Biotechnology. Negative-control siRNA with no homology to
any known mammalian gene was obtained from Bioneer. Different con-
centrations of the siRNAs (0 nM, 1 nM, 5 nM, 10 nM, and 20 nM in 50l
of Opti-MEM) were incubated with Lipofectamine 2000 in Opti-MEM I
(Invitrogen) for 20 min. The siRNA was then transfected into 1.0  104
RD cells for 24 h. Prior to EV-71 infection, the transfection medium was
removed, and the cells were washed twice with growth medium (DMEM
with 10% FBS) and were then incubated with the growth medium for at
least 3 h. The cells transfected with the respective siRNAs were infected
with EV-71 at an MOI of 0.1 for 1 h at room temperature. After 1 h of
incubation, the inoculum was removed, washed twice, and replaced with
maintenance medium (DMEMwith 2% FBS). The viral titers were deter-
mined at 24 h postinfection by using TaqMan quantitative real-time PCR.
Enzymatic removal of GAGs from the surfaces of RD cells. Chon-
droitinase ABC and heparinase I/II/III were reconstituted in digestion
buffer I (phosphate-buffered saline [PBS] containing 0.05 M sodium ac-
etate and 0.02% bovine serum albumin [BSA] [pH 7.5]) and digestion
buffer II (PBS containing 0.5 mM MgCl2, 0.9 mM CaCl2, and 0.1% BSA
[pH 7.5]), respectively, and various concentrations of the enzymes (50
l/well) were added to RD cells, which were then incubated for 1 h at
37°C. Cells were then washed with the respective digestion buffers and
were subsequently infected with EV-71 for 1 h at 4°C. After the incuba-
tion, the cells were washed twice with serum-free medium, and infectivity
was determined 24 h postinfection by TaqMan real-time RT-PCR.
Binding of EV-71 to GAG-deficient cell lines. RD, CHO-K1, CHO-
pgsD677, and CHO-pgsA745 cells in chamber slides (Lab-Tek) and
CellCarrier-96 plates (Perkin-Elmer) were infected with EV-71 (MOI,
100) at 4°C for an hour. After 1 h of incubation, the inocula were
removed and the cells were fixed with 4% formaldehyde. The fixed cells
were permeabilized using 0.25% Triton X-100 (Sigma) for 5 min and
were subsequently blocked with Image-iT FX signal enhancer (Invit-
rogen) for 1 h. EV-71 particles were immunostained with mouse anti-
EV-71 monoclonal antibodies (Millipore) as the primary antibodies
and 1:200-diluted Alexa Fluor 488-labeled anti-mouse IgG (Invitro-
gen) as the secondary antibody for 1 h at 37°C. For nuclear visualiza-
tion, cells were treated with 0.01% 4=,6-diamidino-2-phenylindole
(DAPI; Sigma) for 7 min at room temperature. Immunofluorescence
was detected with a Leica TCS SP5 confocal microscope (Leica Micro-
systems, Germany). The CellCarrier-96 plate was evaluated using a
Cellomics ArrayScan VTI HCS reader with Spot Detector BioApplica-
tion software (Thermo Scientific). The data are presented as the total
viral spot count per cell (calculated as the total number of fluorescent
Tan et al.
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viral spots divided by the total number of cells in the same field) and
were subsequently verified by TaqMan quantitative real-time PCR.
Binding of EV-71 particles to immobilized heparin-Sepharose
beads. Six milliliters of EV-71 or PV vaccine strain supernatant was ap-
plied to a 1-ml HiTrap Heparin HP column (GE Healthcare, Sweden)
previously equilibrated with the binding buffer (0.02M Tris-HCl, 0.14M
NaCl [pH 7.4]) at a flow rate of approximately 0.5 ml/min. After loading,
the column was washed with at least 5 to 10 column volumes of binding
buffer. The bound viral particles were eluted using the elution buffer (0.02
M Tris-HCl, 2 M NaCl [pH 7.4]). Fractions of 1 ml were collected and
analyzed by TaqMan quantitative real-time PCR and plaque assays for
EV-71 and the PV vaccine strain, respectively.
Cytotoxicity analysis. The cytotoxicities of heparin, dextran sulfate,
anti-heparan sulfate peptides, and sodium chlorate were determined us-
ing the CellTiter 96 AQueousOne solution cell proliferation assay reagent
(Promega). Briefly, various concentrations of these compounds were
added to overnight-cultured RD cells, which were then incubated over-
night. Then 20 l of the CellTiter 96 AQueous One solution cell prolifer-
ation assay reagent was added to each well. The plate was then analyzed at
an absorbance of 490 nm after 2 h of incubation at 37°C.
Three-dimensional crystal structure and sequence analysis. The
crystal structure of EV-71 (Protein Data Bank [PDB] identification code
4AED) (39) was obtained from the PDB (http://www.rcsb.org/pdb). The
3-dimensional structure of the EV-71 pentamer was built using the Deep-
View-Swiss PDB Viewer, version 4.0.4 (Swiss Institute of Bioinformatics)
(40). For sequence analysis, 174 VP1 sequences from different genotypes
(41) were downloaded from GenBank (http://www.ncbi.nlm.nih.gov
/protein/) and were aligned using ClustalW2 software (http://www.ebi.ac
.uk/tools/msa/clustalw2/).
Statistical analysis. The data presented are the means  standard
deviations (SD) obtained from at least two independent biological repli-
cates. Error bars represent the SD. Statistical significance was calculated
using the Mann-Whitney test. A P value of 0.05 was considered statis-
tically significant.
RESULTS
Inhibition of EV-71 infection by heparin, dextran sulfate, and
suramin. To determine whether surface GAGs play a significant
role in virus-receptor interactions, various concentrations of dif-
ferent GAGs were preincubated with EV-71 at anMOI of 0.1 for 1
h at 37°C before infection of RD cells. The viral titers were quan-
tified 24 h postinfection by using TaqMan quantitative real-time
PCR and plaque assays. Of the two GAGs evaluated, significant
inhibition of EV-71 by heparin and chondroitin sulfate was ob-
served only at concentrations above 500 g/ml (Fig. 1A). The
inhibitory effect of heparin was more significant, at 79.4% 
2.9%, than that of chondroitin sulfate (38.5% 6.4%) when they
were tested at a concentration of 1,000g/ml (P 0.05). A similar
inhibitory trend was observed in the plaque assays (Table 1).
To further investigate the significance of the carbohydrate
backbone for the inhibition of EV-71, polyanionic dextran sulfate
(2.3 sulfate groups/glucosyl group) and the polysulfonate phar-
maceutical suramin (6.0 sulfate groups/molecule) were used. Pre-
vious studies have shown that suramin inhibits viruses such as
dengue virus (24) and hepatitis B virus (30), which bind to cell
surface heparan sulfate. Viral inhibition increased with the con-
centration of the inhibitors tested, and at 1,000g/ml, the levels of
inhibition were 65.8%  6.7% for dextran sulfate and 63.4% 
6.1% for suramin (Table 1). However, suramin was more effec-
tive, since it was able to inhibit EV-71 infection at a concentration
as low as 20 g/ml (Fig. 1A).
Preincubation of RD cells with heparin or dextran sulfate at
concentrations from 100 to 1,000g/ml before viral infection had
FIG 1 Inhibitory effects of GAGs and inhibitors. (A) For the viral inactivation
assay, various concentrations of GAGs, polyanionic dextran sulfate, and
suramin were preincubated with EV-71 particles for 1 h at 37°C before infec-
tion of RD cells at room temperature. (B and C) For the cell protection assay,
various concentrations of GAGs (B) or of poly-D-lysine or anti-heparan sulfate
peptides, designated peptides G1 and G2 (C), were preincubated with RD cells
for 1 h at 37°C before EV-71 infection. The viral RNA was extracted and
quantified by quantitative real-time PCR 24 h postinfection.
TABLE 1 Effects of GAGs, GAG variants, and other inhibitors on EV-71
infection
Inhibitora
Inhibition (%)
Viral plaque Viral RNA
Heparin 95.5 0.7 79.4 2.9
Chondroitin sulfate 52.4 16.4 38.4 6.4
De-N-sulfated heparin 70.0 1.1 39.7 15.6
Dextran sulfate 95.2 0.7 65.8 6.7
Suramin 76.3 2.4 63.4 6.1
a The concentration of inhibitors used was 1,000 g/ml.
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no inhibitory effect but enhanced virus infectivity. The results
demonstrated that the inhibitory effect was due to direct interac-
tion of these compounds with the virus and not with the target
cells (Fig. 1A and B).
Neutralization of negative charges on cell surfaces reduces
EV-71 infection. To assess the important role of negative charges
carried on the cell surface in the binding of EV-71, we preincu-
batedRDcells with poly-D-lysine to neutralize negative charges on
cell surfaces before infection. As shown in Fig. 1C, poly-D-lysine
strongly decreased the level of EV-71 infection when applied at
concentrations from 1 to 5 g/ml. At 5 g/ml, the inhibition was
99.1%  0.2%. To ascertain whether the negative charge carried
by heparan sulfate present on the cell surface plays a significant
role in viral attachment, two anti-heparan sulfate peptides, G1
(LRSRTKIIRIRH) and G2 (MPRRRRIRRRQK), were evaluated
for their inhibitory effects. The inhibitory effect of G2 was signif-
icant, with viral RNA inhibition of 76.5% 26.8%at 1,000g/ml.
The G1 peptide did not inhibit EV-71 infection (Fig. 1C).
Heparin reduces the infectivity of both laboratory strains
and low-passage-number isolates. Heparin at 2,500 g/ml was
observed to have inhibitory effects both on the laboratory strains
and on the low-passage-number EV-71 isolates tested (Fig. 2). The
inhibitory effects differed between strains. The level of inhibition
of the laboratory strains ranged from 61.4% to 98.0%, while that
of the low-passage-number isolates ranged from 30.4% to 78.4%.
Interestingly, heparin failed to inhibit the PV vaccine strain even
when tested at 2,500 g/ml.
N- and O-sulfation on heparan sulfate are critical for EV-71
infection. To establish whether the degree of sulfation of hep-
arin is critical for viral inhibition, different sulfated heparin
variants were investigated. Completely desulfated heparin
failed to abolish EV-71 infection (Fig. 3A). In contrast, de-N-
sulfated heparin showed moderate inhibition (39.7% 
15.6%) at 1,000 g/ml, indicating that the degree of sulfation
within the GAG carbohydrate structure is functionally impor-
tant. The inhibition of viral plaque formation by these GAGs
and inhibitors is shown in Table 1.
To further confirm the role of the sulfation of heparan sulfate
in EV-71 attachment, we carried out EV-71 infection of RD cells
grown in a medium containing 0 to 50 mM sodium chlorate. The
growth of cells in the presence of sodium chlorate, which inhibits
cellular ATP-sulfurylase, has been shown previously to reduce the
extent of sulfation of heparan sulfate by as much as 60%, and cells
with such modified cell surfaces have been used to examine the
role of GAGs in attachment by other viruses (25, 42). As shown in
Fig. 3B, sodium chlorate was found to reduce the level of EV-71
infection of RD cells significantly, in a dose-dependent manner,
FIG 2 Inhibitory effects of heparin on EV-71 isolates and the PV vaccine
strain. EV-71 and PV particles were pretreated with heparin at a final concen-
tration of 2,500 g/ml for 1 h at 37°C before infection of RD cells. The low-
passage-number EV-71 isolates (14716, 35017, 1657640, and 1687413) and the
PV vaccine strain were obtained from the Diagnostic Virology Laboratory,
University Malaya Medical Center. The titers of EV-71 and the PV vaccine
strain were quantified 24 h postinfection by TaqMan quantitative real-time
PCR and plaque assays, respectively.
FIG 3 (A) EV-71 was preincubated with various concentrations of heparin
and desulfated heparin variants for 1 h at 37°C before infection of RD cells.
(B) Inhibitory effect of sodium chlorate on different EV-71 strains in RD
cells. RD cells were pretreated with increasing concentrations (0 mM, 10
mM, 30 mM, and 50 mM) of sodium chlorate for 24 h before EV-71 infec-
tion at an MOI of 0.1. (C) Transient siRNA knockdown of NDST-1 and
EXT-1 expression. NDST-1, EXT-1, and negative-control siRNAs in the
Lipofectamine 2000 reagent were transfected into RD cells for 24 h before
EV-71 infection. The viral load was determined 24 h postinfection by TaqMan
quantitative real-time PCR.
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with all strains tested. At 50mM, sodium chlorate inhibited infec-
tion with EV-71 strains 41, UH1, SHA66, and BrCr; the percent-
ages of viral RNA inhibition were 92.7% 2.7%, 79.0% 3.3%,
83.2%  4.2%, and 61.5%  5.5%, respectively. To rule out the
possibility that the reduction in the level of EV-71 infection was
due to cytotoxicity, the cytotoxicity of sodium chlorate was eval-
uated by the commercially available 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The data re-
vealed that sodium chlorate has minimal cytotoxicity at 50 mM.
To further confirm that heparan sulfate plays an important
role in EV-71 infection, expression of the NDST-1 and EXT-1
genes was transiently knocked down using siRNA. NDST-1 is a
heparan sulfate modification enzyme that removes N-acetyl
groups from selectedN-acetylglucosamine (GlcNAc) residues and
replaces themwith sulfate groups (43). EXT-1 is a heparan sulfate
polymerase that adds alternating units of glucuronic acid (GlcA)
andGlcNAc to the nonreducing end of the chain. As shown in Fig.
3C, transient knockdownofNDST-1 and EXT-1 expression in RD
cells significantly reduced the level of EV-71 infection, with per-
centages of inhibition as high as 80.1%  7.7% and 57.2% 
19.1%, respectively, at 20 nM siRNA. However, the negative-con-
trol siRNA was unable to reduce EV-71 infection.
Enzymatic removal of heparan sulfate from the cell surface
reduces the levels of EV-71 binding and infection of RDcells.To
identify the type of GAG that is responsible for the binding of
EV-71 to RD cells, we examined EV-71 binding to cells after en-
zymatic removal of cell surface GAGs by chondroitinase ABC and
heparinase I/II/III digestion. Heparinase I degrades heparin and
highly sulfated domains in heparan sulfate, while heparinase II
cleaves both heparin and heparan sulfate, and heparinase III spe-
cifically degrades heparan sulfate (24). Treatment of RD cells with
each of the heparinases at 2.5 mIU/ml and 5.0 mIU/ml for 1 h at
37°C was found to reduce viral RNA levels and plaque formation
significantly (data not shown), in a dose-dependent manner, 24 h
postinfection. Treatment of RD cells with heparinases I, II, and III
at 5.0 mIU/ml significantly inhibited EV-71 RNA levels by
68.6% 6.2%, 91.7% 4.1%, and 82.2% 11.7%, respectively
(Fig. 4A). Removal of cell surface chondroitin sulfate by chon-
droitinase ABC failed to inhibit EV-71 infection (Fig. 4A), even
when chondroitinase ABC was tested at concentrations as high as
20 mIU/ml (data not shown). Removal of cell surface heparan
sulfate significantly reduced the infectivities of the different EV-71
strains tested, but not that of the PV vaccine strain (Fig. 4B). Re-
moval of surface heparan sulfate, but not chondroitin sulfate, was
found to significantly reduce EV-71 attachment to the surfaces of
RD cells (Fig. 4C).
Significant reduction in the level of EV-71 binding to GAG-
deficient CHO cells.CHO cells with defects in the biosynthesis of
GAGs have been used extensively to demonstrate the involvement
of heparan sulfate as the receptor for the binding of various viruses
(29, 30, 33, 42, 44). Mutant CHO-pgsD677 cells are deficient in
N-acetylglucosaminyltransferase and glucuronosyltransferase ac-
tivities, which are required for heparan sulfate polymerization,
and thus completely lack heparan sulfate; these cells also produce
levels of chondroitin sulfate 3- to 4-fold higher than those in wild-
type CHO-K1 cells (45). Mutant CHO-pgsA745 cells are deficient
in the enzyme UDP-D-xylose:serine-1,3-D-xylosyltransferase,
which catalyzes the first sugar transfer reaction inGAG formation,
and thus completely lack GAGs (46). To investigate whether
EV-71 binds differently to these cell lines, cells were seeded in
CellCarrier-96 plates and chamber slides and were infected with
EV-71 at anMOI of 100 for 1 h at 4°C. As shown in Fig. 5A and B,
significantly fewer viral particles were attached to CHO-pgsD677
and CHO-pgsA745 cells than to wild-type CHO-K1 cells, which
expressed heparan sulfate (P 0.001). CHO-pgsD677 and CHO-
pgsA745 cells showed reduced binding levels of 46.7% and 41.6%,
respectively, compared to 100% for CHO-K1 cells. Interestingly,
more viral particles were bound to RD cells than to CHO-K1 cells.
Binding of EV-71 to immobilized heparin-Sepharose. To
characterize the interaction of EV-71 particles withGAGs, a virus-
containing supernatant was applied to a heparin affinity chroma-
tography column. EV-71 particles bound to immobilized hepa-
rin-Sepharose under physiological salt conditions (0.14 M NaCl)
and were eluted by 2 M NaCl. The virus titers in each fraction
collected were quantified by TaqMan quantitative real-time PCR.
As shown in Fig. 6, most of the EV-71 particles were detected in all
the eluates following the application of 2 M NaCl. The EV-71
particles present in eluate 1were concentrated asmuch as 4.1-fold.
In a control experiment, we used a column packedwith Sepharose
alone and found no binding of EV-71 particles to the column
(data not shown). The results confirm that EV-71 particles bind to
heparin andwere eluted by high salt concentrations. In contrast to
EV-71, the PV vaccine strain did not interact with heparin-Sep-
harose, and most of the PV particles were detected in the flow-
through fraction (Fig. 6).
Symmetry clustering of highly conserved amino acids
Arg166,Lys242, andLys244ofVP1 in theEV-71pentamer struc-
ture. To determine the possible heparan sulfate binding site(s) on
EV-71 particles, the 3-dimensional crystal structure of EV-71 was
built using theDeepView-Swiss PDB viewer (40). As shown in Fig.
7A, amino acids Arg166, Lys242, and Lys244 are arranged sym-
metrically in the 5-fold axis of the EV-71 pentamer structure.
These amino acids are also located at positions that are highly
exposed on the surface of the EV-71 particle (Fig. 7B). All these
amino acids were highly conserved across all EV-71 genotypes
except for Lys244, where lysine (K) was replaced by glutamic acid
(E) in genotype A (Fig. 7C). This symmetrically arranged cluster-
ing of positively charged amino acids could serve as the binding
site for heparan sulfate.
DISCUSSION
Virus receptorsmay be one of the determinants of virus host range
and tissue tropism (5). Receptors that are known to bind to EV-71
have been identified over the past few years. P-selectin glycopro-
tein ligand-1 (PSGL-1) was the first to be discovered as the EV-71
receptor. However, PSGL-1 is selectively expressed only in neu-
trophils, monocytes, and most lymphocytes (6). The second re-
ceptor, reported by Yamayoshi et al. (9), was human SCARB2,
which is expressed on most types of cells (7). EV-71 binds to the
SCARB2 receptor and is then internalized through clathrin-medi-
ated endocytosis (47, 48). However, blocking of these receptors
did not abolish EV-71 infection, and this finding led to the discov-
ery of the third receptor, annexin II. Pretreatment of host cells
with an anti-annexin II antibody was found to reduce the level of
viral attachment. Preincubation of EV-71 with annexin II also
reduced the level of EV-71 infection (12).
Besides these known receptors for EV-71, sialylated glycans
were reported by Yang et al. (11) as receptors for EV-71. Treat-
ment of RD, SK-N-SH, and DLD-1 cells with neuraminidase was
found to reduce the ability of EV-71 to bind to the cell surface,
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confirming that EV-71 utilizes sialylated glycans as attachment
factors (10). We have shown in this study that, in addition to the
four receptors published to date, cell surface heparan sulfate is
required for EV-71 attachment. The level of EV-71 infection of
RD cells was significantly reduced when EV-71 particles were pre-
treated with soluble heparin, dextran sulfate, or suramin. How-
ever, preincubation of RD cells with heparin or dextran sulfate did
not inhibit EV-71 infection but unexpectedly enhanced it. This
may be caused by the creation of artificial binding sites through
accumulation of heparin and dextran sulfate on the surfaces of
cells (30, 49). These findings imply that heparin or dextran sulfate
could bind to the positively charged surfaces of viral particles and
prevent the interaction of viral particles with the cell surface, as
demonstrated for foot-and-mouth disease virus (50). Removal of
cell surface heparan sulfate using each of the heparinases (I, II, and
III) also reduced the ability of EV-71 to bind to and infect RD cells,
further confirming the important role of heparan sulfate in EV-71
infection. The possible involvement of chondroitin sulfate as a
receptor for attachment was excluded based on the evidence that
enzymatic removal of chondroitin sulfate did not impair EV-71
infection.
In the present study, we demonstrated that EV-71 can bind to
CHO cells. However, CHO cells defective in the biosynthesis of
heparan sulfate and chondroitin sulfate exhibited a reduced ability
to bind to EV-71, further supporting the role of heparan sulfate in
EV-71 infection.While EV-71 could bind to the CHO-K1 cells, no
infection was observed, suggesting that EV-71 failed to internalize
so as to initiate infection. TMEVGDVII bound to heparan sulfate
has been postulated to use protein entry receptors for virus inter-
nalization (27). A similar mechanism could be utilized by EV-71.
EV-71 particles bound to heparan sulfate may need to interact
with known receptors, such as SCARB2 and sialylated glycan, or
with an unknown protein entry receptor, to gain entry into
cells. CHO cells, of hamster origin, may have a different
FIG 4 Treatment of RD cells with heparinase or chondroitinase ABC. (A) Inhibitory effects of heparinase I/II/III and chondroitinase ABC on EV-71 infection.
RD cells were pretreated with heparinase or chondroitinase ABC for 1 h at 37°C before EV-71 infection at an MOI of 0.1. The viral RNA was extracted and
evaluated by TaqMan quantitative real-time PCR. (B) Inhibitory effect of heparinase I on different EV-71 strains and the PV vaccine strain. (C) Confocal
microscopy analysis (with a 40 objective) of EV-71 binding assays after heparinase I or chondroitinase ABC treatment. EV-71 particles were stained with a
monoclonal anti-EV-71 antibody and were subsequently stained with Alexa Fluor 488-labeled anti-mouse IgG. Nuclei were stained with DAPI. EV-71 particles
and nuclei are shown in green and blue, respectively.
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SCARB2, since it has been reported that EV-71 binding do-
mains in human SCARB2 and murine SCARB2 are different
(51). In this study, we also showed that EV-71 was still able to
bind to the CHO mutant completely lacking in heparan sulfate
and chondroitin sulfate, which further suggests that multiple
receptors are involved during EV-71 infection. This view is
similar to what has been reported for several viruses that use
heparan sulfate (27, 52, 53).
Heparan sulfate is expressed by all cell types.However, heparan
sulfate expressed on different types of cells shows variations in
structure, with differences in the degrees of sulfation, chain
length, and the position of the sulfate group (54). Our data dem-
onstrated that highly sulfated heparin could inhibit EV-71 infec-
tion, whereas decreased sulfation on heparin led to a loss of EV-71
inhibition. Completely desulfated heparin was found to have no
inhibitory effect. These findings suggest that structural differences
in the heparan sulfate present in different cell types could lead to
differences in susceptibility to infection, which may contribute to
the selective tropism of EV-71 (37).
Heparan sulfate binding could arise from adaptation to the
cells in which isolates were propagated. Culture adaptations of
heparan sulfate usage in picornaviruses (55, 56), flaviviruses (57),
and alphaviruses (58) have been demonstrated. In vitro cultivation
of viruses has been shown to rapidly select amino acid substitu-
tions that increase the net positive charge of the envelope protein
(59). However, the heparan sulfate binding phenotype has also
been documented for clinical isolates of the porcine circoviruses
(53) and echoviruses (33). In the present study, we showed that
heparin was able to inhibit EV-71 isolates that had been passaged
only once in tissue culture, suggesting that heparan sulfate bind-
ing phenotypes are not likely to be due to culture adaptation of
EV-71. We also provide evidence that heparin failed to inhibit the
infection of RD cells with the PV vaccine strain, further strength-
ening our view that EV-71 binds to heparan sulfate.
Furthermore, we also presented evidence that EV-71 binds to
heparin-Sepharose under physiological salt concentrations and
that the interaction could be disrupted by high salt concentra-
tions. This finding suggests that EV-71–heparin interactions in-
volve mainly electrostatic charge interactions. Replacement of a
single positively charged amino acid with another amino acid is
sufficient to retard the heparin binding phenotype in TMEVGDVII
FIG 5 Binding of EV-71 to CHO-K1 and CHOmutant cells. CHO-K1 cells and cells of CHOmutants defective in proteoglycan synthesis were assessed for their
abilities to bind to EV-71. The CHO-pgsA745 cell line lacks heparan sulfate and chondroitin sulfate proteoglycans, while the CHO-pgsD677 cell line lacks
heparan sulfate proteoglycan but produces 15% of normal proteoglycans. The binding of EV-71 to parental andmutant CHO cells was assayed by using confocal
microscopic analysis (A) and a Cellomics ArrayScan VTI HCS reader with Spot Detector BioApplication software (B) and was verified by TaqMan quantitative
real-time PCR.
FIG 6 Binding of EV-71 and PV to an immobilized heparin-Sepharose col-
umn. EV-71 and PV supernatants were passed through a column of immobi-
lized heparin-Sepharose and were eluted with 2 M NaCl. The titers of EV-71
and the PV vaccine strain from each fraction were quantified by TaqMan
quantitative real-time PCR and plaque assays, respectively. EV-71 levels are
presented as viral RNA copies per milliliter, and levels of the PV vaccine strain
are presented as PFU per milliliter. Error bars represent means SD for each
fraction.
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and coxsackievirus A9 (27, 34, 60). Thus, positively charged
amino acids on the surfaces of viral particles are critical for the
heparin binding phenotype. Sequence analysis of the VP1 capsid
protein revealed two possible heparan sulfate mimic binding do-
mains, from residues 120 to 123 (-RRKV-) and residues 241 to 244
(-SKSK-). Interestingly, our previous study has shown that pep-
tides with these heparan sulfate binding domains exhibited signif-
icant antiviral activities against EV-71 infection in RD cells (14),
suggesting that the inhibitory effect could have resulted from di-
rect binding to heparan sulfate and blocking of viral attachment.
Heparan sulfate-interacting regions could be linear heparan sul-
fate binding domains, as well as clusters of basic residues that arise
as a result of the 3-dimensional structure, as shown for foot-and-
mouth disease virus and coxsackievirus A9 (34, 50). With the re-
cently available crystal structure of EV-71, the electrostatic surface
of EV-71was determined (61). A few conserved positively charged
amino acids (Arg166, Lys242, and Lys244) were clustered sym-
metrically at the 5-fold axis of the EV-71 pentamer. The linear
arrangement of these amino acids in the cluster could also be
significant for the interactions. These amino acids were also lo-
cated on the surfaces of EV-71 particles. These findings suggest
that the interaction could be due to the electrostatic interactions
between these clusters of basic amino acids arranged in a 3-dimen-
sional array on the virions and concentrated negative charges on
the sulfated heparan sulfate chain.
In this study, we have shown that EV-71 particles utilized cell
surface heparan sulfate as an attachment receptor. Although the
exact mechanism of interaction of EV-71 particles with negatively
FIG 7 Three-dimensional pentameric structure and sequence alignment of EV-71. The structure of the EV-71 pentamer was generated using the DeepView-
Swiss PDB viewer. The molecular structures of EV-71 VP1, VP2, VP3, and VP4 are presented in blue, green, red, and purple, respectively. The amino acids
Arg166, Lys242, and Lys244 are presented in yellow,white, and light blue, respectively. (A) Top viewof the EV-71 pentamer. (B) Side viewof the EV-71 pentamer.
(C)Histogram showing sequence consensus in the VP1 region of EV-71. A total of 174 sequences were aligned and analyzed using ClustalW2. The arbitrary scale
is shown at the left of the histogram; 1.0 denotes perfect consensus at a given amino acid site across all entries. The alignments of Arg166, Lys242, and Lys244 in
representative EV-71 strains from genotypes A, B, and C are shown above the histogram.
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charged heparan sulfate on the cell surface remains unclear, deter-
mination of the molecular basis of the virus-receptor interaction
in target cells will be useful for understanding the pathogenicity of
EV-71 and for the development of antiviral agents against EV-71.
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Enterovirus 71 (EV-71) infections are generally manifested as mild hand, foot and mouth disease, but
have been reported to cause severe neurological complications with high mortality rates. Treatment
options remain limited due to the lack of antivirals. Octaguanidinium-conjugated morpholino oligomers
(vivo-MOs) are single-stranded DNA-like antisense agents that can readily penetrate cells and reduce
gene expression by steric blocking of complementary RNA sequences. In this study, inhibitory effects
of three vivo-MOs that are complementary to the EV-71 internal ribosome entry site (IRES) and the
RNA-dependent RNA polymerase (RdRP) were tested in RD cells. Vivo-MO-1 and vivo-MO-2 targeting
the EV-71 IRES showed signiﬁcant viral plaque reductions of 2.5 and 3.5 log10PFU/ml, respectively. Both
vivo-MOs reduced viral RNA copies and viral capsid expression in RD cells in a dose-dependent manner.
In contrast, vivo-MO-3 targeting the EV-71 RdRP exhibited less antiviral activity. Both vivo-MO-1 and 2
remained active when administered either 4 h before or within 6 h after EV-71 infection. Vivo-MO-2
exhibited antiviral activities against poliovirus (PV) and coxsackievirus A16 but vivo-MO-1 showed no
antiviral activities against PV. Both the IRES-targeting vivo-MO-1 and vivo-MO-2 inhibit EV-71 RNA
translation. Resistant mutants arose after serial passages in the presence of vivo-MO-1, but none were
isolated against vivo-MO-2. A single T to C substitution at nucleotide position 533 was sufﬁcient to confer
resistance to vivo-MO-1. Our ﬁndings suggest that IRES-targeting vivo-MOs are good antiviral candidates
for treating early EV-71 infection, and vivo-MO-2 is a more favorable candidate with broader antiviral
spectrum against enteroviruses and are refractory to antiviral resistance.
 2014 Elsevier B.V. All rights reserved.1. Introduction et al., 2012; Sim et al., 2005; Tan et al., 2007a,b; Wu et al., 2009).Enterovirus 71 (EV-71) is a single-strand, positive-sense RNA
virus. EV-71 usually cause mild hand, foot and mouth disease
(HFMD) characterized by fever with papulovesicular rash on the
palms and soles (Ooi et al., 2010). In recent years, EV-71 infections
were also associated with neurological complications with high
mortalities among infants and young children < 6 years old
(Solomon et al., 2010). To date, no effective antiviral agent is avail-
able for clinical use (Shang et al., 2013b; Tan et al., 2014). Thus,
there is an urgent need to develop effective antiviral agents to treat
EV-71 infection.
Considering the morbidity caused by EV-71, new approaches to
the development of therapeutics are needed. A number of promis-
ing RNA-based therapeutics designed to inhibit EV-71 infections
have shown promising results, including siRNA and shRNA (DengHowever, the limitations of RNA-based therapeutics are short
half-life and it required a delivery agent which might be toxic to
the host. Therefore, nucleic acid-based therapeutics should be
designed to possess favorable pharmacological properties such as
in vivo stability and low toxicity.
A phosphorodiamidate morpholino oligomer (PMO) is a single-
stranded DNA-like compound that has the ability to bind to the
mRNA and inhibit gene expression by steric blockage of comple-
mentary RNA. PMOs are highly nuclease-resistant and do not
require the RNase H or other catalytic proteins for their activity
(Kole et al., 2012; Summerton, 1999). PMOs have been conjugated
with various cell-penetrating compounds such as cell-penetrating
peptides and octaguanidinium dendrimers which are able to
enhance their uptake by cells (Moulton and Jiang, 2009). Peptide
conjugated-PMOs (PPMO) have been demonstrated to inhibit var-
ious viral infections, including Ebola virus (Warﬁeld et al., 2006),
West Nile virus (Deas et al., 2005), dengue virus (Kinney et al.,
2005), sindbis virus (Paessler et al., 2008), coronavirus (Neuman
36 C.W. Tan et al. / Antiviral Research 107 (2014) 35–41et al., 2004), herpes simplex virus 1 (Moerdyk-Schauwecker et al.,
2009), porcine reproductive and respiratory syndrome virus
(Opriessnig et al., 2011; Patel et al., 2008), foot-and-mouth disease
virus (Vagnozzi et al., 2007), poliovirus, rhinovirus (Stone et al.,
2008), and coxsackievirus B3 (Yuan et al., 2006).
In this study, three octaguanidinium dendrimer conjugated-
morpholino oligomers (vivo-MOs) targeting the EV-71 internal
ribosome entry site (IRES) core sequence and the RNA-dependent
RNA polymerase (RdRP) were tested for their inhibitory effects
against EV-71. We demonstrated that the two vivo-MOs targeting
the IRES core sequence showed signiﬁcant inhibition of EV-71
infection.2. Materials and methods
2.1. Cells and viruses
Rhabdomyosarcoma (RD, ATCC) cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Hyclone) supplemented with
10% fetal bovine serum (FBS). EV-71 strains 41 (GenBank accession
number: AF316321), BrCr (GenBank accession number: AB204852)
and UH1/97 (GenBank accession number: AM396587); coxsackie-
virus A16 (CV-A16), PV and chikungunya virus (CHIKV) strain
MY/08/065 (GenBank accession number: FN295485) were
propagated in RD cells.2.2. Vivo-MOs
All vivo-MOs were synthesized by Gene Tools LLC (USA). The
23-mer vivo-MOs were designed to be complementary to the EV-Table 1
Sequence of the 23-mer vivo-MOs and target locations in EV-71 RNA.
Vivo-
MOs
Sequence (5’–3’) Target location in EV-71 RNA
(nucleotide position)
1 CAGAGTTGCCCATTACGACACAC IRES core (512–534)
2 GAAACACGGACACCCAAAGTAGT IRES core (546–568)
3 AAACAATTCGAGCCAATTTCTTC 3D Pol gene (7303–7325)
Control CCTACTCCATCGTTCAGCTCTGA –
Fig. 1. Schematic illustration of the EV-71 genomic structure. Three genomic vivo-MOs
structures of the IRES region and the RdRP gene of EV-71 RNA. The sequences of these71 (strain 41) IRES stem-loop V-VI and the RdRP gene (Table 1,
Fig. 1). All the vivo-MOs were dissolved in phosphate buffer saline
(PBS) at concentration of 0.5 mM. The cytotoxicity of the vivo-MOs
were evaluated using Cell Titer 96 AQueous cell proliferation
reagent (Promega) according to the manufacturer’s instructions.
2.3. In vitro inhibitory effects of vivo-MOs in RD cells
RD cells were seeded at 1.5  104 cells or 1.5  105 cells within
each well of a 96-well plate or 24-well plate, respectively and incu-
bated overnight at 37 C in 5% CO2. After overnight incubation, the
growth medium was removed and replaced with EV-71 inoculum
with a multiplicity of infection (MOI) of 0.1 (PFU per cell) and incu-
bated at 37 C for 1 h. After incubation, the inoculum was removed
and replenished with maintenance medium (DMEM with 2% FBS)
with or without vivo-MOs. The inhibitory effects of the vivo-MOs
were evaluated by plaque assay, TaqMan real-time RT-PCR and
western blot analysis 24 h post-infection (hpi) as previously
described (Tan et al., 2012, 2013). The western blot signal
was enhanced using SuperSignal western blot enhancer (Pierce
Biotechnology).
2.4. Time of addition assay
Vivo-MOs were added to RD cells at various time points relative
to viral inoculation. RD cells were pre-incubated with vivo-MOs at
ﬁnal concentration of 5 lM for 4 h before EV-71 inoculation at a
MOI of 0.1. In concurrent studies, both vivo-MOs and EV-71 were
added into RD cells for 1 h followed by replacement of medium
without vivo-MO. For post-infection studies, RD cells were infected
with EV-71 for 1, 2, 4 and 6 h before vivo-MOs were applied. The
viral titers for each experiment were quantitated 24 hpi by plaque
assays.
2.5. In vitro inhibitory effects of vivo-MOs against various
enteroviruses
To evaluate the efﬁcacy of vivo-MOs against different enterovi-
ruses including CV-A16 and PV, RD cells were pre-incubated with
vivo-MOs at the ﬁnal concentration of 5 lM for 4 h before viraltarget sequences (5’ to 3’) are indicated as (1)–(3) within the proposed secondary
three targeted regions were aligned across all EV-71 genotypes, CV-A16 and PV.
Table 2
Sequence of vivo-MO-1 and the in vitro transcribed infectious RNA with target
sequences.
Target Sequences Mismatch(es)
Vivo-MO-1 3’-CAGAGTTGCCCATTACGACACAC-3’ –
MO-1-WT 5’-GTGTGTCGTAATGGGCAACTCTG-3’ 0
MO-1-mutant-1 5’-GTGTGTCGTAATGGGCAACTCCG-3’ 1
MO-1-mutant-2 5’-GTGTGTCGTAACGGGCAACTCTG-3’ 1
MO-1-mutant-3 5’-GTGTGTCGTAACGGGTAACTCTG-3’ 2
MO-1-mutant-4 5’-GTGCGTCGTAACGGGTAACTCTG-3’ 3
C.W. Tan et al. / Antiviral Research 107 (2014) 35–41 37inoculation at a MOI of 0.1 for 1 h at 37 C. The viral titers were
determined 24 hpi by plaque assay. CHIKV was used as a negative
control virus in this experiment.
2.6. Construction of EV-71 infectious cDNA clones
EV-71 strain 41 infectious clone was constructed using the full-
length genome PCR approach according to Yeh et al. (2011) with
modiﬁcations. The primers involved in the infectious clone con-
structions were listed in Table S1. Full-length genome RT-PCR
was performed with Superscript III reverse transcriptase (Invitro-
gen) and iProof High-Fidelity polymerase (Bio-Rad) using pT50/
EagI-R and pSP6/EV71-F primers. EV-71 expressing enhanced
green ﬂuorescence protein (EGFP) was constructed by overlapping
extension PCR strategy using Q5 High-Fidelity polymerase (NEB).
The EGFP gene was fused into the EV-71 genome between the 5’
UTR and VP4 gene followed by the 2A cleavage site (-AITTL-) as
previously described (Shang et al., 2013a). The full-length PCR
product was then cloned into pCR-XL-TOPO (Invitrogen). In vitro
transcription was performed with linearized DNA using Ribo-
MAX-SP6 large scale RNA production system (Promega) and the
RNA was transfected into RD cells using Lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s instructions.
2.7. Cell free translation inhibition assay
Cell free translation assay was performed with 1 lg of in vitro
transcribed RNA using 1-step human coupled IVT kit (Pierce Bio-
technology) either in the presence or absence of vivo-MOs accord-
ing to the manufacturer’s instructions. An aliquot of 20 ll of in vitro
translated sample was subjected to SDS–PAGE and western blot
analysis as described previously. The immunoblot was developed
with Clarity™ Western ECL substrate (Bio-Rad) and detected by
chemiluminescence.
2.8. EV-71–EGFP inhibition assay
RD cells in a 96-well plate were infected with EV-71–EGFP for
an hour at 37 C. After incubation, the inoculum was removed
and replaced with maintenance medium containing 2.5 lM of
vivo-MOs. The EGFP expression was observed at 6 hpi using ﬂuo-
rescence microscopy.
2.9. Generation of vivo-MOs resistant viruses
EV-71 was passaged in RD cells with increasing concentrations
of either vivo-MO-1 or vivo-MO-2. For the ﬁrst passage, RD cells
were infected with EV-71 at a MOI of 0.1 for 1 h at 37 C and the
inoculum was removed and replaced with maintenance medium
containing 1 lM of vivo-MO-1 or vivo-MO-2. Each selection was
passaged by adding 100 ll of the supernatant into new RD cells.
Viruses were passaged once at each of the concentrations ranging
from 1 lM to 4 lM, followed by passaging four times at 5 lM. To
identify the mutation(s) which conferred resistance to vivo-MOs,
viral RNA of an individual plaque population was ampliﬁed and
subjected to DNA sequencing.
2.10. Reverse genetic analysis of vivo-MO resistant viruses
Point mutations were incorporated into the EV-71 infectious
clone by using QuickChange Lightning site-directed mutagenesis
kit (Agilent Technologies) according to the manufacturer’s instruc-
tions. Four mutants were constructed with different nucleotide
substitutions at the vivo-MO-1 targeted region (Table 2). The
degree of resistance was evaluated using inhibitory assay as
described in Section 2.3.2.11. Statistical analysis
The data presented are the means ± standard deviations (SD)
obtained from at least two independent biological replicates. Error
bars represent the SD. Statistical signiﬁcance was calculated using
the Mann–Whitney test. A P value of <0.05 was considered statis-
tically signiﬁcant.
3. Result
3.1. Vivo-MOs complementary to EV-71 IRES stem-loop structures
exhibited signiﬁcant inhibitory activities
To evaluate the effects of vivo-MOs on EV-71 infectivity in RD
cells, RD cells were treated with vivo-MOs an hour after infection.
As shown in Fig. 2, both vivo-MOs targeting the EV-71 IRES stem-
loop region exhibited signiﬁcant antiviral activity against EV-71
infection with reduction of virus-induced CPE (Fig. 2A), plaque for-
mation (Fig. 2B), RNA (Fig. 2C) and capsid expression (Fig. 2D) in a
dose-dependent manner. The vivo-MO-1 and vivo-MO-2 signiﬁ-
cantly reduced EV-71 plaque formation by up to 2.7 and 3.5 log10-
PFU/ml at 10 lM, respectively. Signiﬁcant inhibition was observed
at concentrations higher than 1 lM. The IC50 values of vivo-MO-1
and vivo-MO-2 were 1.5 lM and 1.2 lM, respectively. However,
vivo-MO-3 exhibited less inhibitory effect against EV-71 infection
in RD cells with a plaque reduction of only 1.2 log10PFU/ml
(Fig. 2B). The vivo-MO-C which has no homologous sequence to
the EV-71 genome has no inhibitory effects at all against all EV-
71 strains tested. None of the vivo-MOs caused more than 20%
reduction of cell viability at concentrations less than 5 lM as mea-
sured by the MTS assay (Fig. 3).
3.2. Vivo-MOs blocked EV-71 infections at multiple time points
To further characterize the efﬁcacy of vivo-MOs at multiple
time points relative to EV-71 infection, vivo-MOs were applied
for 4 h before, or 1, 2, 4, or 6 h after EV-71 infection. Both vivo-
MO-1 and vivo-MO-2 remained effective when administered
before or after EV-71 infection. However, the efﬁcacies were
reduced when treatments were delayed. When vivo-MOs and EV-
71 were added together into the RD cells for 1 h, the inhibitory
effect was reduced, which could have resulted from the incomplete
uptake of the vivo-MOs by the cells. Nonetheless, the antiviral
effects were retained for both IRES-targeting vivo-MOs even when
administered 6 hpi, with 92.8% plaque inhibition. Vivo-MO-3 had
no observable inhibitory effects on EV-71 infection when adminis-
tered 4 h before infection and 2, 4, or 6 hpi (Fig. 4A).
3.3. Vivo-MO-2 exhibited broad-spectrum antiviral activities against
various enteroviruses
Next, we investigate whether any of the vivo-MOs could inhibit
different EV-71 strains as well as other picornaviruses. We evalu-
ated each of the vivo-MOs against two other EV-71 strains (BrCr
Fig. 2. Inhibitory effect of vivo-MOs in RD cells. Various concentrations of vivo-MOs were applied to RD cells one hour post infection and (A) viral induced CPE
(20  objective) were observed 24 hpi. The total infectious particles or total viral proteins were harvested 24 hpi and evaluated by (B) plaque assay, (C) quantitative TaqMan
real-time PCR, and (D) western blot analysis, respectively. EV-71 viral capsid protein was detected by mouse anti-EV-71 monoclonal antibody (Millipore) and cellular b-actin
was detected using mouse anti-b-actin monoclonal antibody (Sigma). The data presented were obtained from at least two independent biological replicates.
Fig. 3. Cell viability analysis. Various concentrations of vivo-MOs were incubated
with RD cells (1.5  104 cells) for 24 h in maintenance medium (DMEM supple-
mented with 2% FBS) followed by MTS assay using Cell Titer 96 AQueous One
solution cell proliferation (Promega). The absorbance reading at 490 nm was
obtained using a microtiter plate reader after 2 h of incubation at 37 C. The
percentage of cell viability (%) was determined by multiplying the ratio of the
absorbance readings obtained from cells treated with vivo-MOs over the non-
treated cells with 100%. The data presented were obtained from at least two
independent biological replicates.
38 C.W. Tan et al. / Antiviral Research 107 (2014) 35–41and UH1/97), PV, CV-A16 and CHIKV as the control virus. The vivo-
MO-2 which targets the highly conserved region of the IRES stem-
loop structure exhibited signiﬁcant inhibitory activity against EV-
71 strains BrCr and UH1/97, PV and CV-A16 with viral plaque
reduction ranging from 1.8 to 3.1 log10PFU/ml (Fig. 4B). However,
vivo-MO-1 only exhibited antiviral activities against EV-71 strains
BrCr and UH1/97, CV-A16, but not against PV (Fig. 4B). EV-71 strain
BrCr which has a single nucleotide mismatch in the middle of the
vivo-MO-1 targeted site (Fig. 1) remained sensitive to the vivo-
MO-1 treatment. The efﬁcacy of vivo-MO-1 against CV-A16 (0.95log10PFU/ml reduction) was signiﬁcantly lower when compared
to EV-71(1.86 log10PFU/ml reduction). This could be due to three
nucleotide mismatches with the vivo-MO-1. PV with ﬁve nucleo-
tide mismatches was completely resistant to the inhibitory effect
of vivo-MO-1. All the vivo-MOs did not show any inhibition of
CHIKV infection.
3.4. IRES-targeting vivo-MOs blocked EV-71 translation
To investigate the mechanism of action of the antiviral vivo-
MOs, cell-free translation analysis was used. As depicted in
Fig. 5A, the presence of either vivo-MO-1 or vivo-MO-2 signiﬁ-
cantly blocked the IRES-dependent translation when compared to
the control. Vivo-MO-3 exhibits reduced efﬁcacies as compared
to IRES-targeting vivo-MOs. In the EV-71–EGFP inhibition assay,
the presence of the vivo-MO-1 or vivo-MO-2 greatly reduced EGFP
expression in RD cells 6 hpi with EV-71–EGFP (Fig. 5B).
3.5. Tolerance of vivo-MO-1 to mismatches within the target RNA
We explored whether EV-71 could become resistant to vivo-MO
treatments. EV-71 was serially passaged in the presence of increas-
ing concentrations of either vivo-MO-1 or vivo-MO-2. Interest-
ingly, only EV-71 mutants resistant to vivo-MO-1 were isolated
after eight passages. We failed to isolate EV-71 mutants that were
resistant to vivo-MO-2.
To investigate the determinant(s) of resistance, viral RNA was
isolated from the resistant population and was sequenced. A single
point mutation from T to C at position 533 was sufﬁcient to confer
resistance to vivo-MO-1 (Fig. 6A). To characterize the loss of inhib-
itory activity by vivo-MO-1, we constructed EV-71 mutants carry-
ing different mismatches at the vivo-MO-1 target site (Table 2),
and the inhibitory effects of vivo-MO-1 against each of the mutants
Fig. 4. Time and speciﬁcity of vivo-MOs antiviral properties. (A) Vivo-MOs at a ﬁnal concentration of 5 lM were applied to RD cells at various time points relative to EV-71
inoculation. In brief, vivo-MOs were applied for 4 h before, or 1, 2, 4, or 6 h after EV-71 infection at a MOI of 0.1. (B) RD cells were pre-treated with each of the vivo-MOs at a
ﬁnal concentration of 5 lM for 4 h at 37 C before infection with other enteroviruses (EV-71 strain BrCr, UH1/97, PV and CV-A16) and CHIKV at a MOI of 0.1. The inhibitory
effects of each of the vivo-MOs were evaluated by plaque assay 24 hpi and the percentages of inhibition are shown. Asterisks indicate statistically signiﬁcant differences
compared to the control. The data presented were obtained from at least two independent biological replicates.
Fig. 5. Translation inhibition assay. (A) In vitro translation was performed with 1 lg of RNA using 1-step human coupled IVT kit (Pierce Biotechnology) either in the presence
of vivo-MOs at a ﬁnal concentration of 10 lM. Aliquots of 20 ll of translated product was subjected to SDS–PAGE and western blot analysis. EV-71 viral protein was detected
by anti-EV-71 monoclonal antibody through chemiluminescence. (B) EV-71–EGFP inhibition assay. RD cells were ﬁrst infected with EV-71–EGFP for one hour, followed by
addition of maintenance medium containing 2.5 lM of vivo-MOs. The EGFP expression was evaluated 6 hpi using a ﬂuorescence microscope. Nuclei were stained with DAPI.
EGFP expression and nuclei are shown in green and blue, respectively. The data presented were obtained from at least two independent biological replicates. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
C.W. Tan et al. / Antiviral Research 107 (2014) 35–41 39were evaluated. The mismatched RNA target sequences were
designed to reﬂect the most likely natural variations that would
arise in the EV-71 sequence. As shown in Fig. 6B, the EV-71 MO-
1-mutant-1, which carried a single point mutation at position
533 (T to C substitution), required higher vivo-MO-1 concentra-
tions to achieve a similar inhibitory effect when compared to the
wild type. The EV-71 MO-1-mutant-2 with a single point mutation
in the middle of the targeted sequence (a T to C substitution at
position 523) remained sensitive to vivo-MO-1, but vivo-MO-1
had reduced inhibitory efﬁcacy when compared with the wild
type. Increasing the number of mutations on the targeted sequence
signiﬁcantly reduced the inhibitory efﬁcacy of vivo-MO-1. The viral
plaque inhibition at 2 lM of vivo-MO-1 against EV-71 MO-1-WT
was 98.9% ± 0.1, and reduced to 89.6% ± 3.4 for the MO-1-
mutant-1 that carried a point mutation at the 3’ end of the targetsequence. The viral plaque inhibition by vivo-MO-1 reduced to
78.0% when the number of nucleotide mismatches increased to
three.4. Discussion
To date, there is no FDA approved vaccine available to prevent
infection and treatment options remain limited due to a lack of
effective antivirals (Chong et al., 2012; Shang et al., 2013b; Tan
and Chan, 2013). Highly negatively-charged compounds like sura-
min or its analog, NF449 that disrupt the virus-host receptor inter-
actions are ineffective when EV-71 mutants acquire Glu98Gln and
Lys244Arg substitutions in the VP1 capsid protein (Arita et al.,
2008; Tan et al., 2013). A single point mutation, Val192Met in
Fig. 6. DNA sequence analysis of vivo-MO-1. (A) EV-71 was serially passaged in the presence of vivo-MO-1 from 1 lM to 5 lM. EV-71 populations that showed resistance to
vivo-MO-1 were plaque puriﬁed, and subjected to DNA sequencing. Analysis of the vivo-MO-1 resistant mutant showed a T to C substitution at position 533. (B) The effect of
sequence mismatches between vivo-MO-1 and target RNA on inhibition assay. Several in vitro transcribed RNA, each having a different number of nucleotide mismatches in
the target region as described in Section 2 were analyzed. Viral titers were quantitated 24 hpi using standard plaque assay. The data presented were obtained from at least
two independent biological replicates.
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BPROZ-194 (Shih et al., 2004). Therefore, there is an urgent need
to develop effective antiviral agents to treat patients with severe
EV-71 infection.
The use of antisense mechanisms to inhibit pathogen replica-
tion has been under investigation and has shown promising
results. Fomivirsen, a 21-mer phosphorothioate oligonucleotide
antisense agent used for intravitreal treatment of cytomegalovirus
retinitis, is the only antisense agent that has been approved by the
FDA to date (de Smet et al., 1999). There are advantages of vivo-
MOs over RNA-based antisense oligomers as they are, nuclease-
resistant and readily penetrate the cells (Kole et al., 2012;
Moulton and Jiang, 2009). These have an advantage over peptide-
based cell penetrating molecules, which are susceptible to protease
degradation that can impact the effectiveness of PPMOs
(Youngblood et al., 2007).
Amongst the three vivo-MOs being examined, the two vivo-
MOs targeting the EV-71 IRES stem-loop region exhibited signiﬁ-
cant antiviral activity. The vivo-MOs blocked EV-71 viral RNA
translation in a cell-free inhibition assay, as well as in a cell-based
EGFP reporter inhibition assay. Previous studies have also reported
that only PMOs targeting the positive strand IRES regions or the
AUG start codon sites were effective when compared to PMOs tar-
geting other regions of the viral RNA (Stone et al., 2008; Vagnozzi
et al., 2007; Yuan et al., 2006). The PMOmay bind with the comple-
mentary viral RNA and disrupt the integrity of the IRES stem-loop
secondary or tertiary structures, hence arresting IRES-dependent
translation (Kole et al., 2012; Warren et al., 2012). The PMOs are
likely to block 40S ribosomal subunit binding the viral RNA in
the vicinity of the stem-loop V in the picornaviral type I IRES
(Belsham, 2009). Furthermore, it has been suggested that the IRES
stem-loop V-VI of EV-71 interacts with IRES-speciﬁc trans-acting
factors such as FUSE-binding protein and heterogeneous nuclear
ribonucleoprotein Al (Lin et al., 2009a,b; Shih et al., 2011). Unlike
synthetic double-stranded siRNA which involve cleavage of mRNA,
PMOs are translation-suppressing oligonucleotides which do not
lead to RNA degradation (Kole et al., 2012; Warren et al., 2012).
This could explain why siRNA targeting the similar viral sequences
as vivo-MO-3 was effective, but not acting as a translation suppres-
sion oligonucleotide which down-regulates gene expression via
steric blockage. IRES-targeting vivo-MO-2 exhibited broad-spec-
trum activities against multiple enteroviruses, but with different
antiviral efﬁcacies. This could have resulted from the IRES stem-
loop structure differences between enteroviruses which affect the
accessibility of the vivo-MOs to the targeted sites (Dias and
Stein, 2002).In this study, an EV-71 mutant that was resistant to vivo-MO-1
carried a single substitution of T to C at position 533. We failed to
isolate any EV-71 resistant to vivo-MO-2 even after eight passages
in vitro, implying that the vivo-MO-2 targeted region is intolerant
to mutation in nature. Our mutagenesis studies further conﬁrm
that the position of mutation and the number of mutations affect
the antiviral efﬁcacies in RD cells. A single mismatch present in
the middle of the targeted sequence (T to C substitution at position
523) was more tolerable than a mutation appearing at the end of
the targeted site (T to C substitution at position 533). These ﬁnd-
ings correlated well with previous ﬁndings that PV, FMDV and
WNV that showed resistance to PPMO also carry a single point
mutation at the end of the PPMO-targeted sequence (Stone et al.,
2008; Vagnozzi et al., 2007; Zhang et al., 2008). A similar observa-
tion has been made for inﬂuenza virus as the degree of inhibition
was associated with the number of mismatches (Ge et al., 2006).5. Conclusion
In summary, we have established two critical locations that are
involved in viral translation initiation in the EV-71 genome as tar-
gets for vivo-MO antiviral intervention. The vivo-MOs worked well
with low micromolar concentrations to inhibit EV-71 infection and
showed little cytotoxicity in RD cells. The potent inhibition of sev-
eral enteroviruses by vivo-MO-2 raises the possibility that it could
be developed as a broad-spectrum antiviral agent. Furthermore,
the degree of tolerance of mismatches by vivo-MOs suggests a
favorable characteristic for their use as a potential antiviral agent.Acknowledgements
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Enterovirus 71 (EV-71) is the main etiological agent of hand, foot and mouth disease (HFMD). Recent EV-71
outbreaks in Asia-Pacific were not limited to mild HFMD, but were associated with severe neurological
complications such as aseptic meningitis and brainstem encephalitis, which may lead to cardiopulmonary failure
and death. The absence of licensed therapeutics for clinical use has intensified research into anti-EV-71
development. This review highlights the potential antiviral agents targeting EV-71 attachment, entry, uncoating,
translation, polyprotein processing, virus-induced formation of membranous RNA replication complexes, and
RNA-dependent RNA polymerase. The strategies for antiviral development include target-based synthetic
compounds, anti-rhinovirus and poliovirus libraries screening, and natural compound libraries screening. Growing
knowledge of the EV-71 life cycle will lead to successful development of antivirals. The continued effort to develop
antiviral agents for treatment is crucial in the absence of a vaccine. The coupling of antivirals with an effective
vaccine will accelerate eradication of the disease.
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replication cycleIntroduction
Human enterovirus A71 (EV-71) belongs to the Entero-
virus genus within the family of Picornaviridae. The EV-
71 genome is a single-stranded, positive sense RNA with
approximately 7411 nucleotides, and consists of an open
reading frame flanked by 5′ and 3′ untranslated regions
(UTRs) [1]. Internal ribosome entry site (IRES)-dependent
translation initiates synthesis of the viral polyprotein,
which is subsequently cleaved into structural proteins
(VP1-VP4) and non-structural proteins (2A-2C and 3A-
3D). The RNA genome is enclosed in an icosahedral cap-
sid assembled from 60 copies of each of the four structural
proteins [2].
EV-71 was first described in 1969, after its isolation
from a two-month-old infant with aseptic meningitis
in California, USA. Several EV-71 epidemics with high
mortality rates occurred in Bulgaria and Hungary in
1975 and 1978 [3-5], respectively. Since then, many* Correspondence: chanyf@ummc.edu.my
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unless otherwise stated.EV-71 outbreaks have been reported in Taiwan [6],
Australia [7], Singapore [8], Malaysia [9], China
[10-14], Vietnam [15] and Cambodia [16].
EV-71 infections usually manifest as mild hand, foot
and mouth disease (HFMD), characterized by fever,
mouth ulcers, and vesicles on the palms and feet. Unlike
other HFMD-related enteroviruses, EV-71 also causes se-
vere neurological manifestations, such as poliomyelitis-
like acute flaccid paralysis and brainstem encephalitis in
infants and children below 6 years old [17,18]. The fatal
brainstem encephalitis is characterized by rapid progres-
sion of cardiopulmonary failure. Patients with neuro-
logical involvement who survive often have permanent
neurological sequelae, with delayed neurodevelopment
and reduced cognitive function [19,20].
Similar to the global poliovirus (PV) eradication initia-
tive, an EV-71 vaccine is likely to be the most effective
way to control, and hopefully eradicate disease [21,22].
Several promising EV-71 vaccine candidates are cur-
rently under clinical trial [23]. Nevertheless, effective an-
tivirals are still needed for treatment of infected patients
with severe disease [21,22]. This review will highlight the
potential targets for EV-71 antivirals as well as recent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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EV-71 infections.
Review
EV-71 virus life cycle
Similar to other viruses, EV-71 infection begins with initial
attachment to attachment factors present on the cell sur-
face, followed by interaction with entry receptors. EV-71
enters the cells through clathrin-mediated endocytosis and
uncoats in the early endosomes. The viral RNA undergoes
IRES-dependent translation, and the polyprotein is cleaved
by 2A and 3C proteases into structural and non-structural
proteins. Non-structural proteins are mainly involved in
negative-sense and positive-sense RNA synthesis. The
positive-sense viral RNA is then packed into the procapsid,
which finally matures into infectious viral particles. Details
of the EV-71 replication steps will be discussed according
to their therapeutic targets [18,21,22].
Therapeutics targeting viral attachment and entry
Virus-host receptor interaction is the first essential event
during virus infection. The ability to recognize and bind
to specific receptors determines the host range and tis-
sue tropism [24]. Cell surface carbohydrates such as
heparan sulfate glycosaminoglycan and sialic acid are
often targeted by pathogens as attachment factors. EV-
71 uses cell surface heparan sulfate [25] and sialylated
glycan [26,27] as attachment receptors, which could
concentrate the virus on the host cell surface and there-
fore enhance infectivity. Further interaction with entry
receptors is required to initiate infection. Two function-
ally important entry receptors have been identified, scav-
enger receptor class B2 (SCARB2) and P-selectin
glycoprotein ligand-1 (PSGL-1) [28,29]. SCARB2 is
expressed in all cell types and regarded as the major
EV-71 entry receptor. At low endosomal pH, SCARB2 is
needed to induce viral uncoating [30,31]. Human
SCARB2 transgenic mice infected with EV-71 showed
lethal neurological manifestations with pathological fea-
tures similar to humans and monkeys, suggesting that
SCARB2 contributes to its pathogenesis [32,33]. PSGL-1
is only present on neutrophils and leukocytes. EV-71
binds to PSGL-1 and enters the cells through the caveo-
lar endocytosis pathway [34]. Transgenic mice express-
ing human PSGL-1 failed to enhance EV-71 infectivity,
suggested that PSGL-1 alone does not contribute to its
pathogenesis [35].
Since host-receptor interactions are the first event dur-
ing infection, inhibitors that block this event could act
as potential therapeutics. The soluble form of cellular re-
ceptors could act as molecular decoys of cell-associated
receptors. Soluble SCARB2, PSGL-1, sialic acid and hep-
arin or heparin mimetics have been demonstrated to ex-
hibit inhibitory effects against EV-71 infection in vitro[25,26,28,30,36]. Highly sulfated suramin and its analog,
NF449, exhibited antiviral activity against EV-71 infec-
tion [25,37]. NF449-resistant mutants consist of two mu-
tations in VP1, E98Q and K244R, implying that NF449
inhibited EV-71 infection by binding to the VP1 protein
[37]. Similarly, kappa carrageenan, a sulfated polysac-
charide from seaweed, also exhibited significant antiviral
activity through targeting EV-71 attachment and entry
[38]. The mechanism of these soluble decoys is possibly
by disruption of the integrity of the EV-71 capsid struc-
ture or steric hindrance of receptor interactions.
Receptor antagonists could also be developed as poten-
tial antiviral agents. A peptide derived from EV-71 VP1,
designated SP40 peptide (Ac-QMRRKVELFTYMRFD-
NH2), was found to exhibit significant antiviral activity
against different strains of EV-71 by blocking viral attach-
ment to the cell surface heparan sulfate [39]. An anti-
heparan sulfate peptide (Ac-MPRRRRIRRRQK-NH2),
previously identified by Tiwari et al. [40], also inhibited
EV-71 infection [25]. Another antimicrobial peptide,
lactoferrin, also exhibited anti-EV-71 properties in vitro
and in vivo through blocking viral attachment to the cell
surface [41-43].
Therapeutics targeting viral uncoating
The proposed EV-71 uncoating event involves attach-
ment to the entry receptor, triggering a series of con-
formational changes resulting in A-particle formation
that is primed for genome release. A second uncoating
event occurs after endocytosis, and an unknown trigger
causes RNA expulsion from the A-particles via the 2-
fold axis, leaving behind an empty capsid [44]. Forma-
tion of the 135S A-particle happens in the presence of
SCARB2 receptors and a low pH environment, suggest-
ing that the A-particle is formed in the early endosomes
[30,31]. Uncoating inhibitors (pocket binders) have been
intensively studied as antiviral agents against many
picornaviruses, including rhinovirus [45], PV [45], echo-
virus [46] and coxsackievirus [47]. The complex of
WIN51711 with the EV-71 hydrophobic pocket under-
neath the canyon depression has recently been resolved
by X-ray crystallography [48]. The key success factor of
these uncoating inhibitors is their ability to fit into the
VP1 hydrophobic pocket, stabilize the capsid structure,
and therefore block the receptor-induced uncoating
mechanism [48].
A series of modified WIN compounds including
BPROZ-194, BPROZ-112, BPROZ-284, BPROZ-103,
BPROZ-299, BPROZ-101, BPROZ-033, and BPROZ-074
were effective against EV-71 infection with IC50 values
ranging from 0.8 nM to 1550 nM [49-54]. However, a
single point mutation in VP1 V192M was sufficient to
confer resistance to BPROZ-194 [51]. Other than modi-
fied WIN compounds, the broad spectrum enterovirus
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in vitro and in vivo [55,56]. However, pleconaril failed to
inhibit the cytopathic effect induced by a Taiwan 1998
EV-71 isolate [49]. Another group of capsid binders,
pyridazinyl oxime ethers chemically derived from piroda-
vir such as BTA39 and BTA188, significantly inhibited
EV-71 infection [57]. Crystallographic studies showed the
pirodavir predecessor R61837 complexed with rhinovirus
14 by binding to the hydrophobic pocket underneath the
canyon floor, similar to the mechanism of WIN com-
pounds [58]. 4′,6-Dichloroflavan (BW683C), previously
identified as an anti-rhinovirus compound, was also
effective against EV-71 infection [59,60]. Mechanistic
studies demonstrated that BW683C binds to and stabi-
lizes rhinovirus to heat or acid inactivation, implying
that BW682C acts as viral uncoating inhibitor [61-63].Therapeutics targeting viral RNA translation
EV-71 protein synthesis commences with translation initi-
ation of the cap-independent IRES element at the 5′UTR
of the EV-71 genome [64]. IRES is a cis-acting element
that forms tertiary RNA structures and requires assistance
from IRES-specific trans-acting factors (ITAFs) to recruit
other cellular translation machinery to the viral RNA. The
EV-71 open reading frame (ORF) is translated into a
single polyprotein, which is subsequently processed by
virus-encoded proteases 2A and 3C into the structural
capsid proteins (VP1-VP4) and the nonstructural proteins
(2A-2C and 3A-3D) mainly involved in the replication of
the viral RNA [65].
The antisense-mediated mechanism consists of oligo-
nucleotides (8-50 nucleotides in length) that bind to
RNA through Watson-Crick base pairing and modulate
the function of the targeted RNA [66]. RNA interference
(RNAi) involves the cleavage of targeted mRNA through
the RNA-induced silencing complex. Small interfering
RNA (siRNA) targeting highly conserved regions of 5′
UTR [67], VP1, VP2 [68], 2C, 3C, 3D [69,70], and 3′
UTR [69] significantly inhibited EV-71 infection in a
dose-dependent manner. In addition, short hairpin RNA
(shRNA) was effective against EV-71 infection in vitro
and in vivo [70-72]. The use of siRNA in clinical settings
is hampered by its short half-life in plasma. Improved
siRNA with 2′O methylation and 2′ fluoro modifications
have recently been demonstrated against EV-71 infection
[67]. However, siRNA also has poor endosomal uptake
which limits the clinical application of these siRNAs.
Other translation suppressing nucleotides, for example,
peptide conjugated phosphodiamidate morpholino oligo-
mers (PPMO) showed promising results in inhibiting PV
and coxsackievirus B3 [73,74]. Unlike siRNA or shRNA,
PPMO interacts with targeted RNA, especially the IRES
region, and blocks ribosome recruitment and thereforeinhibits viral RNA translation [66]. PPMO readily pene-
trates the cells and is resistant to nuclease degradation.
Our unpublished data confirms that PMO are highly
effective against EV-71.
Compounds that down-regulate the activity of IRES-
dependent translation could potentially be developed
into antiviral agents. Quinacrine, which impairs IRES-
dependent translation by preventing the interaction be-
tween polypyrimidine-tract binding protein (PTB) and
IRES, has been demonstrated to act against EV-71 infec-
tion [75]. Kaempferol, a flavonoid, was found to inhibit
EV-71 IRES activity by altering the composition of
ITAFs [76]. Geniposide derived from Fructus gardeniae
inhibited EV-71 replication via inhibition of viral IRES
activity [77]. Amantadine, a tricyclic symmetric amine
previously used against influenza A virus infection, was
found to suppress EV-71 IRES translation [78-80].Therapeutics targeting viral polyprotein processing
Maturation cleavage of polyprotein into different viral
proteins is a critical step during EV-71 infection. EV-71
2A and 3C protease are the key proteases that cleave the
viral precursor polyprotein into each of the component
proteins required for viral replication and packaging.
Interestingly, EV-71 2A and 3C proteases suppress type
I interferon by targeting mitochondrial anti-viral signal-
ing (MAVS) protein and melanoma differentiation asso-
ciated gene (MDA-5) viral recognition receptor signaling
[81,82]. Since EV-71 2A and 3C proteases are involved
in multiple roles in EV-71 infection and evasion of host
innate immunity, they are important potential targets for
development of antiviral therapeutics.
A pseudosubstrate, LVLQTM peptide, could inhibit
EV-71 infection through binding to the active site of 2A
protease [83]. Rupintrivir (AG7088) is an irreversible
peptidomimetic inhibitor of human rhinovirus 3C prote-
ase, which reached phase 2 clinical trials with promising
outcomes [84-89]. Rupintrivir showed significant inhib-
ition of EV-71 infection in vitro and in vivo but with re-
duced efficacy as compared with human rhinoviruses
[90-93]. X-ray crystallography of the complex of EV-71
3C protease with rupintrivir revealed that the half-closed
S2 sub-site and the size reduced S1′ pocket of EV-71 3C
protease limits the access of the rupintrivir’s P1′ group
which contains a lactam ring [94,95]. A series of 3C prote-
ase rupintrivir analogues were designed based on AG7088,
with an aldehyde replacement of the α,β-unsaturated
ester. Compound 10b significantly inhibited EV-71 infec-
tion [96]. An orally bioavailable 3C protease inhibitor, des-
ignated as compound 1, also exhibited antiviral activities
against multiple rhinovirus serotypes and enteroviruses
in vitro [89]. Flavonoids such as fisetin and rutin, have also
been identified as 3C protease inhibitors [97].
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replication complex and other host factors
The genomic replication of enteroviruses has been shown
to occur in membranous compartments in the cytoplasm.
The membranous vesicles induced during PV infection have
been reported to be associated with autophagy signalling
[98,99]. These compartments resemble the autophagosomes
and consist of viral proteins as well as microtubule-
associated protein 1 light chain 3-II (LC3-II). LC3-II is the
membrane-bound form of LC3 that serves as the marker of
autophagy induction [100]. During PV infection, these
double-membrane vesicles consist of viral particles that
undergo autophagic maturation typically characterized by
LC3-II co-localization with lysosomal-associated membrane
protein 1 (LAMP1) [100]. Similarly, EV-71 induces autoph-
agy formation in RD and SK-N-SH cells, and association
between autophagosome-like vesicles and EV-71 VP1 in
neurons of the cervical spinal cords of mice was observed
[101]. The authors concluded that autophagic signalling
induced by EV-71 is crucial for EV-71 replication. This pro-
vides an alternative antiviral strategy for EV-71 to target host
factors related to autophagy that are crucial for viral
replication.
The discovery of antiviral drugs is mainly based on
virus targets. The high replication and mutation rates of
enteroviruses may generate resistance to these direct-
acting antivirals. Targeting host factors may establish a
higher genetic barrier to resistance and can be used in
combination with viral inhibitors. The compound
GW5074, a Raf-1 inhibitor, has been shown to influence
EV-71 viral yield [37,102]. Activation of the Raf-1/ERK
pathway in host cells induces autophagy signalling [103].
The downstream transducer of this pathway, BNIP3
competes with Beclin 1 for binding with Bcl-2 during
autophagy induction [104]. GW5074 may impair au-
tophagy activation through the inhibition of the Raf-1/
ERK pathway. Thus, the replication of EV-71 that re-
quires autophagosome formation may be inhibited in
the presence of the GW5074 compound. Heat shock
protein 90 beta (HSP90β), an isomer of HSP90, has been
reported to have crucial roles in EV-71 entry and assem-
bly. Geldanamycin (GA) and its analog, 17-allyamino-
17-demethoxygeldanamycin (17-AAG), inhibit HSP90β
activities and protect hSCARB2 transgenic mice from
the challenge with EV-71 [105].
Inhibitors that target host factors such as those in-
volved in cellular autophagy and HSP90β could be used
against multiple EV-71 genotypes and enterovirus sero-
types, due to their similar pathways of replication
[106,107]. The major drawbacks of these inhibitors that
target host factors are specificity and cellular toxicity.
Therefore, there is an unmet need to develop specific
and non-toxic antivirals that impair the cellular autoph-
agy pathway and HSP90β during EV-71 infection.The amino acid sequences of the non-structural pro-
teins of EV-71 are highly conserved and have more than
60% similarity to PV. Two hydrophobic regions are
found in the 2B viral protein of PV and are pivotal for
its viroporin functionality [108]. 2B viroporin mediates
the integration of viral protein into the ER membrane
and this increases the membrane permeability to pro-
mote virus release [108]. A study has reported that
EV-71 2B protein might mediate a chloride-dependent
current in oocytes. A chloride-dependent current in-
hibitor, 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid
(DIDS) has been reported to inhibit EV-71 infection in
RD cells [109]. The 2C viral protein of PV consists of
Walker A, B and C motifs that are homologous to the
motifs found in NTP-binding proteins or in members of
the helicase superfamily III [110]. An amphipathic helix
domain is located at the N-terminal of 2C viral protein
that has the function of promoting oligomerization
[110]. Recently, two antiviral compounds, metrifudil
(N-(2-methylphenyl) methyl adenosine) and N6-benzyla-
denosine, blocked EV-71 replication via interaction with
2C viral protein or 2BC precursor protein [37]. Mutants
resistant to metrifudil had a mutation in the 2C viral
protein (E325G), while N6-benzyladenosine-resistant
mutants had double mutations at the 2C viral protein
(H118Y and I324M) [37]. However, the mechanism of
inhibition is yet to be determined. Both MRL-1237 and
TBZE-029, derivatives of benzimidazole, exhibit antiviral
activity against various enteroviruses, and have been
identified to target the picornaviral 2C viral protein
[111,112]. Both of these derivatives may exert potent
antiviral activity against EV-71 since EV-71 and PV shared
high similarity in all the non-structural proteins. Guanidine
hydrochloride is an extensively-studied picornavirus inhibi-
tor [113,114], which inhibits the replication of PV
[115,116], coxsackieviruses [117], echoviruses, and foot-
and-mouth disease virus [118]. Interestingly, guanidine
hydrochloride also inhibits EV-71 infection and a single
mutation, M193L at the 2C protein was sufficient to confer
resistance [119]. This agent is likely to prevent the associ-
ation of 2C/2BC with host membrane structures during
viral replication [120].
The 3A viral protein of PV contains hydrophobic do-
mains that facilitate its binding with membranous vesi-
cles induced during viral RNA replication [121,122]. A
benzimidazole derivative, enviroxime exhibits potent ac-
tivity against PV and rhinovirus by interacting with 3A
viral protein [119]. Strong antiviral effects of enviroxime
have been shown against EV-71 [123]. Bifunctional in-
hibitors AN-12-H5 and AN-23-F6, are enviroxime-like
compound that also targets 3A, VP1 and VP3, inhibits
EV-71 infection efficiently [124]. However, the precise
mechanism of action by enviroxime and AN-12-H5
against EV-71 infection remains unknown. Another
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hibitor that significantly inhibited CV-A16 infection,
with reduced activity against EV-71 [112].
Therapeutics targeting RNA-dependent RNA polymerase
(RdRP) complex
The viral RNA replication of enteroviruses begins with the
linkage of genomic RNA with the 3B protein (VPg) at the
5′ end to form the uridylylated state of VPg (VPg-pUpU).
Additionally, VPg uridylylation is stimulated by the viral
precursor protein 3CD [125]. The positive strand of viral
RNA is used as a template to synthesize the negative strand,Figure 1 Schematic illustration of EV-71 intracellular infection and su
according to their mechanism of actions, which include molecular decoys,
polyprotein processing inhibitors and replication inhibitors.which in turn serves as the template for the synthesis of
new positive strands. The synthesis of both positive and
negative strands of viral RNA is primed by VPg-pUpU
[126]. Nucleotide site 311 of the RNA-dependent RNA
polymerase (RdRP) of EV-71 is pivotal for VPg uridylylation
and viral RNA synthesis, as mutations here impair the
binding of VPg to RdRP, but did not influence normal
RdRP activity [127].
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carbox-
yamine) is a conventional nucleoside analogue that targets
the RdRP of picornaviruses [128]. Ribavirin inhibits EV-71
infection with an IC50 of 266 μM, and prevents EV-71mmary of the antiviral agents. The antiviral agents are classified
receptor antagonists, uncoating inhibitors, translation inhibitors,
Table 1 List of antivirals against EV-71 infection tested in vitro and in vivo
Antivirals EV-71 genotype
tested
IC50/EC50 In vitro cell
type
Resistant
mutants
In vivo mouse model Reference
Therapeutics targeting viral
attachment and entry
Molecular decoys
Recombinant SCARB2 B3 N/R RD [28]
PSGL-1 C2 N/R L-PSGL-1.1 [29]
Heparin mimetics
Heparin C2 205 μg/ml Vero, RD [25,36]
Heparan sulfate C2 290 μg/ml Vero [36]
Pentosan polysulfate C2 238 μg/ml Vero [36]
Dextran sulfate B4 N/R RD [25]
Suramin/NF449 B1, B3, B4 6.7 μM RD VP1 E98Q,
K244R
[25,37]
Kappa carrageenan B4 N/R Vero [38]
Enviroxime-like compounds
AN-12-H5 B1 0.55 μM RD VP1 M119L, VP3
R227K
[124]
AN-23-F6 B1 0.15 μM RD VP1 A224T [124]
Receptor antagonists
Anti-SCARB2 antibodies B3 N/R RD [28]
Anti-PSGL-1 antibodies B3, B4, C1, C2, C4 N/R Jurkat [29]
Bovine lactoferrin C2, MP4a 10.5 –
24.5 μg/ml
RD, Vero, SK-N-
SH
17-days old ICR [42,43]
Human lactoferrin N/R 103.3 –
185.0 μg/ml
RD, Vero [42]
SP40 peptide A, B4, C2 6 – 9.3 μM RD, HeLa, HT-
29, Vero
[39]
Anti-heparan sulfate peptide B4 N/R RD [25,40]
Therapeutics targeting viral
uncoating
Pyridyl imidazolidinone
BPROZ-299 C2 0.02 μM RD VP1 V192M [52]
BPROZ-284 A, B1, C2 0.04 μM RD [49]
BPROZ-194 C2 1.552 μM RD VP1 V192M [51,52]
BPROZ-160 C2 0.011 μM RD VP1 V192M [52]
BPROZ-112 A, B1, C2 0.04 μM RD [49]
BPROZ-103 C2 0.13 μM RD VP1 V192M [52]
BPROZ-101 A, B1, C2 0.0012 μM RD [52,53]
BPROZ-074 A, B1, C2 0.0008 –
0.018 μM
RD VP1 V192M [52,54]
BPROZ-033 A, B1, C2 0.0088 –
0.069 μM
RD [52,54]
WIN51711 B3 N/R RD [48]
Pleconaril A 0.13-0.54 μg/
ml
RD 1-day old ICR [56]
BW683C A > 10 μM HEp-2 [59]
Compound 3 g A 0.45 μM HEp-2 [59]
BTA39 A 0.001 μM Vero [57]
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Table 1 List of antivirals against EV-71 infection tested in vitro and in vivo (Continued)
BTA188 A 0.082 μM Vero [57]
Therapeutics targeting viral
translation
RNA-based therapeutics
siRNA B4 < 1 nM RD 1-day old Balb/c [67-72]
shRNA B4 < 1 nM RD 1-day old Balb/c [67-72]
Quinacrine C4 9.71 μM RD [75]
Amantadine Pseudo-EV-71 N/R COS-1 [78]
Therapeutics targeting viral
polyprotein processing
2A inhibitor
LVLQTM peptide C4 9.6 μM HeLa [83]
3C inhibitors
Rupintrivir C4 0.014 μM RD 2-days old ICR [93]
Compound 10b C2 0.018 μM RD [96]
Fisetin CMUH01* 85 μM RD [97]
Rutin CMUH01* 110 μM RD [97]
Therapeutics targeting viral
replication
2B inhibitor
DIDS C4 N/R RD [109]
2C inhibitors
Metrifudil B1 1.3 μM RD 2C E325G [37]
N6 benzyladenosine B1 0.1 μM RD 2C H118Y,
I324M
[37]
Guanidine-HCl B3 N/R RD 2C M193L [119]
3A inhibitors
Enviroxime A 0.15 μM Vero [112]
AN-12-H5 B1 0.55 μM RD 3A E39G [124]
AN-23-F6 B1 0.15 μM RD [124]
TTP-8307 A > 60 μM Vero [112]
GW5074 B1 6.4 μM RD [124]
3D inhibitors
DTriP-22 A, B2, C2 0.3 μM RD 3D R163K [130]
Ribavirin C2, M2b 266 μM RD, SK-N-SH,
N18
3D G64R, S264L 12-days old ICR [129]
Heat-shock protein 90 inhibitor
Geldanamycin B4, C2 N/R RD [105]
17-AAG C2, C4 N/R N/R 7-days old hSCARB-Tg
C57BL/6 mice
[105]
aMouse-adapted EV-71 strain Tainan/4643/98 (C2); bMouse-adapted EV-71 strain derived from MP4 with additional two passages in mice; *EV-71 strain with
unidentified genotype; and N/R means not reported.
RD: rhabdomyosarcoma cells; Vero: African green monkey kidney cells; SK-N-SH: human neuroblastoma cells; N18: mouse neuroblastoma cells; HeLa: human
cervical adenocarcinoma epithelial cells; HT-29: human colon adenocarcinoma cells; HEp-2: HeLa contaminant cells; Jurkat: human T lymphocytes cells; and COS-1:
monkey kidney fibroblast cells.
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piperazine-containing pyrazolo [3,4-d] pyrimidine deriva-
tive, DTriP-22, was shown to effectively target the RdRPof EV-71 with IC50 values of 0.15 – 0.98 μM, and suppress
the accumulation of both positive and negative strands of
viral RNA during EV-71 infection. DTriP-22-resistant
Tan et al. Journal of Biomedical Science 2014, 21:14 Page 8 of 11
http://www.jbiomedsci.com/content/21/1/14mutants had mutations in the RdRP, implying that DTriP-
22 interacts with RdRP and inhibits poly (U) elongation
activity, but not VPg uridylylation [130].Conclusion
Figure 1 and Table 1 summarizes all the potential targets
of antivirals and lists the recent antiviral agents with sig-
nificant antiviral activities against EV-71 infection as dis-
cussed above. Amongst these drugs, modified WIN
compounds are antivirals with the lowest IC50. Only
bovine lactoferrin, pleconaril, shRNA, siRNA, rupintrivir,
ribavirin and 17-AAG have been tested in vivo. Ribavirin
and amantadine are already in clinical use for other vi-
ruses, and rupintrivir and pleconaril are in clinical
development.
The availability of a suitable animal model carrying all
the required receptors and attachment factors for testing
of the antivirals will accelerate the development of antivi-
rals. The clinical use of other antiviral agents has been
hampered by the potential adverse effects to the host and
emergence of drug resistance mutants. Combination
therapy targeting different replication steps of EV-71
infection cycle has shown synergistic activity [131] and
could minimize the emergence of antiviral resistance. A
new antiviral strategy to screen all licensed drugs against
EV-71 infection would be more promising for clinical
use. Other newer antivirals that act as immunomodula-
tors and lethal mutagens offer a new strategy for develop-
ment of antivirals. With the endemic and epidemic
nature of EV-71, the continued efforts to develop anti-
viral agents for prophylaxis or treatment are crucial in
the absence of a vaccine. Together with an effective vac-
cine, eradication of EV-71 is anticipated.
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Editorial
Human enterovirus 71 (EV-A71) is the 
main etiological agent of hand, foot and 
mouth disease (HFMD). Typical clinical 
symptoms of HFMD are fever, rashes on 
the palms and soles and oral ulcers. Unlike 
other enteroviruses that cause HFMD, 
EV-A71 is more frequently associated with 
severe neurological complications, such as 
brainstem encephalitis and aseptic menin-
gitis in children below 6 years of age. 
The first outbreak was reported in 1969 
and subsequently many large outbreaks 
have been reported in Japan, Hungary, 
Bulgaria, Malaysia, Taiwan, Singapore, 
Australia, Vietnam, China and Cambodia 
[1]. The recent outbreak in China affected 
half a million people with more than 
500 deaths. Fatalities are predominantly 
seen in Asian outbreaks, but neither a vac-
cine nor an antiviral is presently available 
for clinical use.
EV-A71 could emerge as the next signifi-
cant enteroviral health threat after eradica-
tion of polioviruses. Owing to the potential 
severe neurological complications in EV-A71 
infection, there is a pressing need to develop 
effective antiviral thera peutics. Our growing 
knowledge in EV-A71 viral–host  receptor 
interactions provides opportunities to 
identify new targets for rational design of 
 attachment or entry inhibitors.
Discovery of EV-A71 viral–host 
receptors interactions: insights into 
therapeutics development
EV-A71 belongs to the Picornaviridae 
family and the genome is enclosed within 
a non-enveloped, icosahedral capsid, 
assembled from four capsid proteins, VP1–
VP4, of which VP1–VP3 are located on 
the exterior surface while VP4 is located 
on the inner surface. The EV-A71 capsid 
will initially attach to the cell surface, then 
bind to the entry receptor and finally enter 
the cell by endocytosis. Virus–host recep-
tor interaction is the first essential event 
during virus infection. In the absence of 
susceptible host receptors, the virus will 
not enter the cells to initiate an infection. 
Receptor availability is therefore one of 
the factors that determine host range and 
tissue tropism.
Carbohydrates are expressed abundantly 
on the human cell surface and are often 
initial attachment targets of most patho-
gens. The function of these carbohydrate 
attachment factors could be to concen-
trate the virus on the host cell surface 
and, hence, enhance infectivity. EV-A71 
attaches to the cell surface carbohydrate, 
heparan sulfate, possibly by electrostatic 
interactions, before binding to entry recep-
tors. The symmetrical arrangement of pos-
itively-charged amino acids at the fivefold 
axis of the EV-A71 pentamer could be the 
major site where heparan sulfate interacts 
[2]. In addition, EV-A71 also interacts with 
sialylated glycans [3].
Most picornavirus receptors belong to 
the immunoglobulin superfamily, such as 
ICAM-1 for the major group rhinoviruses 
Enterovirus 71 receptors: promising drug 
targets?
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and CD155 for the polioviruses. Cryo-electron microscopy reveals 
that these receptors interact with viral capsids through penetration 
into the canyon, a depression that encircles the fivefold axis, and 
trigger capsid structural transition to allow virus entry [4]. The two 
EV-A71 entry receptors, scavenger receptor class B2 (SCARB2) 
and P-selectin glycoprotein ligand-1 (PSGL-1) are different from 
the known enterovirus receptors. SCARB2 is a type III double 
transmembrane protein that is widely expressed in different cell 
types. In most cell types, EV-A71 binds to the SCARB2 receptor 
and is then internalized via clathrin-mediated endocytosis [5,6]. 
The canyon around the EV-A71 VP1 Gln172 has been showed to 
interact with the amino acids between 144 and 151 of SCARB2 
[7]. Interestingly, desialylation of SCARB2 abolished the EV-A71–
SCARB2 interactions, implying that the sialic acids present on the 
SCARB2 are critical [3]. Involvement of PSGL-1 as an EV-A71 
receptor has also been demonstrated, but this receptor is only 
expressed in neutrophils and lymphocytes [8]. Recent studies 
have demonstrated that SCARB2 is functionally more important 
than PSGL-1 as a receptor. At pH <6.0, EV-A71 uncoating was 
observed when SCARB2 was present, but not PSGL-1 [9].
Recent developments of receptor inhibitors for EV-A71 involve 
targeting the virus capsid proteins (such as hydrophobic pocket 
binders) or host-receptor binding sites (host-receptor inhibitors). 
Small synthetic capsid hydrophobic pocket binders are known to 
be effective inhibitors against picornaviruses through stabilizing 
the capsid against receptor-induced conformational changes and 
thereby preventing uncoating. The mechanism of the capsid-
binding drug WIN51711 (5-[7-[4-(4,5-dihydro-2-oxazolyl)phe-
noxy]heptyl]-3-methylisoxazole) against EV-A71 uncoating was 
recently resolved by x-ray crystallography [10]. BPROZ-194, a pyri-
dyl imidazolidinone, is a novel class capsid binder that exhibited 
antiviral activity against EV-A71 with EC
50
 between 2.13 and 
4.67 µM [11]. The key factor that determines drug efficacy is its 
ability to fit into the hydrophobic pocket of the VP1 capsid pro-
tein and stabilize the virus. Inhibitors of host attachment factors 
include SP40, a VP1-derived synthetic peptide that blocks viral 
attachment to cell surface heparan sulfate with IC
50
 between 6 
and 9 µM [12]. Similarly, bovine lactoferrin that binds to heparan 
sulfate and VP1 also inhibits EV-A71 infection in vivo [13]. Pre-
incubation of cells with anti-SCARB2 antibodies or monoclonal 
antibody targeting the N-terminal of PSGL-1 inhibits EV-A71 
infection in a dose-dependent manner, but does not completely 
protect the cells from infection [5,8,9]. The soluble form of cell-
ular receptors could act as molecular decoys of cell-associated 
receptors. Soluble forms of highly negatively charged heparin, 
dextran sulfate and suramin reduces viral infectivity, possibly 
due to disruption of the integrity of the EV71 capsid structure 
or steric hindrance of receptor interactions [2].
Virus receptors for therapeutics: the success stories of 
HIV entry inhibitors
A successful example of entry inhibitors is the HIV fusion inhibi-
tor enfuvirtide, which obtained US FDA approval in March 
2003. Enfurvitide is used in combination with other antiretro-
viral agents in the treatment of experienced patients with resist-
ance to other antiretroviral drugs. Enfuvirtide is a 36-amino 
acid peptide derived from the heptad repeat region-2 sequence 
of the HIV transmembrane protein GP41. Enfuvirtide interacts 
with the CD4+ T-cell receptor and prevents the critical fusion 
step of the viral entry process. As a result of low bioavailability 
and short half-life, second- and third-generation peptide-based 
fusion inhibitors with improved stability and potency have been 
developed [14]. These include sifuvirtide, which has a more stable 
secondary structure of the α-helix structure and prolonged plasma 
stability of up to 22 h [15]. This will result in lower dosage and 
frequency of administration. Another successful entry inhibitor 
has been maraviroc, which was approved by the FDA in 2007. 
Maraviroc binds to the chemokine co-receptor CCR5, blocking 
the binding of HIV-1 virus envelope glycoprotein GP120, hence 
preventing HIV-1 from entering and infecting immune cells [16].
Challenges of developing EV-A71 entry inhibitors
Cost, efficacy, route of administration and safety will continue 
to be the barriers to the success of taking antivirals targeting 
receptors from benchside to bedside. A possible use for attach-
ment and entry inhibitors is for prophylaxis; for example, during 
an outbreak of HFMD associated with severe neurological dis-
ease in a kindergarden. However, this approach is unlikely to be 
cost-effective for resource-limited countries in Asia where large 
outbreaks frequently occur. The effectiveness of the attachment 
or entry inhibitor would be highly dependent on the timing of the 
treatment provided. The major obstacle is delivering a sufficient 
amount of the inhibitor to the targeted site early enough to delay 
disease progression to neurological involvement or to prevent the 
spread of infection to others. Bioavailability is often a determinant 
of drug efficacy. Although WIN compounds exhibit significant 
in vitro activity against rhinovirus, it has been unsuccessful due 
to their poor bioavailability. Similarly, clinical trials of intranasal 
anti-ICAM-1 antibodies targeting the rhinovirus receptor only 
delays onset of infection, but does not eliminate it [17]. EV-A71 
peptide-based inhibitors such as the SP40 peptide currently have 
limited bioavailability and stability in plasma. Further chemical 
modifications, such as addition of N-terminal pyroglutamate and 
C-terminal homoserine lactone to the peptide, could improve the 
resistance to peptidase [18].
An additional challenge of small synthetic inhibitors such as 
the WIN compounds and peptides is the development of resist-
ant mutants. RNA viruses exist as quasispecies, a cloud of virus 
variants carrying different mutations within a virus population. 
This can eventually lead to selection of mutant viruses resistant 
to the inhibitors. A single Val192Met mutation in VP1 is suf-
ficient to confer resistance to BPROZ-194, the capsid binder [19]. 
EV-A71 mutants with VP1 Glu98Gln and Lys244Arg mutations 
conferred resistance to the suramin analog, NF449 [20]. Based on 
“The major obstacle is delivering a sufficient 
amount of the inhibitor to the targeted site early 
enough to delay disease progression to 
neurological involvement or to prevent the spread 
of infection to others.”
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lessons from HIV combination therapy, targeting multiple stages 
in viral replication can significantly reduce the emergence of 
resistant mutants. Understanding the molecular mechanisms of 
resistance may lead to design of improved inhibitors.
Outlook for the future
Limited antivirals targeting HIV, influenza, herpesviruses and 
hepatitis viruses are available on the market. Emerging infec-
tions with epidemic potential such as EV-A71 warrant greater 
attention. Development of antivirals based on understanding of 
virus–host receptor interactions show promise, exemplified by the 
success of enfuvirtide. However, further chemical modifications 
to improve the potency, efficacy, oral administration, safety and 
cost will be needed for EV-A71 antivirals, such as SP40 pep-
tide, BPROZ-194 and WIN51711. Combination therapy with 
more than one inhibitor may yield more promising results. There 
should be more concerted efforts to screen other targets involved 
in the virus life cycle (e.g., polyprotein processing, capsid assembly 
and virus release) and host cellular pathways (e.g., apoptosis and 
autophagy). Additionally, several EV-A71 inactivated vaccines are 
currently in clinical trials and showing promising results.
While waiting for a new antiviral or vaccine, preventive meas-
ures, such as early detection of infection, social distancing. hand 
hygiene and effective supportive clinical treatment remain the 
cornerstones to combating EV-A71 infection.
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